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Mitogen-activated protein kinase (MAPK) signaling pathways are essential in eukaryotes 
for regulating fundamental processes such as cell growth and proliferation. Most eukaryotes 
possess multiple MAPK pathways, each of which constitutes a conserved three-tiered cascade 
comprising of a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAPK. While 
MAPK pathways are well-characterized in numerous eukaryotes, much less is known about the 
corresponding pathways in Plasmodium falciparum, the most deadly malaria-causing parasite. It 
has been suggested that the MAPK pathway is not conserved in P. falciparum since analyses of 
its kinome could identify only homologues of the MAPKs (Pfmap1 and Pfmap2), but not those of 
the MAPKKs and MAPKKKs. Nonetheless, a P. falciparum NIMA-like kinase, Pfnek3, has 
previously been found to be competent in activating Pfmap2 through phosphorylation of the 
threonine residue within the TSH activation site. As this functionality coincides with that 
expected of a MAPKK, Pfnek3 was consequently recognized as a unique MAPKK in P. falciparum. 
The existing evidence also indicates that P. falciparum is likely to possess a functional MAPK 
pathway, albeit an atypical one where the functionalities of MAPKKs and MAPKKKs are fulfilled 
by non-conventional kinases. With the identification of Pfnek3 as an unusual P. falciparum 
MAPKK, this study was undertaken to investigate its mode of regulation and further elucidate its 
biochemical properties. In addition, identifying the binding partners of Pfnek3 and Pfmap2 was 
pursued to shed light on additional proteins which may constitute the MAPK pathway in P. 
falciparum. 
Through a combination of mass spectrometry and biocomputational analysis, amino 
acid residues T82, S221, S226, Y117, Y122, Y172 and Y238 were identified as 
autophosphorylation sites of Pfnek3. These autophosphorylation sites were thereafter shown to 
be essential for the activation of Pfnek3 via site-directed mutagenesis and functional assays. 
Interestingly, the residues S221 and S226 formed part of the 221SSEQSS226 sequence which 
resides within the activation loop of Pfnek3. This sequence is reminiscent of the conserved 
S/TXXXS/T motif in conventional MAPKKs, where phosphorylation of the first and last residues is 
required for MAPKK activation. In this light, the results obtained indicate that the regulation of 





Apart from autophosphorylation on serine, threonine and tyrosine residues, Pfnek3 was 
also found to phosphorylate an exogenous substrate on threonine and tyrosine residues 
through Western blot analyses. The ability of Pfnek3 to phosphorylate both the aliphatic (i.e. 
serine/threonine) and the aromatic (i.e. tyrosine) hydroxyl amino acid residues thus implies that 
it is a novel dual-specificity protein kinase in P. falciparum. The finding also unveiled an 
additional biochemical property of Pfnek3 which concurs with that of the MAPKKs, whose dual-
specificity kinase activities have been well-defined. Earlier reports on the P. falciparum kinome 
have revealed that the parasite lacks homologues of the classical tyrosine kinases. Nonetheless, 
tyrosine phosphorylation has been detected in vivo and shown to be essential for the 
development of the parasite. Hence, the observed dual-specificity kinase activity in Pfnek3 is of 
biological relevance since P. falciparum may plausibly rely on this kinase to support its cellular 
tyrosine phosphorylation. 
While Pfmap2 has previously been validated as an indispensible MAPK in P. falciparum, 
its exact cellular role remains elusive as its native substrates have yet to be identified. Using the 
GST pull-down assay, Pfmap2 was demonstrated in this study to interact with P. falciparum heat 
shock protein 90 (PfHsp90), an essential molecular chaperone in the parasite. Pfnek3-activated 
Pfmap2 was further shown to phosphorylate PfHsp90 on threonine residue(s), thereby 
supporting PfHsp90 as a substrate of Pfmap2 in vitro. This was an intriguing finding since Hsp90s 
are currently not known to be substrates of MAPKs. Given that MAPKs typically mediate the 
functionality of their substrates by phosphorylation, the result is suggestive that Pfmap2 could 
potentially be involved in regulating the activity of PfHsp90 in vivo. 
In summary, this study has provided insights into the regulation and the dual-specificity 
functionality of Pfnek3. The tyrosine kinase activity detected in Pfnek3 also highlights its 
potential involvement in mediating tyrosine phosphorylation in vivo. In addition, the 
identification of PfHsp90 as a substrate of Pfmap2 indicates that Pfmap2 may play a crucial role 
in P. falciparum by regulating an essential molecular chaperone. More importantly, this finding 
has shed light on the identity of a plausible effector protein which may lie downstream of the P. 
falciparum MAPK cascade. 
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1.1 Mitogen-activated protein kinase signaling pathways are essential in eukaryotes for 
regulating diverse cellular functions 
 
In eukaryotes, signal transduction via the mitogen-activated protein kinase (MAPK) 
pathways is an evolutionarily conserved mechanism for cellular regulation (Morrison, 2012). 
Most eukaryotes possess multiple MAPK pathways which coordinately mediate diverse cellular 
functions in response to specific sets of stimulatory cues. In the budding yeast Saccharomyces 
cerevisiae, five distinct MAPK pathways implicated in mating, filamentation, osmoregulation, cell 
wall remodeling and sporulation have been elucidated (Chen and Thorner, 2007). The mating 
and filamentation pathways are stimulated by mating pheromones and partial nutrient 
deprivation respectively, while the remaining three are responsive to hyperosmolarity, cell wall 
stresses and nutrient depletion. On the other hand, four mammalian MAPK pathways have been 
defined so far. The extracellular signal-regulated kinases 1/2 (ERK1/2) and ERK5 pathways are 
mainly involved in regulating cell proliferation and differentiation upon mitogenic stimulation 
(Nishimoto and Nishida, 2006). Conversely, the c-Jun amino-terminal kinase (JNK) and p38 
cascades are more widely engaged in mediating cell cycle arrest, apoptosis and cytokine 
production in response to environmental stresses and inflammatory signals (Kyriakis and 
Avruch, 2012). 
Each MAPK pathway features a conserved three-kinase cascade which comprises of a 
MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAPK (Figure 1.1). The sequential 
phosphorylation and activation of these kinases enable the stimulatory signals to be transmitted 
down the cascade. Stimulus-triggered MAPKKKs phosphorylate the downstream MAPKKs on the 
serine or threonine residues within the consensus S/TXXXS/T motifs to stimulate their catalytic 
activities. Activated MAPKKs then trigger the activation of MAPKs through phosphorylation of 
the threonine and tyrosine residues within their signature TXY motifs. The MAPKs are 




consequently capable of phosphorylating a broad range of protein substrates, many of which 
are involved in controlling vital cellular events such as gene expression (e.g. transcription 
factors) and protein synthesis (e.g. regulatory protein kinases) (Yoon and Seger, 2006). As a 
result of this, MAPK pathways exert a regulatory influence on a wide array of biological 
functions. 
Given the importance of MAPK pathways in governing crucial cellular processes, their 
functions have to be tightly regulated. In human, abnormalities in MAPK pathways have been 
implicated in numerous pathological disorders including cancers, rheumatoid arthritis and 
Alzheimer's and Parkinson's diseases (Kim and Choi, 2010). Hence, inhibition of MAPK pathways 
has emerged as a promising intervention strategy against these pathological conditions. To date, 
two small molecule inhibitors (sorefenib and vemurafenib) acting against the ERK1/2 pathway 
have been approved for clinical use against advanced renal cell carcinoma, hepatocellular cancer 
and melanoma (Kim and Sim, 2012). With the progress made in elucidating the roles of MAPK 
pathways in various human diseases, as well as heightened efforts in screening for specific 
inhibitors of these cascades, it is anticipated that more human disorders will benefit from such 
MAPK pathway inhibition therapy.    
  




1.2 Elucidating the atypical MAPK pathway in Plasmodium falciparum 
 
Plasmodium falciparum is the most lethal causative agent of human malaria, a disease 
that severely threatens half of the world’s population annually (World Health Organization, 
2012). Recent efforts to control malaria have been hampered by the development of P. 
falciparum resistance to numerous antimalarial drugs, including the most efficacious 
artemisinins (Dondorp et al., 2010). At the same time, no malaria vaccine has been approved for 
clinical use. Among the panel of malaria vaccines under clinical evaluation, RTS,S/AS01 is the 
most promising candidate and is currently in the Phase III trial. Interim reports of the trial have 
revealed that RTS,S/AS01 could reduce malaria in young children and infants by about 50% and 
30%, respectively (Agnandji et al., 2011; The RTS,S Clinical Trials Partnership, 2012). Hence, 
before a fully protective malaria vaccine is developed, antimalarial drugs still remain a crucial 
mode of treatment and control for malaria. The present circumstances thus underscore the 
urgency to identify new drugs and drug targets to overcome the problem of antimalarial drug 
resistance. 
Gaining insights into the regulation of the P. falciparum life cycle is fundamental to 
identify essential parasite proteins and/or cellular pathways that could be exploited for novel 
antimalarial drug development. As the evolutionarily conserved MAPK pathways play a central 
role in controlling growth and proliferation of eukaryotic cells, it raises an enticing possibility 
that MAPK pathways are also present in P. falciparum to regulate its developmental 
progression. Deciphering the P. falciparum MAPK cascades is thus of interest as their inhibition 
might represent a potential strategy to interfere with parasitic growth. In contrast to the wealth 
of information available on the yeast and mammalian MAPK pathways, much less is known 
about the corresponding cascades in P. falciparum. This is attributed to the reports that the P. 




falciparum kinome comprises only homologues of the MAPKs, but not those of the MAPKKs and 
MAPKKKs (Anamika et al., 2005; Ward et al., 2004). 
Pfmap1 and Pfmap2 (PlasmoDB identifiers: PF14_0294 and PF11_0147) are the two 
MAPK homologues present in the P. falciparum kinome (Doerig et al., 1996; Dorin et al., 1999). 
They share approximately 30-40% amino acid sequence identities with the human and yeast 
MAPKs within their catalytic domains. The signature TXY activation motif of MAPKs is conserved 
in Pfmap1 as a TDY, but is replaced with a TSH in Pfmap2. Through transcriptome analyses and 
immunofluorescence microscopy, both kinases were found to be expressed during the asexual 
and sexual stages of the P. falciparum intra-erythrocytic developmental cycle (Bozdech et al., 
2003; Dorin-Semblat et al., 2007). Using a gene knock-out approach, it was further shown that 
parasites deficient in Pfmap2, but not Pfmap1, were unable to complete intra-erythrocytic 
schizogony (Dorin-Semblat et al., 2007). This finding consequently endorsed Pfmap2 as an 
essential MAPK in P. falciparum, and deciphering its associated MAPK pathway may potentially 
provide insightful clues to the regulatory mechanism that underlies P. falciparum development. 
However, mapping of the Pfmap2 MAPK cascade has been a challenging task since 
conventional MAPKKK and MAPKK homologues were not found in the P. falciparum kinome 
(Anamika et al., 2005; Ward et al., 2004). The futile attempts in identifying these homologues 
consequently led to the suggestion that the classical MAPKKK-MAPKK-MAPK cascade may not be 
conserved in P. falciparum (Dorin et al., 2005). Nonetheless, in the midst of searching for 
candidate Pfmap2 activators, a P. falciparum NIMA-like kinase, Pfnek3, intriguingly 
demonstrated the ability to phosphorylate and activate Pfmap2 in vitro (Lye et al., 2006). Mass 
spectrometric and biochemical analyses further validated that Pfnek3 activates Pfmap2 by 
phosphorylation of the threonine residue within the latter’s TSH activation site (Low et al., 
2007). As such modus operandi of MAPK activation coincides with that adopted by conventional 




MAPKKs, Pfnek3 was consequently recognized as an unusual MAPKK in P. falciparum (Low et al., 
2007). The existing data also provides evidence that P. falciparum is likely to possess a 
functional MAPK pathway, albeit an atypical one where the roles of MAPKKs and MAPKKKs are 




































Figure 1.1 An overview of MAPK pathways in human, S. cerevisiae and P. falciparum. 
A typical MAPK cascade consists of a MAPKKK, a MAPKK and a MAPK, which are sequentially 
activated via phosphorylation. Illustrated here are the well-characterized ERK1/2 and FUS3 
pathways of human and S. cerevisiae, respectively. To date, the MAPK pathway of P. falciparum 
remains poorly defined as its kinome reportedly lacks homologues of the conventional MAPKKKs 
and the MAPKKs. Nonetheless, a P. falciparum NIMA-like kinase, Pfnek3, has previously been 
shown to be able to activate Pfmap2 by phosphorylating the threonine residue with its TSH 
activation site. As such functionality coincides with that expected of a MAPKK, Pfnek3 was 





















1.3 Objectives of this study 
The identification of Pfnek3 as an unusual activator of Pfmap2 marked an important 
step forward in uncovering the components of the P. falciparum MAPK cascade. It also sparked 
further interest in characterizing Pfnek3 to gain insights into the regulation and biochemical 
properties of this atypical P. falciparum MAPKK. Meanwhile, as deciphering the MAPK cascade 
of P. falciparum is still in its infancy, identifying regulators and substrates of Pfnek3 and Pfmap2 
is imperative to uncover additional parasite proteins which may constitute the pathway. Hence, 
with these objectives in mind, three broad aims were proposed for this project (Figure 1.2):  
 
Aim 1: Investigating the regulation of Pfnek3 activity 
The catalytic function of MAPKKs is widely known to be regulated through 
phosphorylation of the serine/threonine residues within the conserved S/TXXXS/T motif 
(Roskoski, 2012b). However, prior to this study, the mechanism involved in regulating Pfnek3 
activity remains unexplored. Considering that recombinant Pfnek3 was found to be 
autophosphorylated following heterologous expression in bacterial cells (Lye et al., 2006), this 
project began with investigating the importance of phosphorylation in regulating the kinase 
activity of Pfnek3. In particular, phosphorylation sites of Pfnek3 would be identified and 
assessed for their roles in influencing Pfnek3 kinase activity. 
 
Aim 2: Examining the dual-specificity kinase activity of Pfnek3 
The majority of eukaryotic protein kinases phosphorylate either the aliphatic hydroxyl 
group on serine/threonine residues (i.e. the serine/threonine kinases) or the aromatic hydroxyl 
group on tyrosine residues (i.e. the tyrosine kinases). However, the MAPKKs represent a unique 
group of enzymes termed the dual-specificity protein kinases as they could catalyze phosphoryl-
transfer to both types of hydroxyl side chains (Roskoski, 2012b). As Pfnek3 is functionally akin to 




the MAPKKs due to its activating effect on Pfmap2, this section of the study aimed to examine 
whether Pfnek3 similarly elicits a dual-specificity activity typical of the MAPKKs. In line with this 
objective, the ability of Pfnek3 to phosphorylate substrates on both the serine/threonine and 
the tyrosine residues would be evaluated.   
 
Aim 3: Unveiling the regulators and substrates of Pfnek3 and Pfmap2 
One of the approaches in mapping MAPK cascades is to uncover the regulators and 
substrates of existing components of the cascades. Such a strategy has been successful in 
elucidating the MAPK pathways in various organisms including mammals, plants and yeast 
(Bilsland-Marchesan et al., 2000; Kiegerl et al., 2000; Zhou et al., 1995). Therefore, in an effort to 
gain insights into the atypical MAPK pathway of P. falciparum, this study also set out to uncover 
additional components of the pathway by identifying the regulators and substrates of Pfnek3 
and Pfmap2. The unveiling of Pfnek3 activators will potentially shed light on the P. falciparum 
proteins that can fulfill the function of MAPKKKs. On the other hand, identifying protein 
substrates of Pfmap2 is likely to provide useful leads with regards to its role in mediating the 
intra-erythrocytic development of P. falciparum.  
  





Figure 1.2 Objectives of the project. 
In line with the goal of investigating the atypical MAPK pathway of P. falciparum, three 
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2.1      Malaria: A global health threat 
 
2.1.1  The global health burden of malaria 
Malaria is an ancient infectious disease that continues to pose massive threats to 
human morbidity and mortality even till today. Caused by protozoan parasites from the 
Plasmodium genus, this deadly disease is transmitted among the human population through the 
bite of an infected Anopheles mosquito vector.  Countries in the tropical and subtropical regions 
are most vulnerable to malaria, as their temperatures and rainfalls are optimal for the 
development of Plasmodium parasites within the mosquito vectors (Greenwood et al., 2008). 
According to the latest update by World Health Organization (WHO), malaria remains endemic 
in 104 countries, putting half of the world’s population (approximately 3.3 billion people) at risk 
of contracting the disease (World Health Organization, 2012). On-going malaria transmission still 
occurs in 99 of these territories, while five others are in the prevention of reintroduction phase. 
In 2010, there were more than 200 million episodes of malaria worldwide which resulted in 660 
000 deaths (World Health Organization, 2012). The vast majority of malaria cases and fatality 
concentrates in the sub-Saharan Africa (Figure 2.1), where pregnant women and children less 
than five years of age are the most severely affected. In addition to its intolerable health burden 
on human populations, malaria also greatly impedes the economic development of endemic 
regions. They often suffer from undeveloped markets as traders are reluctant to invest money in 
malaria-plagued regions. Tourism is also crippled with travelers avoiding malarious countries for 
fear of being infected. As a result, the endemic countries are constantly entrapped in the self-
perpetuating vicious cycle of disease and poverty. Given the magnitude and severity of the 
global malaria threat, the call for eliminating, and ultimately eradicating malaria has become a 
top priority on the international agenda (Alonso et al., 2011). 




Nearer to Singapore, the WHO South-East Asia region is the second largest malaria-hit 
territory after Africa with approximately 32 million cases and a death toll of 43 000 in 2010 
(Figure 2.1). Countries with a particularly high level of malaria transmission include Myanmar, 
India and Indonesia, from which foreign labor and domestic workers are extensively recruited 
into Singapore. Additionally, rising globalization and the ease of international travel have also 
increased movements into the country. Hence, despite being declared free of indigenous 
malaria by WHO in 1982, Singapore is constantly threatened by imported malaria given the huge 
influx of migrant labor, tourists and returning travelers from the surrounding malarious 
















WHO Region Estimated Number 
of Cases 
Estimated Number  
of Deaths 
Africa 174 million 596 000 
South-East Asia  32 million 43 000 
Eastern Mediterranean 10 million 15 300 
Western Pacific  2 million 4 000 
Americas  1 million 1 100 




Figure 2.1 The global malaria situation in 2010.  

































2.1.2  Etiology and pathogenesis of malaria 
Human malaria is routinely caused by four species of Plasmodium parasites namely P. 
falciparum, P. vivax, P. ovale and P. malariae (Greenwood et al., 2008). Of these species, P. 
falciparum is the most virulent and is accountable for the vast majority of malaria-related 
deaths. Intriguingly, a simian-specific parasite, P. knowlesi, was recently identified as the 
causative agent of numerous malaria cases among the human population (Collins, 2012). Hence, 
P. knowlesi is now recognized as the fifth human malaria parasite. While the five human 
Plasmodium species exhibit some differences in terms of geographic distribution and clinical 
features (Table 2.1), they share a complex life cycle that alternates between the human host and 
the Anopheles mosquito (Figure 2.2). Understanding the developmental transitions of these 
parasites is fundamental to comprehend the disease manifestation of malaria. 
The Plasmodium life cycle in the human host begins when a malaria-infected female 
Anopheles mosquito takes a blood meal (Figure 2.2, Greenwood et al., 2008). Parasites in the 
form of sporozoites are injected into the bloodstream of the victim, and migrate to the liver 
where they invade the hepatocytes. In the hepatocytes, the sporozoites undergo an extensive 
phase of asexual replication (exo-erythrocytic schizogony) which results in the generation of 
thousands of merozoites. The subsequent rupture of the infected hepatocytes releases the 
merozoites back into the circulatory system. Throughout the liver stage of infection, the human 
host remains asymptomatic. It is also worthy to point out that for P. vivax and P. ovale 
infections, some sporozoites may develop into a dormant stage known as the hypnozoites. The 
hypnozoites may persist in the liver cells for months or even years before resuming 
development to generate infective merozoites that lead to malaria relapses. 
 




The liberated merozoites then infect the erythrocytes where a second phase of asexual 
development (intra-erythrocytic schizogony) takes place. Within the erythrocytes, the 
merozoites first grow into the ring-stage parasites, which then further develop to form the 
trophozoites. After which, the trophozoites undergo asexual divisions to produce schizonts that 
possess multiple nuclei. This is soon followed by the segmentation of the schizonts, through 
which individual merozoites are generated within the host cells. Infected erythrocytes 
eventually rupture, discharging merozoites into the bloodstream where they invade new 
erythrocytes to initiate another round of schizogony. Each cycle of erythrocyte invasion, 
replication and egress typically lasts between 24-72 hours, depending on the Plasmodium 
species (Table 2.1). During this period, the parasite density (also known as parasitemia) 
increases substantially. In addition, it is also the phase where the clinical symptoms of malaria 
manifest. Particularly, the distinctive recurrent bouts of fever and chills exhibited by malaria 
patients are associated with the periodic release of merozoites from ruptured erythrocytes. In 
more severe infections, such as those caused by P. falciparum, life-threatening complications 
such as cerebral malaria, acute renal failure and anemia may develop (Trampuz et al., 2003). 
After several rounds of intra-erythrocytic schizogony, some merozoites may deviate 
from the asexual cycle and engage in the sexual development whereby male and female 
gametocytes are produced. While these gametocytes do not directly cause the clinical 
symptoms of malaria, they represent the only Plasmodium forms that possess the capacity to 
transmit malaria via the mosquito vector. The gametocytes are picked up by another feeding 
mosquito together with a blood meal and transform into gametes in response to environmental 
signals within the insect’s midgut (Kuehn and Pradel, 2010). Subsequent fusion of the male and 
female gametes leads to the formation of the zygote, which will further develop into the 
elongated ookinete and then the oocyst. Soon after, the oocyst undergoes multiple rounds of 




asexual replication, leading to the generation of thousands of sporozoites. Following the rupture 
of the mature oocyst, the sporozoites are released and migrate to the mosquito salivary glands 
where they are stored until being injected into the next human host to perpetuate the 
Plasmodium life cycle.    
  




Table 2.1 Selected features of the five human Plasmodium parasites.  

























Normal Enlarged Enlarged Normal Normal 
Parasite Density 
(Parasitemia) 
















Ability to Cause 
Relapse 
No Yes  Yes  No  No  











Abbreviation: ACT (Artemisinin-based Combination Therapy). Table is generated based on information 
obtained from Kantele and Jokiranta, 2011 and Lee et al., 2009. 
 
  






Figure 2.2 The life cycle of Plasmodium parasites. 
The life cycle of the parasites initiates with the injection of sporozoites into the human host. The 
sporozoites rapidly target the liver cells, where thousands of merozoites are produced through 
exo-erythrocytic schizogony. Upon the rupture of liver cells, the merozoites are released into 
the bloodstream and subsequently invade the erythrocytes. Intra-erythrocytic replication then 
begins whereby the parasites develop through the ring, trophozoite and schizont stages. 
Infected erythrocytes eventually rupture, releasing merozoites back into the bloodstream to 
invade new erythrocytes. After a few cycles of intra-erythrocytic schizogony, some merozoites 
may deviate from asexual propagation and engage in sexual development to produce male and 
female gametocytes. These gametocytes are picked up by a feeding mosquito, and transform 
into gametes within the mosquito midgut. Fusion of the male and female gametes results in the 
formation of the zygote, which will further develop through the ookinete and oocyst stages. 
Sporozoites generated are finally released from ruptured oocysts and migrate to the mosquito 
salivary gland where they are stored until being injected into the next human host.  
  




2.1.3 Strategies and challenges in malaria control 
Over the past decades, valiant global efforts were initiated with the aim of controlling 
(reduction of malaria incidence and deaths), eliminating (cessation of malaria transmission in a 
defined geographical region) and eradicating (permanent reduction of global malaria cases to 
zero) malaria. The Global Malaria Eradication Program (GMEP) was initiated by WHO in 1955 as 
the first international collaboration to combat malaria (Najera et al., 2011). It advocated mainly 
1) indoor residual insecticide spraying as a vector control to interrupt transmission of the 
Plasmodium parasites from mosquitoes to human, and 2) administration of the antimalarial 
drug, chloroquine, as a form of malaria chemotherapy and chemoprophylaxis. These 
intervention strategies were then assumed to be adequate for attaining worldwide malaria 
eradication. However, the rapid emergence of insecticide-resistant Anopheles mosquitoes as 
well as chloroquine-resistant Plasmodium parasites eventually led to the failure and 
abandonment of the program in 1969. Another setback of the campaign was that it did not 
include many parts of the African region, where malaria transmission was most intense. 
Nonetheless, although the ambitious goal of eradicating malaria was not accomplished, the 
GMEP did result in a significant reduction of the malaria burden in dozens of countries (Najera 
et al., 2011). 
Following the collapse of the GMEP, malaria became a much neglected disease owing to 
the limited control efforts and the decline in financial support (Sachs, 2002). Resurgence of 
malaria rapidly occurred in many parts of the world, leading to catastrophic epidemic outbreaks 
in several countries such as Sri Lanka and Madagascar (Roberts et al., 2000). In response to the 
call for a renewed antimalarial campaign at the international level, Roll Back Malaria (RBM) was 
initiated in 1998 by WHO, alongside with the World Bank, United Nations Development Program 
and United Nations Children’s Fund to control the dire situation (Roll Back Malaria, 2008). This 




partnership remains, till today, the main global coordinating body in the battle against malaria. 
In parallel with the concerted emphasis of RBM to shrink the global malaria burden, 
international funding for malaria control had also increased dramatically over the past few years 
with a peak sum of US$2 billion being raised in 2011 (World Health Organization, 2012). As a 
result, an unprecedented number of malaria initiatives were instigated to support malaria 
intervention as well as research and development programs (Table 2.2). 
Presently, a major focus of the malaria control efforts is to scale-up and sustain 
appropriate interventions in all endemic areas, including those in the African region (World 
Health Organization, 2012). Apart from the continued use of indoor residual spraying as was 
recommended during the GMEP regime, newly-developed insecticide-treated nets are also 
currently deployed to prevent malaria (World Health Organization, 2012). In addition, the 
artemisinin-based combination therapy (ACT) has been advocated by WHO as the first-line 
treatment for malaria (World Health Organization, 2012). With proper diagnosis and improved 
accessibility to the malaria control tools, the world witnessed a decline in malaria incidence and 
deaths by 17% and 26%, respectively, between the year 2000 and 2010 (World Health 
Organization, 2012). Notable progress was achieved in Morocco, Turkmenistan, the United Arab 
Emirates and Armenia, which led to the elimination of malaria from these countries (World 
Health Organization, 2012). However, amidst these accomplishments, the observed reduction in 
malaria morbidity and mortality still fall short of the RBM target of halving the global disease 
burden by 2010 (World Health Organization, 2011). The rapid emergence of antimalarial drug 








Table 2.2 Current major malaria intervention and research initiatives.  
Purpose Name of Initiative Specific Mission(s) 
Financing 
The Wellcome Trust 
(www.wellcome.ac.uk) 
Supports a broad spectrum of 
malaria research 
The Global Fund to Fight AIDS, 
Tuberculosis and Malaria 
(www.theglobalfund.org) 
Attracts, manages and disburses 
funding to combat AIDS, 
tuberculosis and malaria 
Bill and Melinda Gates 
Foundation 
(www.gatesfoundation.org) 
Promotes funding and effective 
policies for malaria research and 
control 




Roll Back Malaria 
(www.rbm.who.int) 
Central organization for providing 




Improves accessibility of preventive 
tools, diagnosis and effective 
treatment to populations at risk of 
malaria 
Affordable Medicines Facility 
(www.theglobalfund.org/en/amfm) 
Increases the provision of ACTs in 
malaria endemic areas 
Malaria No More 
(malarianomore.org) 
Ensures the tools required to 
prevent, diagnose and treat malaria 
are accessible in Africa 
Worldwide Antimalarial 
Resistance Network Malaria 
(www.wwarn.org) 
Provides a comprehensive platform 
to track the emergence and spread 





Malaria Research and Reference 
Reagent Resource 
(www.mr4.org) 
Provides a central source 
of malaria-related reagents and 
information to the research 
community 
Medicines for Malaria Venture 
(www.mmv.org) 
Discovers, develops and assists the 
delivery of novel, affordable and 
effective drugs against malaria 
PATH Malaria Vaccine Initiative 
(www.malariavaccine.org) 
Expedites malaria vaccine 
development; Advocates the 
availability and accessibility of 
vaccines in developing world 
 
 




Table 2.2 continued 
 Innovative Vector Control 
Consortium 
(www.ivcc.com) 
Accelerates the development and 
delivery of novel tools for vector 
control 
NIAID Malaria Research Program 
(www.niaid.nih.gov/topics/malaria) 
Supports basic, translational and 
clinical research in malaria 
 
2.1.4 Currently available antimalarial drugs 
The use of drugs for controlling malaria was first documented in the 17th century and 
remains, till today, the principal arsenal in preventing and treating the disease (Achan et al., 
2011). As experienced from past intervention efforts, the deployment of efficacious antimalarial 
compounds played a prominent role in reducing malaria-related morbidity and mortality in 
endemic areas. Therefore, in the context of progressing towards worldwide malaria eradication, 
the long-term availability of potent antimalarial drugs represents a fundamental requirement.  
The currently available antimalarial drugs exert their effects on various stages of the 
Plasmodium life cycle, albeit the majority of them act on the symptomatic asexual intra-
erythrocytic phase (Table 2.3). Compounds that target the liver-stage parasites are beneficial for 
causal malaria prophylaxis. On the other hand, those that interfere with the intra-erythrocytic 
stage elicit a curative effect (asexual-stage inhibition) and/or limit the transmissibility of malaria 
infections (gametocyte inhibition). The major antimalarials may be broadly classified into 3 
groups: the quinoline-containing compounds, the antifolates and the artemisinins.        
The quinoline-containing compounds have been the most widely used drugs in the 
battle against malaria. This group consists of several well-known antimalarial drugs such as 
quinine, chloroquine, and primaquine. Quinine, which occurs naturally in the bark of Cinchona 
tree, is the first pharmaceutical exploited for the routine treatment of malaria (Foley and Tilley, 
1998). Despite being the oldest form of antimalarial, it remains presently in use as the 




recommended treatment for severe malaria in the African region (World Health Organization, 
2012). Chloroquine had been the pillar of malaria eradication efforts for much of the 20th 
century. The success of this drug was attributed to its limited host toxicity, good clinical efficacy, 
ease of administration as well as cost-effective synthesis (Foley and Tilley, 1998). However, the 
potency of chloroquine began to be severely compromised in the 1960s as a result of the 
emergence and spread of drug-resistant P. falciparum parasites. This led to the subsequent 
withdrawal of chloroquine as the first-line treatment against P. falciparum malaria in the 1990s. 
Nevertheless, chloroquine continues to be effective today for treating malaria caused by P. 
ovale, P. malariae, P. knowlesi and some strains of P. vivax (Kantele and Jokiranta, 2011). 
Primaquine distinguishes itself from other antimalarials due to its ability to eliminate the 
dormant hypnozoites of P. ovale and P. vivax (Schlitzer, 2008). It currently represents the sole 
agent approved for preventing the relapse of malaria due to these parasites, and is usually 
prescribed in combination with chloroquine (World Health Organization, 2012). In addition, 
primaquine also targets the gametocyte-stage parasites, thereby limiting the transmission 
potential of the malaria infections. Apart from the aforementioned drugs, other quinoline-
related antimalarials include mefloquine, lumefantrine and amodiaquine (Table 2.3).  Among the 
entire panel of quinoline-related compounds, the inhibitory basis of chloroquine on the 
erythrocytic-stage parasites has been the best studied (Foley and Tilley, 1998). The drug 
accumulates primarily in the parasitic food vacuoles where digestion of the host cell hemoglobin 
occurs. During hemoglobin degradation, the cytotoxic heme is generated as a by-product. To 
circumvent this harmful effect, the Plasmodium parasite converts the heme moieties into the 
non-toxic hemozoin through a polymerization process. Chloroquine reportedly acts by forming a 
complex with heme, thus preventing its polymerization into hemozoin (Foley and Tilley, 1998). 
Consequently, the buildup of the toxic heme inflicts a lethal effect on the parasites. 




The antifolates consist of a group of antimalarial compounds that interfere with the 
production of tetrahydrofolate, an important precursor of thymidine which is required for the 
synthesis of parasite DNA (Schlitzer, 2008). These antimalarials may further be differentiated 
based on the specific enzymes which they act on: both sulphadoxine and dapsone target 
dihydropteroate synthase, while pyrimethamine, proguanil and chlorproguanil inhibit 
dihydrofolate reductase instead (Nzila, 2006). A combination of inhibitors from both groups is 
usually deployed in the context of malaria intervention. For instance, sulphadoxine-
pyrimethamine was once prevalently adopted as the front-line therapy in countries where 
chloroquine resistance had occurred. However, its efficacy lifespan was limited owing to the 
rapid emergence of drug-resistant parasites, and is now mainly used for intermittent preventive 
treatment in pregnant women (Schlitzer, 2008; World Health Organization, 2012). Over the last 
decade, proguanil has also been prescribed in combination with atovaquone, a non-antifolate 
which targets the mitochondrial electron transport chain. This therapy remains currently in use 
for both the treatment and prevention of malaria (World Health Organization, 2012).  
Artemisinin is a potent antimalarial compound which originated from the Chinese sweet 
wormwood, Artemisia annua (Dondorp et al., 2010). With the identification of its chemical 
structure in the 1970s, several artemisinin derivatives exhibiting a higher efficacy were 
subsequently synthesized (Dondorp et al., 2010). These include artesunate, artemether, 
dihydroartemisinin and arteether. At the present moment, the exact inhibitory mechanism of 
the artemisinins remains debatable (Schlitzer, 2008). Nonetheless, it has been recognized that 
the endoperoxide bridge present in all artemisinins is responsible for eliciting the antimalarial 
activity (Schlitzer, 2008). As highlighted earlier in Section 2.1.3, WHO currently advocates the 
use of artemisinins in combination with a partner drug (i.e. the ACTs) as the front-line malaria 
therapy in most endemic areas (World Health Organization, 2012). The artemisinins are highly 




potent and fast-acting, thus allowing a rapid clearance of the parasite load. On the other hand, 
the partner drug typically has a longer half-life which enables the killing of the parasites that 
may have escaped the artemisinin inhibition. Consequently, this combined treatment not only 
maximizes therapeutic benefit, but also seeks to delay the onset of resistance to both 
constituents of the ACTs (Dondorp et al., 2010). Furthermore, the deployment of ACTs also 
limits the transmission potential of malaria due to the anti-gametocyte property of the 
artemisinins. Among the five ACTs approved so far, artemether/lumefantrine and 
artesunate/amodiaquine are the more prevalently prescribed combinations (World Health 
Organization, 2012).   
Other than these three major classes of antimalarial compounds, the antibiotics 
clindamycin and doxycycline are also part of the ammunition against malaria. They exert their 
antimalarial effects by interfering with protein synthesis in the parasites (Schlitzer, 2008). In 
some cases, doxycycline may be administered in combination with quinine for the treatment of 
severe malaria (Kantele and Jokiranta, 2011). It has also been widely deployed as a form of 
malaria chemoprophylaxis.  
  




Table 2.3 Major antimalarial drugs currently in use and the Plasmodium life cycle phase(s) 




Phase(s) Targeted by the Drug  
Current Application Liver Asexual-
erythrocytic 
Gametocyte  
Quinine    
Mainly used for treatment of 
severe malaria (May be 
combined with doxycycline 
in areas where decreased 
susceptibility to quinine occurs) 
Chloroquine    
Effective treatment against P. 
ovale, P. malariae, P. knowlesi 
and non-resistant P. vivax  
Primaquine    
The only compound approved 
to prevent relapse of P. ovale 
and P. vivax infections. Typically 
prescribed in combination with 
chloroquine 
Amodiaquine    
Combined with artesunate as a 
form of ACT 
Lumefantrine    
Combined with artemether as a 
form of ACT 
Mefloquine    
Combined with artesunate as a 




   
Widely used as intermittent 
preventive treatment for 
pregnant women. May also be 
combined with artesunate as a 
form of ACT 
Proguanil    
Commonly combined with 
atovaquone for both treatment 
and prevention of malaria 
Artemisinins    
Combine with specific drugs in 
ACTs as the front-line therapy 
against P. falciparum 
Doxycycline    
Useful for treating severe 
malaria in combination with 
quinine.  Also commonly 
deployed for chemoprophylaxis 
 
 




Table 2.4 Emergence of resistance to antimalarial drugs. Over the past 50 years, the extensive 
use of antimalarial drugs has led to the rapid emergence of drug-resistant Plasmodium 
parasites. While resistance to many commonly-used drugs emerged within five years after their 
introduction, resistance to artemisinins was reported 37 years following their deployment as 








Basis of Drug Resistance 
Quinine 1632 1910  Amplification and mutation (e.g. S1034C, 
N1042D, D1246Y) of Pfmdr1 have been 
associated with the resistance to these 
drugs (Muller and Hyde, 2010; Sidhu et al., 
2005) 




(Basco et al., 1991; 
Brasseur et al., 1993)  
Chloroquine 1945 1957  Point mutations in the PfCRT gene (e.g. 
K76T) were shown to be the hallmark of 
chloroquine resistance (Lakshmanan et al., 
2005). Polymorphisms in PfMDR1 have also 
been associated to modulate the degree of 
chloroquine resistance in parasites (Muller 
and Hyde, 2010) 
Amodiaquine 1955 1975 Cross resistance between amodiaquine and 
chloroquine has been reported and 
associated with mutations in Pfmdr1 and 
PfCRT. However, the exact mechanism of 
resistance remains poorly understood 
Primaquine 1952 1973  
 
Mechanism remains poorly understood 
Sulphadoxine  1964 1967  
(Bjorkman and Phillips-
Howard, 1990) 
Resistance has been linked to the mutations 
in dihydropteroate synthase (e.g. S436A, 
A437G) (Nzila, 2006) 
Pyrimethamine    1950 1953  
(Bjorkman and Phillips-
Howard, 1990) 
Resistance has been linked to the mutations 
in dihydrofolate reductase (e.g. S108N, 
A16V)  (Nzila, 2006) 
Proguanil  1948 1949 
Atovaquone 1996 1996 Polymorphisms in cytochrome 
b gene has been associated with atovaquone 
resistance (Muller and Hyde, 2010)  
Artemisinins 1971 2008 
(Noedl et al., 2008) 
Although the exact mode of resistance 
remains unclear, point mutations in PfATP6 
has been linked to decreased drug 
responsiveness in vitro (Muller and Hyde, 
2010) 
* Information is obtained from http://www.wwarn.org/resistance/malaria/history, unless stated otherwise.  
  




2.1.5 The urgent need for new antimalarial drugs 
 Thus far, malaria prevention and treatment have relied heavily on the limited classes of 
antimalarial compounds as described in the previous section. The effectiveness of these drugs is 
often short-lived due to the rapid emergence of drug-resistant Plasmodium parasites (Table 2.4). 
In particular, the most virulent P. falciparum has developed resistance to almost all of the 
existing drugs, with the exception of the artemisinins (Wongsrichanalai et al., 2002). While the 
latter remains potent against P. falciparum in most endemic countries, recent reports have 
cautioned that resistance to these last-line of antimalarials is emerging along the Thai-Cambodia 
region (Dondorp et al., 2009; Noedl et al., 2008). As there is a lack of immediate alternatives to 
substitute the artemisinins at the present moment, the spread of their resistance would impose 
a devastating setback in the efforts to eliminate the deadly disease.  
At the same time, no vaccine has yet been approved for human use against malaria 
despite decades of research. Nonetheless, the current most promising malaria vaccine 
candidate, RTS,S/AS01 has made a significant breakthrough following its recent advancement 
into the final phase of the clinical trial (Agnandji et al., 2011). This pre-erythrocytic vaccine is 
designed to prevent P. falciparum infection among infants and young children by targeting the 
major surface component (i.e. circumsporozoite protein) of the sporozoites (Cohen et al., 2010). 
According to the interim reports of the on-going phase III trials, the RTS,S/AS01 vaccine was 
found to reduce the risk of malaria in young children and infants by approximately 50% and 
30%, respectively (Agnandji et al., 2011; The RTS,S Clinical Trials Partnership, 2012). While these 
developments mark an important achievement in the quest to develop a malaria vaccine, it 
remains disheartening that RTS,S/AS01 lacks the efficacy to provide complete protection against 
malaria. Hence, until a highly efficacious vaccine is generated, malaria eradication efforts would 
have to continually rely on potent antimalarial drugs for combating the disease. Developing new 




antimalarial drugs is therefore of utmost urgency to circumvent the issue of drug resistance, 
especially in the case for P. falciparum. 
 
2.1.6 Potential Plasmodium falciparum drug targets 
Several approaches to novel antimalarial drug development are being pursued at the 
present moment. These include 1) optimizing current antimalarial therapy with existing agents, 
2) developing analogs of existing antimalarials, 3) exploring novel entities from natural sources, 
4) adopting drugs against other human diseases as antimalarials, 5) whole-cell screening and, 6) 
molecular target-based approach (Figure 2.3). Among these strategies, the molecular target-
based drug discovery has received much attention following the advent of the P. falciparum 
genome data. The 23-megabase, adenine-thymine rich parasite genome consists of 14 
chromosomes encoding for approximately 5300 genes (Gardner et al., 2002). Elucidating the 
cellular functions of these gene products thus forms the basis to gain insights into the complex 
biology of P. falciparum. More importantly, this endeavor is anticipated to hasten the pace of 
identifying molecular targets that are most amenable to rational drug development. So far, 
numerous P. falciparum proteins involved in various cellular processes have been proposed as 
potential antimalarial drug targets (Table 2.5). Of great interest are the protein kinases of the 
parasite since an increasing number of these enzymes have been demonstrated to be 










Figure 2.3 Approaches to antimalarial drug discovery and development.                      
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Rationale for Inhibition Examples of Proposed 
Drug Targets 
References  
Food vacuole Hemoglobin 
degradation 
Hydrolysis of hemoglobin by 
Plasmodium proteases 
provides the essential source 
of amino acids for parasite 
protein synthesis. 
 Falcipain 3 










Digestion of hemoglobin 
produces toxic heme as a by-
product. Detoxification of 
heme via hemozoin 
formation is necessary for the 
survival of parasites.  






Fatty acid synthesis Fatty acid is essential for the 
generation of cell and 
organelle membranes. It also 
serves as an important 






 β-ketoacyl-ACP synthase 
III 




Isoprenoids form prosthetic 
groups on a range of enzymes 
and are fundamental 
precursors to ubiquinones 
and dolichols (involved in 
electron transport and 
formation of glycoproteins, 
respectively).  
Proceeds via a mevalonate 
independent pathway, which 
is distinct from the human 
host. 




(Occurs partly in 
the mitochondrion) 
Heme is an important 
prosthetic group in enzymes 
such as cytochromes. De 
novo synthesis is required as 
the parasites are not 
accessible to the heme that is 
freed from hemoglobin 
degradation in the food 
vacuole.  
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Phosphatidylcholine is the 






















is dependent on transporters 
for nutrient/precursor 
uptake, expulsion of 
metabolic wastes and 
maintenance of ion 
homeostasis.  
 Hexose transporter 
 Purine transporter 
 
(El Bissati et 
al., 2006; 
Joet et al., 
2003)  
Mitochondrion Electron transport 
chain 
Regenerates the electron 
acceptor (ubiquinone) for 
dihydroorotate 
dehydrogenase, an essential 
enzyme in pyrimidine 
synthesis. 






De novo synthesis of 












Lacking the enzymes 
necessary for purine 
generation, parasites are 
reliant on salvaging the host 












Glycolysis  Parasite depends mainly on 
glycolysis for energy 
production. 





Shikimate pathway Responsible for producing 
essential aromatic 
compounds (e.g. aromatic 
amino acids) required for 
parasite growth. 
 5-enopyruvyl shikimate- 
3-phosphate synthase 
 Chorismate synthase 
(Roberts et 
al., 1998; 
Tapas et al., 
2011) 
Antioxidant defense Neutralizing reactive 
oxidative species is a crucial 
mechanism to prevent 
cellular damage. 
 
 Superoxide dismutase 1 





Protein folding Cellular proteins require 
chaperones for folding to 
their biologically active state. 
 Heat shock protein 90 (Banumathy 
et al., 2003) 
Protein kinase 
signaling 
Essential mechanism for 
regulating cell proliferation 
and growth. 
 Cyclin-dependent protein 
kinases 5,6 
 Mitogen-activated 




Jirage et al., 
2010) 
Abbreviations: ACP (Acyl Carrier Protein); DOXP (1-Deoxy-d-Xylulose-5-Phosphate) 




2.2 Eukaryotic protein kinases and the MAPK signaling pathways 
 
2.2.1 Eukaryotic protein kinases: The key mediators of phosphorylation 
 
Protein phosphorylation is one of the most ubiquitous post-translational modifications 
among eukaryotes. It acts as a crucial molecular switch that mediates a myriad of cellular 
processes such as signal transduction, metabolism, cell cycle progression and gene transcription 
(Dissmeyer and Schnittger, 2011). Previously, it was estimated that up to 30% of the total 
cellular proteins may be phosphorylated at any given time, either at one or multiple target sites 
(Cohen, 2000). However, with the advent of more sensitive tools to isolate and detect 
phosphoproteins, it is now estimated that phosphorylation affects as much as 50% or more of 
the eukaryotic proteome (Olsen et al., 2010; Yachie et al., 2011). Since protein phosphorylation 
plays a central role in regulating cellular processes, it is unsurprising that aberrant 
phosphorylation has been implicated in the pathogenesis of major human disorders such as 
cancer, neurodegeneration, rheumatoid arthritis and diabetes (Bamborough, 2012; Eglen and 
Reisine, 2009). 
In eukaryotes, phosphorylation of proteins occurs mostly on the hydroxyl side chain of 
serine, threonine and/or tyrosine residues. The process is catalyzed by a group of enzymes 
known as the protein kinases, which transfer the -phosphate from adenosine-5’-triphosphate 
(ATP) to the recipient amino acid residues (Adams, 2001). Comprehensive analyses of numerous 
eukaryotic genomes have revealed that the complete repertoire of protein kinases (known as 
the kinome) typically constitute 2-3% of all genes present (Table 2.6). The vast majority of these 
kinases phosphorylate the aliphatic hydroxyl groups of serine/threonine residues (i.e. 
serine/threonine kinases), while a smaller group phosphorylates the aromatic hydroxyl group on 
tyrosine residues (i.e. tyrosine kinases) (Hanks et al., 1988). Interestingly, a handful of protein 




kinases were subsequently uncovered which exhibit specificity for both the serine/threonine 
and the tyrosine residues (i.e. dual-specificity kinases) (Lindberg et al., 1992). Despite displaying 
differences with regards to their substrate specificities, all eukaryotic protein kinases are related 
by virtue of their highly-conserved kinase domains and the mechanism by which they catalyze 
the phosphoryl-transfer reaction (Adams, 2001; Hanks et al., 1988). 
  




Table 2.6 Kinome sizes of different eukaryotic organisms.  






Fungi    
Aspergillus nidulans 134 1.4 (Galagan et al., 2005; Kosti et 
al., 2010) 
Saccharomyces cerevisiae 113 1.9 (Goffeau et al., 1996; Hunter 
and Plowman, 1997) 
Plants    
Arabidopsis thaliana 836 3.2 (Krupa et al., 2006) 
Oryza sativa 1386 3.7 (International-Rice-Genome-
Sequencing-Project, 2005; 
Krupa et al., 2006) 
Parasitic protozoa    
Plasmodium falciparum 99/86 1.8 (Anamika et al., 2005; Ward et 
al., 2004) 
Toxoplasma gondii 159 1.9 (Gajria et al., 2008; Peixoto et 
al., 2010) 
Leishmania major 179 2.2 (Ivens et al., 2005; Naula et al., 
2005) 
Trypanosoma brucei 156 1.7 (Berriman et al., 2005; Naula 
et al., 2005) 
Metazoans    
Caenorhabditis elegans 411 2.1 (Plowman et al., 1999) 
Drosophila melanogaster 239 1.75 (Adams et al., 2000; Manning 
et al., 2002a) 
Mus musculus 540 1.8 (Manning et al., 2002a) 
Homo sapiens 518 1.7 (Manning et al., 2002b) 
Note: For P. falciparum, the variation in the number of protein kinases identified was due to the different 
stringency criteria applied during the procurement of protein-kinase encoding sequences by Anamika et al 










2.2.1.1 The conserved protein kinase domain  
 Eukaryotic protein kinases are clustered into the same family as they share substantial 
amino acid sequence similarities within their kinase domains (Hanks et al., 1988). The kinase 
domains, also commonly referred to as catalytic domains, are responsible for imparting the 
phosphoryl-transfer activities of protein kinases. Each domain is typically made up of 
approximately 250-300 amino acid residues, and may further be divided into 12 subdomains (I-
XI) based on the presence of consensus amino acid residues or motifs as revealed via sequence 
alignment analyses (Figure 2.4) (Hanks and Hunter, 1995). Examination of the tertiary structures 
of numerous protein kinases has revealed that the kinase domains fold into a characteristic bi-
lobed architecture, with the catalytic site situated in a deep cleft between the lobes (Figure 2.4). 
The smaller amino-terminal lobe (N-terminal lobe, subdomains I-IV), which is generally made up 
of a 5-stranded β sheet and a single helix, is mainly involved in anchoring and orientating the 
ATP nucleotide (Hanks and Hunter, 1995). On the other hand, the larger carboxyl-terminal lobe 
(C-terminal lobe, subdomains VIa-XI) is dominated by α-helices, and is primarily implicated in 
substrate binding as well as initiating the phosphoryl-transfer process. A noteworthy feature of 
the kinase domain lies in its activation loop, which is defined by the region that spans the DFG 
and APE motifs in subdomains VII and VIII, respectively (Figure 2.4). For many kinases, 
phosphorylation of specific amino acid residues within this segment represents the key 
mechanism involved in regulating their catalytic activities (Adams, 2003). Through analyzing the 
tertiary structures of protein kinases, the precise roles of the conserved amino acid 
residues/motifs in the catalytic function of protein kinases have also been assigned (summarized 
in Table 2.7). 
Based on the amino acid sequence similarities within their kinase domains, Hanks and 
co-workers further categorized eukaryotic protein kinases into eight different groups: AGC, 




CaMK, CMGC, CK1, RGC, STE, TK and TLK (Table 2.8, Hanks, 2003; Hanks et al., 1988). Kinases 
that clustered within the same group typically share more than 35% amino acid sequence 
identities, whereas those that did not map within the same cluster have identities in the range 
of 20-25% (Hanks et al., 1988). Expectedly, such grouping methodology also resulted in 
clustering of protein kinases which possess analogous characteristics such as substrate 
preferences, activation modes and/or cellular functions (Table 2.8). While most of these kinase 
groups are well-represented in all branches of life, kinases from the RGC and TK groups appear 
to be almost exclusive to the metazoans where they are associated with higher level 
multicellularity functions (Martin et al., 2009). In addition, there are some kinases that show no 
obvious similarity to any of the eight kinase groups. Hence, they are collectively clustered into 
the ninth group called the “orphan kinases”. 
  





Figure 2.4 The conserved protein kinase domain. 
(a) A schematic illustration of the 12 subdomains within the kinase catalytic domain. Consensus 
amino acid residues or motifs present in the respective subdomains are depicted. The HRDLKxxN 
motif in subdomain VIb is a consensus signature of serine/threonine kinases. In the case for 
tyrosine kinases, the HRDLAARN or HRDLRAAN motif is more commonly observed.  (b) The 
canonical bi-lobed architecture of a protein kinase domain. Depicted here is the ribbon 
representation of cAMP-dependent protein kinase, the prototype of the protein kinase family 
(PDB identifier: 1ATP). The N- and C-terminal lobes are highlighted in blue and orange 
respectively, while the hinge region is colored in white. The region depicted in magenta 
represents the activation loop of the kinase. The ATP moiety (red) binds in a cleft between the 







VIa VIb VII VIII IX X XI 
N-terminal lobe C -terminal lobe 
(a) 
GxGxxG K E 
Hinge                                                  
region R D APE DFG HRDLKxxN 
(b) 
Activation loop spanning                                          
the DFG and APE motifs 
 




Table 2.7 The invariant amino acid residue or motif present in the various protein kinase 
subdomains and their roles in supporting the function of protein kinases. Tabulated 














I GxGxxG glycine triad For anchoring the α- and β- phosphates and 





An invariant lysine 
residue 
Crucial for orientating the ATP moiety. 
A lysine→ methionine mutation is often 
adopted to generate a kinase-dead mutant 
III An invariant glutamate 
residue 
Forms a salt bridge with the invariant lysine 
in subdomain II to stabilize the latter’s 
interaction with ATP 
IV No conserved residue 
present 
Does not appear to be directly involved in 
catalysis or substrate recognition 
Linker region 
V A hinge region Connects the small lobe and large lobe of 
the kinase domain 
C -terminal 
lobe 
VIa No conserved residue 
present 














Corresponds to the kinase catalytic loop, 
which is distinct between serine/threonine 
and tyrosine kinases 
  
The aspartate residue acts as the catalytic 
residue to accept the proton from the 
attacking substrate hydroxyl group, while 
the asparagine residue is crucial for 
chelating the metal cofactor 
VII A DFG triplet The aspartate residue is essential for 
chelating the metal cofactor 
VIII An APE triplet The glutamate residue forms an ion bridge 
with an invariant arginine in subdomain XI, 
thereby stabilizing the carboxyl-terminal 
lobe 
 
An activation loop is commonly located 
between the DFG and APE motifs where 
phosphorylation sites crucial for regulating 
the kinase activity can be found 
IX An invariant aspartate 
residue 
Contributes to the stability of the catalytic 
loop by forming hydrogen bonds with 
backbone amides within subdomain VI  
X No conserved residue 
present 
The most poorly conserved subdomain 
typically containing insertions of varying 
lengths and its function is therefore obscure 
XI An  invariant arginine Promotes structural stability of the 
carboxyl-terminal lobe by forming a salt 
bridge with a glutamate in subdomain VIII  
 




Table 2.8 The major eukaryotic protein kinase groups and the characteristic properties shared 
by members within each group. Source: Aparicio and Applebury, 1996; Deshmukh et al., 2010; 






Examples of Kinase Member/ 
Functional Roles 
AGC  Group name is derived from the members 
Protein Kinases A, G and C 
 Members are typically activated in response to 
secondary messengers such cAMP, cGMP and 
PtdIns(3,4,5)P3 
 Phosphorylate serine/threonine residues that are 
in close proximity to the basic residues lysine and 
arginine 
 PKA: Mediates glycogen, 
sugar, and lipid metabolism  
 PKG: Regulates smooth 
muscle relaxation, platelet 
formation and cell division 
 PKC: Modulates gene 
transcription and immune 
responses 
CaMK  Group name is derived from the members 
Ca2+/calmodulin (CaM)–activated kinases 
 Activity is triggered in response to elevated 
intracellular Ca2+/calmodulin levels 
 Phosphorylate serine/threonine residues that are 
in close proximity to basic residues 
 CaMK: Regulates gene 
expression, cytoskeletal 
organization and axonal 
growth cone motility 
 MLCK: Important mediator of 
actin–myosin contraction 
CMGC  Group name is derived from the members cyclin-
dependent kinases (CDKs), mitogen-activated 
protein kinases (MAPKs), glycogen synthase 
kinases (GSK) and CDK-like kinases 
 Members possess a conserved arginine residue 
(termed the CMGC-arginine) near the substrate 
binding site 
 Comprises mostly serine/threonine kinases which 
are activated by phosphorylation within the 
kinase activation loop 
 CDK: Regulates DNA 
replication and cell division 
 MAPK: Modulates cell 
proliferation, differentiation 
and migration 
 GSK: Key regulator of 
glycogen metabolism 
 
CK1  The casein kinase 1 group 
 Members phosphorylate serine/threonine 
residues that lie downstream of acidic amino acid 
residues 
 CK1: Regulates cell cycle 
progression and RNA 
metabolism 
RGC  The receptor guanylate cyclases, found mostly in 
metazoans 
 Apart from harboring an intracellular 
serine/threonine protein kinase domain, 
members of the RGC group also possess an 
extracellular ligand binding domain, a 
transmembrane region, and a carboxyl-terminal 
guanylate cyclase catalytic domain 










Table 2.8 continued  
Kinase 
Group 
Characteristic Properties  Examples of Kinase Member 
/Functional Roles 
STE  Include homologues of the yeast Sterile 7, Sterile 
11, and Sterile 20 kinases 
 Most kinases are regulators of the MAPK 
pathways 
 MAPKK: Cellular activator of 
MAPK 
 MAPKKK: Cellular activator of 
MAPKK 
TK  Tyrosine kinase  group, present mostly in 
metazoans 
 Includes kinases that specifically phosphorylate 
substrates on tyrosine residues 
 EGFR: When activated upon 
binding of growth factor, the 
receptor initiates several 
signal transduction cascades 
(e.g. MAPK pathway) leading 
to DNA synthesis and cell 
proliferation 
 Src Kinase: Involved in focal 
adhesion 
formation/disassembly, cell 
cycle progression and cell 
migration 
TKL  Tyrosine kinase-like group, present mostly in 
plants and metazoans 
 Closely related to the TKs, but are in fact 
serine/threonine kinases 
 The most diverse kinase group 
 
 LRR kinase: Regulation of 
cellular cytoskeleton 
architecture  
 IL1 Receptor Associated 
Kinase: Plays critical role in 
controlling immune 
responses 
Abbreviation: cAMP (Cyclic adenosine monophosphate), cGMP (Cyclic guanosine monophosphate), 
PtdIns(3,4,5)P3 (Phosphatidylinositol-3,4,5-trisphosphate), MLCK (Myosin light-chain kinase), EGFR 
(Epidermal growth factor receptor), SRC (Sarcoma), LRR (Leucine-rich repeat), IL1 (Interleukin 1).      
 
  




2.2.1.2 The catalytic mechanism and effects of protein phosphorylation 
Protein kinases are known to catalyze the phosphoryl-transfer process via a sequential 
mechanism, whereby a ternary complex comprising of the enzyme, substrate and ATP must first 
be formed prior to catalysis (Figure 2.5) (Schwartz and Murray, 2011). In addition, divalent 
cations such as magnesium and manganese are required as cofactors to stimulate the enzymatic 
activity of the kinases. Following the formation of the ternary complex, the -phosphate from 
ATP is delivered directly to the substrate via an associative or a dissociative transition pathway, 
without the generation of any phospho-kinase intermediate (Figure 2.6) (Matte et al., 1998). In 
the associative transition pathway, bond formation between the oxygen atom of the hydroxyl 
group (representing the attacking nucleophile) and the phosphorous center precedes bond 
breaking of the departing adenosine diphosphate (ADP). This is in contrast with the dissociative 
transition pathway whereby bond breaking between the phosphorus center and the leaving ADP 
group precedes the attack by the incoming nucleophile. While both transition pathways have 
been reported, the dissociative pathway represents the more prevalent mechanism as 
demonstrated by a combination of X-ray crystallographic, nuclear magnetic resonance and 
kinetic studies (Adams, 2001; Lassila et al., 2011). 
Through phosphorylation, protein kinases can alter virtually any property of their target 
proteins such as activity, specificity, stability, subcellular localization and interaction with other 
proteins (Dissmeyer and Schnittger, 2011). The basis for these phosphorylation-mediated 
modifications lies largely in the conformational changes of the substrates upon attachment of 
the phosphate group(s). At physiological pH, the phosphate groups (pKa= ∼6.7) are 
deprotonated and exist predominantly in the dianionic forms (Dissmeyer and Schnittger, 2011). 
The presence of negative charges enables the phosphate groups to form hydrogen bonds with 
their neighboring amino acid residues. Structural examination of phosphorylated proteins 




revealed that phosphate groups commonly form hydrogen bonds with the positively-charged 
guanidinium side chain of arginine residues (Johnson and Lewis, 2001). The guanidinium side 
chains are well-suited for hydrogen bond formation with the phosphate groups due to their 
planar structures and their propensities to generate multiple hydrogen bondings. Apart from the 
arginine side chains, phosphate groups have also been observed to form hydrogen bonds with 
the main-chain nitrogens at the beginning of -helices. The hydrogen bondings induced by 
phosphorylation consequently alter the conformations of the target proteins, thereby 
modulating their functional properties. In this manner, phosphorylation by protein kinases 
serves as a crucial switch for regulating a diverse array of biological processes such as signal 
transduction, cell proliferation, gene expression, metabolism, motility, membrane transport, 











Figure 2.5 The general catalytic cycle of substrate phosphorylation by a protein kinase.  
Protein kinases phosphorylate substrates via a sequential mechanism. Starting from top left, a 
protein kinase first binds to the ATP nucleotide. This is subsequently followed by binding of the 
protein substrate. After the ternary complex consisting of the kinase, ATP and substrate is 
formed, the -phosphate (represented by red circle) is then transferred to a serine, threonine or 
tyrosine residue of the substrate protein. The cycle ends with the release of the substrate and 
the ADP leaving group. (Note: The order of substrate and ATP binding may vary for different 
kinases.)  





Figure 2.6 The associative and dissociative phosphoryl-transfer transition pathways. 
In the associative pathway, significant bond formation between the phosphorous center and the 
incoming nucleophile (i.e. the substrate, represented by ROH) takes place before the bond with 
the leaving ADP group is completely broken. On the contrary, bond breaking between the 
phosphorus center and the leaving ADP group precedes the attack by the incoming nucleophile 
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2.2.2  The evolutionarily conserved MAPK signaling pathways 
Eukaryotic cells are constantly exposed to varying external conditions. Their abilities to 
sense and respond to environmental changes enable them to rapidly adapt to their extracellular 
milieu. Communication with the external environment relies extensively on signal transduction 
pathways, where protein kinases function as key elements in translating extracellular signals 
into the appropriate cellular responses through phosphorylation cascades (Schenk and Snaar-
Jagalska, 1999). Given the multitude of environmental variations (e.g. temperatures, pHs, 
cytokines, hormones, nutrients) that eukaryotic cells need to react to, it is unsurprising that a 
wide variety of signaling pathways have been discovered (Schenk and Snaar-Jagalska, 1999). 
Among these, the MAPK signaling pathways have been well-conserved throughout eukaryotic 
evolution and are implicated in modulating a diverse array of cellular processes in response to 
changes in the external environment (Pearson et al., 2001). 
Eukaryotic organisms typically possess multiple MAPK pathways, each of which is 
preferentially stimulated by distinct sets of extracellular signals (Table 2.9). In S. cerevisiae, five 
MAPK pathways involved in mating, filamentation, osmoregulation, cell wall remodeling and 
sporulation have been identified (Table 2.9). On the other hand, four mammalian MAPK 
pathways have been elucidated so far: the extracellular signal-regulated kinases 1 and 2 
(ERK1/2), p38, c-Jun amino-terminal kinase (JNK) and ERK5 pathways (Table 2.9). With multiple 
MAPK pathways co-existing within eukaryotic cells, the functioning of each pathway has to be 
tightly regulated to ensure the specificity and fidelity of signal transmission. This is commonly 
achieved through mechanisms such as docking interactions between members of a particular 
MAPK cascade as well as assembly of the signaling components through scaffolding proteins 
(Zhang and Dong, 2007).  




A characteristic feature of the MAPK signaling pathways lies in the presence of a conserved 
three-tiered kinase cascade which consists of a MAPK kinase kinase (MAPKKK), a MAPK kinase 
(MAPKK) and a MAPK (Pearson et al., 2001) (Figure 2.7). Transmission of extracellular signals 
through these kinase cascades usually initiates with the activation of MAPKKKs in response to 
their triggering stimuli. Once activated, MAPKKKs are capable of phosphorylating and activating 
the downstream MAPKKs. Activated MAPKKs in turn phosphorylate the terminal MAPKs, 
thereby stimulating their catalytic activities (Figure 2.7). The MAPKs may then remain in the 
cytoplasm where they phosphorylate their cytoplasmic targets (e.g. cytoskeletal proteins, 
regulatory kinases and phopholipases), or alternatively translocate into the nucleus to 
phosphorylate a variety of transcription factors (Cargnello and Roux, 2011). By regulating the 
functions of a wide array of cellular substrates through phosphorylation, MAPKs consequently 
play a central role in mediating the responses of MAPK pathways. In the context of this project, 
subsequent reviews in this unit will focus on the discovery of MAPKs (Section 2.2.3), the 
activation of MAPKs by the upstream MAPKKs (Section 2.2.4) and the regulation of cellular 
responses through MAPK substrates (Section 2.2.5). In addition, the chemotherapeutic benefits 
of inhibiting MAPK pathways will also be highlighted (Section 2.2.6).    




Table 2.9 The yeast and mammalian MAPK signaling pathways.  
Organism MAPK 
Pathway 






 Mating pheromones          
(a or  factors)  
 
Induces mating by: 
 Triggering polarized 
cell growth towards a 
mating partner 
 Promoting cell cycle 
arrest 
 Increasing expression 
of proteins required for 
cell adhesion, cell 











which is characterized by:  
 Cell elongation 
 Increased cell-cell 
adherence 
 Unipolar cell 
proliferation 
 Substratum invasion 




 Hypertonic stress  Increases intracellular 








 Hypotonic shock 
 Heat stress 
 Mating pheromones   
 Cell cycle 
progression 
 Activates transcription 
factors that induce 
expression of genes 






 Nitrogen starvation 
combined with a 
poor carbon source 
 
 Coordinates proper 
spore wall assembly 
when diploid yeast 
cells undergo 


































Table 2.9 continued 
Organism MAPK 
Pathway 










factor, nerve growth 
factor) 
 Insulin 
 Cell proliferation, 
differentiation and 
survival 








stresses                   




cytokines                    
(Interleukin-1, tumor 
necrosis factor ) 
 Production of pro-
inflammatory cytokines 
 Cell cycle arrest 










stresses (e.g. heat 
shock, oxidative 
stress, DNA-
damaging agents, UV 
irradiation) 
 Growth factors     
(e.g. epidermal 
growth factor, nerve 
growth factor) 
 Induction of apoptosis  
 DNA repair 
 Cell proliferation and 
survival 






 Growth factors     
(e.g. epidermal 
growth factor, nerve 
growth factor)  
 Environmental 
stresses                   
(e.g. oxidative stress, 
hyperosmolarity) 












Figure 2.7 Schematic illustration of the general organization of the MAPK pathways.   
Depicted in the diagram are the four well-studied mammalian MAPK pathways: the ERK1/2, JNK, 
p38 and the ERK5 pathways. In each pathway, a conserved three-tiered kinase cascade exists 
which consists of a MAPKKK, a MAPKK and a MAPK. Signal transduction usually initiates with the 
activation of specific cell surface receptors [e.g. receptor tyrosine kinases (RTK) and G protein-
coupled receptors (GPCR)] by their triggering extracellular stimuli. The signals are subsequently 
transduced within the cells through the sequential phosphorylation and activation of the 
MAPKKKs, MAPKKs and MAPKs. The activated MAPKs will then phosphorylate various cytosolic 
and nuclear proteins, thereby controlling a diverse array of cellular functions. Illustration was 













2.2.3 MAPKs: Discovery of the terminal kinases of MAPK signaling cascades 
   MAPKs are evolutionarily conserved serine/threonine kinases belonging to the CMGC 
kinase group (Table 2.8). Their identification have led to the discovery of a novel signaling 
mechanism for mediating cellular functions in response to changes in the external environment. 
As compared with MAPKKKs and MAPKKs, MAPKs are the most extensively studied components 
of the MAPK cascades. They were named “mitogen-activated protein kinases” as their founding 
mammalian member, ERK1, was shown to be stimulated by diverse mitogenic agents 
(Rossomando et al., 1989). Shortly after the identification of ERK1, the mammalian MAPK family 
was discovered to also encompass ERK2, four p38 isoforms (p38α/β//), three JNK isoforms 
(JNK1-3), ERK5, ERK3, ERK4, ERK7 as well as a Nemo-like kinase (NLK) (Cargnello and Roux, 
2011). Among these 14 MAPKs, ERK1, ERK2, p38α/β//, JNK1-3 and ERK5 are classified as 
conventional MAPKs and their associated MAPKKK-MAPKK-MAPK cascades have been 
elucidated (Figure 2.7). On the other hand, ERK3, ERK4, ERK7 and NLK belong to the group of 
atypical MAPKs. They exhibit characteristics that deviate from the conventional MAPKs and their 
corresponding MAPKKK-MAPKK-MAPK modules remain poorly understood to date (Coulombe 
and Meloche, 2007).   
   ERK1 was originally discovered as a serine/threonine kinase in insulin-treated 3T3-L1 
adipocytes (Ray and Sturgill, 1987). The kinase was found to autophosphorylate on both 
threonine and tyrosine residues and demonstrated the ability to phosphorylate the 
microtubule-associated protein 2 substrate (Ray and Sturgill, 1987, 1988). Based on the peptide 
sequence derived from purified ERK1, isolation of its complementary DNA (cDNA) was 
consequently accomplished through polymerase chain reaction (PCR) using degenerate primers 
(Boulton et al., 1991a; Boulton et al., 1990). The same primers also led to the subsequent 
identification of a closely-related gene, designated as ERK2 (Boulton et al., 1991b). ERK1 and 




ERK2 share 89% amino acid sequence identity in their kinase domains (Table 2.10) and hence 
are often collectively referred to as ERK1/2. Following their identification, ERK1/2 were found to 
be highly homologous to two S. cerevisiae kinases, FUS3 and KSS1 (Boulton et al., 1991b; 
Boulton et al., 1990). This was the first indication that MAPKs are evolutionarily conserved from 
yeast to mammals (Boulton et al., 1991b; Boulton et al., 1990). Further characterization of 
ERK1/2 revealed that they are ubiquitously expressed in all mammalian tissues, with particularly 
high levels in the brain, skeletal muscle, heart and thymus (Cargnello and Roux, 2011). Their 
activation generally requires stimulation by mitogenic factors such as EGF, platelet-derived 
growth factor (PDGF) and serum. However, they may also be activated by inflammatory stimuli 
and osmotic stress, albeit to a lesser extent (Roskoski, 2012a).  
 MAPKs of the p38 subgroup are more preferentially activated by environmental stresses 
and inflammatory cytokines (Table 2.9). The first member, p38α, was contemporaneously 
discovered by three independent groups as 1) a tyrosine phosphoprotein isolated from extracts 
of endotoxin-treated mammalian cells, 2) a protein target of pyridinyl-imidazole compounds 
that inhibited the production of inflammatory cytokines, and 3) a kinase that could activate 
MAPK-activated protein kinase 2 in response to chemical stresses and heat shock (Han et al., 
1994; Lee et al., 1994; Rouse et al., 1994). The cDNA encoding for p38α was derived using a 
similar PCR-based methodology as that used for isolating ERK1 previously (Han et al., 1994). 
Three additional isoforms (p38β,  and ) were subsequently identified by probing cDNAs that 
were homologous to p38α (Jiang et al., 1996; Jiang et al., 1997; Mertens et al., 1996). These 
isoforms share approximately 60-70% amino acid sequence identity within their kinase domains 
(Table 2.10). The p38α and p38β MAPKs are ubiquitously expressed in most tissues (Cargnello 
and Roux, 2011). On the other hand, expression of p38 is restricted mostly to skeletal muscles, 
while p38 is predominantly detected in lung, kidney, endocrine organs and small intestine 




(Chen et al., 2001). The p38 MAPKs are homologues of the S. cerevisiae HOG1, a kinase involved 
in the cellular response to osmotic stress (Tables 2.9 and 2.10).  
 The first member of the JNK subgroup was identified independently as a cycloheximide-
activated kinase that exhibited activity towards microtubule-associated protein 2, and as a 
protein that could be affinity-purified using the immobilized c-Jun transcription factor (Hibi et 
al., 1993; Kyriakis and Avruch, 1990). Via the degenerate PCR approach, three mammalian JNKs 
(JNK1, JNK2 and JNK3) which share more than 85% identity at the amino acid level have been 
identified (Derijard et al., 1994; Kyriakis et al., 1994). Like the p38 MAPKs, JNKs are highly 
homologous to the yeast HOG1 (Table 2.10). They are responsive to a wide array of stimuli such 
as environmental stresses (e.g. heat shock, ultraviolet (UV) irradiation and oxidants) as well as 
mitogenic factors (Table 2.9). Both JNK1 and JNK2 exhibit a broad tissue distribution, whereas 
JNK3 is predominantly localized to testis, neuronal tissues and cardiac myocytes (Cargnello and 
Roux, 2011).      
   ERK5 is the mammalian homologue of the yeast MPK1 (Truman et al., 2006). It was 
simultaneously discovered by two independent groups using homology-based PCR detection 
and yeast-two-hybrid screening (Lee et al., 1995; Zhou et al., 1995). Interestingly, ERK5 was 
found to be twice the size of most conventional MAPKs (Zhou et al., 1995). Its kinase domain lies 
at the N-terminal half of the protein, while a nuclear localization signal and a transcriptional 
activation domain (TAD) are located at the C-terminal half (Figure 2.8). ERK5 is ubiquitously 
expressed in most tissues (Cargnello and Roux, 2011) and becomes activated in response to 
extracellular stimuli such as growth factors and environmental stresses (Table 2.9).   
  The mammalian ERK3, ERK4, ERK7 (also known as ERK8 in human) and NLK belong to 
the group of atypical MAPKs (Coulombe and Meloche, 2007). They were separately identified by 
virtue of their relatedness to ERK1 through the homology-based PCR approach (Abe et al., 1999; 




Boulton et al., 1991b; Brott et al., 1998; Gonzalez et al., 1992). However, many of their 
properties (e.g. kinase regulation and substrate specificities) do not conform to that of the 
conventional MAPKs and their associated MAPKKK-MAPKK-MAPK cascades remain inadequately 
understood to date. Nonetheless, NLK activity has been shown to be stimulated by a number of 
extracellular signals including the Wnt ligand, cytokines and growth factors (Coulombe and 
Meloche, 2007). More recently, the activity of ERK7 was demonstrated to be responsive to 
serum and amino acid depletion (Zacharogianni et al., 2011). Significant progress has also been 
made in understanding the regulation of ERK3/4 with the identification of the p21-activated 










Table 2.10 Amino acid sequence identities and similarities among the yeast, human and P. 
falciparum MAPKs. The yeast, human and P. falciparum MAPKs are highlighted in red, blue and 
green respectively. Classical and atypical human MAPKs are differentiated by light and dark 
blue, respectively. Amino acid sequence identities (%) are shown in yellow, while the similarities 
(%) are denoted in pink. The percent identities/similarities were generated using the MatGAT 
program (Campanella et al., 2003).                 
NCBI accession numbers: FUS3(CAA84835.1), KSS1(CAA97038.1), HOG1(CAA97680.1), MPK1(CAA41954.1), SMK1(CAA94999.1), 
ERK1(NP_002737.2), ERK2(NP_620407.1), ERK3(NP_002739), ERK4(NP_002738.2), ERK5(AAA81381), ERK7(NP_620590.2), 
NLK(NP_057315.3), JNK1(NP_620637.1), JNK(NP_002743.3), JNK3 (NP_620448.1), p38(NP_001306.1), p38β(NP_002742.3), 
p38(NP_002960.2) , p38(NP_002745.1), Pfmap1 (XP_001348468) and Pfmap2(XP_001347818.1). 
  




2.2.4 Activation of MAPKs requires phosphorylation by the upstream MAPKKs 
In the midst of characterizing ERK1/2, it was observed that the activation of these 
kinases were associated with phosphorylation of both threonine and tyrosine residues 
(Anderson et al., 1990; Boulton et al., 1991b). Through mass spectrometry and site-directed 
mutagenesis, two phosphorylation sites involved in stimulating the activity of ERK1/2 were 
identified: T202/Y204 in ERK1 and T183/Y185 in ERK2 (Payne et al., 1991; Robbins et al., 1993). 
In both cases, the threonine and tyrosine residues were found to be separated by a glutamic 
acid (i.e. TEY). Subsequent to this, analogous sequences were found to be present in most 
MAPKs, displaying variation only in the middle amino acid residue (i.e. TXY, Figure 2.8). To 
exemplify, the TGY and TPY sequences were identified in the p38 and the JNK MAPKs 
respectively, while the TEY sequence is preserved in ERK5 (Cargnello and Roux, 2011). As was 
demonstrated for ERK1/2, activation of p38, JNK and ERK5 likewise relies on phosphorylation of 
the threonine and tyrosine residues within their respective TXY sites. In view of this, the TXY 
sequence was consequently referred to as the activation motif of MAPKs. On a side note, some 
MAPKs (i.e. mammalian ERK3, ERK4 and NLK) display sequences that deviate from the 
characteristic TXY motif (Table 2.8), and hence are classified as atypical MAPKs. While ERK7 
possesses a typical TEY motif, its phosphorylation was found to be auto-regulated (Abe et al., 
2001), unlike that shown for the classical MAPKs as discussed below. For this reason, ERK7 was 
grouped together with the atypical MAPKs instead (Abe et al., 2001). 
The MAPKKs are the upstream kinases responsible for activating MAPKs. They belong to 
the group of dual-specificity protein kinases due to their ability to phosphorylate both the 
threonine (aliphatic hydroxyl side chain) and the tyrosine residues (aromatic hydroxyl side chain) 
within the TXY motif of MAPKs. The first mammalian MAPKK was identified through biochemical 
investigations, where cell extracts from EGF-treated cells were fractionated by ion exchange 




chromatography followed by the detection of fractions that could stimulate the activity of 
ERK1/2 in vitro (Seger et al., 1992). The search led to the discovery of two protein kinases, 
termed MAPKK1 and MAPKK2 (also known as MEK1/2 for MAPK/ERK kinases 1/2), that could 
specifically phosphorylate ERK1/2 at their TEY motifs (Crews and Erikson, 1992; Seger et al., 
1992; Zheng and Guan, 1993). Besides MAPKK1/2, five other MAPKKs were subsequently 
identified in mammalian cells which exhibit specificities toward their cognate MAPKs: MAPKK 
3/6 are responsible for the activation of the p38 MAPKs, MAPKK 4/7 are known to activate the 
JNKs, and MAPKK5 (also known as MEK5) is mainly involved in the activation of ERK5 (Figure 
2.7). Prior to activating their MAPK targets, MAPKKs must first be activated by the upstream 
MAPKKKs through phosphorylation of the serine/threonine residues within their signature 
S/TXXXS/T activation sites (phosphorylation sites in bold, Roskoski, 2012b). 
The underlying activation mechanism of MAPKs upon their phosphorylation has been 
extensively studied through structural and kinetic analyses of the unphosphorylated and 
phosphorylated ERK2 (Canagarajah et al., 1997; Prowse and Lew, 2001; Zhang et al., 1994). Like 
most protein kinases, ERK2 adopts a bi-lobed architecture with the catalytic site situated at the 
domain interface (Figure 2.9). A surface pocket, known as the P+1 site, can be found near the C-
terminal lobe. This region is crucial for interacting with the amino acid residue of the substrate 
that lies immediately downstream of the phospho-acceptor site. Contiguous with the P+1 
pocket is the kinase activation loop, where the signature TEY activation site resides (Zhang et al., 
1994). By comparing the structures of the unphosphorylated and phosphorylated ERK2, it was 
observed that the N- and C- terminal lobes of the kinase domain were rotated towards each 
other upon phosphorylation of the TEY motif (Figure 2.9, Canagarajah et al., 1997). The domain 
rotation was associated with the formation of hydrogen bonding networks between phospho-
T183 and the arginine residues from the N-terminal lobe (Canagarajah et al., 1997). This 




structural modification reportedly improves the geometry in the active site, thereby stimulating 
the activity of ERK2 by enhancing the rate of catalysis (Prowse and Lew, 2001). Another 
structural alteration observed in phosphorylated ERK2 was the remodeling of the P+1 surface 
pocket (Figure 2.9, Canagarajah et al., 1997). This modification was linked to the hydrogen bond 
formation between phospho-Y185 and two neighboring arginine residues (Canagarajah et al., 
1997). In addition, the side chain of Y185 was found to be re-positioned to the surface of the 
protein following its phosphorylation (Figure 2.9, Canagarajah et al., 1997). Through kinetic 
analyses, it was suggested that the conformational changes of the P+1 pocket and residue Y185 
following ERK2 phosphorylation were likely to be associated with the improved substrate 
binding affinity of the kinase (Prowse and Lew, 2001). Comparable structural changes were also 
reported for the unphosphorylated and phosphorylated p38, providing evidence that the MAPKs 
share a conserved mechanism of activation (Bellon et al., 1999).   


















Figure 2.8 Schematic illustration of the domain organizations of MAPKs. 
All MAPKs possess a serine/threonine kinase domain (blue) that is flanked by N- and C-terminal 
extensions of varying lengths. The classical TXY activation motifs and their variants are indicated 
within the kinase domains of the conventional and atypical MAPKs, respectively. In some 
MAPKs, additional features may be present. A nuclear localization signal (NLS) is encoded in 
both ERK5 and ERK7/8. ERK5 also possesses a transactivation domain (TAD) which is essential 
for transcriptional regulation. C34 represents a conserved region in ERK3 and ERK4 whose 
function is still poorly understood. In NLK, a region rich in alanine, histidine and glutamine 
(AHQr) lies upstream of the kinase domain. Image is adapted from Cargnello and Roux, 2011.       
  


























Figure 2.9 Conformation changes of ERK2 upon phosphorylation of the TEY motif.  
Left: Ribbon diagram of phosphorylated ERK2 (p-ERK2, colored yellow, PDB identifier: 2ERK) 
superimposed on unphosphorylated ERK2 (ERK2, colored red, PDB identifier: 1ERK). Upon 
phosphorylation, the N- and C-terminal lobes of ERK2 rotate towards each other as shown by 
the white arrows, thereby improving the geometry at the active site for catalysis. Right: 
Enlarged view of the P+1 site in the respective enzymes. The region undergoes significant 
remolding following the phosphorylation of the TEY motif, which is believed to underlie the 
enhanced substrate binding affinity of the activated kinase. Notably, the side chain of phospho-
Y185 (blue) is re-positioned to the surface of the enzyme as compared to that of Y185 (green), 
where it could be involved in interacting with the substrate. 
  




2.2.5 MAPK substrates: Effectors that coordinate cellular responses of MAPK pathway 
Upon activation, MAPKs are able to phosphorylate a plethora of substrates with distinct 
cellular functions (Table 2.10). In this manner, MAPK pathways exert profound influences on 
diverse biological processes such as cell proliferation, cell differentiation, cell migration, 
cytoskeletal rearrangement and inflammatory responses (Table 2.9). MAPK substrates can be 
located in the cytoplasm as well as various cellular compartments including the nucleus and the 
mitochondria (Wortzel and Seger, 2011). In mammals, MAPK substrates may also display tissue-
specific expression. The substrates are typically phosphorylated by MAPKs on the serine or 
threonine residue within the consensus P-X-S/T-P motif (Cargnello and Roux, 2011). 
Phosphorylation by MAPKs induces conformational changes in the substrates, thereby 
modulating their properties in terms of activity, stability, protein-protein association and/or 
subcellular localization (Yoon and Seger, 2006).  
ERK1/2, being the most-extensively studied MAPKs, have so far been associated with 
the regulation of at least 200 substrates (Yoon and Seger, 2006). Their substrates include 
transcription factors, regulatory protein kinases, and cytoskeletal and membrane proteins 
(Figures 2.10 and 2.11). As the ERK1/2 pathway is closely linked to proliferative responses in 
many cell types, it is unsurprising that many ERK1/2 substrates are involved in the regulation of 
cell-cycle progression and cell survival. A prominent ERK1/2 substrate is the Elk-1 transcription 
factor, which is rapidly phosphorylated by ERK1/2 following mitotic stimulation (Yoon and Seger, 
2006). The addition of phosphate groups stimulates the transcriptional activity of Elk-1, which 
then induces the expression of additional transcription factors such as c-Fos. c-Fos, together 
with another transcription factor c-Myc, are similarly activated by ERK1/2 through 
phosphorylation. As these transcription factors are responsible for inducing the expression of 
genes that encode cell-cycle related proteins (e.g.  cyclin D, ribosomal proteins and translation 




factors), ERK1/2 consequently exert a regulatory control on the progression of cell proliferation 
(Meloche and Pouyssegur, 2007). In addition to transcription factors, ERK1/2 are also capable of 
mediating the functions of numerous protein kinases which are collectively referred to as the 
MAPK-activated protein kinases (MAPKAPKs) (Cargnello and Roux, 2011). The MAPKAPKs 
targeted by ERK1/2 have been shown to include the ribosomal S6 kinases 1-4 (RSK1-4), mitogen 
and stress activated kinases 1/2 (MSK1/2) and MAPK interacting kinases 1/2 (MNK1/2) (Figure 
2.10). As the MAPKAPKs are involved in regulating a distinct set of effector proteins, they play a 
major role in diversifying the cellular processes controlled by ERK1/2. ERK5, which is likewise 
crucial for mediating proliferative responses to growth factors, shares a number of substrates 
with ERK1/2 such as c-Myc and the RSKs (Figure 2.10). On the other hand, major effector 
proteins of the p38 and JNK MAPKs include MAPK-activated protein kinases 2/3 (MK2/3) and 
ATF1/2 (Figure 2.10). These substrates act cooperatively to generate pro-inflammatory 
cytokines such as interleukin (IL)-1, IL-6, IL-12 and tumor necrosis factor- to mediate 
inflammatory and stress responses (Cargnello and Roux, 2011).      
 
  





Figure 2.10 Downstream substrates of the mammalian ERK1/2, p38, JNK and ERK5 MAPKs.  
By phosphorylating a diverse array of substrate proteins, MAPKs act as critical molecular 
switches that control a wide range of cellular processes.  
  




Figure 2.11 Schematic diagram illustrating the ERK1/2 substrates and the cellular processes 
they mediate. 
Upon activation by MEK1/2, ERK1/2 phosphorylate numerous transcription factors (blue), 
thereby enhancing their stability and transcriptional activity. This in turn leads to the induction 
of genes encoding cell cycle-related proteins such as cyclin D, ribosomal proteins and translation 
factors. ERK1/2 also target the MAPKAPKs such as RSKs, MSKs and MNKs. They contribute to 
diversifying the ERK1/2 signaling responses by targeting distinct downstream effectors. Other 
ERK1/2 substrates include CD120a (a tumor necrosis factor receptor) and paxillin (a cytoskeletal 
protein), which mediate cell survival and migration, respectively.        
  




2.2.6 Components of MAPK pathways as chemotherapeutic targets 
In light of the importance of MAPK pathways in mediating cellular processes, their 
functions have to be tightly regulated. Aberrant MAPK signaling, particularly in the ERK1/2, p38 
and JNK pathways, has been implicated in the etiology of human disorders such as cancers, 
rheumatoid arthritis, and Alzheimer's and Parkinson's diseases (Kim and Choi, 2010). Hence, 
inhibiting the MAPK signaling pathways has emerged as an attractive approach in the 
intervention of these diseases. 
To exemplify, constitutive activation of the ERK1/2 pathway is frequently observed in a 
number of human tumors, such as that from colon, lung, pancreas, ovary and kidney (Chapman 
and Miner, 2011). This phenomenon has widely been associated with the gain-of-function 
mutations in the RAF proteins (i.e. the MAPKKKs of the ERK1/2 cascade) as well as the 
components that lie upstream of the ERK1/2 cascade (i.e. the RAS GTPases and cell surface 
receptors) (Chapman and Miner, 2011). Typically, persistent activation of ERK1/2 pathway 
results in the overexpression of the ERK1/2 substrates, many of which are proto-oncoproteins 
that drive the cell proliferation process (e.g. c-Myc, c-Fos). Ultimately, tumorigenesis is induced 
as a result of uncontrolled cell proliferation and survival. The association of ERK1/2 signaling in 
tumorigenesis thus renders the kinases of the pathway as promising targets for the 
development of novel anti-cancer drugs. 
Indeed, numerous small molecule inhibitors specific against RAFs, MEKs and ERKs have 
been discovered and shown to be effective in restricting growth and viability in a variety of 
preclinical cancer models (Yap et al., 2011). These inhibitors typically abrogate kinase activity by 
preventing the binding of ATP (i.e. ATP-competitive inhibitors) or by locking the kinases in the 
catalytically inactive conformations (i.e. ATP non-competitive inhibitors) (Chapman and Miner, 
2011). Thus far, two RAF inhibitors (vemurafenib and sorefenib) have been approved for use as 




anti-cancer drugs (Table 2.11). Several other ERK1/2 pathway inhibitors have also entered 
clinical trials for the treatment of various cancers (Table 2.11). The success in discovering 
inhibitors targeting the ERK1/2 pathway is encouraging and it is optimistic that inhibition of this 











Table 2.1 Inhibitors of ERK1/2 pathway currently undergoing clinical trial. Information is 
obtained from http://clinicaltrials.gov (as of Jan 2013). Inhibitors of RAF kinases are typically ATP-
competitive, while that of MEKs act mainly through allosteric inhibition. Inhibitors selective for 
ERK1/2 have only been recently generated and have yet to enter clinical trials.   
Agent Target Status Condition Company 
Vemurafenib RAF Approved Melanoma Hoffmann-La Roche 
Sorafenib RAF Approved Advanced renal cell 
carcinoma,      
Hepatocellular cancer 
Bayer and Onyx 




XL281 RAF Phase 1 Non Small Cell Lung Cancer,  
Colorectal Cancer, Papillary 
Thyroid Cancer, Melanoma 
Exelixis 
LGX818 RAF Phase 1 Melanoma Novartis 
Pharmaceuticals 
GSK1120212 MEK Phase 3 Melanoma GlaxoSmithKline 
AZD6244 MEK Phase 2 Colorectal Cancer, 
Melanoma, 
Non Small Cell Lung Cancer 
AstraZeneca 
ARRY-438162 MEK Phase 1 Advanced Solid Tumors Array BioPharma 
GDC-0973/ 
XL518 
MEK Phase 1 Solid Tumors Genentech 
BAY86-9766 MEK Phase 2 Hepatocellular carcinoma Bayer 
PD-0325901 MEK Phase 1 Advanced Cancer Pfizer 
RO4987655 MEK Phase 1 Advanced Solid Tumors Hoffmann-La Roche 
MEK162 MEK Phase 1 Advanced Solid Tumors Novartis  Pharmaceu
ticals 




2.3 Deciphering the MAPK cascades in Plasmodium falciparum 
 
2.3.1 The unusual kinome of Plasmodium falciparum 
P. falciparum possesses a complex life cycle which alternates between the human host 
and the Anopheles mosquito vector (Figure 2.2). Although the various stages of the life cycle 
have been defined, the molecular mechanisms that regulate the growth and development of P. 
falciparum remain largely enigmatic. Given the importance of protein kinases in controlling a 
plethora of eukaryotic cellular functions, it is foreseeable that the P. falciparum counterparts 
would likewise play critical roles in regulating the biological processes in the parasite. This 
notion is further supported by early studies where protein kinase inhibitors were shown to 
impede the intra-erythrocytic development of P. falciparum (Dluzewski and Garcia, 1996; 
Sharma and Mishra, 1999). Hence, gaining insights into the protein kinases of P. falciparum is 
fundamental to elucidate the intricate biology of P. falciparum.  
The availability of the P. falciparum genome data (available at: http://plasmodb.org) had 
permitted a systematic analysis of the complement of protein kinases in the parasite. As 
reported by two independent studies, the kinome of P. falciparum comprises of at least 80 
protein kinases which constitutes approximately 1.8% of the parasite genome (Anamika et al., 
2005; Ward et al., 2004). Comparative examination of the P. falciparum and the human kinomes 
has revealed several differences between them. Notably, kinases of the TK and STE groups were 
found to be absent in P. falciparum. The non-existence of TK homologues in the malaria parasite 
was anticipated as they are mostly associated with cell-cell communication in multicellular 
organisms (Ward et al., 2004). However, the absence of STE homologues in P. falciparum was 
surprising since this group typically encompasses kinases that function within the MAPK 
cascades, such as the MAPKKs and MAPKKKs. On the other hand, several protein kinases have 




been identified in P. falciparum but are not represented in human. These include the calcium-
dependent protein kinases, which are generally confined to the plants and alveolates, but not 
the mammals. Another example is a group of enzymes known as the FIKK kinases (name derived 
from the consensus FIKK amino acid motif present in kinase subdomain II of these kinases) 
(Ward et al., 2004). The FIKK kinases possess protein export signals which enable them to be 
transported to the host erythrocytic cytoplasm where they associate with membrane structures 
known as the Maurer’s cleft (Nunes et al., 2007).  
Other than the differences at the kinome level, the P. falciparum protein kinases also 
exhibit substantial divergence from their host counterparts at the amino acid sequence level 
(Doerig and Meijer, 2007). Amino acid sequence identities between the P. falciparum and the 
human homologues are often limited, presumably due to the long phylogenetic distance 
between the two organisms (Solyakov et al., 2011). Numerous P. falciparum kinases were also 
found to possess large amino acid insertions of unknown functionality within the kinase 
domains (Ward et al., 2004). The considerable disparity between the human and the P. 
falciparum kinomes thus highlights that the latter constitutes an attractive pool of parasite-
specific targets for antimalarial drug discovery. This perception is further strengthened by gene 
knock-out studies whereby nearly half of the P. falciparum kinases were found to be 











Table 2.12 Essential protein kinases for the asexual and sexual intra-erythrocytic development 
of P. falciparum.  
Kinase PlasmoDB 
Identifier 
Kinase Group   Remark References 
Highly likely to be essential for erythrocytic asexual development 
PfPKG PF14_0346 AGC Biochemically 
characterized  
(Deng and Baker, 2002; 
Taylor et al., 2010)  
PfPKB PFL2250c AGC Biochemically 
characterized 
(Kumar et al., 2004a; 
Solyakov et al., 2011; Vaid 
and Sharma, 2006) 
PfPKA PFI1685w AGC Biochemically 
characterized 
(Solyakov et al., 2011; Syin 
et al., 2001) 
Serine/ threonine 
protein kinase 
PF11_0227 AGC-related - (Solyakov et al., 2011) 
Serine/ threonine 
protein kinase 
PF11_0464 AGC-related - (Solyakov et al., 2011) 
PfPK2 PFL1885c CamK Biochemically 
characterized 
(Kato et al., 2008a; Solyakov 
et al., 2011) 
PfCDPK1 PFB0815w Orphan/CDPK Biochemically 
characterized 
(Kato et al., 2008b; Zhao et 
al., 1993) 
PfCDPK2 PFF0520w Orphan/CDPK Biochemically 
characterized 
(Farber et al., 1997; 
Solyakov et al., 2011) 
PfCDPK3 PFC0420w Orphan/CDPK - (Solyakov et al., 2011) 
PfCDPK5 PF13_0211 Orphan/CDPK Biochemically 
characterized 
(Dvorin et al., 2010) 
Pfcrk1 PFD0865c CMGC/CDK Biochemically 
characterized 
 (Doerig et al., 1995; 
Solyakov et al., 2011) 
 
Pfcrk4 PFC0755c CMGC/CDK - (Solyakov et al., 2011) 
 
PfPK6 PF13_0206 CMGC/CDK Biochemically 
characterized 
(Solyakov et al., 2011) 
 
Pfcrk3 PFD0740w CMGC/CDK Biochemically 
characterized 
(Halbert et al., 2010) 
PfPK5 MAL13P1.279 CMGC/CDK Biochemically 
characterized 
(Ross-Macdonald et al., 
1994; Solyakov et al., 2011) 
Pfmrk PF10_0141 CMGC/CDK Biochemically 
characterized 
(Solyakov et al., 2011; 
Waters et al., 2000) 
 
Pfmap2 PF11_0147 CMGC/MAPK Biochemically 
characterized 
(Dorin-Semblat et al., 2007; 
Dorin et al., 1999) 
PfCK2 PF11_0096 CMGC/CK2 Biochemically 
characterized 
(Holland et al., 2009) 
Protein kinase, 
putative 
MAL13P1.84 CMGC/GSK3 - (Solyakov et al., 2011) 
 
PfGSK3 PFC0525c CMGC/GSK3 Biochemically 
characterized 
(Droucheau et al., 2004; 








Table 2.12 continued 
PfCLK1/ Pflammer PF14_0431 CMGC/CDK-like Biochemically 
characterized 
 (Agarwal et al., 2011) 
PfCLK2 PF14_0408 CMGC/CDK-like Biochemically 
characterized 
 (Agarwal et al., 2011) 
PfCLK3 PF11_0156 CMGC/CDK-like -  (Solyakov et al., 2011) 
PfCLK PFC0105w CMGC/CDK-like -  (Solyakov et al., 2011) 
 
PfCK1 PF11_0377 CK1 Biochemically 
characterized 
(Barik et al., 1997; Solyakov 
et al., 2011) 
PfTKL3 PF13_0258 TKL Biochemically 
characterized 
 (Abdi et al., 2010) 
PfTKL1 PFB0520w TKL - (Solyakov et al., 2011) 
 




(Mohrle et al., 1997; 
Solyakov et al., 2011) 
 
Pfnek1 PFL1370w Orphan/NIMA Biochemically 
characterized 
 (Dorin-Semblat et al., 2011; 
Dorin et al., 2001) 
PfARK1 PFF0260w Orphan/Aurora Biochemically 
characterized 
 (Reininger et al., 2011) 
PfARK2 PFC0385c Orphan/Aurora -  (Solyakov et al., 2011) 
 
PfARK3 MAL13P1.278 Orphan/Aurora -  (Solyakov et al., 2011) 
 
PfEST MAL7P1.91 Orphan - (Solyakov et al., 2011) 
Serine/threonine 
protein kinase 
PF11_0488 Orphan - (Solyakov et al., 2011) 
PfKIN PF14_0516 Orphan Biochemically 
characterized 
(Bracchi et al., 1996; 
Solyakov et al., 2011) 
PfPK9 PF13_0085 Orphan Biochemically 
characterized 
(Philip and Haystead, 2007; 
Solyakov et al., 2011) 
Highly likely to be essential for sexual development 
Pfnek2 PFE1290w Orphan/NIMA Biochemically 
characterized 
(Reininger et al., 2009) 
PfPK7 PFB0605w Orphan Biochemically 
characterized 
(Dorin-Semblat et al., 2008; 










2.3.2 The Plasmodium falciparum kinome encompasses two MAPK homologues 
As MAPK pathways are evolutionarily conserved in eukaryotes for regulating growth and 
proliferation, it is envisaged that analogous pathways are also present in P. falciparum to 
mediate its developmental process. In this context, gaining insights into the MAPK pathway(s) of 
P. falciparum is enticing as their inhibition might represent a potential strategy to impede 
parasite growth. Therefore, intense efforts have been set out to identify and characterize 
components of the P. falciparum MAPK pathway(s). 
The P. falciparum kinome harbors two MAPK homologues which are annotated as 
Pfmap1 and Pfmap2 (Ward et al., 2004). Both kinases were fortuitously identified through 
homology-based PCR prior to the completion of the P. falciparum genome sequencing (Doerig et 
al., 1996; Dorin et al., 1999). The number of MAPKs present in P. falciparum is significantly 
smaller as compared with that found in some other protozoan parasites such as Leishmania 
major and Trypanosoma brucei (Table 2.13). Pfmap1 was the first MAPK homologue identified in 
P. falciparum (Doerig et al., 1996; Graeser et al., 1997). It exhibits a characteristic TDY activation 
motif and is most similar to ERK7/8 in terms of amino acid sequence within their kinase domains 
(49% identity, Table 2.10). On the other hand, Pfmap2 possesses an unconventional TSH 
activation motif despite sharing the highest amino acid sequence identity (~40%) with ERK1/2 
(Dorin et al., 1999). The absence of a consensus TXY activation motif in Pfmap2 indicates that it 
is an atypical MAPK in P. falciparum.  
Both Pfmap1 and Pfmap2 are expressed during the intra-erythrocytic schizogony and 
gametocyte stages of the P. falciparum life cycle, with Pfmap2 particularly up-regulated in the 
latter stage (Bozdech et al., 2003). Using a gene knock-out approach, Pfmap1 was demonstrated 
to be dispensable for both the intra-erythrocytic schizogony and gametocytogenesis of P. 
falciparum (Dorin-Semblat et al., 2007). Nonetheless, it was observed that the protein level of 




Pfmap2 was elevated in the Pfmap1 knock-out parasites (Dorin-Semblat et al., 2007). This 
suggests that Pfmap1 may fulfill an important, yet presently unknown cellular function that 
necessitates compensatory adaptation in parasites lacking the kinase (Dorin-Semblat et al., 
2007). On the other hand, parasites deficient in Pfmap2 were unable to complete asexual 
development in the erythrocytes, thereby supporting Pfmap2 as an essential protein kinase in P. 
falciparum (Dorin-Semblat et al., 2007). In view of this, deciphering the Pfmap2 MAPK pathway 





































Table 2.13 Current knowledge of MAPKs in the major human parasitic protozoa. The number of 
MAPKs encoded in P. falciparum is evidently fewer compared to those found in the other 
parasites listed. Although MAPKKs have been identified in Toxoplasma gondii and Trypanosoma 
brucei, their roles in modulating MAPK activity remain unknown. 
Parasite Number of MAPKs Potential Cellular Role Presence of Upstream 





(Dorin-Semblat et al., 
2007; Low et al., 2007; 











 Pfmap2 shown to be 
activated by Pfnek3 
through phosphorylation 





(Brumlik et al., 2011; 
Peixoto et al., 2010) 
 
2 1  TgMAPK1 
Essential for 
tachyzoite/bradyzoite 
stage differentiation and 
stress response 




(Brumlik et al., 2011; 





0  MPK 1 and 2 
Essential for amastigote 
survival 
 




 MPK 4 
Essential for pro- 
amastigote and 
amastigote  survival 
 Yes (5 copies) 
 
 MPK4 was demonstrated 
to be activated by MKK5  
via dual phosphorylation 





(Brumlik et al., 2011; 
Parsons et al., 2005) 
 
13 0  MPK 1 and 2 










 Yes (5 copies) 
 
Note: Typical MAPKs represent those that display the classical TXY activation motif, while the atypical 
MAPKs possess activation sites that deviate from the consensus.  




2.3.3 Identification of the upstream kinases of Pfmap2 
Prior to the reports on the P. falciparum kinome, attempts have been made to identify 
the MAPKK homologues in the parasite through homology-based PCR and BLAST analyses (Dorin 
et al., 2001). However, these approaches were unsuccessful in isolating the desired protein 
kinases of interest. The futile efforts were eventually attributed to the absence of conventional 
MAPKK homologues in P. falciparum, as revealed by analyses of the parasite kinome 
subsequently (Anamika et al., 2005; Ward et al., 2004). Together with a lack of P. falciparum 
kinases that are homologous to the MAPKKKs, it was consequently suggested that the classical 
MAPKKK-MAPKK-MAPK cascade may not be conserved in P. falciparum (Dorin et al., 2005).  
Nonetheless, in the midst of characterizing Pfmap2, the recombinant kinase was found 
to be activated upon incubation with cell lysates derived from the asexual blood-stage as well as 
the gametocyte-stage parasites (Dorin et al., 1999). Notably, the gametocyte-stage lysate was 
able to stimulate the activity of Pfmap2 to a higher extent as compared to the asexual blood-
stage lysate (Dorin et al., 1999). These observations thus support the notion that upstream 
activators of Pfmap2 do exist, and thereby sparked the interest in identifying protein kinases 
that are able to stimulate the activity of Pfmap2. Success in this endeavor is not only crucial for 
understanding the regulatory mechanism of an essential P. falciparum MAPK, but is also of 
utmost importance in establishing the presence of the MAPK pathway in the parasite. 
A P. falciparum NIMA-like kinase, Pfnek1, was the first kinase identified as a plausible 
candidate activator of Pfmap2 (Dorin et al., 2001). It was discovered through BLAST analyses 
based on the activation loop sequences of human MAPKK1/2 (Dorin et al., 2001). While Pfnek1 
possesses a MAPKK-like activation site (SMANS), its kinase domain showed highest homology to 
the NIMA-like kinases instead. The latter are generally involved in the mitotic progression of 
eukaryotic cells, where they mediate specific events such as chromatin condensation, spindle 




organization and cytokinesis (O'Regan et al., 2007). Interestingly, recombinant Pfnek1 
demonstrated the ability to phosphorylate Pfmap2 in vitro (Dorin et al., 2001). It was also shown 
that co-incubation of both kinases led to a synergistic increase in exogenous substrate 
phosphorylation (Dorin et al., 2001). However, despite these observations, it remains unknown 
whether the Pfnek1-mediated phosphorylation is implicated in the regulation of Pfmap2. 
Capitalizing on the above finding, a second P. falciparum NIMA-like kinase, Pfnek3, was 
subsequently cloned and assessed for its role as a plausible upstream kinase of Pfmap2 (Lye et 
al., 2006). Pfnek3 was particularly conspicuous among the remaining NIMA-like kinases (i.e. 
Pfnek2-4) as it is expressed in both the asexual blood-stage and the gametocyte-stage parasites, 
akin to that of Pfmap2 (Bozdech et al., 2003). Furthermore, its expression was observed to be 
significantly up-regulated in the gametocyte-stage parasites, a trend which was also detected 
for Pfmap2. These observations, together with the earlier report that Pfmap2 activity was 
enhanced significantly by the gametocyte cell lysates (Dorin et al., 1999), provided the impetus 
to examine the relationship between Pfnek3 and Pfmap2 (Lye et al., 2006). Similar to Pfnek1, 
recombinant Pfnek3 was found to be able to phosphorylate Pfmap2 in vitro (Lye et al., 2006). 
Apart from this, the Pfnek3-mediated phosphorylation was validated to stimulate the kinase 
activity of Pfmap2 (Lye et al., 2006). Through mass spectrometry and biochemical assays, it was 
further demonstrated that Pfnek3 activates Pfmap2 by phosphorylation of the threonine residue 
within the TSH activation motif of Pfmap2 (Low et al., 2007). As this mechanism of MAPK 
activation coincides with that expected of a MAPKK (Roskoski, 2012b), Pfnek3 was consequently 
recognized as a unique MAPKK in P. falciparum (Low et al., 2007).  











3.1  Cultivation and maintenance of Escherichia coli  
 In this study, E. coli BL21 (DE3)-CodonPlus™ (Strategene) and TOP10 (Invitrogen) cells 
were used as the protein expression and the cloning hosts, respectively. Both bacterial strains 
were cultivated using sterile Luria-Bertani (LB) broth comprising of 1% (w/v) tryptone, 0.5% 
(w/v) yeast extract and 1% (w/v) NaCl, or LB agar which contained an additional 1.5% (w/v) agar. 
Bacterial liquid cultures were grown at 37oC on a rotary shaker set at 220 rpm, while bacterial 
cells on agar plates were cultivated at 37oC in an oven incubator. When necessary, the culture 
media used were supplemented with antibiotics such as kanamycin (50 µg/ml), chloramphenicol 
(40 µg/ml) and/or ampicillin (100 µg/ml) to select for cells harboring the plasmid of interest. For 
long term preservation, stocks of E. coli were kept frozen at -80oC in 10% (w/v) sterile glycerol.  
 
3.2  Preparation of electrocompetent Escherichia coli 
In order to prepare electrocompetent E. coli with the highest level of competency, it is 
necessary that the cells are harvested in the early to mid-logarithm growth phase. Avoiding the 
late-logarithm phase is critical as the cell competency will be significantly reduced. A single 
colony of E. coli was picked from LB agar plate and inoculated into 5 ml of sterile LB broth. The 
liquid culture was incubated overnight at 37oC on a rotary shaker set at 220 rpm. The next day, 1 
ml of the overnight bacterial culture was diluted in 100 ml of sterile LB broth. This culture was 
incubated at 37oC with agitation at 220 rpm until the mid-log phase (OD600 = 0.6-0.8). 
Subsequently, the culture was transferred to a sterile centrifuge tube and chilled on ice 
for 30 min. The cells were then pelleted via centrifugation at 7000 rpm for 10 min at 4oC. After 
discarding the supernatant, the cells were washed twice by resuspending the pellet in 50 ml of 
ice-cold 10% (w/v) glycerol. After the second wash, the cell pellet was gently mixed in 0.5 ml of 
ice-cold 10% glycerol. A 40 µl of the resuspended cells was then aliquoted into separate sterile 





microfuge tubes. The cells were then used directly for electro-transformation or stored frozen at 
-80°C for subsequent use. 
 
3.3 Transformation of electrocompetent Escherichia coli 
Electrocompetent E. coli cells were allowed to thaw on ice. Following which, 1 to 5 µl of 
plasmid DNA or ligation mixture was gently resuspended in the electrocompetent cells. The 
resultant mix was then transferred to an ice-chilled electroporation cuvette with an electrode 
gap of 0.2 cm (Bio-Rad). The Bio-Rad Gene Pulser® used for transformation was adjusted to 2.5 
kV and a short electric pulse was rendered across the cuvette. Following the pulse, 1 ml of 
sterile LB broth was immediately added to the mixture. This rapid addition of the LB medium is 
essential for maximizing the recovery of transformants. The cells were then allowed to recover 
by incubation at 37°C for 1 h with agitation at 220 rpm. Selection for transformed colonies was 
achieved by spreading the transformation mixture onto LB agar supplemented with the relevant 
antibiotics, depending on the antibiotic resistance marker encoded in the plasmid. The plates 
were incubated overnight at 37oC and well-isolated colonies that grew on the selection agar 
plates were picked the following day. 
 
3.4 Generation of Pfnek3 site-directed mutants  
To introduce amino acid residue substitutions into Pfnek3, the QuikChange site-
directed mutagenesis (SDM) protocol (Stratagene) was adopted. A recombinant pGEX-6P-1 
plasmid (GE Healthcare) carrying the truncated version of the Pfnek3 gene has previously been 
constructed in the laboratory (Lye et al., 2006). It was used in this study as the mutagenesis 
template. The primers utilized for constructing the various single mutants of Pfnek3 are listed in 
Table 3.1. Both the forward and reverse oligonucleotides of each primer pair were designed to 





carry the desired mutation and anneal to the same sequence on opposite strands of the 
template. The SDM reaction mixture was prepared according to constituents listed in Table 3.2, 
and subsequently subjected to thermal cycling using the parameters summarized in Table 3.3. 
The Pfu DNA polymerase (Promega) used in the PCR supports replication of both plasmid 
strands with high fidelity. Following thermal cycling, the product was treated with 10 U of the 
restriction enzyme DpnI for 3 h at 37°C to digest the methylated parental plasmid. The DpnI-
treated mixture was then electro-transformed into E. coli BL21 (DE3)-CodonPlus™ cells and 
transformants were selected on LB agar supplemented with chloramphenicol and ampicillin. 
Single colonies of the transformants were then picked and grown in 5 ml LB broth containing the 
same antibiotics. A 2 ml aliquot of overnight the bacterial culture was eventually harvested by 
centrifugation at 8000 rpm for 5 min and the plasmid DNA was extracted using the WizardTM 
Plus SV Minipreps DNA purification system (Promega) according to the manufacturer’s 
instructions. DNA sequencing was subsequently carried out as described in Section 3.5 to verify 
the respective nucleotide modification sites and to ensure that no spontaneous amino acid 
substitution was introduced. Double and triple mutants of Pfnek3 were subsequently generated 
from the verified pGEX-6P-1-Pfnek3 plasmids harboring the single and double mutations, 
respectively, using the appropriate mutagenic primers. 
  





Table 3.1 Primers used for generating Pfnek3 site-directed mutants. The designations F and R denote the 
forward and reverse primers respectively, with the sites of mutagenesis underlined. Primers were 
synthesized either by 1
st
 BASE or Sigma-Aldrich. 
Mutation sites Sequence of Primers (5' -3') 
T82A 
F: TGTTAGATTTCATGGCATCAGATAGTGAAATTCATTTG                                       
R: CAAATGAATTTCACTATCTGATGCCATGAAATCTAACAC 
T82D 
F: TGTTAGATTTCATGGATTCAGATAGTGAAATTCATTTG                                       
R: CAAATGAATTTCACTATCTGAATCCATGAAATCTAACAC 
T82E 
F: TGTTAGATTTCATGGAATCAGATAGTGAAATTCATTTG                                       
R: CAAATGAATTTCACTATCTGATTCCATGAAATCTAACAC 
S221A 








































































Table 3.2 Reaction components used for site-directed mutagenesis of Pfnek3. 
Reaction Composition Amount (µl) 
Plasmid DNA  1.0 (approximately 0.5 - 0.8 µg) 
dNTPs (Applied Biosystems) 1.0 
Forward primer (10 pmol/µl) 1.0 
Reverse primer ( 10 pmol/µl) 1.0 
Pfu DNA Polymerase (Promega) 0.5 






Table 3.3 Thermal cycling parameters used for mutant strand synthesis. 
Temperature (°C) Duration  
95 1 min   
95 30 sec 
 45-55 30 sec                         28 cycles 
72 14 min 
4 Hold  
 
3.5 DNA sequencing 
 DNA sequencing was carried out using the ABI PRISMTM BigDye® Terminator v3.1 cycle 
sequencing kit (Applied Biosystems) following the manufacturer’s recommendations. Briefly, 
about 250-500 ng of double-stranded DNA was mixed with 4 µl of BigDye® Reaction Mix and 3.2 
pmole of the relevant sequencing primer (Table 3.4). Deionised water was then added to a final 
volume of 10 µl. Cycle sequencing of the samples was subsequently carried out using the 
following conditions: (1) 96°C for 1 min, (2) 96°C for 10 sec, (3) 50°C for 5 sec, (4) 60°C for 4 min 
and (5) 30 cycles of step 2 to 4.   
To purify the extension products, the entire 10 µl reaction content was transferred to a 
1.5 ml microfuge tube containing 1.5 µl of 3 M sodium acetate (pH 4.6), 7.25 µl of deionised 
water and 31.25 µl of 95% (v/v) ethanol. The mixture was allowed to precipitate for 15 min, 
followed by centrifugation at 12,000 rpm for 20 min. The supernatant was then aspirated and 
the pellet was rinsed with 250 µl of 70% (v/v) ethanol to remove salt content before drying in an 





incubator (50°C) for 10-15 min. The dehydrated extension products were then sent for 
sequencing by the Department of Microbiology Sequencing Team, National University of 
Singapore, using the ABI PRISMTM 3100 Gene Analyzer (Applied Biosystems).  
 
Table 3.4 Primers used for sequencing DNA fragments in the various plasmid vectors. The 
designations F and R denote the forward and reverse primers respectively. They were 
synthesized either by 1st BASE or Sigma-Aldrich.     








F:  GGATTGTCAGAATCATATAAAAGAG 
R: CGGATCCGTGCCTACCACCTCTTAGCC   
pET24a 




















3.6 Bacterial expression of recombinant Plasmodium falciparum proteins 
E. coli BL21 (DE3)-CodonPlus™ clones expressing the pGEX-derived Pfnek3 mutants 
(obtained in Section 3.4) and various other P. falciparum proteins (Table 3.5) were inoculated in 
5 ml of LB medium containing chloramphenicol and ampicillin. The same E. coli strain expressing 
a His6-tagged Pfmap2 from the pET24a vector (generated in Section 3.16) was cultured in LB 
medium containing chloramphenicol and kanamycin instead. The cultures were grown at 37°C 
overnight with agitation at 220 rpm. Thereafter, 1 ml of each overnight culture was diluted in 
100 ml of LB medium comprising of the appropriate antibiotics and grown at 37°C on a rotary 
shaker set at 220 rpm. Subsequently, 1 mM of isopropyl-beta-D-thiogalactopyranoside (IPTG) 
was added to induce the expression of fusion proteins when the bacteria culture has reached 
the mid-log phase (OD600 = 0.6-0.8). The cultures were then incubated overnight at ambient 
temperature. 
The next day, the IPTG-induced cultures were harvested by centrifugation at 7000 rpm 
for 5 min at 4°C and the supernatant was discarded. The cell pellet was rinsed twice with 30 ml 
of 1X Phosphate Buffered Saline (PBS, pH 7.5) and thereafter resuspended in 1.5 ml of the same 
buffer. The cell suspension was then transferred into a Bijou bottle prior to cell lysis by 
sonication on ice with a 1/8” probe (Sanyo MSE Soniprep). The cells were disrupted at an 
intensity of 10 μm for nine cycles, with an 8 sec pulse and a 12 sec rest period in each cycle. 
Following which, centrifugation of the cell lysate was carried out at 12,000 rpm for 20 min at 4°C 
to remove cell debris. The clear supernatant obtained was then transferred into clean microfuge 
tube and is hereafter referred to as the soluble protein fraction. 










Table 3.5 Existing E. coli clones used in this study for the expression of GST-tagged P. 
falciparum proteins. Listed clones were previously generated in the laboratory except for 
Pfmap2, which was kindly provided by Professor Christian Doerig (University of Glasgow). 









 For expression of a GST-tagged, wild-
type (WT) Pfnek3                         
(Amino acid residues 60- 347) 
 
 




 For expression of a GST-tagged, 
catalytically inactive Pfnek3         
(Amino acid residues 60- 347, harboring a 
K102M mutation) 
 
(Lye et al., 
2006) 
Pfmap2 pGEX-3X-Pfmap2  For expression of a GST-tagged, WT-
Pfmap2                                          
(Amino acid residues 37- 508)  
 
(Dorin et al., 
1999) 
∆Pfmap2 pGEX-3X-∆Pfmap2  For expression of a GST-tagged, 
catalytically inactive Pfmap2             
(Amino acid residues 37- 508, harboring a 
K135M mutation) 
 




pGEX-3X-∆Pfmap2/T290  For expression of a GST-tagged, 
catalytically inactive Pfmap2 with an 
additional phospho-site mutation               
(Amino acid residues 37- 508, harboring a 
K135M/T290A double mutation) 
(Low et al., 
2007) 
    
 
 
3.7 Purification of recombinant Plasmodium falciparum proteins 
GST-tagged fusion proteins were purified from the soluble protein fraction via affinity 
chromatography using the MicroSpinTM GST purification module as recommended by the 
manufacturer (GE Healthcare). Briefly, each protein fraction was added into a spin column 
containing glutathione-sepharose beads pre-washed twice with 1X PBS (pH 7.5). Incubation was 
then carried out at 4°C for 15 min with periodic mixing. Unbound proteins were removed from 
the spin column by centrifugation at 3000 rpm for 1 min and the beads were then washed thrice 
with 1X PBS (pH 7.5). For elution of the GST-tagged proteins, the beads were incubated with 150 
µl of ice-cold reduced glutathione (10 mM, GE Healthcare) for 15 min and the purified proteins 





were then collected in a fresh microfuge tube by centrifugation at 3000 rpm for 1 min. In 
experiments that required cleavage of the GST fusion partner, purified proteins were incubated 
overnight at 4°C with the PreScission Protease following the manufacturer’s protocol (GE 
Healthcare).  
His6-tagged recombinant proteins were purified from the soluble protein fraction by Ni
2+ 
affinity chromatography using nickel-nitrilotriacetic acid (Ni-NTA) beads (Qiagen). Protein 
fractions were added into a clean microfuge tube containing Ni-NTA beads pre-washed twice 
with 50 mM Tris-HCl (pH7.5). After incubation for 15 min at 4°C, the protein-bound beads were 
collected at the bottom of the microfuge tubes by centrifugation at 3000 rpm for 1 min. Upon 
removing the supernatant, the beads were then washed thrice with 20 mM imidazole in 50 mM 
Tris-HCl (pH7.5). Bound proteins were then eluted from the beads using a buffer containing 300 
mM imidazole in 50 mM Tris-HCl (pH7.5).  
 
3.8 Estimation of protein concentration by Bradford assay 
 The concentration of purified recombinant proteins was determined by Bradford assay 
using the Bio-Rad protein assay reagent. Prior to use, the reagent was diluted five-folds in 
deionised water and filtered through a Whatman® No.1 filter paper. For each batch of diluted 
reagent, a protein standard curve using a range of concentrations of bovine serum albumin 
(BSA; 0 to 1 mg/ml) was prepared (Appendix I). Each assay was conducted in duplicates, by 
adding 250 µl of the diluted reagent to 10 µl of BSA standard or test sample in each well of a 
clear-bottom 96-well plate. After 5 min of incubation, the samples were measured at OD595 
using a plate reader (Tecan® Genios). The protein concentration of each test sample was then 
determined with reference to the standard curve. 
 





3.9 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were resolved by SDS-PAGE using the SE 260 Mighty Small II System 
(Hoefer). Each protein sample was mixed with 1X SDS-PAGE gel loading buffer [50 mM Tris-HCl 
(pH 6.8), 100 mM dithiothreitol (DTT), 2% SDS (w/v), 0.1% bromophenol blue (w/v), 10% glycerol 
(v/v)] and denatured by boiling for 5 min before loading into the gel wells. A pre-stained protein 
standard (Bio-Rad) was used as the molecular weight markers.  
 Electrophoresis was carried out at 20 mA per gel in Tris-glycine electrophoresis buffer 
[25 mM Tris-base, 250 mM glycine, 0.1% (w/v) SDS] until the bromophenol blue dye front 
reached the bottom of the resolving gel. For visualization of protein bands, the gel was first 
stained with Coomassie Blue [0.25% (w/v) Coomassie Brilliant Blue R-250, 45% (v/v) methanol, 
10% (v/v) acetic acid] for 30 min. Subsequently, the gel was de-stained by soaking in a de-
staining solution [30% methanol (v/v), 10% acetic acid (v/v)] until distinct protein bands 
appeared. Images of the gels were photographed using the Bio-Rad Gel-Doc™ system equipped 
with the Quantity One® software.  
 
3.10 Liquid chromatography-tandem mass spectrometric (LC-MS/MS) analyses 
 LC-MS/MS analyses were performed to identify the phosphorylation sites in Pfnek3. 10 
µg of the recombinant wild-type (WT) or catalytically inactive Pfnek3 was first gel-purified by 
10% SDS-PAGE. The Coomassie-stained bands that corresponded to the proteins of interest 
were then excised. In-gel digestion with trypsin and the subsequent LC-MS/MS were conducted 
by A*STAR Experimental Therapeutics Centre using API QSTAR Pulsar (Applied Biosystems).  
All MS/MS samples were analyzed using Mascot (Matrix Science, London, UK; version 
2.2.0). Mascot was set up to search the NCBInr_20070223 database, specifying trypsin as the 
digestion enzyme. Mascot was searched with a fragment ion mass tolerance of 0.80 Da and a 





parent ion tolerance of 500 PPM. Scaffold (version Scaffold-01_07_00, Proteome Software Inc., 
Portland, OR) was used to validate MS/MS based peptide and protein identifications. Peptide 
identifications were accepted if they could be established at greater than 95.0% probability as 
specified by the Peptide Prophet algorithm (Keller et al., 2002). Protein identifications were 
accepted if they could be established at greater than 95.0% probability and contained at least 2 
identified peptides.  Protein probabilities were assigned by the Protein Prophet algorithm 
(Nesvizhskii et al., 2003). 
 
3.11 Enzyme-Linked ImmunoSorbent Assay (ELISA)-based protein kinase assay 
To determine the kinase activity of Pfnek3 and its mutants, an ELISA-based kinase assay 
was performed as described in Lye et al (2006). The assays were carried out with 96-well 
microtiter plates (Costar) using dephosphorylated myelin basic protein (MBP, Millipore) as the 
kinase substrate. For each assay, 5 ug of MBP was first immobilized onto microplate wells by 
overnight incubation in 1X PBS (pH 7.5) at 4°C. Prior to use, the remaining adsorptive surfaces 
were blocked with 2% (w/v) BSA in 1X TBS (pH 7.5) for 1 h at room temperature. 
Each kinase assay reaction mix typically comprised 10 µg of WT- or mutant Pfnek3 
enzymes, 500 µM ATP, 40 mM MgCl2 and 50 mM Tris-HCl (pH 7.2), unless stated otherwise. The 
assay was initiated by adding the kinase reaction mix to each well. Following incubation at 30°C 
for 30 min, the reactions were quenched by washing the wells five times with 1X Tris Buffered 
Saline (TBS, pH 7.5). The mixed monoclonal anti-phosphoserine/threonine antibodies (100 µl; 
1:500 dilution, Millipore) or the monoclonal anti-phosphotyrosine antibody (100 µl; 1:1000 
dilution, Millipore) were/was subsequently added to each well and incubated for 1 h at room 
temperature. These antibodies were respectively used for assaying the serine/threonine and the 
tyrosine kinase activity of Pfnek3. During the incubation period, any phosphorylation of MBP 





that arose from the activities of the kinases would be detected by these antibodies. After 
another round of extensive washing with 1X TBS (pH 7.5), the wells were incubated with a 
peroxidase-conjugated secondary antibody (100 ul; 1:2000 dilution, Thermo Scientific) for 45 
min at room temperature. All antibodies were diluted using the blocking buffer. Following 
incubation with the secondary antibody, the wells were again rinsed and the SuperSignal West 
Femto peroxidase substrate (50 µl each of substrates A and B, Thermo Scientific) was then 
added to each well. The resulting chemiluminescent signal arising from the presence of 
phosphorylated residues was then measured using the Genios™ microplate reader (Tecan). In 
experiments that involved quantification of the Pfmap2 kinase activity, the same protocol was 
adopted except that a kinase reaction mix comprising both Pfnek3 and Pfmap2 was added to 
each MBP-coated well and allowed to incubate for 15 min.    
 
3.12 Phosphoprotein analysis 
The Pro-Q® Diamond stain (Invitrogen) was used to examine the phosphorylation state 
of the recombinant proteins of interest. It is a non-selective fluorescent dye that concomitantly 
detects for phosphoserine-, phosphothreonine- and phosphotyrosine-containing proteins. In 
each experiment, a desired amount of the purified protein of interest or the kinase assay mix 
was subjected to SDS-PAGE using 10% polyacrylamide gels. Following electrophoresis, the gels 
were processed with the phosphoprotein gel stain according to the manufacturer’s protocol. 
Visualizing and imaging of the gels were then carried out on a UV transilluminator (Bio-Rad Gel-
Doc™ system). The gels were subsequently stained with Coomassie Blue to detect for the total 
protein loaded for each sample. Results from phosphostaining were quantified by densitometry 
using the ImageJ software (Abramoff, 2004). 
 





3.13 Western blot analysis 
 In addition to Pro-Q® Diamond gel staining, analysis of protein phosphorylation was also 
conducted via Western blotting. Unlike the former, Western blotting enabled the differentiation 
of serine, threonine and tyrosine phosphorylation with the use of specific phospho-antibodies as 
described below. Protein samples were first resolved by SDS-PAGE using either 8% or 15% 
polyacrylamide gels. Thereafter, resolved proteins were transferred to polyvinylidene fluoride 
(PVDF) membranes (Millipore), which were then blocked with 2% (w/v) BSA in TBS for 1 h at 
room temperature. Membranes were subsequently probed with either the anti-phosphoserine 
(1:1000 dilution, Millipore), anti-phosphotyrosine (1:2000 dilution, Millipore) or anti-
phosphothreonine (1:1000 dilution, Cell Signaling Technology) monoclonal primary antibodies 
for 1 h at room temperature. All antibodies were diluted in 1X TBS containing 1% BSA (w/v) and 
0.2% (v/v) Tween-20 (BSA/TBST). After five rounds of washing with TBST, a peroxidase-
conjugated secondary antibody (1:3500 dilution in BSA/TBST, Thermo Scientific) was incubated 
with the membranes for 1 h at room temperature. The blots were then washed five times with 
TBST and developed using either the Advance Western Blotting Detection Kit (GE Healthcare) or 
the ECL Plus Western Blotting Substrate (Thermo Scientific). The blots were subsequently 
exposed to the CL-XPosure films (Thermo Scientific). To serve as controls for protein loading, 
duplicated SDS-PAGE gels were run and stained with Coomassie Blue. Densitometric 
quantification of the Western blot results was performed using the ImageJ software (Abramoff, 
2004). In some experiments, Western blotting was also performed with the Anti-His6 primary 









3.14 Dephosphorylation of Pfnek3 
 Purified recombinant Pfnek3 (10 µg) was dephosphorylated with either lambda 
phosphatase (500U, Millipore) or protein tyrosine phosphatase 1B (PTP1B, 5U, Millipore) 
following manufacturers’ recommendations. Each reaction mixture was allowed to incubate for 
30 min at 30°C. Subsequently, the activity of lambda phosphatase was terminated with a 10X 
phosphatase inhibitor cocktail (Thermo Scientific), while that of the PTP1B was inhibited using 
20 mM sodium orthovanadate (NEB). An aliquot of the resultant mixture was thereafter 
subjected to Pro-Q® Diamond gel staining/Western blotting as well as the ELISA-based kinase 
assay. 
 
3.15 Generation of Pfnek3 and Pfmap2 vector constructs for the split-ubiquitin assay 
 In order for Pfnek3 and Pfmap2 to be used as bait proteins in the split-ubiquitin assay, 
the genes of interest were cloned into the Cub-RUra3p bait vector (kindly provided by A/P 
Norbert Lehming, National University of Singapore) as described below. The gene encoding the 
full-length (FL)-Pfnek3 has been previously cloned in the laboratory and inserted into the pGEX-
6P-1 vector (Lye et al., 2006). The resultant recombinant plasmid was used in this study as the 
DNA template to amplify the FL-Pfnek3. On the other hand, the FL-Pfmap2 was amplified from 
the genomic DNA of P. falciparum (3D7 strain, MR4). The reaction components, primers and 
thermal cycling parameters used for PCR amplification are listed in Tables 3.6, 3.7 and 3.8, 
respectively.  
 Following PCR, the products were mixed with DNA loading dye (Fermentas) and 
resolved on 0.8% (w/v) agarose gel electrophoresis. DNA bands of the appropriate molecular 
weights were excised and extracted from the agarose gel using the QIAquick® Gel Extraction Kit 
(Qiagen) following the manufacturer’s instructions. The purified PCR products were then ligated 





into the pCR™-Blunt II-TOPO® vector using the Zero Blunt® TOPO® PCR Cloning kit (Invitrogen) 
according to manufacturer’s recommendations. After which, ligated products were transformed 
into the One Shot® TOP10 Chemically Competent E. coli cells (Invitrogen). The transformed cells 
were then selected on kanamycin-supplemented LB agar plates incubated overnight at 37oC. 
The next day, selected transformants were grown in LB broth containing kanamycin and the 
recombinant plasmids were thereafter extracted from the bacterial cells using the WizardTM Plus 
SV Minipreps DNA purification system (Promega). Recombinant plasmids that carried the 
desired DNA inserts were screened by restriction endonuclease (RE) analysis using EcorRI and 
SalI (NEB) according to manufacturer’s protocol. This was followed by verification of the gene 
sequences in the vector through DNA sequencing using the appropriate primers listed in Table 
3.4. 
Authenticated DNA fragments were subsequently subcloned into the Cub-RUra3p vector. 
For this procedure, gene inserts cloned into the pCR™-Blunt II-TOPO® vector were first released 
by EcorRI/SalI double digestion. The Cub-RUra3p vector was also subjected to the same RE 
treatment. RE-digested samples were then resolved by 0.8% agarose gel electrophoresis. The 
gene inserts and the linearized vector were respectively extracted from the gel, and purified 
using the QIAquick® Gel Extraction Kit (Qiagen). After which, ligation was carried out using T4 
DNA ligase following manufacturer’s recommendations (Invitrogen). Ligated products were 
thereafter transformed into the electrocompetent TOP10 cells (Sections 3.2 and 3.3) and 
transformants were selected on LB agar supplemented with ampicillin. The transformants were 
subsequently grown in LB broth containing ampicillin, before their plasmids were harvested and 
screened for the presence of DNA inserts by RE analysis. DNA sequencing was then carried out 
using the appropriate primers (Table 3.4) to verify the authenticity of the gene inserts in the Cub-
RUra3p vector.       





Table 3.6 PCR reaction components for the amplification of FL-Pfnek3 and FL-Pfmap2. 
Reaction Composition Amount (µl) 
DNA template  1.0 (approximately 0.5 - 0.8 µg) 
dNTPs (Applied Biosystems) 1.0 
Forward primer (10 pmol/µl) 1.0 
Reverse primer (10 pmol/µl) 1.0 
Pfu DNA polymerase (Promega) 0.5 





Table 3.7 Primers designed for cloning Pfnek3 and Pfmap2 into the Cub-RUra3p vector. The 
EcorRI and SalI restriction enzyme sites (underlined) were introduced at the 5’ end of the 
forward (F) and reverse (R) primers respectively. Primers were synthesized by Sigma-Aldrich.    











Table 3.8 Thermal cycling parameters used for the amplification of FL- Pfnek3 and FL-Pfmap2.   
Temperature (°C) Duration  
95 1 min   
95 30 sec 
 45  2 min                             35 cycles 
72 4 min 
4 Hold  
 
  





3.16 Vector construction for the bacterial expression of His6-tagged Pfmap2 
 The FL-Pfmap2 gene was cloned into the pET24a vector (Novagen) to facilitate 
expression of the His6-tagged Pfmap2 using bacterial cells. The methodology employed was 
similar to that described in Section 3.15 with minor variations. Briefly, the FL-Pfmap2 gene was 
first amplified by PCR from the verified pCR™-Blunt II-TOPO® plasmid carrying the gene of 
interest (generated in Section 3.15). PCR was performed using the reaction components and the 
thermal cycling conditions as listed in Tables 3.6 and 3.8 with the following primer pair: 5’-
ATCGTCGAATTCATGTTAAAAAAAAAAAAGG-3’ (Forward, EcoRI site underlined) and 5’- 
CGGAATCTCGAGCATATTGTAGAAACTTTTTTG-3’ (Reverse, XhoI site underlined). After the PCR 
product was resolved by 0.8% agarose gel electrophoresis, the DNA fragment of interest was 
excised and purified using the QIAquick® Gel Extraction Kit (Qiagen). The purified DNA fragment 
was subsequently double-digested with EcorRI and XhoI, and ligated into the pET24a vector 
linearized by the same RE treatment. Ligated products were next electro-transformed into E. coli 
BL21 (DE3)-CodonPlus™ cells. Transformants were selected on LB agar supplemented with 
chloramphenicol and kanamycin. The following day, selected transformants were grown in LB 
broth containing the same antibiotics, before their plasmids were harvested and screened for 
the presence of DNA inserts by RE analysis. Recombinant pET24a plasmids that carry an insert of 
the appropriate size was then subjected to DNA sequencing with the relevant primers (Table 
3.4) to validate the authenticity of the gene insert.  
  
3.17 Transformation of the Pfnek3- and Pfmap2- Cub-RUra3p recombinant plasmids into 
yeast cells 
 The Pfnek3- and Pfmap2-Cub-RUra3p constructs generated in Section 3.15 were 
independently transformed into Saccharomyces cerevisiae (JD52 strain, kindly provided by A/P 
Norbert Lehming) to examine the functionality of the respective Cub-RUra3p fusion proteins. A 





fresh colony of JD52 was picked from YPDA agar [1% (w/v) yeast extract, 2% (w/v) peptone, 2% 
(w/v) dextrose, 0.003% (w/v) adenine hemisulfate, 2% (w/v) agar] and inoculated into 5 ml of 
sterile YPDA broth. The liquid culture was incubated overnight at 28oC on a rotary shaker set at 
220 rpm. The next day, the yeast culture was diluted 50X in sterile YPDA broth, and allowed to 
grow for 3-5 h until OD600 was approximately 1. Yeast cells were subsequently harvested by 
centrifugation at 2000 rpm for 5 min, washed twice using sterile deionised water, and 
resuspended in an appropriate volume of lithium acetate solution (0.1 M lithium acetate/TE 
buffer). After incubation at 28oC for 1 h, a 5 µl aliquot of the yeast mixture was combined with 2 
µl of carrier DNA (fish sperm DNA, Roche Diagnostics) and 1 µl of DNA plasmids of interest. This 
was followed by addition of a 5X volume of PEG (polyethylene glycol). The contents were mixed 
by vortexing and thereafter incubated at 28oC for 30 min. Heat shock was then performed at 
42oC for 15 min. Transformed yeast cells were pelleted by a brief centrifugation and 
resuspended in an appropriate volume of deionised water. The resuspended cells were then 
plated on synthetic dropout agar medium lacking either tryptophan, or both tryptophan and 
uracil (Clontech). The plates were incubated at 28oC for three days, and the formation of 
colonies on both dropout agar plates would indicate the expression of functional Cub-RUra3p 
fusion proteins. 
 
3.18 In vitro interaction assay between Pfmap2 and PfHsp90 
Pfmap2 was examined for its interaction with the Plasmodium heat shock protein 90 
(PfHsp90) using a GST-pull down strategy as described in Chua et al, (2010). A pGK plasmid 
containing PfHsp90 (PlasmoDB identifier: PF07_0029) was previously generated in the 
laboratory (Chua et al., 2010) and provided as an E. coli BL21 (DE3)-CodonPlus™ recombinant 
clone for this investigation. PfHsp90 expressed from the pGK vector is a dual-tagged fusion 





protein, possessing an N-terminal GST tag and a C-terminal His6 tag. Following its expression in 
bacterial cells, the Ni2+ affinity chromatography was employed to purify the protein from the cell 
lysate (as illustrated in Section 3.7). The dual-tagged PfHsp90 was used as the bait protein in the 
interaction assay, while the His6-tagged Pfmap2 expressed from the pET24a vector (obtained in 
Section 3.16) served as a potential prey protein. 
For each experiment, 2 µg of PfHsp90 protein was incubated with 50 µl of glutathione-
sepharose beads at 4°C for 15 min. Thereafter, the beads were washed thrice with 50 mM Tris-
HCl (pH 7.5) to remove unbound proteins. Binding assay was then initiated with the addition of 
25 µg of purified Pfmap2 in 500 µl of reaction buffer [50 mM Tris-HCl (pH 7.5), 2 mM 
dithiothreitol and 0.01% (v/v) Triton X-100]. The assays were performed under different 
conditions, either in the presence or absence of 5 mM MgCl2, 5 mM ADP and 5 mM ATP. 
Samples were incubated at 30°C for 30 min for the PfHsp90-Pfmap2 complex formation. 
Following this, the beads were washed thrice with the reaction buffer prior to elution of the 
bound proteins with 150 µl of reduced glutathione. A 50 µl aliquot of the eluted sample was 
then subjected to analysis by SDS-PAGE. In some experiments, the eluted samples were also 
analyzed by Western blotting using the anti-His6, anti-GST or the anti-phosphothreonine 
antibodies.   
In experiments that required Pfmap2 to be phosphorylated prior to binding assay, the 
recombinant Pfmap2 was first subjected to kinase assay in the presence of immobilized GST-
tagged Pfnek3. For this reaction, 100 µl of bacterial cell lysate containing approximately 10 µg of 
GST-tagged Pfnek3 was applied to 50 µl of glutathione-sepharose beads. Unbound proteins 
were then removed by repeated washing with 50 mM Tris-HCl (pH 7.5). Following which, the 
glutathione-sepharose beads immobilized with Pfnek3 were reconstituted in 250 µl of kinase 
assay buffer. Subsequently, 25 µg of His-tagged Pfmap2 was added to the mixture and 





incubated at 30°C for 30 min. The reaction mix was then centrifuged and the supernatant 
containing the phosphorylated form of Pfmap2 was collected. As a control, His-tagged Pfmap2 
was subjected to a similar kinase assay reaction but without the presence of Pfnek3 (i.e. the 
unphosphorylated form). The respective supernatants were then added to bead-bound PfHsp90 
for the GST pull-down assay.   
 
3.19 Biocomputational analyses  
  Tertiary structure of Pfnek3 was predicted using the SWISS-MODEL program 
(http://swissmodel.expasy.org//SWISS-MODEL.html) (Schwede et al., 2003), based on templates 
which share at least 25% amino acid sequence similarity. The Pfnek3 amino acid sequence 
submitted for modeling process was retrieved from the Plasmodium genome database 
(http://plasmodb.org/). The Pfnek3 tertiary model, together with the crystal structure of human 
MAPKK1 (PDB identifier: 1S9J) (Ohren et al., 2004), were analyzed and compared using the 
Swiss-PdbViewer (http://expasy.org/spdbv/) (Guex and Peitsch, 1997). Prediction of potential 
tyrosine phosphorylation sites in Pfnek3 was carried out using the NetPhos server 
(http://www.cbs.dtu.dk/services/NetPhos/) (Blom et al., 1999). Using the Swiss-PdbViewer, the 
locality of the predicted phospho-tyrosine sites was determined in the Pfnek3 3D model 
generated above. Multiple sequence alignment analysis, when required, was performed using 
the ClustalW program (http://www.ebi.ac.uk/Tools/msa/clustalw2/ ) (Larkin et al., 2007).         
 
3.20 Reproducibility of results 
  All experiments conducted in this study were performed at least thrice to ensure the 
reproducibility of results, unless stated otherwise.  
  





4. Regulation of Pfnek3 relies on phosphorylation at its activation loop and at threonine 82 
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Chapter 4 Regulation of Pfnek3 relies on phosphorylation at its 
activation loop and at threonine 82  
 
(Low, H., Chua, C.S., and Sim, T.S. (2009). Regulation of Plasmodium falciparum Pfnek3 relies on 
phosphorylation at its activation loop and at threonine 82. Cell Mol Life Sci 66, 3081-3090) 
 
During the initial investigations on Pfnek3, the recombinant protein kinase was shown 
to activate Pfmap2 through phosphorylation of the threonine residue within the latter’s TSH 
activation site (Low et al., 2007; Lye et al., 2006). While the mechanism by which Pfnek3 
activates Pfmap2 has been elucidated, the regulation of its own catalytic activity remains 
unknown prior to this project. In a previous study, bacterially-expressed Pfnek3 was observed to 
exhibit a substantial level of phosphorylation (Lye et al., 2006). Given that phosphorylation is a 
widespread mechanism that governs the catalytic activity of numerous protein kinases including 
the MAPKKs (Roskoski, 2012b), the relevance of this post-translational modification in regulating 
Pfnek3 activity was thus investigated in this project.  
 
4.1 The activity of Pfnek3 was abrogated following dephosphorylation 
From an earlier study conducted in the laboratory, recombinant GST-Pfnek3 expressed 
from the pGEX-6P-1 vector was found to be a phosphorylated protein (Lye et al., 2006). As its 
catalytically inactive counterpart (GST-Pfnek3) lacks detectable phosphorylation (Lye et al., 
2006), Pfnek3 was postulated to possess an autophosphorylation activity. To validate this 
supposition, GST-Pfnek3 was treated with PreScission protease to cleave off the GST moiety 
from the fusion protein. Phosphoprotein gel staining was then performed to analyze the 
phosphorylation state of the resulting untagged Pfnek3. As illustrated in Figure 4.1a, the 
phosphoprotein stain detected a band of approximately 30 kDa which corresponded to that of 
the untagged Pfnek3. This observation indicates that the phosphorylation observed in the GST-





Pfnek3 fusion is attributed to the kinase and thereby supports the notion that Pfnek3 exhibits an 
autophosphorylation activity.    
 To further evaluate whether phosphorylation of Pfnek3 plays an essential role in 
regulating its kinase activity, GST-Pfnek3 was dephosphorylated with lambda phosphatase (an 
enzyme which removes phosphate groups on serine, threonine and tyrosine residues) before its 
activity was assayed. As revealed by the phosphoprotein gel stain analysis (Figure 4.1b), the 
lambda phosphatase-treated GST-Pfnek3 exhibited a significantly lower phosphorylation level as 
compared to that of the mock-treated sample. This observation verified the dephosphorylated 
state of GST-Pfnek3. Following which, dephosphorylated GST-Pfnek3 was subjected to an ELISA-
based kinase assay which has routinely been used to evaluate the kinase activity of Pfnek3 (Low 
et al., 2007; Lye et al., 2006). Since Pfnek3 was classified as a serine/threonine kinase due to the 
presence of a serine/threonine kinase-like signature motif (HGDLKSTN) on its catalytic loop, the 
kinase assay has been designed to determine its ability to phosphorylate serine and threonine 
residues in the exogenous MBP substrate (Lye et al., 2006). As illustrated in Figure 4.1c, the 
lambda phosphatase-treated GST-Pfnek3 did not exhibit a detectable level of kinase activity. On 
the other hand, pre-incubation of lambda phosphatase with a phosphatase inhibitor cocktail 
was shown to block both the dephosphorylation and the inactivation of GST-Pfnek3 (Figure 4.1b 
and c). Taken together, these results imply that the abrogation of Pfnek3 activity upon lambda 
phosphatase treatment was associated with the dephosphorylation of the kinase, and hence 
provide evidence that phosphorylation of Pfnek3 is implicated in enhancing its kinase activity.  
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Figure 4.1 Phosphorylation of Pfnek3 is essential for stimulating its kinase activity. 
(a) To authenticate the autophosphorylation activity of Pfnek3, purified GST-Pfnek3 was 
incubated with PreScission protease to cleave off the GST tag. The phosphorylation state of the 
resulting untagged Pfnek3 was subsequently analyzed using the Pro-Q® Diamond 
phosphoprotein gel stain. Coomassie-staining of the same gel depicts the total protein loaded 
for each lane. Lane M denotes the protein standard marker (Fermentas) used for estimating 
molecular weights of the proteins of interest. Result illustrated is representative of two 
independent experiments. (b and c) Dephosphorylation of Pfnek3 was carried out by incubating 
10 µg of the purified kinase (GST-tagged) with 500U of lambda phosphatase. After the 
dephosphorylation reaction, a 10X phosphatase inhibitor cocktail was added to the reaction mix 
to terminate the activity of lambda phosphatase. An aliquot of the mixture was then subjected 
to phosphoprotein analysis using the Pro-Q® Diamond phosphoprotein gel stain (b, lane 2) or 
the ELISA-based kinase assay (c, lane 2). For the protein kinase assay, the activity of Pfnek3 was 
examined based on its ability to phosphorylate MBP on the serine and threonine residues. In the 
mock-treated sample, lambda phosphatase was omitted from the dephosphorylation reaction (b 
and c, lane 1). The experiment conducted for lane 3 was similar to that of lane 2, except that the 
10X phosphatase inhibitor cocktail was pre-incubated with lambda phosphatase prior to 
dephosphorylation of Pfnek3. The phosphostain result is representative of two independent 
experiments. The ELISA-based kinase assay result is presented as a percentage of mock-treated 
Pfnek3 activity, with each bar representing the mean activity + standard deviation from two 
independent assays. ND denotes kinase activity not detected.  
  





4.2 Amino acid residue T82 is a phosphorylation site crucial for enhancing Pfnek3 activity 
 
Having validated the importance of phosphorylation in stimulating the kinase activity of 
Pfnek3, identification of its phosphorylation site(s) was subsequently pursued to gain further 
insights into the regulatory mechanism of Pfnek3 activity. For this part of the investigation, the 
purified GST-Pfnek3 was first resolved using SDS-PAGE, and the band which corresponded to the 
fusion kinase was excised and subjected to LC-MS/MS analysis (Materials and Methods, Section 
3.10). 
In total, ten unique tryptic peptides were identified by LC-MS/MS which constitute 38% 
of the Pfnek3 amino acid sequence (Figure 4.2). Among these, 74FETVLDFMTSDSEIHLIR91 was the 
only peptide found to be phosphorylated. It was further revealed that amino acid residue T82 is 
the exact phosphorylation site in the peptide as an additional 80 Da corresponding to the 
molecular weight of a phosphate group (HPO3) was detected on this residue (Figure 4.3a). When 
LC-MS/MS analysis of the catalytically inactive GST-Pfnek3 was performed, no phosphorylation 
was detected on the same site (Figure 4.3b). This finding validates that phosphorylation of 
residue T82 is attributed to the autocatalytic activity of Pfnek3. 
To assess whether T82 phosphorylation plays a crucial role in regulating the kinase 
activity of Pfnek3, site-directed mutagenesis was carried out to replace the threonine residue 
with a structurally-similar alanine to mimic dephosphorylation at this site (Figure 4.4). The 
phosphorylation state and the kinase activity of the resulting Pfnek3 mutant, hereafter referred 
to as T82A (GST-tagged), was then analyzed using the phosphoprotein gel stain and the ELISA-
based kinase assay, respectively. As illustrated in Figure 4.5, the T82A mutant exhibited a 
decrease in autophosphorylation by more than 50% relative to the wild-type kinase. This result 
was anticipated since elimination of the T82 phosphorylation site should lead to a reduction in 
the overall phosphorylation content of the kinase. In addition, the kinase activity of the T82A 





mutant was found to be diminished by more than 80% as compared with the wild-type Pfnek3 
(Figure 4.6). The obtained results support that phosphorylation of residue T82 is pivotal for 
stimulating the activity of Pfnek3. However, there remains the likelihood that this mutation may 
have compromised the structure and stability of the protein, and hence led to reduced Pfnek3 
activity and its autophosphorylation activities. Further investigations, such as circular dichroism 
spectroscopy would be useful for verifying this postulation.  
 
 
Figure 4.2 Sequence coverage obtained from LC-MS/MS analyses of Pfnek3.  
The amino acid sequence of Pfnek3 is shown. Sequences that were detected from two 
independent LC-MS/MS analyses are highlighted in yellow, and the identified T82 



































































Figure 4.3 MS/MS spectra of the 74FETVLDFMTSDSEIHLIR91 tryptic peptides derived from GST-
Pfnek3 and GST-∆Pfnek3. 
(a) When the wild-type GST-Pfnek3 was analyzed by LC-MS/MS, an additional 80 Da 
corresponding to the molecular weight of a phosphate group (HPO3) was detected on amino 
acid residue T82 (circled in red). The obtained result validates that residue T82 is a 
phosphorylation site in Pfnek3. (b) When LC-MS/MS analysis was performed on the catalytically 
inactive GST-Pfnek3, residue T82 was not found to be phosphorylated (circled in red). These 
results imply that the T82 phosphorylation detected in (a) was attributed to the autocatalytic 
activity of Pfnek3. The b and y ions represent the daughter ions yielded from the fragmentation 
of the 74FETVLDFMTSDSEIHLIR91 peptide during MS/MS analysis. The spectra shown are 
representative of two independent experiments.   
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Figure 4.4 Generation and validation of the T82A mutant of Pfnek3. 
The T82A mutant was generated via a PCR-mediated site-directed mutagenesis approach 
(Materials and Methods, Section 3.4). The recombinant pGEX-6P-1 plasmid carrying the wild-
type Pfnek3 served as the template for PCR, and the mutagenic primers used are listed in Table 
3.1. Illustrated in (a) is the agarose gel analysis of the mutagenesis PCR product. The authenticity 
of the mutant was then verified by DNA sequencing using the pGEX forward sequencing primer 
(Table 3.4). The section of the electropherogram shown in (b) corresponds to the site of 
mutation (underlined in red). All Pfnek3 site-directed mutants generated subsequently in this 
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Figure 4.5 Autophosphorylation levels of the Pfnek3 alanine-substituted mutants.  
(a) Affinity-purified GST-Pfnek3 and its mutants were resolved using SDS-PAGE and their 
autophosphorylation levels were analyzed using the Pro-Q® Diamond phosphoprotein gel stain 
(upper panel). The same gel was subsequently stained with Coomassie Blue and the visualized 
protein bands served as the loading control (lower panel). Result depicted is representative of two 
independent experiments. (b) Densitometric analysis of the result obtained in (a). Data is expressed 
as a percentage of wild-type GST-Pfnek3 autophosphorylation, with each bar representing the mean 
autophosphorylation level + standard deviation from two independent assays. ND denotes 

















Figure 4.6 Kinase activities of the Pfnek3 alanine-substituted mutants.  
The serine/threonine kinase activities of GST-Pfnek3 and its mutants were determined via the 
ELISA-based kinase assay using MBP as the substrate. Data is presented as a percentage of wild-
type GST-Pfnek3 activity, with each bar representing the mean activity + standard deviation 
from two independent assays. ND denotes kinase activity not detected. *Indicates significant 
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4.3 Pfnek3 possesses a SSEQSS sequence in its activation loop which resembles the 
activation motif conserved in the MAPKKs 
 
The low level of phosphorylation observed in the T82A mutant is indicative that residue 
T82 is not the sole phosphorylation site in Pfnek3. Additional Pfnek3 phosphorylation sites are 
likely to be present, and their identification may provide further insights into the regulatory 
mechanism of Pfnek3 activity. However, despite subjecting Pfnek3 to repeated LC-MS/MS 
analyses, residue T82 remained the only phosphorylation site detected. As such, an in silico 
approach was consequently adopted to predict candidate phosphorylation sites in Pfnek3. 
Activation of many eukaryotic protein kinases requires phosphorylation of the activation 
loop, a region in the kinase domain that spans the conserved DFG (subdomain VII) and APE 
(subdomain VIII) motifs (Figure 2.4). In Pfnek3, the APE motif was found to be substituted with a 
SYE sequence, and the segment bound by the DFG and SYE motifs corresponds to its kinase 
activation loop instead (Figure 4.7a). This segment encompasses five hydroxyl amino acid 
residues which might potentially be activating phosphorylation sites of Pfnek3: S221, S222, 
S225, S226 and T232. Notably, the SSEQSS sequence constituted by the four serine residues is 
reminiscent of the signature S/TXXXS/T motif present in the activation loop motif of MAPKKs, 
where the serine/threonine residue at both terminals have been identified as activating 
phosphorylation sites (Roskoski, 2012b). Moreover, when the 3D model of Pfnek3 was 
compared with the crystal structure of human MEK1, a well-characterized MAPKK, the SSEQSS 
motif was found to reside in a position that is analogous to the SMANS activation site of MEK1 
(Figure 4.7b). As such, it is reasonable to propose that the SSEQSS motif may represent the 
activation site in Pfnek3 and that phosphorylation of residues S221, S222, S225 and/or S226 may 
induce a stimulatory effect on Pfnek3 activity.  
 
 



































Figure 4.7 Pfnek3 possesses a MAPKK-like activation motif within its activation loop. 
(a) The Pfnek3 amino acid sequence flanked by the DFG and SYE motifs corresponds to its kinase 
activation loop. The SSEQSS motif within this segment (underlined) bears a resemblance to the 
S/TXXXS/T activation sites in MAPKKs. (b) As the crystal structure of Pfnek3 has not been solved, 
the 3D model of the kinase was generated using the SWISS-MODEL program. The modeled 
Pfnek3 (coloured blue), together with the crystal structure of human MEK1 (coloured pink, PDB 
identifier: 1S9J), were then visualized and examined using the Swiss-PdbViewer. The segment 
that represents the Pfnek3 activation loop is highlighted in yellow. The SSEQSS motif was found 
to reside on the surface of this loop, akin to that observed for the SMANS activation motif in 
MEK1 (both boxed up in blue). 
    
  





4.4 Mutation of residues S221 and S226 within the SSEQSS motif diminished Pfnek3 
autophosphorylation and kinase activity 
 
Based on the postulation that Pfnek3 activity may be regulated through phosphorylation 
of residues S221, S222, S225 and/or S226, site-directed mutagenesis was performed to replace 
each of the serine residues with a non-phosphorylatable alanine. In the event that any of these 
serine residues are activating phosphorylation sites, the mutation is anticipated to bring about a 
simultaneous reduction in the autophosphorylation level and the kinase activity of Pfnek3, akin 
to that observed for the validated T82A phosphorylation site mutant. 
The various serine-to-alanine mutants (hereafter referred to as S221A, S222A, S225A 
and S226A) were expressed as GST-tagged proteins in E. coli cells, and purified by affinity 
chromatography using glutathione-sepharose beads. The mutants were then analyzed by the 
Pro-Q® Diamond gel stain to examine their autophosphorylation levels. As depicted in Figure 
4.5, the S222A and S225A mutants displayed a level of autophosphorylation which was 
comparable with that of the wild-type Pfnek3. In contrast, autophosphorylation signals of the 
S221A and S226A mutants were substantially reduced by 55% and 40%, respectively, relative to 
that of the wild-type Pfnek3 (Figure 4.5). A double mutant combining the S221A and S226A 
mutations (S221A/S226A) was thereafter constructed, and it showed a lower 
autophosphorylation signal as compared to either of the individual single mutants. 
Following which, the effect of these serine-to-alanine mutations on Pfnek3 activity was 
examined using the microtiter plate kinase assay, based on the abilities of the mutant kinases to 
phosphorylate MBP on serine and threonine residues. The kinase activities of the S221A and 
S226A mutants were found to be considerably reduced (53% and 67% of the wild-type Pfnek3 
activity, respectively), while the activity of the S225A mutant was similar to that of the wild-type 
kinase (Figure 4.6). On the other hand, the S222A mutant exhibited a 26% increase in kinase 





activity relative to the wild-type Pfnek3. As for the S221A/S226A double mutant, its detected 
kinase activity was noticeably lower as compared to the respective single mutants. Taken 
together, since the S221A and S226A mutations brought about a concomitant reduction in the 
autophosphorylation level and the kinase activity of Pfnek3, it supports the notion that residues 
S221 and S226 within the SSEQSS motif are the activating phosphorylation sites in Pfnek3.  
 
4.5 S226E is a phosphomimetic mutant of Pfnek3 
 
Aspartate and glutamate substitutions have been used in many studies to mimic 
phosphorylation since both amino acids carry negative charges similar to that of a 
phosphorylated residue (Dissmeyer and Schnittger, 2011; Huang and Erikson, 1994). 
Analogously, replacing residues T82, S221 and S226 in Pfnek3 with an aspartate or a glutamate 
is anticipated to simulate the effects of phosphorylation at these positions and maintain the 
kinase in a constitutively activated state. Acquiring such phosphomimetic Pfnek3 mutants is of 
interest as they could serve as useful tools to investigate the cellular events that may occur 
upon its activation. The T82D/E, S221D/E and S226D/E mutants were consequently generated 
and assayed for their kinase activities. As depicted in Figure 4.8, S226E was the only mutant that 
displayed a considerably higher activity in comparison with the corresponding non-
phosphorylatable mutant (S226A). The result indicates that the presence of a glutamate at 
position 226 could mimic the activating effects of S226 phosphorylation and hence supports 
S226E as a phosphomimetic mutant of Pfnek3.      
  
 
   
















T82 14±2 24±5 25±4 
S221 53±10 ND ND 
S226 67±5 68±4 145±9 
 
 
Figure 4.8 Kinase activities of the phosphomimetic Pfnek3 mutants. 
Residues T82, S221 and S226 were each replaced with either an aspartate or a glutamate to 
mimic the effects of phosphorylation at these residues. The activities of these mutants were 
analyzed using the ELISA-based kinase assay, based on their abilities to phosphorylate MBP on 
serine and threonine residues. The assay result is presented as a percentage of wild-type Pfnek3 
activity, with each bar representing the mean activity + standard deviation from two 
independent assays. For easy reference, the kinase activities of the alanine-, aspartate- and 
glutamate-substituted mutants of T82, S221 and S226 are summarized in the lower panel. ND 






































































4.6 T82 and S226 phosphorylation are crucial for Pfnek3 to activate Pfmap2 
 
Thus far, the results obtained have shed light on the importance of T82, S221 and S226 
phosphorylation in enhancing Pfnek3 activity. Since Pfnek3 has been demonstrated as an 
upstream activator of Pfmap2 (Lye et al., 2006), further investigation was pursued to evaluate if 
these phosphorylation sites could also influence Pfnek3’s ability to activate Pfmap2. For this part 
of the study, a co-incubation kinase assay was employed whereby Pfmap2 (GST-tagged, 3µg) 
was mixed with Pfnek3 or its mutants (Pfnek3, T82A, S221A or S226A, GST-tagged, 5ng) in the 
MBP-coated microtiter wells. The detection of a synergistic increase in MBP phosphorylation 
would serve as an indication of Pfmap2 activation by Pfnek3, as validated previously in Lye et al., 
(2006). 
As depicted in Figure 4.9a, co-incubation of Pfmap2 with the wild-type Pfnek3 led to an 
increase in Pfmap2 activity by approximately 70 folds (Figure 4.9a). A comparable trend was 
observed when Pfmap2 was mixed with the S221A mutant, indicating that the latter was as 
competent as the wild-type kinase in stimulating Pfmap2 activity. However, the T82A and the 
S226A mutants were less competent in activating Pfmap2 as their presence could only enhance 
Pfmap2 activity by 17 and 45 folds, respectively. One possible explanation for these outcomes 
could be that T82 and S226 phosphorylation, but not S221 phosphorylation, are essential for 
Pfnek3 to phosphorylate and thereby activate Pfmap2. To verify this supposition, the 
phosphorylation level of Pfmap2 was analyzed following its incubation with the wild-type or the 
mutant Pfnek3 proteins in a kinase assay mix. The phosphostain result in Figure 4.9b revealed 
that the S221A mutant could phosphorylate Pfmap2 to a similar extent as the wild-type Pfnek3. 
Conversely, the T82A and the S226A mutants showed reduced abilities in phosphorylating 
Pfmap2 (Figure 4.9b). Taken together, these results provide evidence that T82 and S226 





phosphorylation are essential for Pfnek3 to phosphorylate and activate its downstream Pfmap2 















































































   














































Figure 4.9 Effects of the T82A, S221A and S226A mutations on the ability of Pfnek3 to activate Pfmap2.  
(a) Using the co-incubation kinase assay, 5 ng of wild-type GST-Pfnek3 or the indicated mutants were 
mixed with 3 µg of GST-Pfmap2 in MBP-coated microtiter plate wells. When existed alone, or mixed with 
the kinase-dead GST-Pfnek3, GST-Pfmap2 displayed a low level of kinase activity (lanes 1 and 3). In the 
presence of the wild-type GST-Pfnek3, the activity of GST-Pfmap2 was increased by approximately 70 
folds. A similar trend was observed with the S221A mutant, while both the T82A and the S226A mutants 
showed diminished abilities to activate GST-Pfmap2. The kinase activity detected here corresponded 
largely to that of Pfmap2, since no measurable kinase activity was observed when 5 ng of the respective 
Pfnek3 proteins were assayed individually using the same protocol (result not shown).  (b) After GST-
Pfmap2 was incubated with the indicated Pfnek3 proteins in a kinase assay mix, the kinases were resolved 
by SDS-PAGE and subjected to phosphoprotein staining to determine the phosphorylation level of GST-
Pfmap2. Coomassie-stained gel of the same experiment served as the loading control. M denotes the 
protein standard marker. Densitometric analysis of the phosphostaining result is presented in the lower 
panel. Data is expressed as a percentage of GST-Pfmap2 phosphorylation by wild-type GST-Pfnek3, with 
each bar representing the mean phosphorylation level + standard deviation from two independent assays.   
*Indicates significant differences with P-values of <0.05.   
  






As Pfnek3 has previously been found to be an unusual MAPKK in P. falciparum (Lye et 
al., 2006), further characterization of Pfnek3 was pursued in this study to elucidate its mode of 
regulation. The validation that Pfnek3 was autophosphorylated following bacterial expression 
led to the postulation that its kinase activity could be regulated through phosphorylation. This 
notion was supported when dephosphorylation of the recombinant Pfnek3 resulted in the 
abrogation of its kinase activity (Figures 4.1b and c). To identify Pfnek3 autophosphorylation 
sites that might be implicated in enhancing its kinase activity, LC-MS/MS analyses of the kinase 
was subsequently conducted. The results obtained revealed that residue T82 within the 
74FETVLDFMTSDSEIHLIR91 tryptic peptide is a site of phosphorylation in Pfnek3 (Figure 4.3). Since 
phosphorylation of the same amino acid residue was not detected in the catalytically inactive 
Pfnek3, it verifies that T82 phosphorylation was attributed to the autocatalytic activity of the 
kinase. Using a combination of site-directed mutagenesis and ELISA-based kinase assays, 
phosphorylation of T82 was further shown to be essential for stimulating the activity of Pfnek3 
(Figure 4.6). 
In most eukaryotic protein kinases, subdomain I harbors a characteristic glycine triad 
(GXGXXG) which is crucial for anchoring ATP during the phosphoryl-transfer process (Dissmeyer 
and Schnittger, 2011). However, sequence analysis of Pfnek3 has revealed that the glycine triad 
is not present in the kinase (Lye et al., 2006). The corresponding region is instead replaced by a 
non-consensus FMTSDS sequence where residue T82 is located (highlighted in bold). Presently, 
assessing the basis by which T82 phosphorylation induces Pfnek3 activation remains a challenge. 
This is because the crystal structure of Pfnek3 has yet been solved and the region where residue 
T82 resides was not represented in the Pfnek3 model (presumably due to low sequence 
similarities between Pfnek3 and the modeling templates at this region). Moreover, 





phosphorylation in the vicinity of the glycine triad has not been reported in other eukaryotic 
kinases. Nonetheless, since residue T82 resides in kinase subdomain I which typically interacts 
with the ATP moiety, its phosphorylation might plausibly induce a remodeling of the ATP binding 
site and thereby increase the activity of Pfnek3 by improving its affinity for ATP. However, until 
the crystal structures of Pfnek3 in both the unphosphorylated and phosphorylated states are 
made available, the bona fide role of T82 phosphorylation in enhancing Pfnek3 activity remains 
debatable.   
The phosphorylation detected in the T82A mutant is indicative that amino acid residue 
T82 is not the sole phosphorylation site in Pfnek3. Additional phosphorylation sites are likely to 
be present, which could potentially undertake an important role in regulating Pfnek3 activity. 
However, despite subjecting Pfnek3 to repeated LC-MS/MS analyses, residue T82 remained the 
only phosphorylation site detected. Considering that the sequence coverage of Pfnek3 yielded 
from LC-MS/MS analyses was incomplete (38%, Figure 4.2), phosphorylation sites that may 
reside within the unidentified sequences could have escaped detection. Incomplete protein 
sequence coverage is a prevalent limitation in mass spectrometry, since not all protease-
digested peptides will fall within an optimum mass range for efficient detection by the mass 
spectrometer (Blackburn and Goshe, 2009). Besides the issue of low protein sequence coverage, 
phosphorylated peptides are also intrinsically more difficult to be detected by mass 
spectrometry as compared to their unphosphorylated counterparts (Lee et al., 2002). This is 
because the phosphate groups are often not as efficiently protonated and peptides which are 
not completely protonated tends to be undetectable by the mass spectrometer (Lee et al., 
2002). Hence, in this context, it remains plausible that the identified non-phosphorylated 
peptides of Pfnek3 may possess phosphorylated counterparts which mass spectrometry had 
failed to detect due to inefficient protonation. 





Given the aforementioned limitations of detecting Pfnek3 phosphorylation sites by LC-
MS/MS, an in silico approach was consequently adopted to identify candidate phosphorylation 
site(s) in the kinase. For a number of eukaryotic kinases, phosphorylation within specific motifs 
found in the kinase activation loop is fundamental for their activation (Adams, 2003). In NIMA-
like kinases, stimulation of catalytic activities requires phosphorylation of the threonine residue 
within the consensus FXXT motif (Pu et al., 1995). However, Pfnek3 was observed to possess a 
SSEQSS motif within its activation loop which resembles the characteristic S/TXXXS/T activation 
site of MAPKKs instead. A comparison of the Pfnek3 model with the human MEK1 crystal 
structure revealed that the SSEQSS motif resides in a position that is analogous to the SMANS 
activation motif of MEK1 (Figure 4.7). Phosphorylation of both serines within the SMANS motif 
has been validated to be a prerequisite for MEK1 activation (Zheng and Guan, 1994). Thus, the 
co-location of the SSEQSS motif with known activation site of MEK1 highlights its potential to 
serve as a phospho-activating site in Pfnek3. To verify this notion, the serine residues within the 
SSEQSS motif were separately mutated to an alanine residue and the mutants were examined 
for their autophosphorylation levels and kinase activities. With reference to Figures 4.5 and 4.6, 
the S221A and S226A mutants exhibited significant reduction in kinase activities which was 
accompanied by simultaneous decrease in autophosphorylation levels. These results support 
residues S221 and S226 as phosphorylation sites associated with enhancing the activity of 
Pfnek3. A serine residue differs from an alanine by the presence of a hydroxyl group in its amino 
acid side chain. However, the absence of a hydroxyl group due to the S221A or S226A mutation 
is unlikely to have diminished Pfnek3 activity due to structural perturbation, since both hydroxyl 
groups were not observed to form hydrogen bondings with neighboring amino acid residues 
upon analysis of the Pfnek3 model (Figure 4.10). 





Structural studies of eukaryotic protein kinases have revealed that activation loop 
phosphorylation is often accompanied by conformational changes in the loop region (Nolen et 
al., 2004). In the unphosphorylated state, activation loops are typically disordered and adopt 
distinct configurations in different protein kinases (Nolen et al., 2004). Upon phosphorylation, 
the loops undergo a remodeling process which consequently stabilizes them in a highly similar 
configuration (Figure 4.11). This conformational change reportedly enhances the activity of 
protein kinases by improving their substrate binding affinity and/or catalytic efficiency (Nolen et 
al., 2004). With regards to Pfnek3, the lack of crystal structures of its unphosphorylated and 
phosphorylated forms also impeded evaluation of the mechanism by which activation loop 
phosphorylation stimulates its activity. Nonetheless, the activation loop of the Pfnek3 model 
was observed to adopt a configuration that deviates from the phosphorylated counterparts of 
several well-studied protein kinases (Figure 4.11). Hence, it indicates that the modeled Pfnek3 
activation loop is not likely to have assumed an active conformation. Phosphorylation of 
residues S221 and S226 may thus be essential to induce a rearrangement of the Pfnek3 
activation loop and thereby promotes its activation through enhancing substrate binding and/or 

















Figure 4.10 Structural analysis of amino acid residues S221 and S226 in the Pfnek3 model. The 
region where the activation loop resides is enlarged and shown on the right. Residues S221 and 
S226 are both colored red, with their hydroxyl side chains highlighted in a lighter shade. Amino 
acid residues that are within 4Å distance from S221 and S226 are coloured grey. The side chains 
of S221 and S226 were not observed to form hydrogen bondings with the neighboring amino 
acid residues.  
 








































Figure 4.11 Comparison of the activation loop of Pfnek3 with the phosphorylated counterparts 
of well-studied protein kinases.  
Using the Swiss-PdbViewer, the modeled Pfnek3 was superimposed with the crystal structures 
of well-studied protein kinases phosphorylated at the activation loop [ERK2 (PDB identifier: 
2ERK), insulin receptor protein kinase (PDB identifier: 1IR3), cyclin-dependent protein kinase 
(PDB identifier: 1QMZ) and cAMP-dependent protein kinase (PDB identifier: 1CDK); kinases are 
individually coloured as depicted]. The center of the figure shows the superimposed activation 
loops of the respective protein kinases. Notably, the conformation of the Pfnek3 activation loop 
(yellow) was observed to be distinct from the rest of the phosphorylated activation loops.  





Having demonstrated that phosphorylation of residues T82, S221 and S226 plays a 
critical role in enhancing Pfnek3 activity, the T82D/E, S221D/E and S226D/E mutants were 
subsequently generated. These replacements were anticipated to simulate the activating effects 
of phosphorylation at the respective sites, since aspartate and glutamate carry negative charges 
similar to that of a phosphorylated residue (Dissmeyer and Schnittger, 2011; Huang and Erikson, 
1994). In successful cases, such as that reported for MEK1 (Huang et al., 1995), the 
aspartate/glutamate-substituted mutants were constitutively activated and served as valuable 
tools for investigating the functions of the kinases in vivo. For Pfnek3, the S226E mutation was 
found to be competent in mimicking the activating effect of S226 phosphorylation (Figure 4.8). 
Peculiarly, a similar trend was not observed for the S226D mutation which likewise introduced a 
negative charge at position 226. This phenomenon could be reasoned by the fact that glutamate 
residue, which is one bond longer than aspartate at the side chain, is structurally more similar to 
phosphoserine. Hence, it implies that other than introducing negative charges, the length of the 
amino acid side chain is as crucial for recapitulating the effect of S226 phosphorylation. With 
regards to the ineffective T82D/E and S221D/E mutations, it could be the case that the single 
negative charge on aspartate/glutamate is insufficient to mimic the effects that arise from the 
double negative charges carried on a phosphorylated residue. 
As the P. falciparum MAPK homologue, Pfmap2, was previously found to be activated 
through phosphorylation by Pfnek3 (Lye et al., 2006), this study also examined whether T82, 
S221 and S226 phosphorylation exert an influence on the ability of Pfnek3 to activate Pfmap2. 
As illustrated in Figure 4.9, the T82A and S226A mutants showed diminished competency to 
phosphorylate and trigger Pfmap2 activation. The result implies that T82 and S226 
phosphorylation are crucial for Pfnek3 to regulate Pfmap2 activity. However, the S221A mutant 
was found to phosphorylate and activate Pfmap2 in a manner that was similar to the wild-type 





kinase, suggesting that S221 phosphorylation is dispensable for the process. This finding was in 
contrast to the diminished activity detected when the S221A mutant was assayed using the MBP 
substrate. A plausible explanation is that phosphorylated S221 may serve as an essential binding 
site for Pfnek3 to interact with the MBP substrate, but not Pfmap2. Hence, the absence of the 
binding site via alanine substitution could have distorted the Pfnek3-MBP interaction and 
thereby lead to a reduced phosphorylation of the MBP substrate. 
In summary, the results obtained in this chapter have demonstrated that regulation of 
Pfnek3 relies on phosphorylation within the SSEQSS activation motif and at residue T82. Hence, 
apart from sharing a similar mode of MAPK activation as the classical MAPKKs, Pfnek3 was also 
revealed to be regulated in a manner that closely resembles the MAPKKs. It is also noteworthy 
to mention that although the detected T82, S221 and S226 phosphorylation was attributed to 
the autocatalytic activity of Pfnek3, the possibility remains that these sites may be 
phosphorylated by regulatory kinases in vivo, as reported previously for several protein kinases 
(Adams, 2003). In view of this, it is imperative to identify interacting protein partners of Pfnek3 
so as to gain further insights into its mode of regulation. 





Chapter 5 Pfnek3 exhibits a unique dual-specificity serine/threonine 
and tyrosine kinase activity 
 
(Low, H., Chua, C.S., and Sim, T.S. (2012). Plasmodium falciparum possesses a unique dual-specificity 
serine/threonine and tyrosine kinase, Pfnek3. Cell Mol Life Sci 69, 1523-1535.) 
 
  
Eukaryotic protein kinases are broadly classified into two major classes based on 
whether they phosphorylate the aliphatic hydroxyl group of serine/threonine residue or the 
aromatic hydroxyl group of tyrosine residue. Despite sharing a significant degree of sequence 
similarities within their kinase domains, both groups of protein kinases can generally be 
differentiated by their signature amino acid motifs located in the catalytic loops: the 
serine/threonine kinases typically exhibit a HRDLKxxN motif, while the tyrosine kinases display 
either a HRDLAARN or a HRDLRAAN sequence (Hanks and Hunter, 1995). Apart from the 
serine/threonine and the tyrosine protein kinases, there is also a small group of dual-specificity 
kinases that catalyzes phosphorylation of both types of hydroxyl amino acid residues. These 
kinases lack a distinguishing sequence motif and typically possess amino acid sequences that are 
more related to the serine/threonine kinases (Lindberg et al., 1992). Consequently, most of the 
dual-specificity protein kinases were discovered serendipitously rather than by rational 
identification. In the case of the dual-specificity MAPKKs, their existence came to light as a result 
of searching for protein kinases that are responsible for phosphorylating MAPKs on the 
threonine and tyrosine residues within the TXY motifs (Seger et al., 1992). Instead of isolating 
separate kinases that could phosphorylate either the threonine or the tyrosine residue, a single 
kinase (i.e. the MAPKK) was unexpectedly found to be capable of phosphorylating both residues 
(Seger et al., 1992). Considering that the dual-specificity functionality signifies a physiologically-
relevant characteristic of MAPKKs, investigations were pursued to evaluate whether Pfnek3 
similarly possesses such unique property. 





5.1 Pfnek3 is autophosphorylated on tyrosine in addition to serine and threonine residues  
 In Chapter 4, mass spectrometry and site-directed mutagenesis studies had 
demonstrated that residues T82, S221 and S226 are autophosphorylation sites in Pfnek3. These 
findings are reflective of the serine/threonine kinase activity expected of Pfnek3. To explore 
whether Pfnek3 possesses a dual-specificity kinase activity, its competency to 
autophosphorylate on tyrosine residues was consequently evaluated. As the phosphoprotein gel 
stain used in Chapter 4 was unable to distinguish phosphorylation among serine, threonine and 
tyrosine residues, Western blot analysis of Pfnek3 was therefore performed using the anti-
phosphotyrosine antibody to detect the presence of tyrosine phosphorylation in Pfnek3. As 
illustrated in Figure 5.1, the wild-type Pfnek3 (GST-tagged) was found to be immunoreactive 
with the anti-phosphotyrosine antibody. On the contrary, no detectable signal was observed for 
its catalytically inactive counterpart (∆Pfnek3). These findings validate that recombinant Pfnek3 
is autophosphorylated on tyrosine residue(s). In addition, a significant signal was detected when 
wild-type Pfnek3 was probed with either the anti-phosphoserine or the anti-phosphothreonine 
antibody (Figure 5.1). This could plausibly be attributed to the phosphorylation of residues 
S221/S226 and T82, respectively. Collectively, the competency of Pfnek3 to autophosphorylate 
on tyrosine, in addition to serine and threonine residues, supports that the kinase possesses a 


























Figure 5.1 Recombinant Pfnek3 is autophosphorylated on tyrosine, serine and threonine 
residues. 
Recombinant wild-type Pfnek3 and its kinase-dead counterpart (4 µg each) were resolved in 
quadruplicates using 8% polyacrylamide gels. Three of the replicates were then transferred to 
PDVF membranes and probed separately with the anti-phosphotyrosine, anti-phosphoserine or 
the anti-phosphothreonine antibodies (denoted by Anti P-Tyr, Anti P-Ser and Anti P-Thr, 
respectively). The remaining gel was stained with Coomassie-blue and served as the loading 















5.2  Pfnek3 exhibits a dual-specificity activity on the exogenous MBP substrate, but 
phosphorylates its Plasmodium substrate, Pfmap2, mainly on threonine 290 
 
 To further characterize the dual-specificity kinase activity of Pfnek3, its ability to 
phosphorylate substrates on both the tyrosine and the serine/threonine residues was examined. 
As MBP has routinely been used as the exogenous substrate to assay for the serine/threonine 
kinase activity of Pfnek3, it was also employed in the present investigation to assay for the 
tyrosine kinase activity of Pfnek3. Kinase assay was first performed by co-incubating MBP and 
the recombinant Pfnek3 in a buffer that contained ATP and the metal cofactor (Mg2+ or Mn2+). 
An aliquot of the assay mixture was subsequently subjected to Western blotting using the anti-
phosphotyrosine antibody to analyze the tyrosine phosphorylation state of MBP. As observed in 
Figure 5.2, the presence of Pfnek3 in the assay mix considerably increased the level of 
phosphotyrosine signal detected in MBP, thus implying that Pfnek3 exerts a tyrosine kinase 
activity towards the exogenous MBP substrate. Furthermore, densitometric analysis of the 
immunoblot revealed that the phosphotyrosine signal of MBP detected in the presence of Mn2+ 
was 61% higher as compared to that detected in the presence of  Mg2+ (Figure 5.2). This 
observation is suggestive that Mn2+ is the preferred metal cofactor for supporting the tyrosine 
kinase activity of Pfnek3 in vitro.  
 Typically, the mixed anti-phosphoserine and anti-phosphothreonine antibodies were 
used in the ELISA-based kinase assay to determine the serine/threonine kinase activity of Pfnek3 
towards the MBP substrate. However, whether phosphorylation had occurred on serine and/or 
threonine residues could not be distinguished. In view of this, a separate aliquot of the Pfnek3-
MBP assay mix was also subjected to Western blotting using either the anti-phosphoserine or 
the anti-phosphothreonine antibodies to delineate the Pfnek3 phosphorylation specificity on 
MBP. As illustrated in Figure 5.2, a significant MBP phosphothreonine signal was detected in the 
presence of Pfnek3. Notably, the phosphothreonine signal of MBP observed in the presence of 





Mg2+ was higher as compared to that detected in Mn2+, a trend which contrasted that observed 
for the tyrosine phosphorylation of MBP (Figure 5.2). On the other hand, no significant 
difference in the phosphoserine signal of MBP was observed in the presence or absence of 
Pfnek3. Collectively, the results presented in Figure 5.2 indicate that Pfnek3 phosphorylates the 
MBP substrate on tyrosine and threonine, but not on serine residues. As Pfnek3 exhibited the 
ability to phosphorylate its substrate on both the aliphatic and the aromatic hydroxyl amino acid 
residues, its functionality as a dual-specificity kinase is further strengthened. In addition, the 
Mg2+ and Mn2+ cofactors could plausibly play distinct roles in stimulating the serine/threonine 
and the tyrosine kinase activities of Pfnek3. 
Of the two MAPKs (Pfmap1 and Pfmap2) in P. falciparum, Pfnek3 was demonstrated to 
phosphorylate only Pfmap2 in vitro (Lye et al., 2006). Hence, the dual-specificity kinase activity 
of Pfnek3 was also evaluated using Pfmap2 as the substrate to assess the potential relevance of 
this unique activity in vivo. A catalytically inactive form of Pfmap2 (denoted as ∆Pfmap2, GST-
tagged) was used as the assay substrate to rule out any effects that might arise from its 
autophosphorylation. ∆Pfmap2 was co-incubated with Pfnek3 in the presence of ATP and 
Mg2+/Mn2+ before aliquots of the mixture were analyzed by Western blotting. As depicted in 
Figure 5.3, a notable phosphothreonine signal was detected in ∆Pfmap2 upon its incubation 
with Pfnek3. Densitometric quantification of the immunoblot further revealed that the 
phosphothreonine signal detected in the presence of Mg2+ was 154% more intense as compared 
to that detected in Mn2+ (Figure 5.3). On the other hand, ∆Pfmap2 was not observed to exhibit a 
phosphotyrosine signal in the presence or absence of Pfnek3 (Figure 5.3). The basal 
phosphoserine signal of ∆Pfmap2 was also not evidently enhanced upon the addition of Pfnek3 
into the reaction mixture. Since ∆Pfmap2 is catalytically inactive, the detected phosphoserine 
signal could plausibly be an effect of bacterial kinase phosphorylation when it was 





heterologously expressed in E. coli. Taken together, the results shown in Figure 5.3 imply that 
Pfnek3 mainly exerts a threonine kinase activity on Pfmap2, with Mg2+ being the preferred metal 
cofactor. 
Via mass spectrometry, Pfnek3 was previously verified to phosphorylate Pfmap2 on the 
T290 threonine residue within the TSH activation site (Low et al., 2007). Hence, the 
phosphothreonine signal detected in ∆Pfmap2 following its incubation with Pfnek3 was likely to 
be attributed to the phosphorylation of T290 by Pfnek3. To investigate whether residue T290 
represents a major site in Pfmap2 that is phosphorylated by Pfnek3, the ∆Pfmap2/T290A 
mutant was generated via site-directed mutagenesis. Following which, phosphorylation of 
∆Pfmap2 and ∆Pfmap2/T290A by Pfnek3 was examined using the Pro-Q® phosphoprotein gel 
stain. As illustrated in Figure 5.4, the phosphorylation detected for ∆Pfmap2/T290A was 
diminished by 89% as compared to that detected for ∆Pfmap2. Since the absence of the T290 
phosphorylation site led to a significant reduction in the phosphorylation of Pfmap2 by Pfnek3, 




























Figure 5.2 Pfnek3 exhibits a dual-specificity kinase activity on the exogenous MBP substrate. 




 using MBP as the 
substrate. Aliquots of the mixtures were resolved by SDS-PAGE and the phosphorylation level of MBP was 
analyzed by Western blot using the indicated phospho-specific antibodies. To serve as loading control, an 
aliquot of the assay mixture was also subjected to SDS-PAGE followed by Coomassie-staining. Blots and 
gel depicted is representative of three independent experiments. Densitometric quantification of the 
Western blots is presented in graphical format at the lower panel. For referencing purpose, 





). Each bar depicts the mean phosphorylation level ± standard deviation 
from three independent experiments. ND denotes kinase activity not detected. *Indicates significant 



































Figure 5.3 Pfnek3 exerts a threonine kinase activity on Pfmap2.  




 using ∆Pfmap2 as the 
substrate. Aliquots of the mixtures were resolved by SDS-PAGE and the phosphorylation status of 
∆Pfmap2 was analyzed by Western blot using the indicated phospho-specific antibodies. To serve as 
loading control, an aliquot of the assay mixture was also subjected to SDS-PAGE followed by Coomassie-
staining. Blots and gel depicted is representative of three independent experiments. Densitometric 
quantification of the Western blot results is presented in graphical format at the lower panel. For 
referencing purpose, phosphorylation levels are expressed as percentages of ∆Pfmap2 phosphorylation in 




). Each bar depicts the mean phosphorylation 
level ± standard deviation from three independent experiments. ND denotes kinase activity not detected. 








































































































































































Figure 5.4 Residue T290 of Pfmap2 is the major site phosphorylated by Pfnek3.  
In vitro Pfnek3 assay was conducted in reaction buffers supplemented with ATP, Mg2+ and either 
the ∆Pfmap2 or the ∆Pfmap2/T290A substrate. Phosphorylation of the respective substrates 
was subsequently examined using the Pro-Q® Diamond phosphoprotein gel stain. Coomassie-
staining of the same gel served as the loading control for each sample. A representative 
phosphostain result of three independent experiments is illustrated. Densitometric 
quantification of the phosphostain result is shown at the lower panel. Result is expressed as a 
percentage of ∆Pfmap2 phosphorylation, with each bar representing the mean phosphorylation 
level ± standard deviation from three independent assays. *Indicates significant differences with 













5.3 Tyrosine phosphorylation plays a crucial role in stimulating the serine/threonine and 
the tyrosine kinase activities of Pfnek3 
 
In Chapter 4, both threonine and serine phosphorylation (i.e. at T82 and S221/S226 
respectively) were demonstrated to play an integral role in stimulating the kinase activity of 
Pfnek3. With the revelation that recombinant Pfnek3 is also autophosphorylated on tyrosine 
residue(s), it is thus of interest to examine whether tyrosine phosphorylation likewise exerts an 
influence on Pfnek3 activity. In line with this objective, recombinant Pfnek3 was 
dephosphorylated with a tyrosine-specific phosphatase, PTP1B, before its activity was examined 
via the ELISA-based kinase assay using MBP as substrate. As Pfnek3 was found to phosphorylate 
MBP on both the aliphatic and the aromatic hydroxyl amino acid residues (Figure 5.2), the 
effects of PTP1B treatment on both its serine/threonine and tyrosine kinase activities were 
evaluated. In comparison with the untreated Pfnek3 control, the PTP1B-treated kinase showed a 
34% reduction in its serine/threonine kinase activity, while its tyrosine kinase activity was 
lowered by 73% (Figure 5.5a). Since PTP1B treatment of Pfnek3 significantly diminished 
phosphorylation of its tyrosine, but not its serine or threonine residues (Figure 5.5b), it implies 
that the decreased activities of Pfnek3 was associated with the reduction of its tyrosine 
phosphorylation. Collectively, these results support the notion that tyrosine phosphorylation is 
critical for stimulating the serine/threonine and the tyrosine kinase activities of Pfnek3.  
 
5.4 Residues Y99, Y117, Y122, Y172, Y238 and Y286 are candidate tyrosine 
phosphorylation sites in Pfnek3  
 
Having demonstrated the importance of tyrosine phosphorylation in enhancing the 
dual-kinase activity of Pfnek3, identifying the tyrosine phosphorylation sites in Pfnek3 was 
subsequently pursued to gain further insights into the regulation of its activity. However, the 
mass spectrometric analyses conducted in Section 4.2 could not detect the sites of tyrosine 





phosphorylation in Pfnek3. Moreover, the activation loop of Pfnek3 lacks tyrosine residues 
which impeded the mapping of potential tyrosine phosphorylation sites. Due to these obstacles, 
a biocomputational approach was undertaken to predict tyrosine phosphorylation sites in 
Pfnek3 using the NetPhos software (Blom et al., 1999). As listed in Table 5.1, six candidate 
Pfnek3 tyrosine phosphorylation sites at positions 99, 117, 122, 172, 238 and 286 were 
identified. Upon analyzing the 3D model of Pfnek3, these tyrosine residues were found to be 
located on the surface of the protein structure with their hydroxyl side chains projecting 
outwards (Figure 5.6a).  





















Figure 5.5 Effects of PTP1B treatment on the serine/threonine and the tyrosine kinase 
activities of Pfnek3.  
(a) Recombinant GST-tagged Pfnek3 (10 µg) was treated with 5U of PTP1B as described in 
Section 3.14 (Material and Methods). In the control experiment, PTP1B was omitted. After 
incubation at 30°C for 30 min, sodium orthovanadate (final concentration: 20 mM) was added to 
the reaction mixture to terminate the activity of PTP1B. Aliquots of the mixtures were then 
subjected to the ELISA-based kinase assay using MBP as the substrate. The serine/threonine and 
the tyrosine kinase activities of Pfnek3 were separately assessed, based on the level of MBP 
phosphorylation detected using the mixed anti-phosphoserine/threonine and the anti-
phosphotyrosine antibodies respectively. Results are expressed as a percentage of untreated 
Pfnek3 activity, with each bar representing the mean activity ± standard deviation from two 
independent assays. (b) Aliquots of the PTP1B-treated and the control samples were resolved by 
SDS-PAGE and subjected to Western blot using the indicated antibodies or Coomassie-staining 
which served as the loading control. The results illustrated are representative of two 
independent experiments. *Indicates significant differences with P-values of <0.05. 





Table 5.1 Potential Pfnek3 tyrosine phosphorylation sites predicted by the NetPhos program 
(http://www.cbs.dtu.dk/services/NetPhos/). The score represents the probability of each 
tyrosine residue to be a phosphorylation site. The locality of the residues in the 3D model of 
Pfnek3 is also indicated.   
 
Tyrosine Position Score Location in Pfnek3 Model 
99 0.981 Surface 
117 0.539 Surface 
122 0.936 Surface 
172 0.959 Surface 
238 0.923 Surface 
286 0.510 Surface 
 
  














































Figure 5.6 Positions of the predicted tyrosine phosphorylation sites in the tertiary model of 
Pfnek3. 
(a) Using the Swiss-PdbViewer, the positions of the predicted tyrosine phosphorylation sites 
were located in the Pfnek3 model (highlighted in red). (b) Neighboring amino acid residues that 
fall within 4Å distance of the predicted tyrosine phosphorylation sites were identified and 
shown in white. The side chains of residues Y117 and Y22 were observed to form hydrogen 
bonding (indicated by dotted green lines) with residues Y104 and N119 respectively.  





5.5 Mutation of residues Y117, Y122, Y172 and Y238 led to drastic reduction in both the 
tyrosine autophosphorylation and the catalytic activity of Pfnek3 
 
Based on the hypothesis that residues Y99, Y117, Y122, Y172, Y238 and Y286 are 
phosphorylation sites essential for stimulating the kinase activity of Pfnek3, site-directed 
mutagenesis was performed to replace each tyrosine residue with a phenylalanine. 
Phenylalanine is structurally-similar to tyrosine except that it lacks a hydroxyl group at its side 
chain and thus mimics a non-phosphorylatable site. In the event that any of these tyrosine 
residues are activating phosphorylation sites, the tyrosine-to-phenylalanine mutation would 
adversely affect both the tyrosine autophosphorylation and the catalytic activity of Pfnek3. 
The tyrosine phosphorylation site mutants (hereafter referred to as Y99F, Y117F, Y122F, 
Y172F, Y238F and Y286) were similarly expressed from the pGEX-6P-1 vector in bacterial cells 
and affinity-purified using the glutathione-sepharose beads. To examine the tyrosine 
autophosphorylation of these mutants, Western blot analysis was subsequently performed 
using the anti-phosphotyrosine antibody. As illustrated in Figure 5.7, both the Y99F and Y286F 
mutants displayed a comparable level of tyrosine autophosphorylation as the wild-type kinase. 
On the contrary, tyrosine autophosphorylation levels of the Y117F, Y122F, Y172F and Y238F 
mutants were significantly reduced (29%, 51%, 27% and 34%, respectively, of the wild-type 
Pfnek3 tyrosine autophosphorylation level based on densitometric analysis of the immunoblot). 
The ELISA-based kinase assay was subsequently conducted to examine the effects of the 
respective mutations on the serine/threonine and the tyrosine kinase activities of Pfnek3. 
Interestingly, the trend displayed by the various mutants in the serine/threonine kinase assay 
coincided with that in the tyrosine kinase assay (Figure 5.8). The serine/threonine and tyrosine 
kinase activities of the Y99F mutant were observed to be similar to the wild-type Pfnek3. On the 
other hand, the Y117F, Y122F and Y172F mutants displayed a significant decrease in both their 





serine/threonine (5%, 26% and 2%, respectively, of the wild-type Pfnek3 serine/threonine 
kinase activity) and tyrosine (13%, 26% and 7%, respectively, of the wild-type Pfnek3 tyrosine 
kinase activity) kinase activities. As for the Y238F and Y286F mutants, no significant 
serine/threonine or tyrosine kinase activities were detected. Since the Y117F, Y122F, Y172F and 
Y238F mutations adversely affected the tyrosine autophosphorylation and the kinase activities 
of Pfnek3, it supports the notion that these tyrosine residues are phosphorylation sites 
associated with the activation of Pfnek3. In addition, phosphorylation of these tyrosine residues 
is likewise crucial for Pfnek3 to activate Pfmap2, since the Y117F, Y122F, Y172F and Y238F 
mutants stimulated Pfmap2 activity to a lesser extent as compared to the wild-type kinase 
(Figure 5.9). 
As with the T82, S221 and S226 phosphorylations sites, attempts were made to 
generate mutants of Pfnek3 that could mimic the activating effects of phosphorylation at 
residues Y117, Y122, Y172 and Y238. Site-directed mutagenesis was performed to replace each 
tyrosine residue with a negatively-charged aspartate or glutamate. The resultant mutants were 
then assayed for their serine/threonine and tyrosine kinase activities. As depicted in Figure 5.10, 
no significant serine/threonine and tyrosine kinase activities were detected for the Y117D/E, 
Y172D/E and Y238D/E mutants. Furthermore, the kinase activities of the Y122D/E mutants did 
not surpass that of the non-phosphorylatable Y122F mutant. Collectively, the results 
demonstrate that these mutations were unable to simulate the activating effects of tyrosine 
phosphorylation at these sites. Nonetheless, it is important to note that although aspartate and 
glutamate are negatively-charged amino acids, they may not efficiently mimic the effects of 
tyrosine phosphorylation due to the lack of an aromatic ring in their side chains. Moreover, as 
the Y117D/E, Y172D/E and Y238D/E mutants lacked detectable kinase activities, the absence of 





an aromatic side chain at positions 117, 172 and 238 may have adversely affected the structural 













































































































Figure 5.7 Tyrosine autophosphorylation levels of the Pfnek3 phenylalanine-substituted 
mutants.  
(a) Purified wild-type Pfnek3 and its indicated mutants were resolved by SDS-PAGE and analyzed 
by Western blot using the anti-phosphotyrosine antibodies. Coomassie-staining of duplicated 
SDS-PAGE gel served as the loading control for each sample. Representative blot and gel of 
three independent experiments is shown. The graph at the lower panel summarizes the 
densitometric analysis of the phosphotyrosine signals exhibited by the respective Pfnek3 
proteins. Data is expressed as a percentage of wild-type Pfnek3 tyrosine autophosphorylation, 
with each bar representing the mean autophosphorylation level ± standard deviation from three 
independent assays. *Indicates significant differences with P-values of <0.05. 
 
 












































Figure 5.8 Serine/threonine and tyrosine kinase activities of the Pfnek3 phenylalanine-
substituted mutants.  
(a) Via the ELISA-based kinase assay, the serine/threonine (upper panel) and the tyrosine (lower 
panel) kinase activities of the respective Pfnek3 mutants were evaluated using the MBP 
substrate. Results are presented as a percentage of wild-type Pfnek3 activity, with each bar 
representing the mean activity ± standard deviation from two independent assays. ND denotes 
kinase activity not detected.  *Indicates significant differences with P-values of <0.05. 
 
 













































































Figure 5.9 Effects of the Y117F, Y122F, Y172F and Y238F mutations on the ability of Pfnek3 to 
activate Pfmap2. 
Adopting the co-incubation kinase assay used in Section 4.6, the activity of Pfmap2 was 
evaluated in the presence of the wild-type Pfnek3 or the indicated mutants. Data presented has 
been normalized with the basal Pfmap2 activity, and reflects the extent of Pfmap2 activation by 
the respective Pfnek3 proteins. For referencing purposes, results are expressed as percentages 
of Pfmap2 activation by the wild-type Pfnek3. Each bar corresponds to the mean + standard 


































































Figure 5.10 Catalytic activities of Pfnek3 tyrosine phosphomimetic mutants.  
Residues Y117, Y122, Y172 and Y238 were each replaced with either an aspartate or a glutamate to mimic 
phosphorylation at these residues. Serine/threonine (upper panel) and tyrosine (lower panel) kinase activities of 
these mutants were analyzed using the standard ELISA-based kinase assay. Results are presented as a percentage of 
wild-type Pfnek3 activity, with each bar representing the mean activity ± standard deviation from two independent 
assays. ND denotes kinase activity not detected. *Indicates significant differences with P-values of <0.05. 






 In this chapter, investigations were conducted to examine whether Pfnek3 possesses a 
dual-specificity functionality. Via Western blot analyses, Pfnek3 was found to be 
autophosphorylated on tyrosine, in addition to the serine and threonine residues (Figure 5.1). 
Furthermore, the kinase was observed to phosphorylate its exogenous MBP substrate on 
threonine as well as tyrosine residues (Figure 5.2). The ability of Pfnek3 to phosphorylate both 
the aliphatic and the aromatic hydroxyl amino acid residues thus support that it is a dual-
specificity protein kinase. This observation also unveiled an additional biochemical property of 
Pfnek3 which concurs with that of the MAPKKs, which are well-characterized eukaryotic dual-
specificity kinases. Prior to this investigation, Pfnek3 has been classified as a serine/threonine 
protein kinase since it possesses a HGDLKSTN catalytic loop motif which is diagnostic of 
members belonging to the serine/threonine kinase family. Hence, without a more in-depth 
biochemical examination of Pfnek3, its dual-specificity functionality would have been 
overlooked. 
Typically, MAPKKs exert their dual-specificity activities by phosphorylating MAPKs on 
the threonine and tyrosine residues within the TXY activation site (Roskoski, 2012b). Hence, to 
assess whether Pfnek3 could likewise exert a dual-specificity kinase activity on a Plasmodium 
MAPK, its ability to phosphorylate Pfmap2 on both the serine/threonine and the tyrosine 
residues was examined. As shown in Figure 5.3, Western blot analyses revealed that Pfnek3 
could phosphorylate Pfmap2 on threonine, but not the serine or tyrosine residues. These 
observations indicate that Pfnek3 does not exert a dual-specificity activity on Pfmap2, but 
mainly mediates its threonine phosphorylation instead. The finding coincided with that from a 
previous study where the threonine residue (T290) within the TSH activation motif of Pfmap2 
was identified as a site phosphorylated by Pfnek3 (Low et al., 2007). In view of this, the 





phosphothreonine signal detected in Pfmap2 is likely to be attributed to the Pfnek3-mediated 
T290 phosphorylation. Moreover, since replacement of residue T290 with a non-
phosphorylatable alanine led to a significant reduction in the phosphorylation of Pfmap2 by 
Pfnek3 (Figure 5.4), it supports residue T290 as the major Pfnek3-mediated phosphorylation site 
in Pfmap2. 
Based on the Western blot results depicted in Figures 5.2 and 5.3, Pfnek3 was shown to 
exhibit both threonine and tyrosine kinase activities in vitro. In addition, the threonine kinase 
activity of Pfnek3 was found to be stimulated to a higher extent in the presence of Mg2+ as 
compared to Mn2+. On the contrary, a higher Pfnek3 tyrosine kinase activity was detected with 
Mn2+ instead of Mg2+. These observations imply that Pfnek3 is likely to be a more efficient 
threonine kinase in the presence of Mg2+, but a more efficient tyrosine kinase in the presence of 
Mn2+. A similar phenomenon has also been documented for the dual-specificity phosphorylase 
kinase, where the use of Mg2+ and Mn2+ favored phosphorylation of the serine and tyrosine 
residues, respectively (Yuan et al., 1993). The interaction of phosphorylase kinase with the 
different metal cofactors was proposed to stabilize its active site in distinct conformations, 
thereby promoting phosphorylation of either the serine or the tyrosine residues (Yuan et al., 
1993). In this light, the Mg2+ and Mn2+ cofactors may likewise influence the hydroxyl amino acid 
preference of Pfnek3 through modulation of its active site configuration. 
The kinase activity of Pfnek3 has earlier been demonstrated to be regulated by both 
threonine and serine phosphorylation (Chapter 4). In particular, phosphorylation of residues 
T82, S221 and S226 was shown to play a pivotal role in enhancing the kinase activity of Pfnek3. 
To complement these findings, the results illustrated in Figure 5.5 further support that tyrosine 
phosphorylation is implicated in stimulating the activity of Pfnek3. With the revelation that 
Pfnek3 activation is associated with serine, threonine and tyrosine phosphorylation, the 





mechanism involved in regulating Pfnek3 activity has thus become more evident. Attempts were 
also made to identify the tyrosine phosphorylation sites in Pfnek3 and investigate their influence 
on Pfnek3 activity. As detecting Pfnek3 phosphorylation sites via LC-MS/MS is technically 
challenging (Chapter 4, Discussion Section), and that its activation loop lacks tyrosine residues 
which could otherwise be candidate phospho-regulatory sites, the NetPhos program was 
consequently employed to predict tyrosine phosphorylation sites in Pfnek3. Among the six 
candidate Pfnek3 tyrosine phosphorylation sites (Table 5.1), the tyrosine-to-phenylalanine 
substitutions at Y117, Y122, Y172 and Y238 led to drastic reduction in both the tyrosine 
autophosphorylation and the kinase activities of Pfnek3. Hence, these results support the notion 
that residues Y117, Y122, Y172 and Y238 are sites of phosphorylation associated with the 
activation of Pfnek3. In addition, the Y117F, Y122F, Y172F and Y238F mutants were observed to 
display similar trends in both the serine/threonine and the tyrosine kinase assays (Figure 5.8). In 
view of this, phosphorylation of these tyrosine residues is unlikely to exert an influence on 
Pfnek3’s hydroxyl amino acid selectivity, but is postulated to promote its activation by altering 
its catalytic efficiency instead. Separately, the side chain of residues Y117 and Y122 were 
observed to form hydrogen bonding with a neighboring amino acid residue (Figure 5.6b). Hence, 
there remains a likelihood that the diminished kinase activities exhibited by the Y117F and 
Y122F mutants might be due to the loss of a potentially important hydrogen bond for 
maintaining the structural integrity of Pfnek3. Further investigations, such as circular dichrosim 
analysis, would be useful to validate whether these mutations exert any impact on the structural 
stability of Pfnek3. 
  The results obtained thus far revealed that phosphorylation of residues T82, S221, 
S226, Y117, Y122, Y172 and Y238 plays an essential role in the activation of Pfnek3. While 
phosphorylation of these residues was a result of the autocatalytic activity of recombinant 





Pfnek3, it remains plausible that their phosphorylation in vivo are mediated by other regulatory 
kinases. Such a phenomenon has previously been documented for the mammalian ERK2, where 
the bacterially-expressed protein kinase was found to be autophosphorylated on the threonine 
and tyrosine residues within its consensus TEY activation site (Seger et al., 1991). However, 
phosphorylation of these residues in vivo was found to be accomplished through the activity of 
its upstream MAPKK instead (Seger et al., 1992). In light of this, identifying upstream kinases of 
Pfnek3 is still of physiological relevance and this endeavor is likely to facilitate mapping of the 
Plasmodium MAPK pathway, which remains elusive to date.   
It is also noteworthy to mention that the P. falciparum kinome is devoid of kinases that 
belong to the classical eukaryotic tyrosine kinase family (Ward et al., 2004). Despite this, 
tyrosine phosphorylation was detected throughout the intra-erythrocytic maturation of P. 
falciparum, and was demonstrated to be essential for parasite development (Sharma, 2000; 
Sharma and Mishra, 1999; Solyakov et al., 2011). This has therefore raised queries regarding the 
identity of the protein kinases responsible for tyrosine phosphorylation in vivo. Uncovering dual-
specificity kinases such as Pfnek3 is thus of biological significance as P. falciparum might 
potentially rely on such kinases to regulate its intracellular tyrosine phosphorylation. Among the 
P. falciparum kinases characterized thus far, Pfmap1, PfGSK3 and PfCLK3 are other kinases that 
reportedly possess a dual-specificity functionality (Graeser et al., 1997; Solyakov et al., 2011). 
Given that tyrosine-specific phosphatases have also been identified in P. falciparum (Kumar et 
al., 2004b; Pendyala et al., 2008), regulation of its intracellular tyrosine phosphorylation may 









Chapter 6 In search of interacting protein partners of Pfnek3 and 
Pfmap2 
 
6.1 Evaluation of the split-ubiquitin system for screening interacting protein 
partners of Pfnek3 and Pfmap2 
 
6.2 Investigation of the association between Pfmap2 and the Plasmodium 
falciparum heat shock protein 90   
  
One of the strategies in deciphering cell signaling pathways is to probe for proteins that 
interact with known components of the pathways. Such an approach has been successful in 
elucidating MAPK pathways of various eukaryotic organisms including mammals, plants and 
yeast (Bilsland-Marchesan et al., 2000; Kiegerl et al., 2000; Zhou et al., 1995). In Chapters 4 and 
5, phosphorylation of serine, threonine and tyrosine residues was demonstrated to play a 
pivotal role in regulating the catalytic activity of Pfnek3. These findings have consequently 
triggered an interest in identifying Plasmodium kinases that could mediate the phosphorylation 
of Pfnek3. Protein kinases with such an activity are likely to act as MAPKKKs in P. falciparum, 
which remain unidentified to date based on sequence homology. Meanwhile, although Pfmap2 
was shown to be an indispensible protein kinase for the intra-erythrocytic schizogony of P. 
falciparum (Dorin-Semblat et al., 2007), its bona fide cellular functions remains poorly 
understood. As such, identifying the downstream substrates of Pfmap2 may provide insightful 
clues to its role in regulating P. falciparum development. With these considerations in mind, this 










6.1 Evaluation of the split-ubiquitin system for screening interacting 
protein partners of Pfnek3 and Pfmap2 
  
 An attempt was made to identify binding partners of Pfnek3 and Pfmap2 using the split-
ubiquitin system. The split-ubiquitin system is a variant of the classical yeast two-hybrid assay, 
designed based on the conditional degradation of a protein upon its fusion to a ubiquitin moiety 
(Figure 6.1, Lehming, 2002). In this system, the ubiquitin molecule is split into an N-terminal half 
(Nub) and a C-terminal half (Cub) where neither half is capable of inducing proteolytic cleavage. 
The bait protein (X) is typically fused to the N-terminus of Cub whereas the prey protein is 
attached to the C-terminus of Nub. A modified Ura3p with arginine as the first amino acid residue 
(RUra3p, fused to the C-terminal end of Cub) serves as the reporter gene. Ura3p is an orotidine-
5’-phosphate decarboxylase essential for the biosynthesis of uracil. The enzyme is also 
competent in converting 5-fluoroorotic acid (5-FOA) into a toxic fluorouracil. Consequently, 
yeast cells expressing the X-Cub-RUra3p fusion are uracil prototrophs and sensitive to 5-FOA. In 
the event that X-Cub-RUra3p and Nub-Y are co-expressed in yeast cells, and that Protein X 
interacts with Protein Y, the Cub and Nub halves are brought into close proximity and 
reconstituted into a native-like ubiquitin molecule. This is recognized by the ubiquitin-specific 
proteases and results in the cleavage of the RUra3p reporter. As the N-terminal arginine of 
RUra3p represents a destabilizing residue in the N-end rule pathway of protein degradation 
(Varshavsky, 1997), the freed RUra3p is rapidly degraded by the 26S proteasome. Protein-
protein interaction can therefore be detected by the absence of yeast growth in media lacking 
uracil and its resistance to 5-FOA. The split-ubiquitin system is advantageous over the 
conventional yeast two-hybrid assay as it allows detection of protein-protein interaction in situ, 
without the need for the bait and prey proteins to localize to the nucleus where transcriptional 
activation occurs (Lehming, 2002). Moreover, the split-ubiquitin system is useful for the 





identification of interacting transcription factors which will otherwise interfere with the 
transcriptional readout employed in the classical yeast two-hybrid studies. Since MAPKs are 
widely involved in the regulation of a wide range of transcription factors (Figure 2.10), the split-
ubiquitin system was thus adopted for identifying protein partners of Pfnek3 and Pfmap2 in this 
study.        
  





































Figure 6.1 Schematic illustration on the principle of split-ubiquitin assay.  
(a) RUra3p tagged with a ubiquitin moiety is recognized and cleaved by ubiquitin-specific proteases. 
The freed RUra3p is rapidly degraded by the N-end rule protein degradation pathway. As RUra3p is 
required for uracil biosynthesis and can convert 5-FOA to the toxic fluorouracil, the degradation of 
RUra3p in yeast cells will result in the absence of growth in uracil-lacking media and the resistance to 
5-FOA. (b) The bait protein (X) is typically expressed as a fusion with the C-terminal half of ubiquitin 
(Cub) and RUra3p. The resultant X-Cub-RUra3p fusion is not recognized by ubiquitin-specific proteases 
and hence, RUra3p remains functional. Yeast cells are able to grow in uracil-lacking media and are 
sensitive to 5-FOA. (c) When Protein X interacts with Protein Y fused to the N-terminal half of 
ubiquitin (Nub), the Cub and Nub moieties are brought in close proximity and assemble into a native-
like ubiquitin molecule. This results in the recognition by ubiquitin-specific proteases and leads to the 
degradation of RUra3p. Protein-protein interaction can thus be detected based on the absence of 
growth in uracil-lacking media and the resistance to 5-FOA. Illustration is adapted from Lehming, 
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6.1.1 The Pfnek3- and Pfmap2-Cub-RUra3p fusion proteins are non-functional    
(Results and Discussion are combined for this section) 
 
In the split-ubiquitin system, protein-protein interaction is inferred based on the 
conditional degradation of the reporter protein, RUra3p (Figure 6.1c). This detection method 
thus requires RUra3p to be functional upon its fusion with the bait of interest (Figure 6.1b). 
Hence, after the Pfnek3 and Pfmap2 genes were cloned into the Cub-RUra3p vector (Figure 6.2) 
and transformed into S. cerevisiae (JD52 strain), the functionality of RUra3p was examined.  
As shown in Figure 6.3, growth was observed on agar deficient in tryptophan for yeast 
cells transformed with the Pfnek3- and the Pfmap2-Cub-RUra3p recombinant plasmids. This 
indicates successful transformation as the Cub-RUra3p vector carries a TRP1 selection marker 
that encodes an enzyme (i.e. phosphoribosylanthranilate isomerase) required for tryptophan 
biosynthesis. However, when the respective transformed cells were streaked onto agar deficient 
in both tryptophan and uracil, no evident growth was observed as compared to the control 
sample. The lack of yeast growth on the uracil-deficient agar indicates the absence of a 
functional RUra3p. This could plausibly be due to the lack of expression of the Pfnek3- and 
Pfmap2-Cub-RUra3p fusion proteins in the yeast cells. Pfnek3 and Pfmap2, like most P. 
falciparum genes, are higher in AT nucleotide-content as compared to the S. cerevisiae genes 
(Gardner et al., 2002; Goffeau et al., 1996). Heterologous expression of Pfnek3 and Pfmap2 in 
yeast may thus be impeded by incompatible codon usage, resulting in the lack of expression of 
RUra3p which is present at the C-terminal end. However, validation of the expression of the 
Pfnek3- and Pfmap2-Cub-RUra3p recombinant proteins will have to rely on Western blot analysis 
of the yeast cell lysates when antibodies against the Cub moiety, RUra3p or the Plasmodium 
proteins are made available in the laboratory. As the RUra3p reporter is non-functional when 





fused with either Pfnek3 or Pfmap2, identification of Pfnek3 and Pfmap2 protein binding 



















































Figure 6.2 Plasmid construction for the split-ubiquitin assay.  
The Pfnek3 and Pfmap2 genes were amplified and cloned into the Cub-RUra3p vector (Materials 
and Methods, Section 3.15). Agarose gel analysis of the recombinant plasmids following 
EcoRI/SalI double digestion indicated the presence of the respective genes of interest. The 
recombinant plasmids were subsequently subjected to DNA sequencing to validate the 


































1. Restriction digested              
Pfnek3- Cub-RUra3p plasmid 
2. Restriction digested              
Pfmap2- Cub-RUra3p plasmid 
L. 1 kb DNA ladder   
 















Figure 6.3 Analysis of yeast cells transformed with the Pfnek3- and Pfmap2-Cub-RUra3p 
recombinant plasmids.  
S. cerevisiae (JD52 strain) cells were transformed with the indicated recombinant plasmids and 
plated onto synthetic dropout agar lacking either tryptophan (left), or both tryptophan and 
uracil (right). Growth on the tryptophan dropout agar indicates successful transformation, while 
growth on the tryptophan and uracil dropout media indicates the presence of a functional 
RUra3p fusion protein. The results implied that both the Pfnek3- and Pfmap2-Cub-RUra3p 
recombinant plasmids were successfully transformed into yeast cells, but neither of the RUra3p 
was functional. Yeast cells expressing TPI1-Cub-RUra3p served as the positive control (kindly 
provided by A/P Norbert Lehming). Result shown is representative of three independent 


































6.2 Investigation of the association between Pfmap2 and the 
Plasmodium falciparum heat shock protein 90   
 
In parallel to testing the feasibility of the split-ubiquitin system for identifying binding 
partners of Pfnek3 and Pfmap2, investigations were concurrently carried out to examine the 
protein-protein interaction between Pfmap2 and the P. falciparum heat shock protein 90 
homologue (PfHsp90). In eukaryotes, Hsp90 represents a highly conserved molecular chaperone 
essential for the proper folding of a diverse array of cellular proteins (collectively referred to as 
Hsp90 client proteins) (Zuehlke and Johnson, 2010). The main groups of Hsp90 client proteins 
include transcription factors, steroid hormone receptors as well as protein kinases from various 
branches of the kinome (Zuehlke and Johnson, 2010). By supporting client proteins to attain 
their active conformations, Hsp90 consequently plays a pivotal role in a myriad of cellular 
processes such as transcription regulation, cell cycle control and signal transduction. In human 
and yeast, Hsp90 has been implicated in mediating multiple MAPK signaling pathways. 
Abrogation of Hsp90’s functionality through the use of specific inhibitors (e.g. geldanamycin and 
radicicol) was shown to result in the suppression of the ERK1/2, p38, JNK as well as ERK5 
pathways (Hsu et al., 2007; Schulte et al., 1996; Truman et al., 2006). Hsp90 reportedly exerts its 
influence on the MAPK pathways by maintaining the stability and activity of protein kinases at 
each level of the cascade, with MAPKKKs being the most prominent Hsp90 clients (Citri et al., 
2006; Haupt et al., 2012). In view of the widespread involvement of Hsp90 in regulating MAPK 
pathways, it provided an impetus to investigate if the P. falciparum Hsp90 homologue, PfHsp90, 
could undertake a similar function. To address this query, the association between PfHsp90 and 
Pfmap2 was thus pursued.      
       





6.2.1  Pfmap2 interacts with PfHsp90 in the presence of MgCl2 and ATP 
A GST pull-down assay was employed to investigate the interaction between Pfmap2 
and PfHsp90 (Materials and Methods, Section 3.18). In this assay, a His6-tagged Pfmap2 and a 
dual-tagged PfHsp90 (with an N-terminal GST-tag and a C-terminal His6-tag) served as the prey 
and bait proteins, respectively. To facilitate heterologous production of the His6-tagged Pfmap2, 
the Pfmap2 gene was cloned into the pET24a expression vector (Figure 6.4) and the verified 
recombinant plasmid was transformed into the bacterial host. The dual-tagged PfHsp90 was 
bacterially-expressed from the PfHsp90-pGK recombinant plasmid constructed previously in the 
laboratory (Chua et al., 2010). The His6-tag enabled recombinant PfHsp90 to be purified via Ni
2+ 
affinity chromatography, while the GST-tag was exploited for the GST-pull down assay. 
To perform the binding assay, 2 µg of PfHsp90 was immobilized onto glutathione- 
sepharose beads and used to pull-down Pfmap2 that was added in an excess of 25 µg. The 
association between PfHsp90 and Pfmap2 was tested in various conditions, either in the 
presence or absence of 5mM MgCl2, 5mM ADP and 5mM ATP. In the event that interaction 
between the two proteins occurs, Pfmap2 would be co-eluted with PfHsp90 and detected via 
SDS-PAGE analysis. Under the different conditions tested, Pfmap2 was observed to interact with 
PfHsp90 only in the presence of MgCl2 and ATP (Figure 6.5a). No interaction was detected 
between Pfmap2 and GST in the controls performed under similar experimental conditions 




















Figure 6.4 Plasmid construction for binding assay.  
The Pfmap2 gene was amplified and inserted into the pET24a vector as described in Section 3.16 
(Materials and Methods). Agarose gel analysis of the recombinant plasmid following EcoRI/XhoI 
double digestion indicated the presence of the gene of interest. The recombinant plasmid was 
subsequently subjected to DNA sequencing to validate the authenticity of the gene insert and to 
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Figure 6.5 SDS-PAGE analysis of the interaction between Pfmap2 and PfHsp90.  
(a) The interaction between Pfmap2 and PfHsp90 was investigated by GST pull-down assay using 
purified recombinant proteins (Materials and Methods, Section 3.18). In each assay, 2 µg of 
PfHsp90 was immobilized on glutathione-sepharose beads and used to pull-down Pfmap2 that 
was added in excess of 25 µg. The assay was performed either in the presence or absence of 5 
mM MgCl2, 5 mM ADP and 5 mM ATP. Pfmap2 was observed to interact with PfHsp90 only in 
the presence of MgCl2 and ATP. (b) No interaction was observed between Pfmap2 and GST in 
the control experiments performed under similar reaction conditions. Results shown are 
representative of two independent experiments. 
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6.2.2 PfHsp90 interacts with both the phosphorylated and unphosphorylated forms of 
Pfmap2 
 
A study in yeast has revealed that the ERK5 MAPK engaged in a stronger association 
with Hsp90 following its phosphorylation within the TEY activation motif (Truman et al., 2006). 
Hence, to investigate whether a similar relationship exists between Pfmap2 and PfHsp90, 
PfHsp90’s interaction with both the unphosphorylated and phosphorylated forms of Pfmap2 
was compared. Phosphorylated Pfmap2 was obtained via a kinase assay conducted in the 
presence of bead-bound GST-Pfnek3 (Materials and Methods, Section 3.18). Binding assays 
were carried out in the presence of MgCl2 and ATP, and eluted proteins were subsequently 
analyzed by Western blotting using the anti-His6 and the anti-phosphothreonine antibodies. The 
anti-His6 antibody was used for detecting the dual-tagged PfHsp90 and the His6-tagged Pfmap2, 
whereas the anti-phosphothreonine antibody was expected to be immunoreactive with the 
Pfnek3-phosphorylated Pfmap2 as validated earlier in Figure 5.2. 
In the binding assay performed between PfHsp90 and the unphosphorylated Pfmap2, 
Western blot using anti-His6 antibody detected a band of approximately 60 kDa which 
corresponded to that of Pfmap2 (Figure 6.6a, lane 2). A comparable band was also observed for 
the binding assay conducted in the presence of PfHsp90 and the phosphorylated Pfmap2 (Figure 
6.6a, lane 3). When the membrane was stripped and reprobed with the anti-phosphothreonine 
antibody, a faint band was observed at a position identical to that of Pfmap2 detected in the 
anti-His6 immunoblot for the reaction between PfHsp90 and phosphorylated Pfmap2 (Figure 
6.6b, lane 3). Collectively, these results indicate that PfHsp90 interacts with both the 
unphosphorylated and phosphorylated forms of Pfmap2. In addition, the phosphorylated 
Pfmap2 was not observed to exhibit an increased binding to PfHsp90 as compared to the 
unphosphorylated form based on the anti-His6 immunoblot analysis.    






























Figure 6.6 Western blot analyses of PfHsp90 interaction with the unphosphorylated and 
phosphorylated Pfmap2.  
(a) PfHsp90 was tested for its interaction with both the unphosphorylated and phosphorylated 
Pfmap2 using GST pull-down assay in the presence of MgCl2 and ATP. Phosphorylated Pfmap2 
was derived from a kinase assay with immobilized Pfnek3 (Materials and Methods, Section 
3.18). The unphosphorylated Pfmap2 used was also subjected to a similar kinase assay 
condition, but without the presence of Pfnek3. Western blotting using the anti-His6 antibody 
detected a band of approximately 60 kDa (indicated with *) which corresponded to that of 
Pfmap2 (lanes 2 and 3). This is indicative of PfHsp90 interaction with both the unphosphorylated 
and phosphorylated Pfmap2. (b) The immunoblot in (a) was stripped and reprobed with the 
anti-phosphothreonine antibody. As shown in lanes 4 and 5, the Pfnek3-phosphorylated Pfmap2 
displayed a significant level of phosphothreonine signal as compared to its unphosphorylated 
counterpart. A faint band of approximately 60 kDa (indicated with **) that was detected in lane 
3 but not in lane 2 is likely to correspond to the phosphorylated Pfmap2. Results shown are 
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6.2.3 Phosphorylated Pfmap2 increases the level of threonine phosphorylation in PfHsp90 
Although Pfmap2 did not exhibit an enhanced binding to PfHsp90 following its 
phosphorylation, PfHsp90 was observed to elicit a higher level of threonine phosphorylation 
upon incubation with the phosphorylated Pfmap2. In Figure 6.6a, the anti-His6 immunoblot 
showed that the level of PfHsp90 in the presence of phosphorylated Pfmap2 was comparable to 
that in the presence of unphosphorylated Pfmap2. However, when the membrane was reprobed 
with the anti-phosphothreonine antibody, it was observed that the signal exhibited by PfHsp90 
was higher in the presence of phosphorylated Pfmap2 as compared to that in the presence of 
unphosphorylated Pfmap2 (Figure 6.6b). The results indicate that the Pfnek3-phosphorylated 
Pfmap2 is likely to phosphorylate PfHsp90 on threonine residue(s). 
  
6.2.4 Pfnek3 does not increase the level of threonine phosphorylation in PfHsp90 
As phosphorylated Pfmap2 used in the interaction study was obtained through pre-
incubation with Pfnek3, it was necessary to investigate whether the increased PfHsp90 
threonine phosphorylation could be attributed to contaminating Pfnek3 in the phosphorylated 
Pfmap2 protein preparation. Following similar experimental procedures, immobilized GST-
tagged Pfnek3 (10 µg) was incubated in kinase assay buffer and the whole reaction mix was 
subsequently combined with PfHsp90 (2 µg) for standard binding assay. Following elution and 
Western blotting with the anti-GST antibody, bands that corresponded to both PfHsp90 and 
Pfnek3 were detected (Figure 6.7a). It is important to note that Pfnek3 and PfHsp90 were both 
GST-tagged and hence, their simultaneous presence in the anti-GST Western blot is not 
indicative of interaction between the two proteins. When the same blot was subsequently 
reprobed with the anti-phosphothreonine antibody, the PfHsp90 incubated with Pfnek3 showed 
a comparable threonine phosphorylation level relative to the PfHsp90 that was not incubated 





with Pfnek3 (Figure 6.7b). These results indicate that Pfnek3, despite added in an excess of 10 
µg, does not phosphorylate PfHsp90 on threonine residue. Hence, the increased threonine 
phosphorylation observed earlier in PfHsp90 is likely to be due to the kinase activity of 













































































Figure 6.7 Pfnek3 does not enhance the threonine phosphorylation signal in PfHsp90.  
(a) Pfnek3 was assessed for its ability to phosphorylate PfHsp90 under the binding assay 
conditions used for investigating the PfHsp90-Pfmap2 interaction. Similar to the treatment by 
which phosphorylated Pfmap2 was derived, immobilized-Pfnek3 was first incubated in kinase 
assay buffer before mixing with PfHsp90 in the GST pull-down assay conditions. Western blot 
analysis of the eluted sample using anti-GST antibody revealed the presence of PfHsp90 and 
Pfnek3 in the reaction mixture. As 10 µg of Pfnek3 and 2 µg of PfHsp90 were immobilized to 
glutathione beads for the kinase and binding assays respectively, a stronger signal displayed by 
Pfnek3 relative to PfHsp90 was within anticipation. (b) The immunoblot in (a) was stripped and 
further analyzed with the anti-phosphothreonine antibody. No significant increase in the 
PfHsp90 phosphothreonine signal was detected in the presence of Pfnek3. The results indicate 
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 Using recombinant proteins and GST pull-down assay, Pfmap2 was demonstrated to 
interact with PfHsp90 in the presence of MgCl2 and ATP (Figure 6.5). This interaction was shown 
to be unaffected by the phosphorylation status of Pfmap2, unlike the finding in yeast where 
phosphorylated ERK5 showed increased binding to Hsp90 (Truman et al., 2006). Intriguingly, 
Pfnek3-phosphorylated Pfmap2, but not the unphosphorylated form, was found to enhance the 
threonine phosphorylation of PfHsp90. As phosphorylation of Pfmap2 by Pfnek3 has been 
associated with Pfmap2 activation (Low et al., 2007), the increased threonine phosphorylation 
of PfHsp90 is likely to be effected by activated Pfmap2 upon its phosphorylation by Pfnek3. 
Collectively, these results indicate that PfHsp90 is a substrate of Pfmap2 in vitro.  
Pfmap2 has previously been validated as an essential protein kinase for the intra-
erythrocytic development of P. falciparum (Dorin-Semblat et al., 2007). However, its precise 
cellular functions remain elusive since its native substrates have yet been identified. Typically, 
eukaryotic MAPKs exert their cellular influence by phosphorylating substrates such as 
transcription factors, regulatory protein kinases, as well as cytoskeletal and membrane proteins 
(Yoon and Seger, 2006). However, their involvement in phosphorylating Hsp90 has yet to be 
reported. The ability of Pfmap2 to phosphorylate PfHsp90 was therefore surprising and provides 
a lead that Pfmap2 may be involved in regulating the functionality of PfHsp90, an essential 
molecular chaperone in the parasite. In both mammals and yeast, phosphorylation of Hsp90 by 
protein kinases has recently emerged as a key mechanism in governing Hsp90 functionality 
(Trepel et al., 2010). For instance, studies in yeast have revealed that casein kinase 2 could 
phosphorylate Hsp90 at the threonine residue T22 (Mollapour et al., 2011). Through a 
combination of site-directed mutagenesis and biochemical assays, T22 phosphorylation was 
shown to disrupt the ability of Hsp90 to chaperone some of its known kinase clients such as 





Ste11 and Mpk1/Slt2 (Mollapour et al., 2011). Given the current finding that Pfmap2 could 
phosphorylate PfHsp90, further investigation is hence warranted to identify the Pfmap2-
mediated phosphorylation sites in PfHsp90 and examine their influence on the functionality of 












7.1 Gaining insights into the atypical MAPK pathway in Plasmodium falciparum 
 In eukaryotes, MAPK pathways play a pivotal role in regulating fundamental processes 
such as cell growth, proliferation and differentiation (Morrison, 2012). Although these pathways 
have been well-characterized in numerous organisms, very little is known regarding their 
counterparts in the malaria parasite, P. falciparum. It has been suggested that the classical 
MAPKKK-MAPKK-MAPK cascade is not conserved in P. falciparum since only homologues of the 
MAPKs (Pfmap1 and Pfmap2), but not those of the MAPKKs and MAPKKKs, were identified in its 
kinome (Anamika et al., 2005; Ward et al., 2004). Nonetheless, during the search for potential 
upstream kinases of Pfmap2, the P. falciparum NIMA-like kinase, Pfnek3, was found to possess 
the ability to activate Pfmap2 (Lye et al., 2006). Moreover, Pfnek3 was verified to enhance 
Pfmap2 activity by phosphorylation of the threonine residue within the latter’s TSH activation 
site (Low et al., 2007; Lye et al., 2006). Considering that such functionality coincides with that 
expected of a MAPKK, Pfnek3 was consequently recognized as a unique MAPKK in P. falciparum. 
The existing evidence also supports the view that P. falciparum is likely to possess a functional 
MAPK pathway, albeit an atypical one where the MAPKK- and MAPKKK-like functionalities are 
fulfilled by non-conventional protein kinases. In this project, further investigation on Pfnek3 was 
pursued to gain insights into the regulation and biochemical properties of this unusual P. 
falciparum MAPKK. Furthermore, with the aim of uncovering additional components of the 
MAPK pathway in P. falciparum, investigations were conducted to identify protein binding 










7.2 Amino acid residues T82, S221, S226, Y117, Y122, Y172 and Y238 are activating 
phosphorylation sites in Pfnek3  
 
Although the mechanism by which Pfnek3 activates Pfmap2 has been elucidated (Low et 
al., 2007), the regulation of Pfnek3 activity was previously unknown. In this study, 
phosphorylation of Pfnek3 was shown to play a pivotal role in stimulating its kinase activity in 
vitro. Furthermore, through a combination of mass spectrometry, biocomputational analysis, 
site-directed mutagenesis and functional assays, amino acid residues T82, S221, S226, Y117, 
Y122, Y172 and Y238 were identified as the phosphorylation sites associated with the activation 
of Pfnek3. Interestingly, the residues S221 and S226 were found to be part of the 221SSEQSS226 
sequence within the kinase activation loop. This sequence is reminiscent of the conserved 
S/TXXXS/T activation motif in the MAPKKs, where phosphorylation of the first and last 
serine/threonine residues is essential for MAPKK activation. In view of this, the results obtained 
imply that the regulation of Pfnek3 closely resembles that of the MAPKKs. It would be 
interesting to further validate if these phosphorylation sites likewise exist in endogenous Pfnek3 
and examine their roles in regulating Pfnek3 activity in vivo.   
  
7.3 Pfnek3 is a unique dual-specificity protein kinase of Plasmodium falciparum 
 Besides autophosphorylation on serine, threonine and tyrosine residues, Pfnek3 was 
also demonstrated to phosphorylate the exogenous MBP substrate on threonine and tyrosine 
residues via Western blot analysis. By exhibiting kinase activity towards both the aliphatic (i.e. 
serine/threonine) and the aromatic (i.e. tyrosine) hydroxyl amino acid residues, Pfnek3 was 
consequently unveiled as a novel dual-specificity protein kinase of P. falciparum. Given that 
MAPKKs are well-known eukaryotic dual-specificity protein kinases, the current finding also 





sheds light on an additional biochemical property of Pfnek3 which concurs with that of the 
MAPKKs. 
Prior to this investigation, Pfnek3 has been classified as a serine/threonine kinase due to 
the resemblance of its HGDLKSTN sequence with the signature HRDLKXXN catalytic loop motif of 
the serine/threonine kinases (Lye et al., 2006). Hence, without a more in-depth examination of 
the amino acid specificity of Pfnek3, its dual role in phosphorylation would have been 
overlooked. The revelation of Pfnek3 as a dual-specificity kinase is also of biological relevance. 
So far, analyses of the P. falciparum kinome have not identified any classical tyrosine kinases 
(Anamika et al., 2005; Ward et al., 2004). Nonetheless, tyrosine phosphorylation has been 
detected in vivo and shown to be essential for the development of the parasite. In this light, P. 
falciparum may potentially rely on Pfnek3 as an important dual-specificity kinase to support its 
cellular tyrosine phosphorylation.      
 
7.4 PfHsp90 is a potential substrate of Pfmap2 
Pfmap2 has previously been validated as an essential protein kinase for the intra-
erythrocytic development of P. falciparum (Dorin-Semblat et al., 2007). However, the exact 
cellular role of Pfmap2 remains elusive as its native substrates have yet been identified. Using 
the GST pull-down assay, Pfmap2 was shown in this study to interact with an essential P. 
falciparum molecular chaperone, PfHsp90. Western blot analysis further revealed that Pfmap2 
could phosphorylate PfHsp90 on threonine residue(s). In particular, the threonine 
phosphorylation of PfHsp90 was found to be mediated only by Pfmap2 that has been pre-
activated by Pfnek3. Collectively, these results support that PfHsp90 is a substrate of Pfmap2 in 
vitro. 





Thus far, MAPKs are mostly associated with phosphorylation of targets such as 
transcription factors, regulatory protein kinases, as well as cytoskeletal and membrane protein 
(Yoon and Seger, 2006). Their involvement in Hsp90 phosphorylation, however, has yet been 
reported in other organisms. Hence, the ability of Pfmap2 to phosphorylate PfHsp90 was an 
intriguing finding. It also provides a hint that Pfmap2 may undertake an important role in P. 
falciparum by regulating the functionality of PfHsp90. Further investigation is therefore 
warranted to evaluate the influence of Pfmap2 phosphorylation on the activity of PfHsp90. This 
will require identification of the PfHsp90 amino acid residues that are targeted by Pfmap2 and 
assessing their effects in regulating the activity of PfHsp90.   
  
7.5 The continual need to identify interacting protein partners of Pfnek3 and Pfmap2 
  A useful approach in deciphering cell signaling pathways is to identify interacting 
proteins of known components of the pathways. In a parallel conception, elucidating protein 
binding partners of Pfnek3 and Pfmap2 will likely facilitate mapping of the MAPK pathway in P. 
falciparum. The yeast split-ubiquitin system was attempted in this study with the aim of 
screening for interacting proteins of Pfnek3 and Pfmap2. However, the methodology was found 
to be unsuitable to achieve the intended objective since the Pfnek3- and Pfmap2-RUra3p fusion 
proteins were not functional when expressed in yeast cells.      
 In view of the obstacle met, the goal of identifying binding partners of Pfnek3 and 
Pfmap2 would have to rely on alternative strategies. For instance, co-immunoprecipitation assay 
may be useful for isolating their interacting proteins from the parasite cell lysate. Any co-
immunoprecipitated proteins may be identified via mass spectrometric analysis subsequently. 
Recently, a chemical method has been developed which could facilitate the identification of 
upstream kinases responsible for phosphorylating a protein at a verified site (Statsuk and 





Shokat, 2012). This approach necessitates a chemical cross-linker and a fluorescent-labeled 
substrate peptide which harbors the phosphorylation site (i.e. the bait). When applied to cell 
lysates, the substrate peptide will be covalently trapped with its phosphorylating kinase by the 
chemical cross-linker. As the substrate peptide is fluorescently-labeled, the resultant kinase-
substrate peptide complex may then be analyzed through SDS-PAGE followed by fluorescent 
scanning (Statsuk and Shokat, 2012). The identity of the phosphorylating kinase can 
subsequently be verified via mass spectrometry. In this study, several phospho-activating sites 
of Pfnek3 have been identified. Therefore, this chemical-based method represents an attractive 
strategy to probe for upstream kinases of Pfnek3 (i.e. the MAPKKKs) which can phosphorylate it 
at a site of interest.  
  
7.6 Concluding remarks 
Despite progress made in battling malaria, the disease remains one of the most 
widespread and intractable health threats. The rapid emergence of drug-resistant P. falciparum 
strains and the lack of a licensed malaria vaccine have thwarted current efforts to control the 
disease. The most promising malaria vaccine candidate so far, RTS,S/AS01 has reached the final 
phase of clinical evaluation. However, its efficacy to protect young children and infants against 
malaria currently stands at about 50% and 30%, respectively (Agnandji et al., 2011; The RTS,S 
Clinical Trials Partnership, 2012). Before a fully protective malaria vaccine is developed, 
antimalarial drugs are expected to remain as a crucial mode of treatment and control against 
malaria. Discovery of new antimalarial drugs and drug targets is therefore imperative to 
overcome the problem of antimalarial drug resistance.  
Gaining insights into the P. falciparum biology is fundamental to identify specific 
pathways and/or proteins which could be targeted for antimalarial drug discovery. In 





eukaryotes, the highly conserved MAPK pathways are essential for controlling vital cellular 
functions such as growth and proliferation (Morrison, 2012). Analogously, MAPK pathways are 
postulated to play crucial roles in regulating the cellular processes in P. falciparum, and their 
inhibition might represent an attractive strategy to interfere with parasitic growth. However, 
while MAPK pathways have been well-characterized in many eukaryotes, much less is known 
about the corresponding pathways in P. falciparum. The progress in deciphering the P. 
falciparum MAPK pathways has been hindered by several obstacles, among them are the 
absence of typical MAPKK and MAPKKK homologues in the parasite kinome (Anamika et al., 
2005; Ward et al., 2004), and the difficulty in studying the parasite as it is inherently less 
amenable to genetic manipulation and cell biology analyses (Caro et al., 2012). Nonetheless, 
following the identification of Pfmap2, investigations conducted in this project and two earlier 
studies (Low et al., 2007; Lye et al., 2006) have shed light on its upstream MAPKK (i.e. Pfnek3) 
and also its potential downstream substrate (i.e. PfHsp90). It is anticipated that the continued 
search for the interacting proteins of Pfnek3 and Pfmap2 will offer new insights into the MAPK 
pathway of P. falciparum. Furthermore, since Plasmodium kinases are distantly-related from 
their host counterparts (Anamika et al., 2005; Ward et al., 2004), it is optimistic that generating 
specific inhibitors against the former is an eminently achievable goal. 
  





































Figure 7.1 Schematic illustration of the findings obtained in this project.  
In this study, the activity of Pfnek3, an unconventional MAPKK of P. falciparum, was found to be 
modulated through serine (activation loop S221 and S226), threonine (T82) and tyrosine (Y117, 
Y122, Y172 and Y238) phosphorylation. Evidence obtained also indicates that Pfnek3 is a novel 
dual-specificity kinase of the parasite. In addition, the demonstration of Pfmap2’s ability to 
phosphorylate PfHsp90 implies that the latter is a potential substrate of Pfmap2. Taken 
together, these results have 1) shed light on the regulation and biochemical characteristics of 
Pfnek3 and, 2) provided a valuable clue with regards to the identity of the effector protein which 
might lie downstream of the P. falciparum MAPK cascade.  
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Abstract Despite the absence of classical tyrosine kinases
encrypted in the kinome of Plasmodium falciparum, bio-
chemical analyses have detected significant tyrosine
phosphorylation in its cell lysates. Supporting such phos-
phorylation is critical for parasite development. These
observations have thus raised queries regarding the plasmo-
dial enzymes accountable for tyrosine kinase activities in
vivo. In the current investigation, immunoblot analysis
intriguingly demonstrated that Pfnek3, a plasmodial mitogen-
activated protein kinase kinase (MAPKK), displayed both
serine/threonine and tyrosine kinase activities in autophos-
phorylation reactions as well as in phosphorylation of the
exogenous myelin basic protein substrate. The results
obtained strongly support Pfnek3 as a novel dual-specificity
kinase of the malarial parasite, even though it displays a
HGDLKSTN motif in the catalytic loop that resembles the
consensus HRDLKxxN signature found in the serine/threo-
nine kinases. Notably, its serine/threonine and tyrosine kinase
activities were found to be distinctly influenced by Mg2? and
Mn2? cofactors. Further probing into the regulatory mecha-
nism of Pfnek3 also revealed tyrosine phosphorylation to be a
crucial factor that stimulates its kinase activity. Through
biocomputational analyses and functional assays, tyrosine
residues Y117, Y122, Y172, and Y238 were proposed as
phosphorylation sites essential for mediating the catalytic
activities of Pfnek3. The discovery of Pfnek3’s dual role in
phosphorylation marks its importance in closing the loop for
cellular regulation in P. falciparum, which remains elusive to
date.
Keywords Malaria  Plasmodium falciparum 
MAPKK  Dual-specificity kinase  Phosphorylation
Abbreviations
BSA Bovine serum albumin
GST Glutathione S-transferase
MAPK Mitogen-activated protein kinase
MAPKK Mitogen-activated protein kinase kinase
MAPKKK Mitogen-activated protein kinase kinase
kinase
MBP Myelin basic protein
PTP1B Protein tyrosine phosphatase 1B
PVDF Polyvinylidene fluoride
SDS-PAGE Sodium dodecyl sulphate–polyacrylamide
gel electrophoresis
TBS Tris buffered saline
Introduction
In the eukaryotes, modification of proteins through
reversible phosphorylation is an essential mechanism for
regulation of cellular processes. This post-translational
event is catalyzed by enzymes belonging to the protein
kinase superfamily that constitutes approximately 2–3% of
the eukaryotic proteome [1, 2]. Eukaryotic protein kinases
share extensive sequence and structural homologies within
their catalytic domains [1, 3]. Depending on their speci-
ficities for the target hydroxyl amino acids, protein kinases
are traditionally classified into two major classes: the
serine/threonine kinases and the tyrosine kinases [1]. In
addition, a smaller class of protein kinases, termed as the
dual-specificity kinases, is subsequently discovered with
specificity for both the serine/threonine and the tyrosine
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residues [4]. Through the phosphorylation of specific tar-
gets on serine, threonine and/or tyrosine residues, protein
kinases play integral roles in a diverse array of cellular
events. Thus, their activities have to be tightly regulated.
Abnormal functioning of protein kinases has been impli-
cated in a number of major human diseases such as cancer,
arthritis, and Alzheimer’s condition [5–7]. Therefore, they
have emerged as prime molecular targets for the develop-
ment of therapeutic intervention against these diseases. In
2001, the Food and Drug Administration approved the first
kinase inhibitor, imatinib (GleevecTM), for the treatment of
chronic myelogenous leukemia [8]. Its clinical success
provided compelling evidence for the effectiveness of
kinase-specific inhibitors in the treatment of human
diseases.
The growing number of kinase inhibitors for clinical use
has raised the interest in whether kinase-targeted therapy
can be extended to the treatment of malaria, a parasitic
disease that currently causes 800,000 deaths annually
[9, 10]. Current efforts to control this disease have been
marred by the propensity of Plasmodium falciparum, the
most lethal causative agent, to rapidly develop resistance
against the front-line artemisinin combination therapies
[11]. Therefore, in the context where producing efficacious
malarial vaccines remains a great challenge, continued
efforts to develop novel antimalarial chemotherapeutics is
imperative. One widely adopted strategy for discovering
new antimalarial agents is the target-based approach,
through which novel targets are first identified followed by
the design of parasite-specific inhibitors that act on these
targets [12]. The search for promising drug targets from the
P. falciparum kinome is relevant, since plasmodial kinases
are reportedly divergent in terms of their primary sequen-
ces and biochemical properties as compared to their
mammalian counterparts [13–15]. More importantly, a
number of plasmodial protein kinases have been demon-
strated to be essential in the life cycle of P. falciparum,
further supporting their potential as ‘‘druggable’’ targets
(summarized in [16]).
One of the plasmodial kinases under intense investiga-
tion is Pfmap2, a mitogen-activated protein kinase
(MAPK) homologue of P. falciparum [17, 18]. It is rec-
ognized as an antimalarial drug target following a knock-
out study that validated its essentiality in the asexual
propagation of P. falciparum [18]. To further probe into the
molecular mechanisms by which Pfmap2 is engaged for
mediating P. falciparum development, identifying its
upstream activating kinases is fundamental. Unfortunately,
the P. falciparum kinome lacks clear homologues of the
MAPK kinase (MAPKK) and MAPKK kinase (MAP-
KKK), both of which are components of the conserved
MAPK signaling pathway that lead to the activation of
MAPKs. On hindsight, this indicates that P. falciparum
may possess a MAPK pathway that is distinctively differ-
ent from the other eukaryotes, including its human host.
Hence, other than gaining insights into the mechanistic
basis leading to the activation of Pfmap2, identification of
its upstream kinases is critical for deciphering the elusive
P. falciparum MAPK pathway where novel kinase targets
suitable for antimalarial drug discovery can be discerned.
In the absence of traditional MAPKK homologues,
distinguishing upstream kinases of Pfmap2 is reliant on the
detection and biochemical characterization of plasmodial
kinases capable of phosphorylating and activating it. A
potential Pfmap2 regulator was first illustrated by Dorin
et al. [19], whereby Pfnek1, a kinase belonging to the
NIMA-like kinase family, demonstrated the competency to
catalyze Pfmap2 phosphorylation in vitro. However, the
relevance of this phosphorylation event on the activity of
Pfmap2 was not clarified. Contrary to Pfnek1, a second
plasmodial NIMA-like kinase, Pfnek3, was subsequently
reported to display both the ability to phosphorylate and
stimulate Pfmap2 activity [20]. The molecular mechanism
by which Pfnek3 activates Pfmap2 was further verified to
involve phosphorylation within the latter’s activation motif
[21]. As this mode of activation mechanism is highly
conserved among the eukaryotes, where the MAPKKs
phosphorylate their downstream MAPKs within the
activation motif to stimulate them [22], Pfnek3 was con-
sequently recognized as a MAPKK-like enzyme of
P. falciparum.
In the current study, further characterization of this
unusual MAPK activator is pursued to assess whether it
possesses additional properties of a typical MAPKK.
Results obtained via Western-blot analysis had intrigu-
ingly unveiled the ability of Pfnek3 to autophosphorylate
and phosphorylate an exogenous substrate at tyrosine-
specific sites, in addition to the serine/threonine residues.
Like the serine and threonine phosphorylation illustrated
earlier [23], tyrosine phosphorylation was demonstrated
to play a crucial role in regulating the kinase activity of
Pfnek3. Collectively, the findings of this study indicate
that Pfnek3 is a novel dual-specificity kinase of P. fal-
ciparum and further highlight the similarities between
Pfnek3 and the MAPKKs, which also exert both threo-
nine and tyrosine kinase activities on their MAPK
substrates.
Materials and methods
Heterologous expression and purification
of recombinant proteins
Escherichia coli BL21-CodonPlusTM cells expressing the
glutathione S-transferase (GST)-tagged wild-type Pfnek3,
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the DPfnek3 and DPfmap2 mutants were obtained previously
[20, 21]. They were cultured in 100 ml of Luria–Bertani
broth supplemented with ampicillin and chloramphenicol
(100 and 40 lg/ml, respectively) at 37C with continuous
agitation until an OD600 of 0.6–0.8 was obtained. They
were afterwards induced with 1 mM isopropyl-beta-D-
thiogalactopyranoside (Sigma) and incubated at room tem-
perature overnight with shaking. Subsequently, the cells
were harvested and lysed by sonication as previously
reported [21]. Fusion proteins were purified from soluble
cell-free extracts by affinity chromatography using the Mi-
crospin GST Purification Module (GE Healthcare) according
to the manufacturer’s instructions. Protein concentrations of
the purified samples were determined by the Bio-Rad protein
assay, using bovine serum albumin (BSA, Sigma) as
the reference protein standard. New Pfnek3 site-directed
mutants generated in the current study were similarly
expressed and purified using the same protocol.
Western blot
Protein samples were routinely boiled for 5 min and sepa-
rated by either 8 or 15% sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS-PAGE). Resolved
proteins were transferred to polyvinylidene fluoride (PVDF)
membranes (Millipore), which were then blocked with 2%
(w/v) BSA in Tris buffered saline (TBS), following which,
the membranes were probed with either the anti-phospho-
serine (1:1,000 dilution, Millipore), anti-phosphotyrosine
(1:2,000 dilution, Millipore) or anti-phosphothreonine
(1:1,000 dilution, Cell Signaling Technology) primary
antibodies. A peroxidase-conjugated secondary antibody
(1:3,500 dilution, Thermo Fisher Scientific) was then incu-
bated with the membranes. The blots were developed using
either the Advance Western Blotting Detection Kit (GE
Healthcare) or the ECL Plus Western Blotting Substrate
(Thermo Fisher Scientific) and exposed to the CL-XPosure
film (Thermo Fisher Scientific). Densitometric quantifica-
tion of the Western-blot results was performed using ImageJ
software [24]. To serve as controls for protein loading,
duplicated SDS-PAGE gels were run and stained with
Coomassie Blue. Stained gels were visualized using the Bio-
Rad Molecular Imager Gel Doc XR system equipped with
the Quantity One software.
Phospho-protein staining
Following in vitro kinase assays, reaction mixtures were
subjected to SDS-PAGE using 8% polyacrylamide gels. The
gels were stained with Pro-Q Diamond phosphoprotein gel
stain (Invitrogen) according to the manufacturer’s protocol
and visualized on a UV transilluminator. Densitometric
quantification of the result was performed using ImageJ
software [24]. To ensure uniform loading of protein samples
for each lane, the gels were subsequently stained with
Coomassie Blue.
Tyrosine dephosphorylation of Pfnek3 using protein
tyrosine phosphatase 1B
For tyrosine dephosphorylation reactions, a 24 ll assay
mixture contained 10 lg of wild-type Pfnek3 and 5 U of
protein tyrosine phosphatase 1B (PTP1B, Millipore) in a
reaction buffer provided by the manufacturer. The phos-
phatase was omitted in samples that served as negative
controls. Incubations were carried out for 1 h at 30C
before 6 ll of 100 mM sodium orthovanadate was added to
the reaction mixture to inhibit the activity of PTP1B (final
concentration: 20 mM, NEB). A 12-ll aliquot of the
resultant mixture was thereafter subjected to both Western
blot and ELISA-based kinase assay for verifying the
dephosphorylated status and the kinase activity of the
PTP1B-treated Pfnek3.
Generation of Pfnek3 mutants through site-directed
mutagenesis
The truncated Pfnek3 gene, encoding a catalytically active
form of Pfnek3, was earlier cloned into the GST-encoding
pGEX-6P-1 vector [20]. The resultant recombinant
expression plasmid was used as the template for site-
directed mutagenesis reactions. All GST-tagged Pfnek3
mutants were constructed according to the QuikChangeTM
site-directed mutagenesis protocol (Stratagene), using
mutagenic primers listed in Table 1. The authenticity of the
respective Pfnek3 mutants was verified through DNA
sequencing to ensure that no spontaneous nucleotide sub-
stitution was introduced during the PCR amplification
process.
Protein kinase assays
Kinase assay mixtures of 40 ll aliquots prepared for
Western blot comprised of 4 lg of wild-type or mutant
Pfnek3 proteins, 500 lM ATP, 10 mM MgCl2/MnCl2 and
50 mM Tris–HCl (pH 7.2). The samples were incubated at
30C for 30 min before they were boiled for SDS-PAGE
and Western-blot analysis. When required, the assay mix-
tures were supplemented with 10 lg of dephosphorylated
myelin basic protein (MBP, Millipore) substrate or the cata-
lytically inactive Pfmap2 mutants [DPfmap2 or DPfmap2
(T290A)].
To quantify the kinase activities of the tyrosine
dephosphorylated Pfnek3 or its site-directed mutants, an
ELISA-based kinase assay was adopted as described in [23].
P. falciparum possesses a unique dual-specificity serine/threonine and tyrosine kinase, Pfnek3 1525
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Briefly, the assays were performed using 96-well microtiter
plates (Costar) coated with dephosphorylated MBP. Kinase
reaction mix (60 ll) added into each well comprised of
4 lg of recombinant protein, 500 lM ATP, 10 mM MgCl2
and 50 mM Tris–HCl (pH 7.2). The assays were allowed to
proceed at 30C for 30 min. Following which, the serine/
threonine and the tyrosine kinase activities of the enzymes
were independently assessed, based on the levels of MBP
phosphorylation detected using the mixed anti-phospho-
serine/threonine (1:500 dilution, Millipore) and the anti-
phosphotyrosine (1:1,000 dilution) antibodies, respectively.
Biocomputational analysis
The NetPhos server (http://www.cbs.dtu.dk/services/NetPhos/)
was utilized for predicting potential tyrosine phosphoryla-
tion sites in Pfnek3 [25]. Using the Swiss-PdbViewer [26],
the locality of the predicted phospho-tyrosine sites was
determined in the Pfnek3 three-dimensional model gener-
ated previously [23].
Results
Recombinant Pfnek3 autophosphorylates on serine,
threonine as well as tyrosine residues
Using a generic phosphostain, it was earlier shown that the
heterologously expressed Pfnek3 purified from bacterial
cells exhibited detectable autophosphorylation [23]. To
further examine the autophosphorylation specificity of
Pfnek3, Western-blot analysis was performed on the purified
fusion kinase using antibodies specific against phospho-
serine, phospho-threonine as well as phospho-tyrosine resi-
dues. As illustrated in Fig. 1a, the wild-type Pfnek3 was
immunoreactive with all three phospho-specific antibodies,
indicating that the kinase was autophosphorylated on serine,
threonine and tyrosine residues following its expression in
bacterial cells. The absence of detectable signals by its cat-
alytically inactive counterpart (DPfnek3) supports that
phosphorylation of these hydroxyl residues is indeed due to
the intrinsic activity of Pfnek3, and not the result of any
bacterial kinase phosphorylation.
When the wild-type Pfnek3 was incubated in a kinase
assay mix consisting of the ATP phosphate donor and the
Mn2?/Mg2? cofactor prior to Western blotting, a signifi-
cant increase in its phospho-tyrosine signals was observed
(Fig. 1b). Notably, the rise in signal was more evident in
the presence of Mn2? as compared to Mg2? [294 vs. 211%
of untreated Pfnek3 tyrosine autophosphorylation based on
densitometric quantification of the Western-blot data
(Fig. 1c)]. This indicates that Pfnek3 could undergo further
tyrosine autophosphorylation in vitro, with Mn2? as the
preferred metal cofactor. On the other hand, no significant
increment was detected for both its phospho-serine and
phospho-threonine signals. One plausible explanation
could be that the heterologously expressed Pfnek3 has
already been substantially autophosphorylated on serine
and threonine residues in the bacterial cells. Hence, any
further enhancement in the autophosphorylation of serine
and threonine residues would not be significantly detected
through in vitro experiments.
The ability of Pfnek3 to autophosphorylate on both the
serine/threonine and the tyrosine residues suggests its
potential as a dual-specificity kinase in P. falciparum. This
is intriguing since Pfnek3 is predicted to exert only serine/
threonine kinase activity based on its primary sequence
homology to the classical serine/threonine-type kinases and
thus is not expected to phosphorylate tyrosine residues.
Table 1 Primers used for generating Pfnek3 site-directed mutants





























The designations F and R denote the forward and reverse primers,
respectively, with the sites of mutagenesis underlined
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Recombinant Pfnek3 exhibits dual-specificity activity
on the exogenous MBP substrate, but phosphorylates
its potential in vivo Pfmap2 substrate largely
on threonine 290
To provide additional support for Pfnek3 as a dual-speci-
ficity kinase, further investigations were pursued to
determine if the kinase could likewise phosphorylate sub-
strates on both tyrosine and serine/threonine residues. The
in vitro serine/threonine kinase activity of recombinant
Pfnek3 has been previously assessed using a panel of
generic kinase substrates consisting of MBP, histone H1,
casein kinase I and casein kinase II peptide substrates [20].
However, Pfnek3 was found to be competent in phos-
phorylating only the MBP substrate. In view of this, the
MBP substrate is used in the present study to evaluate the
tyrosine phosphorylation capacity of Pfnek3. The recom-
binant kinase was co-incubated with MBP in the presence
of ATP and Mg2?/Mn2? before Western blot was per-
formed to detect for the presence of phospho-tyrosines in
the MBP substrate. As observed in Fig. 2a, incubation with
Pfnek3 considerably increased the level of phospho-tyro-
sine signal detected in MBP, providing evidence that
Pfnek3 does exert a tyrosine kinase activity towards the
exogenous MBP substrate. Furthermore, similar to the
phenomenon observed for tyrosine autophosphorylation in
Fig. 1b, densitometric analysis of the immunoblot revealed
that the MBP phospho-tyrosine signal was 61% higher when
the assay mix was supplemented with Mn2? as compared to
Mg2? (Fig. 2b). This offers additional support that the in vitro
tyrosine kinase activity of Pfnek3 is triggered to a greater
extent in the presence of the Mn2? cofactor.
As the serine/threonine kinase activity of Pfnek3 was
previously examined using mixed antibodies specific
against both phospho-serines and phospho-threonines, it
was unable to clearly distinguish whether phosphorylation
had occurred on serine and/or threonine residues. In view
of this, Western blot was performed using antibodies spe-
cific against either the phospho-serines or the phospho-
threonines to further delineate the Pfnek3 phosphorylation
specificity on MBP. The results shown in Fig. 2a indicate
that Pfnek3 phosphorylates MBP on threonine, but not
serine residues. Additionally, in contrast to the trend seen
for tyrosine phosphorylation, a stronger phospho-threonine
signal was observed when the kinase assay was performed
in the presence of Mg2? instead [141% higher compared to
that in the presence of Mn2? following densitometric
quantification of the Western-blot data (Fig. 2b)]. With the
competency of Pfnek3 to similarly phosphorylate the
exogenous MBP substrate on both the threonine and tyro-
sine residues, the functionality of Pfnek3 as a dual-
specificity kinase is strengthened. In addition, it appears
that the dual-specificity activity of the kinase is distinctly
influenced by the type of divalent cation present.
Of the two MAPKs (Pfmap1 and Pfmap2) found in the
P. falciparum kinome, Pfnek3 was earlier demonstrated to
phosphorylate only Pfmap2 in vitro [20]. Hence, other than the
exogenous MBP substrate, the dual-specificity kinase activity
of Pfnek3 was also evaluated using its plasmodial Pfmap2
substrate in an attempt to gain insights into the functional
relevance of its dual-specificity activity in vivo. A catalyti-
cally inactive mutant of Pfmap2 (denoted as DPfmap2) was
used as the substrate to rule out the effect of its autophos-
phorylation. In Fig. 2c, Western-blot analysis illustrated that
Pfnek3 phosphorylated DPfmap2 at threonine residues. Fur-
ther densitometric quantification of the immunoblot indicates
(a) (b)
(c)
Fig. 1 Autophosphorylation characteristics of recombinant Pfnek3.
a Recombinant Pfnek3 and its kinase-dead mutant (DPfnek3) were
transferred to PVDF membrane and probed with antibodies specific
against phospho-tyrosine, serine, or threonine (denoted by Anti P-Tyr,
Anti P-Ser, and Anti P-Thr, respectively). Coomassie staining of
duplicated SDS-PAGE gels indicates similar protein loading for each
lane. Representative blots/gel from three independent experiments is
shown. b Following protein expression and purification, Pfnek3 was
incubated in a kinase assay mix comprising ATP and Mn2?/Mg2? as
shown in the top panel. The mixtures were then subjected to
immunoblotting using the specified antibodies. Coomassie staining of
duplicated SDS-PAGE gels indicates similar protein loading for each
lane. The result shown is representative of three independent
experiments. c Densitometric analysis of the results obtained in
b. Data is expressed as a percentage of Pfnek3 autophosphorylation in
the absence of ATP/Mn2?/Mg2?, with each bar representing the
mean autophosphorylation level ± standard deviation from the three
independent assays
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that the phospho-threonine signal detected in the presence of
Mg2? was 154% more intense as compared to that in Mn2?
(Fig. 2d). This observation coincides with the result obtained
from an earlier mass spectrometry study where Pfnek3 was
validated to phosphorylate Pfmap2 at the threonine residue,
T290 [21]. Apart from threonine residues, Pfnek3 was not
observed to phosphorylate DPfmap2 at serine or tyrosine
residues. The basal DPfmap2 phosphorylation detected in the
phospho-serine blot could be an effect of bacterial kinase
phosphorylation when it was heterologously expressed in
E. coli. It is believed that Pfnek3 phosphorylates Pfmap2
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was diminished by 89% based on densitometric quantification
when the threonine was mutated to a non-phosphorylatable
alanine (Fig. 2e, f).
Tyrosine phosphorylation is involved in regulation
of the serine/threonine and tyrosine kinase activities
of Pfnek3
The detection of Pfnek3 tyrosine autophosphorylation in
Fig. 1a has prompted the evaluation of its importance in
regulating the catalytic activity of Pfnek3. With this in mind,
recombinant Pfnek3 was treated with a tyrosine-specific
phosphatase, PTP1B, before its activity was tested in an
ELISA-based kinase assay using MBP as the exogenous
substrate. In comparison to the untreated Pfnek3, the phos-
phatase-treated recombinant kinase showed a reduction in its
serine/threonine kinase activity by 34%, while its tyrosine
kinase activity was lowered by 73% (Fig. 3a). Since prior
treatment of Pfnek3 with PTP1B resulted only in the removal
of phosphorylation from tyrosine, but not from serine and
threonine residues (Fig. 3b), it indicates that the decrease in
the activities of Pfnek3 is mainly attributed to the deficiency in
tyrosine phosphorylation. Hence, this supports that tyrosine
phosphorylation is crucial for the serine/threonine and tyro-
sine kinase activities of Pfnek3.
Probing for potential tyrosine phosphorylation sites
involved in mediating Pfnek3 kinase activity
Regulation of protein kinase activities can be generally
achieved through several mechanisms including phos-
phorylation by upstream kinases or through autocatalytic
events, and/or interaction with regulatory domains or
subunits [27, 28]. Among these, phosphorylation within the
activation loop, a segment located between the DFG and
APE motifs of kinase subdomains VII and VIII, respec-
tively, is a widespread mechanism that controls the
function of a wide range of protein kinases [29]. This mode
of regulation is similarly adopted by Pfnek3, where pre-
vious site-directed mutagenesis and phosphorylation
analyses supported S221 and S226 within the activation
segment as phospho-activating sites [23]. Other than this,
Pfnek3 activity was also demonstrated to rely on phos-
phorylation of residue T82, located at the N-terminal of the
catalytic domain [23]. With the additional observations that
Pfnek3 is autophosphorylated on tyrosines residues and
that the phosphorylation is essential for its kinase activities
(Figs. 1, 3a), determining the specific phospho-tyrosine
sites is fundamental to further comprehend the enzymatic
regulation of Pfnek3.
However, due to the nature of its amino acid sequence,
delineating Pfnek3 phosphorylation sites via mass spec-
trometry is technically difficult. Despite substantial
optimization and troubleshooting, limited protein sequence
coverage was constantly obtained, which greatly deterred
phospho-site detection [23]. Moreover, as no tyrosine
residue is present within the activation loop of Pfnek3,
mapping of potential tyrosine phosphorylation sites is
further impeded. Hence, a biocomputational approach was
undertaken in this study to screen for potential tyrosine
phosphorylation sites in Pfnek3. Using the online NetPhos
software [25], a total of six candidate phospho-tyrosine
sites at Y99, Y117, Y122, Y172, Y238, and Y286 were
identified in Pfnek3 (Table 2). With reference to the 3D
model of Pfnek3 generated earlier [23], these residues were
found to be located on the surface of the protein structure
with their hydroxyl side chains projecting outwards
(Fig. 4a).
Mutation of residues Y117, Y122, Y172, and Y238 led
to drastic reductions in both Pfnek3 tyrosine
phosphorylation and catalytic activities
Based on the hypothesis that phosphorylation occurs at
positions Y99, Y117, Y122, Y172, Y238, and Y286, which
is in turn essential for stimulating the kinase activity of
Pfnek3, site-directed mutagenesis was performed to replace
each tyrosine with a non-phosphorylatable phenylalanine.
In the event that these tyrosines function as critical phos-
pho-regulatory sites, the mutation would result in the
reduction of both the tyrosine phosphorylation of Pfnek3 as
well as its catalytic activity.
The GST-tagged mutants (hereafter referred to as Y99F,
Y117F, Y122F, Y172F, Y238F, and Y286F) were similarly
expressed in E. coli cells as the wild-type kinase and
Fig. 2 Recombinant Pfnek3 exhibits dual-specificity kinase activity
on the exogenous MBP substrate but not Pfmap2. In vitro Pfnek3
kinase assays were performed in the presence of ATP and Mn2?/
Mg2? using a MBP or c DPfmap2 as substrates. The mixtures were
resolved by SDS-PAGE and phosphorylation status of the respective
substrates was analyzed by Western blot using the indicated phospho-
specific antibodies. Coomassie staining of duplicated SDS-PAGE gels
indicates similar loading of the respective proteins. Results depicted
are representative of three independent experiments. b, d Densitomet-
ric quantification of the results obtained in a and c, respectively. For
referencing purposes, phosphorylation levels are expressed as
percentages of MBP/DPfmap2 phosphorylation in the presence of
Pfnek3/ATP/Mn2?. Each bar depicts the mean phosphorylation
level ± standard deviation from the three independent experiments.
e In vitro kinase assays for Pfnek3 were repeated in reaction buffers
supplemented with ATP, Mg2? and either the DPfmap2 or the
DPfmap2/T290A substrates. Phosphorylation status of the substrates
was subsequently assessed using the Pro-Q Diamond phosphopro-
tein gel stain. Coomassie staining of the same gel at the lower panel
demonstrates comparable protein loading. A representative result of
three independent experiments is illustrated. f Graphical representa-
tion of the densitometric analyses for e. Result is expressed as a
percentage of DPfmap2 phosphorylation, with each bar representing
the mean phosphorylation level ± standard deviation from the three
independent assays. ND denotes kinase activity not detected
b
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affinity-purified using the glutathione agarose beads. To
detect for possible decrease in the tyrosine autophospho-
rylation of these purified mutants, Western blot was
performed using the anti-phosphotyrosine antibody. As
illustrated in Fig. 5a, b, both the Y99F and Y286F mutants
displayed a comparable level of tyrosine phosphorylation as
seen in wild-type kinase. On the contrary, the phospho-
tyrosine levels of Y117F, Y122F, Y172F, and Y238F were
significantly reduced (29, 51, 27, and 34%, respectively, of
wild-type Pfnek3 tyrosine autophosphorylation level based
on densitometric analysis of the immunoblot). This supports
that tyrosine phosphorylation could originate from residues
Y117, Y122, Y172, and Y238, and not from residues Y99
and Y286.
The ELISA-based kinase assays were subsequently
conducted to examine the effects of the respective muta-
tions on the serine/threonine and tyrosine kinase activities
of Pfnek3. Interestingly, the profile displayed by the
mutants for the serine/threonine kinase activity coincided
with that for the tyrosine kinase activity (Fig. 5c). It was
observed that the Y99F mutant exhibited serine/threonine
and tyrosine kinase activities that were similar to the wild-
type Pfnek3. On the other hand, the Y117F, Y122F, and
Y172F mutants demonstrated significant decrease in both
their serine/threonine (5, 26, and 2%, respectively, of wild-
type Pfnek3 serine/threonine kinase activity) and tyrosine
(13, 26, and 7%, respectively, of wild-type Pfnek3 tyrosine
kinase activity) kinase activities. For both the Y238F and
Y286F mutants, no significant activity was detected. As the
Fig. 3 Effects of tyrosine dephosphorylation on the serine/threonine
and tyrosine kinase activities of Pfnek3. Recombinant Pfnek3 was
treated with PTP1B as described in the Materials and methods
section. In control experiments, PTP1B was omitted. a Aliquots of the
mixtures were subjected to ELISA-based kinase assays using MBP as
substrate to determine the serine/threonine and tyrosine kinase
activities of the PTP1B-treated Pfnek3. Results are expressed as
percentage of untreated Pfnek3 activity, with each bar representing
the mean activity ± standard deviation from two independent assays.
b Phosphorylation status of the PTP1B-treated and control Pfnek3
were verified by Western blot using the indicated antibodies.
Coomassie staining of duplicated SDS-PAGE gel illustrates similar
loading of the proteins. The results illustrated are representative of
two independent experiments
Table 2 Potential Pfnek3 tyrosine phosphorylation sites predicted by











The score represents the probability for each tyrosine residue to
undergo phosphorylation. The locality of the residues in the 3D model
of Pfnek3 is also indicated
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reduction in tyrosine autophosphorylation was concomitant
with the decrease in kinase activities for the Y117F, Y122F,
Y172F, and Y238F mutants, it supports the notion that
phosphorylation does occur at these tyrosine residues and is
critical for regulating the catalytic activity of Pfnek3.
Nevertheless, structural analyses of the Pfnek3 model
revealed that residues Y117 and Y122 each form a hydro-
gen bond with their neighboring amino acids (Fig. 4b).
Therefore, it remains a possibility that the reduction in
kinase activity observed for the Y117F and Y122F mutants
might be due to the loss of hydrogen bond that could be
important for maintaining the structural integrity of the
protein.
Based on the results obtained for the Y286F mutant, it is
interesting to note that although Y286 is unlikely to be a
phosphorylation site, the tyrosine residue was found to be
critical for Pfnek3 to phosphorylate the MBP substrate.
Considering that autophosphorylation of the Y286F mutant
was comparable to that of the wild-type Pfnek3, it suggests
that the mutation did not drastically alter the catalytic
activity of the kinase. However, the mutant did not exhibit
detectable kinase activity using the MBP substrate. A
plausible explanation is that the residue Y286 in Pfnek3 is
an important binding site residue required for the interaction
with the MBP substrate. Therefore, removal of the tyrosine
residue via site-directed mutagenesis could have led to a
loss of the Pfnek3-MBP interaction and thereby resulted in a
lack of phosphorylation in the MBP substrate.
In an attempt to constitutively mimic the effects of
phosphorylation at residues Y117, Y122, Y172, and Y238,
the tyrosine at these sites were each altered to the negatively
charged aspartate or glutamate. The resultant mutants were
then assayed for their kinase activities. As depicted in
Fig. 6, no significant serine/threonine or tyrosine kinase
Fig. 4 Positions of predicted
phospho-tyrosine sites in the
tertiary model of Pfnek3. a The
3D model of Pfnek3 was
generated in an earlier study
[23] and viewed using the
Swiss-PdbViewer. Location of
the predicted phospho-tyrosines
are shown and highlighted in
red. b Neighboring residues that
fall within 4 A˚ of the predicted
phospho-tyrosines were
identified and are shown in
white. Only residues that form
hydrogen bonds (indicated by
dotted green lines) with the
respective tyrosines are labeled
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activity was detected for the Y117D, Y117E, Y172D,
Y172E, Y238D, and Y238E phospho-mimetic mutants. In
addition, the kinase activities of the Y122D and Y122E
mutants did not surpass that of the non-phosphorylatable
Y122F mutant. Collectively, it appears that these phospho-
mimetic mutations were unable to restore the wild-type
activity of Pfnek3. However, it is noteworthy to mention
that although aspartate and glutamate are negatively
charged amino acids, they may not efficiently mimic the
effect of phospho-tyrosines due to the lack of an aromatic
ring in their side chains.
Discussion
The majority of eukaryotic protein kinases are categorized
into two broad classes based on whether they phosphorylate
serine/threonine or the tyrosine residues. Although the pre-
cise basis for conferring amino acid specificity is not entirely
clear, serine/threonine and tyrosine kinases can generally be
distinguished based on consensus signatures located within
the catalytic loop of the kinase domain. The serine/threonine
kinases typically contain a HRDLKxxN motif while the
tyrosine kinases possess either a HRDLAARN or a
HRDLRAAN sequence [1]. However, identification of the
third group of protein kinases, the dual-specificity kinases, is
less straightforward, as no unique consensus motif has been
identified in these kinases. In fact, many of the dual-speci-
ficity kinases were initially isolated through phospho-tyrosine
antibody screening of cDNA expression libraries designed
for detecting novel tyrosine kinases [4]. However, instead of
possessing a catalytic domain that was expected to resemble
the typical tyrosine kinases, these kinases displayed extensive
primary sequence homology to the serine/threonine kinases.
Subsequent biochemical analysis revealed their abilities to
phosphorylate both the serine/threonine and the tyrosine
residues, thus identifying them as dual-specificity kinases.
Hence, kinases that are originally predicted as serine/threo-
nine kinases by virtue of their catalytic loop sequences could
potentially emerge as dual-specificity kinases.
In the current study, the P. falciparum Pfnek3 was dem-
onstrated via Western-blot analysis to undergo
Fig. 5 Tyrosine phosphorylation levels and catalytic activities of
Pfnek3 phenylalanine-substituted mutants. a Purified wild-type
Pfnek3 and the indicated site-directed mutants were subjected to
Western blot using the phospho-tyrosine antibody. Coomassie
staining of duplicated SDS-PAGE gel demonstrates similar protein
loading for each lane. The result illustrated is representative of three
independent experiments. b Densitometric analysis of the result
obtained in a. Data is expressed as a percentage of wild-type Pfnek3
tyrosine autophosphorylation, with each bar representing the mean
autophosphorylation level ± standard deviation from the three inde-
pendent assays. c Via the ELISA-based kinase assay, the in vitro
serine/threonine (upper panel) and tyrosine (lower panel) kinase
activities of the respective Pfnek3 mutants were determined by their
ability to phosphorylate the MBP substrates. Results are presented as
a percentage of wild-type Pfnek3 activity, with each bar representing
the mean activity ± standard deviation from two independent assays.
ND denotes kinase activity not detected
b
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autophosphorylation at not only the serine/threonine but also
the tyrosine residues (Fig. 1). Additionally, the kinase could
also catalyze phospho-transfer to both groups of hydroxyl
amino acids in the exogenous MBP substrate (Fig. 2a, b).
These intriguing observations thus point towards a novel
dual-specificity kinase activity in Pfnek3. Prior to this study,
Pfnek3 was anticipated to phosphorylate merely on serines
and/or threonines, since it possesses a catalytic loop
(HGDLKSTN) that coincides with the HRDLKxxN con-
sensus element of serine/threonine kinases. Hence, without a
more in-depth biochemical examination, the dual-specificity
property of Pfnek3 would inevitably be overlooked. These
findings thus shed light on another biochemical similarity
between Pfnek3 and the classical MAPKK. The latter rep-
resents an important dual-specificity kinase in the MAPK
signaling pathway essential for activating the downstream
MAPK through the concomitant phosphorylation of both
threonine and tyrosine residues within the TXY activation
site [22].
To assess whether Pfnek3 could exert a similar dual-
specificity kinase activity on its Pfmap2 MAPK substrate,
its ability to phosphorylate both the serine/threonine and
tyrosine residues in Pfmap2 was also investigated. Via
mass spectrometry, Pfnek3 was previously verified to
phosphorylate Pfmap2 at the threonine residue, T290,
within its conserved TSH activation site [21]. This was
reflected in the current work where immunoblot analysis
demonstrated threonine phosphorylation of Pfmap2 by
Pfnek3 (Fig. 2c, d). Other than threonine phosphorylation,
no serine or tyrosine phosphorylation was detected. It
therefore appears that Pfnek3 exhibits only threonine
kinase activity on Pfmap2, and this could occur mainly on
residue T290 as phosphorylation of Pfmap2 was largely
abrogated when the threonine residue was substituted to an
alanine (Fig. 2e, f).
It was also noted that the threonine and tyrosine kinase
activities of Pfnek3 were distinctly influenced by the Mg2?
and Mn2? cofactors (Figs. 1, 2). In the presence of Mn2?,
the recombinant Pfnek3 displayed a stronger tyrosine
kinase activity in vitro. On the other hand, phosphorylation
of threonine residues was more evident in the presence of
Mg2?. These findings is in line with the metal cofactor
preferences of classical serine/threonine kinases and tyro-
sine kinases, where Mg2? and Mn2? cofactors are favored,
respectively [30, 31]. It is plausible that binding of dif-
ferent metal cofactors may induce Pfnek3 to adopt distinct
conformations at its active site for promoting the phos-
phorylation of either serine/threonine or the tyrosine
residues.
The catalytic activity of recombinant Pfnek3 has earlier
been validated to be influenced by both threonine and serine
phosphorylation [23]. In particular, it was demonstrated that
phosphorylation of residues T82, S221, and S226 was
critical for enhancing the kinase activity of Pfnek3. To
complement this finding, results highlighted in Fig. 3 fur-
ther indicate that tyrosine phosphorylation is also a crucial
factor for mediating the kinase activity of Pfnek3. Collec-
tively, the regulatory mechanism involved in controlling
Pfnek3 activity seems to become increasingly evident with
both serine/threonine and tyrosine phosphorylation playing
a pivotal role. Phosphorylation is a major post-translational
modification that can modulate protein activity, protein–
protein interaction, and protein translocation. Hence, other
than acting as molecular switches to regulate its activity, it
would be interesting to pursue whether phosphorylation of
Pfnek3 can play additional roles in terms of substrate
interaction and cellular localization. Efforts have also been
made in this study to identify the tyrosine phosphorylation
sites that are crucial for modulating Pfnek3 kinase activity.
However, as mass spectrometric identification of Pfnek3
Fig. 6 Catalytic activities of Pfnek3 tyrosine phospho-mimetic
mutants. Residues Y117, Y122, Y172, and Y238 were each replaced
with either an aspartate or a glutamate to mimic phosphorylation at
these residues. Serine/threonine (upper panel) and tyrosine (lower
panel) kinase activities of these mutants were analyzed using the
ELISA-based kinase assay. Results are presented as a percentage of
wild-type Pfnek3 activity, with each bar representing the mean
activity ± standard deviation from two independent assays.
ND denotes kinase activity not detected
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tyrosine phosphorylation sites is technically challenging,
the current investigation adopted an alternative biocompu-
tational approach for identifying potential tyrosine
phosphorylation sites. The NetPhos program predicted a
total of six tyrosines that could potentially be phosphory-
lated (Table 2). The combined data obtained following site-
directed mutagenesis and biochemical assays support resi-
dues Y117, Y122, Y172, and Y238 as phosphorylation sites
crucial for mediating the catalytic activity of Pfnek3
(Fig. 5). Although these tyrosines were phosphorylated
based on the autocatalytic activity of recombinant Pfnek3,
there remains a possibility for them to be phosphorylated by
regulatory kinases in vivo. This would ultimately aid in
mapping protein kinase signaling pathways of P. falciparum,
which still remains elusive to date. A similar phenomenon has
been previously documented for the mammalian ERK2,
where bacterially expressed ERK2 was shown to undergo
autophosphorylation at the threonine and tyrosine residues
within its consensus TEY activation site [32, 33]. However, in
vivo, these residues require phosphorylation by the upstream
MEK activator to enable ERK2 to achieve its fully activated
state [22]. Other than tyrosine phospho-regulatory sites,
results obtained from Fig. 5 also suggest that the residue Y286
of Pfnek3 could be an important binding site residue for the
interaction with the MBP substrate. This notion, however,
requires further investigation and the ability to obtain a crystal
structure of the Pfnek3-MBP complex would be advantageous
in evaluating the hypothesis.
To summarize, this investigation has provided evidence
to support Pfnek3 as a novel dual-specificity kinase of
P. falciparum and illustrates an additional biochemical
similarity with the MAPKKs. Its serine/threonine and
tyrosine kinase activities were also found to be indepen-
dently stimulated through the binding of distinct metal
cofactors. Among all the P. falciparum kinases investigated
thus far, Pfmap1, another MAPK homologue, is the only
other kinase that reportedly phosphorylates at both the
serine/threonine and the tyrosine residues [34]. However, in
contrast to Pfnek3, its dual-specificity kinase activity was
only restricted to autophosphorylation reactions and whe-
ther it exhibits a corresponding activity on its substrates is
unclear [34]. An interesting observation highlighted from
the study of P. falciparum kinome is that members
belonging to the tyrosine kinase family are absent [13].
Despite this, tyrosine phosphorylation was evident
throughout the intra-erythrocytic maturation of P. falcipa-
rum, and was demonstrated to be essential for parasite
survival [35, 36]. This has therefore raised queries regard-
ing the kinases involved in undertaking the role of tyrosine
phosphorylation in vivo. The discovery of dual-specificity
kinases such as Pfnek3 and Pfmap1 is thus of great bio-
logical significance as they could be exploited as key
players to perform crucial tyrosine phosphorylation in vivo.
More specifically, these kinases may play critical roles in
modulating the functions of cellular proteins that require
activation by both the serine/threonine and tyrosine phos-
phorylation. It is also noteworthy to mention that tyrosine-
specific phosphatases have been identified in the parasite
[37, 38]. Therefore, cellular tyrosine phosphorylation in P.
falciparum may be modulated through the cooperative
function of these phosphatases and the dual-specificity
kinases. Finally, as the dual-specificity property of kinases
is difficult to be predicted based on amino acid sequence
analysis alone, it is highly likely that additional members of
such kinases in P. falciparum could be unveiled through
assessment of plasmodial kinases for their tyrosine kinase
activities by the biochemical characterization approach.
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a  b  s  t  r  a  c  t
The  recent  recognition  of Plasmodium  falciparum  Hsp90  (PfHsp90)  as  a promising  anti-malaria  drug  target
has  sparked  interest  in  identifying  factors  that  regulate  its  function  and  drug-interaction.  Co-chaperones
are  well-known  regulators  of  Hsp90’s  chaperone  function,  and  certain  members  have been  implicated  in
conferring  protection  against  lethal  cellular  effects  of  Hsp90-speciﬁc  inhibitors.  In this  context,  studies
on PfHsp90’s  co-chaperones  are  imperative  to gain  insight  into  the  regulation  of the  chaperone  in  the
malaria  parasite.  In this  study,  a  putative  co-chaperone  P. falciparum  Aha1  (PfAha1)  was  identiﬁed  and
investigated  for its interaction  and  regulation  of  PfHsp90.  A previous  genome-wide  yeast  two-hybrid
study  failed  to identify  PfAha1’s  association  with  PfHsp90,  which  prompted  us  to  use  a  directed  assay  to
investigate  their  interaction.  PfAha1  was  shown  to interact  with  PfHsp90  via the  in  vivo  split-ubiquitin
assay  and  the  association  was  conﬁrmed  in  vitro  by GST  pull-down  experiments.  The  GST  pull-down  assay
further revealed  PfAha1’s  interaction  with  PfHsp90  to  be dependent  on  MgCl2 and  ATP, and  was  competed
by  co-chaperone  Pfp23  that  binds  PfHsp90  under  the same  condition.  In  addition,  the PfHsp90–PfAha1
complex  was  found  to be sensitive  to disruption  by high  salt,  indicating  a polar  interaction  between
them.  Using  bio-computational  modelling  coupled  with  site-directed  mutagenesis,  the polar  residue
N108  in PfAha1  was found  to be strategically  located  and essential  for PfHsp90  interaction.  The  functional
signiﬁcance  of  PfAha1’s  interaction  was clearly  that of  exerting  a  stimulatory  effect on the ATPase  activity
of PfHsp90,  likely  to  be essential  for  promoting  the activation  of  PfHsp90’s  client  proteins.. Introduction
Protein folding and activation mediated by the molecular chap-
rone Hsp90 (Heat shock protein 90) is a complex ATP-driven
rocess that is regulated by a cohort of accessory proteins termed
o-chaperones (reviewed in Pearl and Prodromou, 2006; Neckers
t al., 2009; Taipale et al., 2010). A subset of these co-chaperones
e.g. Hop, p23, and Aha1) coordinates the progression of Hsp90’s
haperone cycle by modulating the ATPase activity of Hsp90 that
s tightly coupled to its conformational states (Wandinger et al.,
008; Hessling et al., 2009; Li et al., 2011). The co-chaperone Aha1
Activator of Hsp90 ATPase) is known to associate with Hsp90 and
Abbreviations: 5-FOA, 5-ﬂuoroorotic acid; ADP, adenosine diphosphate; Aha1,
ctivator of Hsp90 ATPase 1; ATP, adenosine triphosphate; Cub, C-terminal half
f  ubiquitin; DNA, deoxyribonucleic acid; GST, glutathione S-transferase; His6,
exa-histidine; Hsp90, Heat shock protein 90; Ni-NTA, nickel-nitrilotriacetic acid;
MR, nuclear magnetic resonance; Nub, N-terminal half of ubiquitin; PCR, poly-
erase chain reaction; PDB, Protein Data Bank; SDS–PAGE, sodium dodecyl
ulfate–polyacrylamide gel electrophoresis; WT,  wild-type.
∗ Corresponding author. Tel.: +65 65163280; fax: +65 67766872.
E-mail address: micsimts@nus.edu.sg (T.S. Sim).
357-2725/$ – see front matter ©  2011 Elsevier Ltd. All rights reserved.
oi:10.1016/j.biocel.2011.10.021© 2011 Elsevier Ltd. All rights reserved.
activate its ATPase activity to promote the activation of Hsp90’s
client protein.
Aha1 was  initially discovered as a homologue of Saccha-
romyces cerevisiae Hch1, a suppressor of growth defect observed
in temperature sensitive yeast strain carrying mutant Hsp82
(Hsp90 in yeast) with E381K substitution (Nathan et al., 1999;
Panaretou et al., 2002). Gene deletion studies in yeast indicated
that both Aha1 and Hch1 are non-essential for viability, although
temperature sensitive phenotypes were observed in the single
and double deletion-strains constructed i.e. AHA1, HCH1 and
AHA1–HCH1 (Panaretou et al., 2002; Lotz et al., 2003). Never-
theless, the deletion of Aha1 signiﬁcantly impaired the activation
of glucocorticoid receptor and v-Src kinase in yeast, suggesting that
the presence of the co-chaperone is essential for functional matu-
ration of these Hsp82 client proteins (Lotz et al., 2003; Meyer et al.,
2003). Similar observation has been made in an siRNA study con-
ducted on mammalian cell culture where downregulation of Aha1
led to drastically reduced level of activated glucocorticoid receptors
(Harst et al., 2005). Together with the observed role in activat-
ing Hsp90’s ATPase activity, Aha1 has been proposed as a positive
regulator of Hsp90’s chaperone function, whose association with
Hsp90 is important in driving certain client proteins towards their
activated states.



























































Primers designed for gene cloning and mutations.
































































a Restriction enzyme sites are in lowercase; F represents forward primer; R rep-34 C.S. Chua et al. / The International Journal o
In Plasmodium falciparum,  a putative Aha1 (PfAha1; PlasmoDB
ccession number: PFC0270w) that shares approximately 20%
mino acid sequence identity with that of the yeast homologue
as been described in a computational study (Kumar et al., 2007).
s the putative PfAha1 has not been characterized prior to this
tudy, its role as a co-chaperone of P. falciparum Hsp90 (PfHsp90)
emains elusive. PfHsp90 has recently emerged as a promising drug
arget for malaria inhibition (Pesce et al., 2010; Shonhai, 2010) as
ts speciﬁc inhibitors have been shown to cause growth arrests in
. falciparum intra-erythrocytic stage cultures (Banumathy et al.,
003; Kumar et al., 2003). This indicates PfHsp90’s involvement
n crucial biological pathways in P. falciparum and thereafter its
nhibition, an attractive avenue to abrogate the cellular activities
f the parasite. Despite recognizing the importance of PfHsp90 for
he survival of the parasite, knowledge on the chaperone function
nd regulation of PfHsp90 remains limited, partly due to difﬁcul-
ies in genetic manipulation of the Plasmodium parasite. So far,
o-immunoprecipitation and yeast two-hybrid experiments were
nable to provide evidence on the association between PfHsp90
nd many putative co-chaperones (e.g. Aha1, Hop, and p23) that
re known to play essential roles in the yeast and human Hsp90
haperone cycle (Banumathy et al., 2003; LaCount et al., 2005). The
nteraction between P. falciparum p23 (Pfp23) and PfHsp90 was
nly recently elucidated using recombinant proteins and GST pull-
own approach, whereby Pfp23 reportedly exerts an inhibitory
ffect on the ATPase activity of PfHsp90 (Chua et al., 2010). In view
f the importance of Aha1 in the yeast and human Hsp90 chap-
rone system for client protein activation, the putative PfAha1 is
nvestigated in this study with the intention of characterizing its
nteraction and regulation of PfHsp90.
. Materials and methods
.1. Split-ubiquitin assay
The use of the split-ubiquitin system for investigating protein
nteraction in yeast has been described previously (Lehming, 2002;
aser et al., 2000). PfHsp90 (PF07 0029) and PfAha1 (PFC0270w)
ere reverse transcribed and ampliﬁed from the mRNA extracted
rom P. falciparum 3D7 (MRA-102, MR4, ATCC Manassas, VA) and
ubsequently used as a template to clone the respective PfHsp90
PfHsp90N, PfHsp90M and PfHsp90C) and PfAha1 (PfAha1N and
fAha1C) domains using appropriate forward and reverse primers
Table 1). PfHsp90N, PfHsp90M and PfHsp90C DNA products were
igested with EcoRI and SalI and ligated into the Cub-RUra3p vector
Wittke et al., 1999), whereas PfAha1, PfAha1N and PfAha1C were
igested with BglII and SalI  and subsequently cloned into the Nub
ector (Laser et al., 2000). The recombinant plasmids were trans-
ormed into Escherichia coli DH5 cells and their authenticity were
eriﬁed by DNA sequencing.
To investigate the interaction between PfHsp90 and PfAha1,
he appropriate PfHsp90-Cub-RUra3p and Nub-PfAha1 fusion con-
tructs were co-transformed into the S. cerevisiae strain JD52 and
lated onto media lacking leucine and tryptophan to select for
ransformants that carried both constructs. Subsequently, the yeast
ells that contained both the recombinant PfHsp90-Cub-RUra3p
nd Nub-PfAha1 fusion constructs were tenfold serial-diluted and
ropped onto plates lacking leucine and tryptophan, onto plates
dditionally lacking uracil and onto plates additionally containing
-ﬂuoroorotic acid (5-FOA).
.2. Construction of PfHsp90 and PfAha1 plasmids for
ecombinant protein expression
The molecular cloning of PfHsp90 into expression vectors pGK
nd pET24a (Novagen) has been reported (Chua et al., 2010). Forresents reverse primer.
b Codons mutated in PfAha1 are in bold and underlined.
cloning of PfAha1 into bacterial expression vector, PfAha1 was  re-
ampliﬁed by PCR from the Nub-PfAha1 recombinant plasmid using
appropriate forward and reverse primers (Table 1), digested with
BamHI and XhoI, and ligated into the expression vector pET24a.
The ligated recombinant plasmid was  transformed into E. coli BL21
(DE3) cells that contained a RIG plasmid (Baca and Hol, 2000) for
recombinant protein expression. DNA sequencing was  performed
to authenticate the recombinant clone that carries PfAha1.
2.3. Expression and puriﬁcation of PfHsp90, Pfp23 and PfAha1
recombinant proteinsThe expression and puriﬁcation of PfHsp90 and Pfp23 recom-
binant proteins have been described (Chua et al., 2010). An
identical protocol used for the expression and puriﬁcation of Pfp23
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xpression vector, pET24a (Novagen). The concentration of the
uriﬁed fusion proteins were determined by Bradford Assay (Bio-
ad) using bovine serum albumin (Sigma) as a standard.
.4. In vitro interaction assay between PfHsp90 and PfAha1
The puriﬁed dual-tagged PfHsp90 fusion protein (GST-tag at the
-terminus and His6-tag at the C-terminus of PfHsp90) expressed
rom the pGK vector was used as bait to capture interacting PfAha1
ecombinant protein. In each 500-l reaction, 2 g PfHsp90 fusion
rotein was incubated with 50 l of glutathione Sepharose beads
GE Healthcare) at 4 ◦C for 15 min. The bound PfHsp90 fusion pro-
eins were washed thrice with 50 mM Tris–HCl, pH 7.5 buffer, to
emove unbound proteins. Subsequently, the beads were reconsti-
uted in 500 l of binding buffer (50 mM Tris–HCl, pH 7.5, 25 mM
Cl, 2 mM dithiothreitol, 0.01% (v/v) Triton X-100). The binding
ssay was carried out in the presence of 5 mM  MgCl2, 5 mM ATP and
 M PfAha1, unless stated otherwise. Samples were incubated at
0 ◦C for 30 min  to allow any formation of PfHsp90–PfAha1 com-
lex. In the case of competitive binding assays between PfAha1
nd Pfp23, this was followed by the addition of 0.1–4 M Pfp23 and
ncubated for an additional 30 min  at 30 ◦C. Thereafter, the samples
ere washed thrice with 500 l of binding buffer prior to elution
n 150 l of reduced glutathione buffer. 50 l of the eluted sample
as analyzed by SDS–PAGE. Gel image analyses and densitometric
easurements were performed using Bio-Rad Molecular Imager
el Doc XR system equipped with the Quantity One® Software.
.5. Construction of PfAha1 single, double and quadruple mutants
QuikChangeTM Site-directed Mutagenesis Kit from Stratagene
as employed for the construction of PfAha1 single mutants, using
he recombinant pET24a plasmid that contains PfAha1 as a tem-
late. Appropriate primers were designed (Table 1) and the desired
utations were introduced using the following PCR cycling param-
ters: (1) 95 ◦C for 1 min, (2) 95 ◦C for 30 s, (3) 55 ◦C for 30 s,
4) 72 ◦C for 14 min, (5) 28 cycles of steps 2–4 and (6) 72 ◦C for
 min. DNA sequencing was carried out to verify the substitution
f the nucleotide sequences, followed by transformation into E. coli
L21 (DE3) with the RIG plasmid for recombinant fusion protein
xpression. PfAha1 double and triple mutants were respectively
onstructed from veriﬁed PfAha1-containing plasmids with single
nd double mutations, using the appropriate mutagenic primers.
.6. ATPase assay
The ATPase activity of PfHsp90 was measured using the
yruvate kinase/lactate dehydrogenase-coupled assay described
reviously with some modiﬁcations (Chua et al., 2010). In this
xperiment, recombinant PfHsp90 with a single His6-tag at the
-terminus, expressed from the pET24a vector was used. As
fHsp90–PfAha1 interaction is salt-sensitive, a low KCl concentra-
ion was used to promote their association. Brieﬂy, the assay was
arried out in a 200-l reaction containing 2 M PfHsp90, 25 mM
ris–HCl pH 7.5, 4 mM KCl, 1.2 mM MgCl2, 0.8 mM ATP, 2 mM
hosphoenolpyruvate, 0.2 mM NADH, 50 g/ml lactate dehydro-
enase and 0.2 mg/ml  pyruvate kinase. Radicicol, a Hsp90-speciﬁc
nhibitor, was used at a ﬁnal concentration of 200 M to speciﬁcally
nhibit the ATPase activity of PfHsp90 for accurate determination
f its ATP turnover rate.
.7. Bio-computational analyses of PfHsp90 interaction with
fAha1 and Pfp23
A modelled PfHsp90–PfAha1 complex was  constructed using
he crystal structure of PfAha1 (PDB accession number: 3N72) and aemistry & Cell Biology 44 (2012) 233– 245 235
computationally predicted structure of PfHsp90 (Chua et al., 2010).
To model the PfHsp90–PfAha1 complex, the yeast Hsp82–Aha1
crystal structure complex (PDB accession number: 1USV) was used
as a template for superimposition. Similarly, Pfp23 was modelled
and superimposed against the yeast Hsp82–Sba1 crystal struc-
ture (PDB accession number: 2CG9) and compared with that of
the modelled PfHsp90–PfAha1 complex. The superimposition and
visualization of the tertiary structures were performed using the
Swiss-PdbViewer (SPdbV) program (Guex et al., 1999).
3. Results
3.1. P. falciparum genome encodes two putative Aha1
Homology search revealed two  putative copies of Aha1 in
the genome of P. falciparum,  namely PFC0270w and PFC0360w.
PFC0270w encodes a 349 amino acid protein that shares approx-
imately 20% amino acid identity with the human and yeast Aha1.
On the other hand, PFC0360w is relatively shorter with 140 amino
acid residues and displayed only approximately 13% amino acid
identity with the human and yeast Aha1. The proteins of both puta-
tive homologues of Aha1 were detected in the intra-erythrocytic
stages of P. falciparum (Le Roch et al., 2003). Multiple sequence
analysis further revealed that the shorter PFC0360w is aligned to
the C-terminal portion of the human and yeast Aha1 (Fig. 1) with
no homologous N-terminal domain. As the N-terminal domain of
Aha1 has been shown to be important for interaction and induc-
ing structural rearrangement in Hsp90 to promote ATP hydrolysis
(Meyer et al., 2003, 2004), the lack of a homologous N-terminal
domain in PFC0360w has prompted the study to focus on the char-
acterization of PFC0270w, the longer putative copy of Aha1 in P.
falciparum (PfAha1 refers to PFC0270w hereafter). Moreover, the
crystal structure of the N-terminal domain of PFC0270w (PDB:
3N72) was  recently resolved, and thus warrants investigation on
its functionality as a co-chaperone of PfHsp90.
3.2. Detection of the PfAha1–PfHsp90 interaction by the
split-ubiquitin assay
To characterize the putative co-chaperone, the putative PfAha1
was ﬁrst investigated for its ability to interact with PfHsp90
using the split-ubiquitin system. The split-ubiquitin system is an
alternative yeast two-hybrid assay that exploits the principle of
conditional proteolysis which occurs when a ubiquitin molecule is
fused to a protein. In this system, the ubiquitin molecule is split
into an N-terminal half (Nub) and a C-terminal half (Cub) where
neither half is capable of inducing proteolytic cleavage. A modiﬁed
Ura3p with an arginine at the ﬁrst position (RUra3p) fused to the C-
terminal end of Cub is used as a reporter gene. Yeast cells expressing
protein X-Cub-RUra3p fusion proteins are uracil prototrophs and
sensitive to 5-FOA, as Ura3p, orotidine-5′-phosphate decarboxy-
lase, is required for the biosynthesis of uracil and also converts
5-FOA into toxic ﬂuorouracil. In the event that protein X interacts
with protein Y fused to Nub, the Cub and Nub halves are brought into
close proximity and reconstitute into a native-like ubiquitin. This
is recognized by the ubiquitin-speciﬁc proteases and results in the
cleavage of RUra3p. The free RUra3p is rapidly degraded due to the
inclusion of the arginine that is a destabilizing residue in the N-
end rule pathway (Varshavsky, 1996). Hence protein interaction is
inferred from the degradation of RUra3p in yeast cells, indicated by
the lack of growth in media lacking uracil and resistance to 5-FOA.To test whether the putative PfAha1 interacts with PfHsp90,
the full-length and respective domains of PfHsp90 (PfHsp90N,
PfHsp90M and PfHsp90C; Fig. 2) were cloned into the Cub-RUra3p
vector and PfAha1 into the Nub vector. All the PfHsp90Cub-RUra3p







aig. 1. Protein sequence alignment of human, yeast and putative P. falciparum Aha1. P
ith  the human Aha1 (NP 036243.1) and yeast Aha1 (NP 010500.1). (A) PFC0270w
B)  PFC0360w mapped to the C-terminal domain.usion constructs when transformed into yeast cells respectively
onferred growth on plates lacking uracil (results not shown).
his indicated that the various PfHsp90 constructs were expressed
s functional Cub-RUra3p fusion proteins. The expression of thearum genome encodes two  putative Aha1, PFC0270w and PFC0360w. When aligned
yed high homology to the N-terminal domain whereas the shorter homologue andPfAha1 constructs in yeast was veriﬁed by Western blotting against
the HA-tag found at the Nub fusion proteins (Fig. 2). Subsequently,
the PfHsp90-Cub-RUra3p and Nub-PfAha1 fusion constructs were
co-transformed into yeast cells and titrated onto plates lacking
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Fig. 2. Analysis of the PfAha1–PfHsp90 interaction by the split-ubiquitin assay. (A) Schematic representation of the various PfHsp90 and PfAha1 constructs generated for
the  split-ubiquitin assay. (B) Western blot analysis of Nub-PfAha1 fusion proteins. All the Nub-PfAha1 fusion proteins contain a HA-tag respectively and were probed using
anti-HA antibody. The Nub-PfAha1N and Nub-PfAha1C fusion proteins were expressed at a signiﬁcantly higher level than Nub-PfAha1FL. For each lane, 10 g of lysate from
yeast  cells carrying the respective Nub-PfAha1 constructs were loaded. (C) PfAha1FL, PfAha1N and PfAha1CNub fusion constructs were respectively co-transformed with each








gdditionally lacking uracil (-LWU) and onto plates additionally containing 5-ﬂuoro
LWU  plate with complementary increased growth on the 5-FOA plate.
ryptophan and leucine (as a control to detect for yeast cells car-
ying both Cub-RUra3p and Nub recombinant plasmids), lacking
ryptophan, leucine and uracil (reduced growth indicates degrada-
ion of RUra3p and hence interaction between PfAha1 and PfHsp90)
nd lacking tryptophan, leucine but containing 5-FOA (increased
rowth indicates PfAha1–PfHsp90 interaction). acid (5-FOA). A protein–protein interaction is indicated by reduced growth on the
Initial split-ubiquitin assay performed using full-length
PfHsp90-Cub-RUra3p did not reveal any signiﬁcant interaction
with Nub-PfAha1 (data not shown). As the interaction is inferred
from the degradation of RUra3p that occurs when the Cub and
Nub halves are brought in close proximity, the lack of interac-
tion observed between the full-length PfHsp90-Cub-RUra3p and
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Fig. 3. Expression of PfHsp90 and PfAha1 recombinant proteins. PfHsp90 and
PfAha1 were solubly expressed as recombinant tagged fusion proteins; PfHsp90 has




































Fig. 4. SDS–PAGE analysis of the interaction between PfAha1 and PfHsp90 deter-
mined by GST pull-down assay. GST pull-down assay was employed to investigate
the interaction between PfAha1 and PfHsp90. In each 500-l reaction, 2 g PfHsp90
was immobilized on 50-l glutathione Sepharose beads and used to pull-down
PfAha1 that was added in an excess of 2 M (44 g). The assay was performed either
PfAha1 on PfHsp90 interactionis6-tag. M:  protein marker (Biorad).
ub-PfAha1 could possibly be due to the large protein size of
fHsp90 that hinders the proximity required for the reconstitution
f the Cub and Nub halves. Thus, if two proteins interact but the
ub and Cub fused to them respectively are not brought sufﬁciently
lose enough (e.g. due to steric hindrance, size, orientation, etc.)
o be reconstituted as a native-like ubiquitin molecule, their
nteraction will not be reﬂected in this assay. Hence, PfHsp90 was
ubsequently dissected into its respective smaller domains and
ested for their interaction with PfAha1.
When Nub-PfAha1 was  co-transformed with the respective
fHsp90-Cub-RUra3p domain constructs, a slight growth reduction
n the uracil-lacking plate was observed for yeast cells harboring
he Nub-PfAha1 and PfHsp90M-Cub-RUra3p constructs (Fig. 2). This
as complemented by an increased growth on the 5-FOA plate.
ence, the result suggested that PfAha1 interacts with the middle
omain of PfHsp90. To further analyze the interaction, PfAha1 was
issected into two parts, the N- and C-terminal domains (PfAha1N
nd PfAha1C, respectively; Fig. 2), based on sequence alignment to
he yeast Aha1 and Hch1 to investigate the domain that is inter-
cting with PfHsp90. The PfAha1 domains were cloned into the
ub vector and they were each co-transformed with the respective
fHsp90-Cub-RUra3p fusion constructs. Signiﬁcant growth reduc-
ion on the uracil-lacking plate and growth increment on the 5-FOA
late were observed for yeast cells harboring Nub-Aha1N/Aha1C
nd PfHsp90M-Cub-RUra3p (Fig. 2). The results indicated that both
he N- and C-terminal domains of Aha1 interact with the middle
omain of PfHsp90.
.3. Expression and puriﬁcation of recombinant PfAha1 and
fHsp90
To verify the interaction observed between PfAha1 and PfHsp90
n the split-ubiquitin assay, recombinant proteins were prepared
or in vitro interaction assay. PfAha1 was expressed and puriﬁed as
 recombinant fusion protein with a C-terminal His6-tag of approx-
mately 44 kDa whereas PfHsp90 as a 114 kDa dual-tagged fusion
rotein with an N-terminal GST and a C-terminal His6-tag (Chua
t al., 2010) (Fig. 3).in  the presence or in the absence of 5 mM MgCl2, 5 mM ADP or/and 5 mM ATP. The
interaction between PfAha1 and PfHsp90 was only observed in the presence of MgCl2
and ATP. Result shown is representative of three independent experiments.
3.4. PfAha1 interacts with PfHsp90 in the presence of MgCl2 and
ATP
The interaction between the PfAha1 and PfHsp90 was probed
using GST pull-down assay where 2 g of PfHsp90 was  immobi-
lized on glutathione Sepharose beads and used to pull-down PfAha1
that was  added in excess. PfHsp90’s association with the putative
PfAha1 was  tested in various conditions, either in the presence
or absence of 5 mM MgCl2, ADP and/or ATP. Consistent with the
results from the split-ubiquitin assay, PfAha1 was found to inter-
act with PfHsp90. In addition, based on the different conditions
tested, the interaction between PfHsp90 and PfAha1 was observed
to require MgCl2 and ATP (Fig. 4). No interaction was  detected
between PfAha1 and GST in the controls performed under similar
experimental conditions (data not shown).
3.5. PfAha1 and PfHsp90 interaction is disrupted under high salt
condition
Previous study on yeast indicated that the interaction between
Aha1 and Hsp82 to be sensitive to high salt concentration
(Panaretou et al., 2002). To test whether the binding of PfAha1
to PfHsp90 is also affected by high salt content, their association
was investigated using buffers with increasing salt concentra-
tions i.e. 10 mM,  25 mM,  50 mM,  75 mM,  100 mM,  125 mM and
150 mM KCl. High salt concentration is known to disrupt ion-
pair and polar–polar interaction by ‘insulating’ the charges on the
protein through the salt ions, and hence preventing effective inter-
action between the two  proteins. At a low concentration of KCl
(i.e. 10 mM),  PfAha1 binds PfHsp90 as expected. However, in the
presence of increasing concentrations of KCl (25–100 mM KCl),
the association between PfAha1 and PfHsp90 was progressively
reduced (Fig. 5). At 150 mM KCl, the interaction between PfAha1
and PfHsp90 was  almost completely disrupted. The observed
results indicated that the association between PfAha1 and PfHsp90
may  be dependent on ion-pair and/or polar–polar interaction medi-
ated by charged and/or polar amino acid residues in the two
proteins.
3.6. Mutational effects of residues E15, R58, E67, D94 and K127 inThe crystal structure of yeast Aha1 complexed with Hsp82
(PDB accession number: 1USV) revealed two interacting interfaces
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Fig. 5. Interaction between PfAha1 and PfHsp90 is sensitive to disruption by high salt concentration. (A) To investigate whether the association between PfAha1 and PfHsp90
is  dependent on polar–polar and ion-pair interaction, the PfAha1–PfHsp90 binding assay was carried out in the presence of 5 mM MgCl2, 5 mM ATP and with increasing
concentrations of KCl (10–150 mM).  SDS–PAGE analysis revealed a gradual reduction in the level of PfAha1 bound to PfHsp90 when KCl was introduced in increasing
concentrations. (B) The effect of KCl on PfAha1 binding to PfHsp90 was  analyzed by densitometry. The percentage of PfHsp90 bound was calculated with respect to the
























tample  with PfHsp90 only; PfAha1 with respect to the PfAha1 bound to PfHsp90 at
isrupted. Result shown is representative of three independent experiments.
nvolving polar amino acid residues in Aha1 that are important for
inding Hsp82 i.e. (1) residues D53, D68, E97, and D101 (inter-
ct with residues K387, K390, K394, and K398 in Hsp82) and
2) residues E122, D110 and R128 (interact with residues K469,
514, and E515 in Hsp82). Of these residues, three were found
o be conserved in PfAha1 by sequence alignment, namely, E67
D68 in yeast Aha1), D94 (E97 in yeast Aha1) and K127 (R128 in
east Aha1) (Fig. 1). In addition, analyses of the modelled com-
lex of PfHsp90–PfAha1 structure revealed two additional charged
esidues in PfAha1, E15 and R58, that could potentially interact with
fHsp90. Hence, to investigate whether these conserved charged
mino acid residues in PfAha1 are essential in forming ion-pair
nteraction with PfHsp90, site-directed mutagenesis was  carried
ut where alanine substitutions were introduced to replace the
ighlighted residues. The PfAha1 single mutants E15A, R58A, E67A,
94A and K127A were solubly expressed, puriﬁed and their ability
o interact with PfHsp90 was tested and compared to that of PfAha1
ild-type (PfAha1-WT).
Results from the GST pull-down assay showed that these
fAha1 single mutants had comparable PfHsp90 binding capacity
s PfAha1-WT (Fig. 6), indicating that single amino acid mutation
t these residues did not affect PfAha1’s interaction with PfHsp90.
o further evaluate the effect of these substitutions, the muta-
ions were combined and the resulting PfAha1 mutants were tested KCl. At 150 mM KCl, the interaction between PfAha1 and PfHsp90 is signiﬁcantly
for their ability to interact with PfHsp90. Similar to that of the
single mutants, PfAha1 double (E15A/R58A and E67A/D94A) and
quadruple (E15A/R58A/E67A/D94A) mutants were able to bind
PfHsp90 at levels comparable to that of PfAha1-WT. Likewise,
substituting these single, double and quadruple PfAha1 mutants
to an amino acid residue with oppositely charged side chain
(i.e. E15K, R58D, E67K, D94K, K127D, E15K/R58D, E67K/D94K
and E15K/R58D/E67K/D94K) did not signiﬁcantly affect PfAha1’s
interaction with PfHsp90 (results not shown). Hence, the results
indicated that residues E15, R58, E67, D94 and K127 in PfAha1 are
not important for interaction with PfHsp90. All the PfAha1 mutants
were solubly expressed and no interaction was observed between
these mutants and GST in the controls performed under similar
experimental conditions (results not shown).
3.7. Amino acid residue N108 in PfAha1 is essential for PfHsp90
interaction
As the proposed conserved charged residues in PfAha1 were
found to be non-essential for PfHsp90 interaction, other residues
that were observed in the modelled PfHsp90–PfAha1 complex
to be potentially involved in binding PfHsp90 were investi-
gated i.e. E91, F98, N108, E110, R111 and R119 (Fig. 7). As
residues in proximity may  potentially form interfaces that are
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Fig. 6. Amino acid substitutions at residues E15, R58, E67, D94 and K127 in PfAha1 did not affect interaction with PfHsp90. (A) Amino acid residues in PfAha1 that were
postulated to be important for forming ion-pair interaction with PfHsp90 were mutated to investigate their importance for PfHsp90 interaction. SDS–PAGE analysis revealed
that  the respective PfAha1 single mutants (i.e. E15A, R58A, E67A, D94A and K127A) possessed comparable PfHsp90 binding capacity to that of PfAha1-WT. Combination
of  these substitutions in PfAha1 double (E15A/R58A and E67A/D94A) and quadruple (E15A/R58A/E67A/D94A) mutants also did not compromise their binding to PfHsp90.


























sutants bound to PfHsp90. The percentage of PfHsp90 and PfAha1 bound are calcul
ndependent experiments.
mportant for interaction, these residues were mutated singly and
ubsequently combined into double, triple or quadruple PfAha1
utants to investigate their involvement in PfHsp90 interac-
ion. Similarly, these residues were substituted to an alanine
nd the PfAha1 mutants were tested for their ability to interact
ith PfHsp90 using the GST pull-down assay. Seven additional
ha1 mutants were constructed; 3 single mutants (E91A, F98A
nd N108A), a double mutant (E91A/N108A), 2 triple mutants
E67A/D94A/F98A and E110A/R111A/R119A) and a quadruple
utant (E110A/R111A/R119A/K127A). SDS–PAGE analysis of the
ulled down complexes revealed that PfAha1 single mutant N108A
ad signiﬁcantly diminished binding to PfHsp90, retaining only
pproximately 20% of PfAha1-WT binding (Fig. 8). When further
ombined with the E91A mutation, the resulting PfAha1 double
utant E91A/N108A displayed almost no observable binding to
fHsp90. Hence, the results indicated that the residue N108 in
fAha1 is essential for interaction with PfHsp90. On the other
and, alanine substitutions at residues F98, E110, R111 and R119
n PfAha1 had negligible effects on PfHsp90 interaction, suggest-
ng that these residues are not important for binding PfHsp90.
ll the PfAha1 mutants were solubly expressed and no interac-
ion was observed between these mutants and GST in the controls
erformed under similar experimental conditions (results not
hown).ith respect to the sample with PfAha1-WT. Result shown is representative of three
3.8. PfAha1 competes with Pfp23 to interact with PfHsp90
Previous study on the interaction between the co-chaperone
Pfp23 and PfHsp90 demonstrated the requirement of MgCl2 and
ATP for effective association (Chua et al., 2010). Since the bind-
ing conditions were similar to that required for the formation of
PfAha1–PfHsp90 complex as shown in this study, the interaction
between PfHsp90 and PfAha1 was  further examined in the pres-
ence of Pfp23. In the experiment, the immobilized PfHsp90 was
ﬁrst incubated with PfAha1 (2 M)  for complex formation, followed
by the addition of Pfp23 in increasing concentrations (0.5–4 M).
SDS–PAGE analyses of the complexes pulled down by PfHsp90
revealed that Pfp23, when introduced in increasing concentrations,
gradually displaced PfAha1 from PfHsp90 (Fig. 9A). Repeating the
experiment with an initial incubation of PfHsp90 with Pfp23 (2 M)
and a subsequent addition of PfAha1 in increasing concentrations
(0.5–4 M)  yielded a similar interaction trend whereby the co-
chaperone that is added at a higher concentration (i.e. PfAha1)
would displace the other co-chaperone that is of lower concentra-
tion (i.e. Pfp23) from PfHsp90 (Fig. 9B). Hence, the results indicated
competition between PfAha1 and Pfp23 for binding to PfHsp90.
No interaction was observed between PfAha1 and Pfp23 under
the experimental condition used for the competitive binding assay
(data not shown).
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Fig. 7. Analysis of PfAha1 and PfHsp90 tertiary structures. (A) The tertiary structures of PfHsp90 (modelled) and PfAha1 (PDB: 3N72) were superimposed against the
yeast  Hsp82–Aha1 complex (PDB: 1USV). Residues in PfAha1 that were investigated for their importance in PfHsp90 interaction by site-directed mutagenesis are highlighted.















AfAha1’s residue N108 was  observed to be in proximity with residues N472 and T476
PDB:  1USV) and Hsp82–Sba1 (PDB: 2CG9) crystal structures, the PfHsp90–PfAha1–
verlapping PfHsp90-interaction interfaces (boxed), supporting the experimentally
.9. PfAha1 stimulates the ATPase activity of PfHsp90
Following PfAha1 and PfHsp90 interaction study, the binding
ffect of PfAha1 on the ATPase activity of PfHsp90 was subse-
uently investigated. The ATPase activity of PfHsp90 (2 M)  was
easured in the absence or presence of increasing concentrations
f PfAha1 (0.1–2 M).  PfAha1 was observed to stimulate the ATPase
ctivity of PfHsp90 to approximately 300% of its original activ-
ty when added in equimolar concentration (Fig. 10).  However,
hen incubated with equimolar concentration of PfAha1 single
utant N108A with reduced binding to PfHsp90, the ATPase stimu-ation was diminished to approximately 150% of its original activity.
sing the PfAha1 double mutant E91A/N108A that displayed fur-
her reduced binding to PfHsp90, the stimulation of PfHsp90’s
TPase activity was almost abolished. The results indicated thatsp90, presumably forming polar–polar interaction. (B) Using the yeast Hsp82–Aha1
 complex was  modelled and constructed. PfAha1 and Pfp23 were observed to have
ved binding competition between the two co-chaperones for PfHsp90.
PfAha1 interaction with PfHsp90 is essential for the co-chaperone
to exert its stimulatory effect on the ATPase activity of PfHsp90.
4. Discussion
In P. falciparum,  several putative homologues of Hsp90’s co-
chaperones have been identiﬁed in the genome sequence of
the malaria parasite. The co-chaperones found include Pfp23
(PF14 0510), PfAha1 (putative, PFC0270w and PFC0360w), PfHop
(putative, PF14 0324), FKBP35 (PFL2275c), Cyp19 (PFC0975c) and
PP5 (PF13 0294). Many of these putative co-chaperones have
not been characterized for their functionality and regulation on
PfHsp90. Generally, they share low sequence homology with
the human and yeast homologues (Kumar et al., 2007) and
thus, inevitably raises questions as to whether they interact and
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Fig. 8. Residue N108 in PfAha1 is essential for interaction with PfHsp90. (A) SDS–PAGE analysis showed that mutation at residue N108 in PfHsp90 resulted in diminished
binding  to PfHsp90 as compared to PfAha1-WT. The interaction was  almost abolished when substitution N108A was combined with E91A in the PfAha1 double mutant. On


























Kmportant for PfHsp90 interaction. (B) Densitometric analysis of PfAha1-WT and m
ith  respect to the sample with PfAha1-WT. Result shown is representative of thre
egulate PfHsp90 in a manner similar to that of the human/yeast
sp90 system. Considering that Aha1 is one of the only two  co-
haperones (Cpr6 is the other co-chaperone) known to be capable
f stimulating the ATPase activity of Hsp90 that is essential for
romoting the activation of Hsp90’s client proteins, the putative
ha1 in P. falciparum is characterized in this study to investigate its
utative role as a co-chaperone of PfHsp90.
As previous genome wide yeast two-hybrid study on plas-
odial proteins (LaCount et al., 2005) and co-immunoprecipitation
xperiments on PfHsp90 (Banumathy et al., 2003) were unable
o establish the interaction between PfHsp90 and the putative
fAha1, a directed protein–protein interaction approach using
he yeast split-ubiquitin assay was employed to investigate the
ssociation between PfAha1 and PfHsp90. Results from the split-
biquitin assay indicated that there is interaction between PfAha1
nd PfHsp90, and the binding site for PfAha1 is likely to be at
he middle domain of PfHsp90. This was further conﬁrmed using
ecombinant proteins and the in vitro GST pull-down assay that
as been established and used previously to investigate the inter-
ction between PfHsp90 and Pfp23 (Chua et al., 2010). PfAha1
as expressed as a soluble 44 kDa recombinant protein and was
hown to interact with PfHsp90 in the presence of MgCl2 and ATP.
lthough recent studies indicated that the human Aha1 could inter-
ct with Hsp90 in the absence of nucleotide (Hessling et al., 2009;
oulov et al., 2010), this was not observed between PfAha1 andts bound to PfHsp90. The percentage of PfHsp90 and PfAha1 bound are calculated
pendent experiments.
PfHsp90. This may  reﬂect differences in the binding preference of
the plasmodial homologue or could be due to low concentrations
of PfHsp90–PfAha1 nucleotide-free complexes that are difﬁcult to
detect.
Since PfAha1 shares similar Hsp90-binding requirements with
Pfp23 that has been reported previously (Chua et al., 2010), the
inﬂuence of Pfp23 on PfHsp90–PfAha1 interaction was investi-
gated. Using similar binding assay, PfAha1 was shown to compete
with Pfp23 to interact with PfHsp90. The experimental observa-
tion was  supported by in silico modelled PfHsp90–PfAha1–Pfp23
tertiary complex which revealed overlapping PfAha1 and Pfp23
binding sites on PfHsp90 (Fig. 7).
Probing into the interaction between PfAha1 and PfHsp90, pri-
mary sequence and tertiary structure analyses further revealed
several conserved charged residues in PfAha1 (i.e. E15, R58, E67,
D94 and K127) that could be essential for PfHsp90 interaction.
These residues in PfAha1 were substituted by site-directed muta-
genesis and subsequently tested for their ability to interact with
PfHsp90. Contrary to expectations, these PfAha1 mutants with
substitution at the charged residue to a non-charged alanine or
an oppositely charged amino acid residue, displayed no signiﬁ-
cant defects in their interaction with PfHsp90 when compared
to PfAha1-WT. Further mutational studies revealed the residue
N108 in PfAha1 to be essential for PfHsp90 interaction instead.
Based on the modelled structure, the amino acid residue N108
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Fig. 9. PfAha1 competes with Pfp23 to interact with PfHsp90. (A) (Top) In each 500-l reaction, 2 g PfHsp90 was immobilized on 50-l glutathione Sepharose beads
and  incubated with 2 M Pfp23 for 30 min. Following that, PfAha1 was  added in increasing concentrations (0.1–4 M) into the respective reactions and incubated for an
additional 30 min. SDS–PAGE analysis of the eluted PfHsp90 complex showed that the level of Pfp23 bound to PfHsp90 was progressively reduced in the presence of increasing
concentrations of PfAha1. (Bottom) Densitometric analysis of Pfp23 bound to PfHsp90 in increasing concentrations of PfAha1. Percentage of PfHsp90 bound is calculated with
respect to the sample with PfHsp90 only; Pfp23 with respect to the Pfp23 bound to PfHsp90 in the absence of PfAha1; PfAha1 with respect to the PfAha1 bound to PfHsp90
in  the presence of 4 M PfAha1. (B) (Top) The experiment was repeated using a similar protocol but a ﬁxed concentration of PfAha1 (2 M)  and increasing concentrations of
Pfp23  (0.1–4 M).  Results from the SDS–PAGE analysis revealed reduced level of PfAha1 bound to PfHsp90 in the presence of increasing concentrations of Pfp23. (Bottom)
D fp23. Percentage of PfHsp90 bound is calculated with respect to the sample with PfHsp90
o 23; Pfp23 with respect to the Pfp23 bound to PfHsp90 in the presence of 4 M Pfp23.









































































 PfHsp90 + Pf Aha1
Fig. 10. PfAha1 stimulates the ATPase activity of PfHsp90. PfAha1 was added in
increasing concentrations (0.1–2 M)  to a ﬁxed amount of PfHsp90 (2 M) to inves-
tigate its effect on the ATPase activity of PfHsp90. The ATPase activity of PfHsp90 was
stimulated in the presence of PfAha1. At equimolar concentration, PfAha1 enhanced
the  ATPase activity of PfHsp90 to approximately 300% of its original activity. On
the contrary, when PfAha1 single mutant N108A that exhibited reduced binding to
PfHsp90 was  added in equimolar concentration, the stimulation of PfHsp90’s ATPase
activity was signiﬁcantly reduced to approximately 150% of its original activity. The
PfAha1 double mutant E91A/N108A that had defective binding to PfHsp90 displayed
negligible stimulation of the ATPase activity of PfHsp90. The relative activity is cal-ensitometric analysis of PfAha1 bound to PfHsp90 in increasing concentrations of P
nly;  PfAha1 with respect to the PfAha1 bound to PfHsp90 in the absence of Pfp
ollectively, the results indicated that PfAha1 competes with Pfp23 for binding to P
resumably interacts with the residues N472 and T476 in PfHsp90
hrough polar–polar interaction. The observation is surprising as
he interaction between yeast Hsp82 and Aha1 are known to
e contributed by multiple binding interfaces and that single
mino acid substitution are unlikely to destabilize their association
Meyer et al., 2004). Nevertheless, in the case of PfAha1, a single
utation at residue N108 signiﬁcantly diminished its binding to
fHsp90, indicating that PfAha1’s interaction with PfHsp90 may
epend primarily on certain strategic amino acid residues instead
f interfaces for stable association. Similar analyses of putative
ha1s in other Plasmodium sp. i.e. Plasmodium vivax (PVX 119435),
lasmodium chabaudi (PCHAS 040550) and Plasmodium berghei
PBANKA 040460) showed that the asparagine residue is iden-
ically conserved in all the plasmodial Aha1s (data not shown),
uggesting that they may  play similar importance for interaction
ith the respective Hsp90s in the various species.
The functional signiﬁcance of PfAha1’s binding to PfHsp90 was
ubsequently examined and PfAha1 was found to stimulate the
TPase activity of PfHsp90 to approximately 300% of the origi-
al activity when added in equimolar concentration. The ATPase
timulatory effect is consistent with that of the human/yeast Aha1
inding effect on Hsp90 where the increased ATP hydrolysis has
een reported to be essential for the activation of Hsp90’s client
roteins e.g. glucocorticoid receptors, v-Src and c-Raf (Panaretou
t al., 2002; Harst et al., 2005; Holmes et al., 2008). In addition, a
ecent study in yeast demonstrated that Aha1 is capable of restoring
he functionality of Hsp90 mutants with defective ATPase activity
Mollapour et al., 2011). This may  highlight the importance of Aha1
n maintaining the functional integrity of Hsp90, where its ATPaseculated with respect to the ATPase activity of PfHsp90 in the absence of PfAha1.
Result shown is representative of three independent experiments.
stimulatory effect can compensate for the diminished activity in
compromised Hsp90.
In the battle against P. falciparum that is increasingly resis-
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t al., 2009)), PfHsp90 has emerged as a promising new drug-
arget for malaria therapy (Neckers and Tatu, 2008; Pesce et al.,
010; Shonhai, 2010). The recognition stemmed from the obser-
ation that Hsp90-speciﬁc inhibitors are capable of inhibiting the
rowth and development of P. falciparum at the intra-erythrocytic
tages (Banumathy et al., 2003; Kumar et al., 2003). The struc-
ure of PfHsp90’s N-terminal domain that was resolved recently
evealed subtle differences between the ATP/inhibitor-binding
ockets of PfHsp90 and the human Hsp90, prompting exploitation
f the disparity to engineer inhibitors that are selective towards
fHsp90 (Corbett and Berger, 2010). A recent high-throughput
mall molecule screening study has also reportedly identiﬁed
nhibitors that can selectively inhibit the ATPase activity of PfHsp90
ithout incurring signiﬁcant effects on the function of human
sp90 (Shahinas et al., 2010), further supporting the possibility of
esigning inhibitors that are highly speciﬁc and selective against
fHsp90.
While the search for PfHsp90-speciﬁc inhibitors is essential,
nowledge on the factors that regulate the function of PfHsp90
nd its afﬁnity for the inhibitors are similarly crucial for effec-
ive anti-malaria therapeutic intervention. Genetic studies have
emonstrated that certain co-chaperones, apart from regulating
sp90’s chaperone function, can inﬂuence the sensitivity of cells
o the biological effects of Hsp90-speciﬁc inhibitors (Piper et al.,
003). Co-chaperones Hop/Sti1, p23/Sba1 and Aha1 have respec-
ively been shown to confer protection against lethal cellular effects
f Hsp90-speciﬁc inhibitor, albeit through different mechanisms
Prodromou et al., 1999; Forafonov et al., 2008; Zurawska et al.,
010). In the case of Aha1, the protective effect observed was
ttributed to improved Hsp90’s chaperone function (by having
 higher ATPase activity) upon Aha1’s association, that would
egate the loss of function in a subset of Hsp90 with the inhibitors
ound which would normally lead to the collapse of cellular
ctivities. Hence, with increasing understanding on the roles of
o-chaperones in the regulation of Hsp90’s function and their inﬂu-
nce on the biological effects exerted by Hsp90-speciﬁc inhibitor, it
s imperative to uncover and validate Hsp90-co-chaperone inter-
ctions with regards to the Plasmodium parasite. This is crucial
o facilitate assessment on the potential use of Hsp90-speciﬁc
nhibitors as anti-malarials, as well as to provide a mechanis-
ic understanding on plausible drug resistance that may  arise
hrough modulation of PfHsp90’s sensitivity to the inhibitors. Taken
ogether, the ﬁndings in this study would contribute to the knowl-
dge of PfHsp90’s co-chaperones and may  serve as a useful platform
or future studies on the regulation of PfHsp90, with regards to its
n vivo function and sensitivity to the inhibitors.
thical standards
The authors declare that the experiments comply with the cur-
ent laws of the country in which they were performed.
onﬂict of interest
The authors declare that they have no conﬂict of interest.
cknowledgement
We thank MR4  for providing the malaria parasites (MRA-102)
ontributed by Daniel Carucci and Alister Craig.eferences
aca AM,  Hol WG.  Overcoming codon bias: a method for high-level overexpression
of Plasmodium and other AT-rich parasite genes in Escherichia coli. Int J Parasitol
2000;30:113–8.emistry & Cell Biology 44 (2012) 233– 245
Banumathy G, Singh V, Pavithra SR, Tatu U. Heat shock protein 90 function is
essential for Plasmodium falciparum growth in human erythrocytes. J Biol Chem
2003;278:18336–45.
Chua CS, Low H, Goo KS, Sim TS. Characterization of Plasmodium falciparum co-
chaperone p23: its intrinsic chaperone activity and interaction with Hsp90. Cell
Mol Life Sci 2010;67:1675–86.
Corbett KD, Berger JM. Structure of the ATP-binding domain of Plasmodium falci-
parum Hsp90. Proteins 2010;78:2738–44.
Forafonov F, Toogun OA, Grad I, Suslova E, Freeman BC, Picard D. p23/Sba1p protects
against Hsp90 inhibitors independently of its intrinsic chaperone activity. Mol
Cell Biol 2008;28:3446–56.
Guex N, Diemand A, Peitsch MC.  Protein modelling for all. Trends Biochem Sci
1999;24:364–7.
Harst A, Lin H, Obermann WM.  Aha1 competes with Hop, p50 and p23 for binding to
the molecular chaperone Hsp90 and contributes to kinase and hormone receptor
activation. Biochem J 2005;387:789–96.
Hessling M,  Richter K, Buchner J. Dissection of the ATP-induced conformational cycle
of  the molecular chaperone Hsp90. Nat Struct Mol  Biol 2009;16:287–93.
Holmes JL, Sharp SY, Hobbs S, Workman P. Silencing of HSP90 co-chaperone AHA1
expression decreases client protein activation and increases cellular sensitivity
to  the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res
2008;68:1188–97.
Koulov AV, Lapointe P, Lu B, Razvi A, Coppinger J, Dong MQ,  et al. Biological and
structural basis for Aha1 regulation of Hsp90 ATPase activity in maintain-
ing proteostasis in the human disease cystic ﬁbrosis. Mol  Biol Cell 2010;21:
871–84.
Kumar R, Musiyenko A, Barik S. The heat shock protein 90 of Plasmodium falciparum
and antimalarial activity of its inhibitor, geldanamycin. Malar J 2003;2:30.
Kumar R, Pavithra SR, Tatu U. Three-dimensional structure of heat shock protein
90  from Plasmodium falciparum: molecular modelling approach to rational drug
design against malaria. J Biosci 2007;32:531–6.
LaCount DJ, Vignali M,  Chettier R, Phansalkar A, Bell R, Hesselberth JR, et al. A pro-
tein  interaction network of the malaria parasite Plasmodium falciparum. Nature
2005;438:103–7.
Laser H, Bongards C, Schuller J, Heck S, Johnsson N, Lehming N. A new screen for pro-
tein  interactions reveals that the Saccharomyces cerevisiae high mobility group
proteins Nhp6A/B are involved in the regulation of the GAL1 promoter. Proc Natl
Acad Sci USA 2000;97:13732–7.
Le Roch KG, Zhou Y, Blair PL, Grainger M,  Moch JK, Haynes JD, et al. Discovery of
gene function by expression proﬁling of the malaria parasite life cycle. Science
2003;301:1503–8.
Lehming N. Analysis of protein–protein proximities using the split-ubiquitin system.
Brief Funct Genomic Proteom 2002;1:230–8.
Li  J, Richter K, Buchner J. Mixed Hsp90–cochaperone complexes are important for
the  progression of the reaction cycle. Nat Struct Mol  Biol 2011;18:61–6.
Lotz GP, Lin H, Harst A, Obermann WM.  Aha1 binds to the middle domain of Hsp90,
contributes to client protein activation, and stimulates the ATPase activity of the
molecular chaperone. J Biol Chem 2003;278:17228–35.
Meyer P, Prodromou C, Hu B, Vaughan C, Roe SM, Panaretou B, et al. Structural and
functional analysis of the middle segment of hsp90: implications for ATP hydrol-
ysis and client protein and cochaperone interactions. Mol  Cell 2003;11:647–58.
Meyer P, Prodromou C, Liao C, Hu B, Roe SM,  Vaughan CK, et al. Structural basis for
recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery.
EMBO J 2004;23:1402–10.
Mollapour M,  Tsutsumi S, Truman AW,  Xu W,  Vaughan CK, Beebe K, et al. Threonine
22  phosphorylation attenuates hsp90 interaction with cochaperones and affects
its chaperone activity. Mol  Cell 2011;41:672–81.
Muller O, Sie A, Meissner P, Schirmer RH, Kouyate B. Artemisinin resistance on the
Thai-Cambodian border. Lancet 2009;374:1419.
Nathan DF, Vos MH,  Lindquist S. Identiﬁcation of SSF1, CNS1, and HCH1 as multicopy
suppressors of a Saccharomyces cerevisiae Hsp90 loss-of-function mutation. Proc
Natl  Acad Sci USA 1999;96:1409–14.
Neckers L, Mollapour M, Tsutsumi S. The complex dance of the molecular chaperone
Hsp90. Trends Biochem Sci 2009;34:223–6.
Neckers L, Tatu U. Molecular chaperones in pathogen virulence: emerging new tar-
gets for therapy. Cell Host Microbe 2008;4:519–27.
Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S, et al. Activation
of  the ATPase activity of hsp90 by the stress-regulated cochaperone Aha1. Mol
Cell  2002;10:1307–18.
Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone
machinery. Annu Rev Biochem 2006;75:271–94.
Pesce ER, Cockburn IL, Goble JL, Stephens LL, Blatch GL. Malaria heat shock pro-
teins: drug targets that chaperone other drug targets. Infect Disord Drug Targets
2010;10:147–57.
Piper PW,  Millson SH, Mollapour M,  Panaretou B, Siligardi G, Pearl LH, et al. Sensitiv-
ity  to Hsp90-targeting drugs can arise with mutation to the Hsp90 chaperone,
cochaperones and plasma membrane ATP binding cassette transporters of yeast.
Eur J Biochem 2003;270:4689–95.
Prodromou C, Siligardi G, O’Brien R, Woolfson DN, Regan L, Panaretou B, et al.
Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain
co-chaperones. EMBO J 1999;18:754–62.Shahinas D, Liang M,  Datti A, Pillai DR. A repurposing strategy identiﬁes novel syn-
ergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med  Chem
2010;53:3552–7.
Shonhai A. Plasmodial heat shock proteins: targets for chemotherapy. FEMS





Wittke S, Lewke N, Muller S, Johnsson N. Probing the molecular environment ofC.S. Chua et al. / The International Journal o
aipale M,  Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging
mechanistic insights. Nat Rev Mol  Cell Biol 2010;11:515–28.
arshavsky A. The N-end rule: functions, mysteries, uses. Proc Natl Acad Sci USA
1996;93:12142–9.
andinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. J Biol Chem
2008;283:18473–7.emistry & Cell Biology 44 (2012) 233– 245 245membrane proteins in vivo. Mol  Biol Cell 1999;10:2519–30.
Zurawska A, Urbanski J, Matuliene J, Baraniak J, Klejman MP,  Filipek S, et al. Muta-
tions that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance
in  vivo. Biochim Biophys Acta 2010;1803:575–83.
RESEARCH ARTICLE
Characterization of Plasmodium falciparum co-chaperone p23:
its intrinsic chaperone activity and interaction with Hsp90
Chun-Song Chua • Huiyu Low • Kian-Sim Goo •
T. S. Sim
Received: 1 September 2009 / Revised: 23 December 2009 / Accepted: 15 January 2010 / Published online: 6 February 2010
 Springer Basel AG 2010
Abstract It is well known that the co-chaperone p23
regulates Hsp90 chaperone activity in protein folding. In
Plasmodium falciparum, a putative p23 (Pfp23) has been
identified through genome analysis, but its authenticity
has remained unconfirmed since co-immunoprecipitation
experiments failed to show its interaction with P. falcipa-
rum Hsp90 (PfHsp90). Thus, recombinant Pfp23 and
PfHsp90 proteins purified from expressed clones were used
in this study. It was clear that Pfp23 exhibited chaperone
activity by virtue of its ability to suppress citrate synthase
aggregation at 45C. Pfp23 was also shown to interact with
PfHsp90 and to suppress its ATPase activity. Analyses of
modeled Pfp23-PfHsp90 protein complex and site-directed
mutagenesis further revealed strategically placed amino
acid residues, K91, H93, W94 and K96, in Pfp23 to be
crucial for binding PfHsp90. Collectively, this study has
provided experimental evidence for the inherent chaperone
function of Pfp23 and its interaction with PfHsp90, a
sequel widely required for client protein activation.
Keywords Heat shock protein 90  p23 
Plasmodium falciparum  Chaperone 
Site-directed mutagenesis
Introduction
The co-chaperone, p23, is a small protein involved in the
cascade of Hsp90 chaperone activity [1, 2]. It is well
documented that Hsp90 folds and activates proteins essen-
tial in cellular signaling and development (e.g., kinases and
transcription factors) by undergoing a cycle of conforma-
tional changes driven by the binding and hydrolysis of ATP
at its N-terminal domain [3–6]. The interaction between p23
and Hsp90 occurs at the late stage of the chaperone cycle
and is ATP-dependent [7–9]. Reportedly, the binding of p23
reduces the rate of ATP hydrolysis and traps Hsp90 in the
ATP-bound conformation [10]. It was also proposed that
p23 binding prolongs the interaction between Hsp90 and its
client proteins, thereby securing their maturation. Subse-
quently, the hydrolysis of ATP leads to the release of
activated client proteins [11]. This latter feature was dem-
onstrated using an in vitro reconstituted Hsp90 chaperone
system, whereby the incorporation of p23 significantly
increased the competence of mature progesterone and glu-
cocorticoid receptors in binding steroid hormones [12, 13],
as such attesting to p23’s importance in driving the Hsp90
functional repertoire.
In the recently resolved crystal structure complex of
Hsp82 and SbaI, homologues of Hsp90 and p23 in yeast,
respectively, the two proteins were shown to interact
through their N-terminal domains [14]. Hsp82 was crys-
tallized in the ATP-bound conformation and possessed a
closed ‘lid’ segment positioned over the ATP-binding
pocket, which would otherwise remain open in the absence
of ATP. In the case of SbaI, the N-terminal domain was
found to bind over the ATP-binding pocket of Hsp82, with
the closed ‘lid’ forming one of the interaction interfaces.
The requirement for this ATP-induced closed ‘lid’ con-
formation in Hsp82 to interact with SbaI is circumstantially
supported by experiments showing the preferential binding
of p23 to ATP-bound Hsp90 [7–9].
Apart from regulating Hsp90 chaperone functions, p23
is also capable of binding partially folded proteins and
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suppressing protein aggregation in vitro [15, 16]. This has
led to the suggestion that p23 may itself function as a
chaperone, independent of Hsp90. When the C-terminal
tail of p23 was truncated, its chaperone activity was
abolished, suggesting that the acidic amino acid-rich tail
may be instrumental for its function [17]. This intrinsic
chaperone activity of p23 has been demonstrated to be
essential for the recycling of steroid receptors and telo-
merase [18, 19].
In Plasmodium falciparum, the species that causes the
most severe form of human malaria, a putative homologue
of p23 (Pfp23) has been reported [20]. Pfp23 was initially
identified as a 36-kDa major phosphoprotein associated
with the kinase activity of an unknown protein in P. fal-
ciparum [21, 22]. Subsequent procurement of its protein
sequence revealed its homology to the co-chaperone p23
[20]. However, validation of its role as a co-chaperone of
P. falciparum Hsp90 (PfHsp90) has been unsuccessful so
far [20, 23]. Co-immunoprecipitation experiments per-
formed using either antibodies specific to Pfp23 or
PfHsp90 did not detect complexes containing both the
proteins. However, as alluded to earlier, p23 has important
roles in the activation of a plethora of Hsp90 client pro-
teins, many of which are crucial in signal transduction and
regulating cell growth. Thus, it would be unusual to
exclude its role in P. falciparum, as implicated in reports so
far. Therefore, in this study, the putative Pfp23 was probed
for its intrinsic chaperone activity and interaction with
PfHsp90.
Materials and methods
Cloning of Pfp23 and PfHsp90
The DNA sequences of Pfp23 (PF14_0510) and PfHsp90
(PF07_0029) were retrieved from PlasmoDB, and primers
were designed to clone these genes (Table 1). The genes
were cloned from the mRNA of P. falciparum 3D7. The
mRNA extraction and reverse transcription procedures
were carried out as previously described [24].
Briefly, the PCR-amplified gene products were sepa-
rated by agarose gel electrophoresis using 0.8% (w/v)
agarose gel, and the bands that corresponded to the
expected size of the genes were excised and purified using
the MinEluteTM Gel Extraction Kit (Qiagen). Subse-
quently, the purified fragments were ligated into pCR-
BluntII-TOPO Vector using the Zero BluntTM TOPOTM
PCR Cloning Kit (Invitrogen). The plasmids of the
recombinant clones were extracted using the Wizard Plus
SV Minipreps DNA Purification System from Promega.
Full sequencing was carried out using the ABI PRISMTM
BigDyeTM Terminator Cycle Sequencing Ready Reaction
Kit from Perkin Elmer and analyzed using the ABI PRISM
3100 DNA sequencer to identify recombinant clones that
contained the genes of interest.
Subsequently, the recombinant clones that contained
Pfp23 and PfHsp90 were double-digested with BamHI/SalI
and BamHI/XhoI, respectively. Pfp23 was subcloned into
the expression vector, pET24a (Novagen), whereas
PfHsp90 was ligated to pET24a and pGK [25] expression
vectors. PfHsp90 expressed using the pGK vector con-
tained a GST- and a His6 tag and would be used for the
GST pull-down assay. However, the more highly expressed
PfHsp90 from the recombinant pET24a vector possessed
only a His6 tag. This fusion protein would be used for the
ATPase assay. The ligated recombinant vectors were
transformed into Escherichia coli BL21 (DE3) cells that
contained a RIG plasmid [26] for expression of the
recombinant fusion proteins. DNA sequencing was per-
formed to authenticate the recombinant clones carrying the
genes of interest.
Construction of Pfp23-truncated and single mutants
The recombinant pET24a plasmid that contained Pfp23
was used as a template for the construction of Pfp23-
truncated mutants. Pfp23-truncated mutants T1, T2, T3, T4
and T5 were PCR-amplified using appropriate forward
primers and a common reverse primer used for Pfp23 wild-
type (Pfp23-WT) previously. On the other hand, amplifi-
cations of Pfp23-truncated mutants, Pfp23-(D135–275) and
Pfp23-(D220–275) were carried out using appropriate
designed reverse primers and a common forward primer
from Pfp23-WT (Table 1). Similar cloning procedures
described earlier were adopted for the subsequent steps.
The QuikChangeTM Site-directed Mutagenesis Kit from
Stratagene was used for the construction of Pfp23 single
mutants [27]. Primers were designed to introduce the
desired mutations using PCR protocols described previ-
ously [28]. DNA sequencing was performed subsequently
to verify the changes in the nucleotide sequences prior to
transformation into E. coli BL21 (DE3) with the RIG
plasmid for recombinant fusion protein expression.
Expression and purification of Pfp23 and PfHsp90
Bacterial cultures carrying the PfHsp90 and Pfp23
recombinant plasmids were grown in 100 ml Luria-Bertani
broth with 50 lg/ml kanamycin (Sigma) and 40 lg/ml
chloramphenicol (Sigma) for protein expression. The cul-
tures were grown at 37C with agitation at 250 rpm until an
OD600 of 0.8 was reached. Protein expression was induced
by the addition of 1 mM isopropyl-b-D-1-thiogalactopyr-
anoside (Sigma) followed by incubation at 16C with
shaking at 250 rpm for 16 h.
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Following induction, the cultures were harvested by
centrifugation at 6,000 rpm for 5 min at 4C. The super-
natant was discarded, and the pelleted cells were
resuspended in cold 50 mM Tris-HCl, pH 7.5 buffer. The
cells were lysed via sonication with a 1/8-inch probe at an
intensity of 10 lm for eight cycles with 10-s pulse and 10-s
rest in each cycle. Cell lysates were subsequently centri-
fuged at 12,000 rpm for 20 min, and the soluble protein
fractions that contained the fusion proteins of interest were
subjected to purification.
The PfHsp90 and Pfp23 recombinant proteins, both
carrying a C-terminal His6 tag, were purified by affinity
chromatography using nickel-nitrilotriacetic acid (Ni-
NTA) beads (Qiagen). For each purification, an aliquot of
1 ml of the soluble protein fraction was incubated with
50 ll of Ni-NTA beads for 15 min at 4C. Unbound pro-
teins were removed by washing thrice with 250 ll of
50 mM Tris-HCl, pH 7.5, 20 mM imidazole buffer. The
recombinant proteins were eluted in 50 ll of 50 mM Tris-
HCl, pH 7.5, 300 mM imidazole buffer.
To remove co-purified contaminating proteins, the eluted
proteins were further purified by gel filtration chromatog-
raphy on a Superdex 200 column (GE Healthcare). The
recombinant proteins were separated at a flow rate of
0.5 ml/min in buffer containing 50 mM Tris-HCl, pH 7.5.
The eluted samples were analyzed by SDS-PAGE to
determine the fractions that contained the recombinant
proteins of interest. These fractions were pooled and con-
centrated using Amicon Ultra-4 Centrifugal Filter Units
with appropriate molecular weight cutoff and stored at 4C
for subsequent assays. The concentrations of the purified
fusion proteins were determined by Bradford assay (Biorad)
using bovine serum albumin (Sigma) as a standard.
Expression and purification of the recombinant proteins
were upscaled proportionately when necessary to obtain a
sufficient amount of recombinant proteins for the sub-
sequent assays.
Citrate synthase aggregation assay
The intrinsic Hsp90-independent chaperone activity of
Pfp23 was assayed based on the aggregation of citrate
synthase [29] using a slightly modified protocol. Porcine
citrate synthase (Sigma) was dialyzed with 40 mM
HEPES, pH 7.5 buffer, overnight and concentrated to an
8.5-lM stock solution. Aggregation was induced by the
Table 1 Primers designed for
gene cloning and mutations
a Restriction enzyme sites are
in lower case, F represents
forward primer, R represents
reverse primer
b Codons mutated in Pfp23 are
bold and underlined
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incubation of citrate synthase (0.15 lM) in 40 mM
HEPES, pH 7.5 buffer, at 45C. The assays were performed
in the presence or absence of five-fold excess (0.75 lM) of
Pfp23-WT and Pfp23-(D220–275). The extent of aggre-
gation was measured by the increase in absorbance due to
light scattering and monitored at 334 nm using the Tecan
Safire spectrophotometer. The absorbance was recorded
every 2.5 min for 20 min.
In vitro interaction between Pfp23 and PfHsp90
The in vitro interaction of Pfp23 and PfHsp90 was inves-
tigated using GST pull-down assay. Nickel affinity purified
dual-tagged PfHsp90 fusion protein expressed from the
pGK vector was used as a bait. For each experiment, 2 lg
of PfHsp90 fusion protein was incubated with 50 ll of
glutathione Sepharose beads (GE Healthcare) at 4C for
15 min. The bound fusion proteins were washed thrice with
50 mM of Tris-HCl, pH 7.5, buffer to remove unbound
proteins. Subsequently, the beads were reconstituted in
500 ll of binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM
KCl, 2 mM dithiothreitol, 0.01% (v/v) Triton X-100). The
binding assays were carried out in the presence of 5 mM
MgCl2, 5 mM ATP and 10 lg of Pfp23, unless stated
otherwise. Samples were incubated at 30C for 30 min for
PfHsp90-Pfp23 complex formation. Thereafter, the sam-
ples were washed thrice with 500 ll of binding buffer prior
to elution in 150 ll of reduced glutathione buffer. Fifty
microliters of the eluted sample was analyzed by SDS-
PAGE. Gel image analyses and densitometric measure-
ments were performed using Bio-Rad Molecular Imager
Gel Doc XR system equipped with the Quantity One
Software.
ATPase assay
The ATPase activity of PfHsp90 was measured using the
pyruvate kinase/lactate dehydrogenase-coupled assay [6,
30]. The assay was carried out in a 200-ll reaction con-
taining 2 lM PfHsp90 incubated in 100 mM Tris-HCl, pH
7.5, 6 mM MgCl2, 20 mM KCl, 0.8 mM ATP, 2 mM
phosphoenolpyruvate, 0.2 mM NADH, 50 lg/ml lactate
dehydrogenase and 0.2 mg/ml pyruvate kinase at 37C.
The decrease in NADH level, which is in direct stoichi-
ometry to the amount of ATP hydrolysed, was determined
spectrophotometrically at 340 nm. The authenticity of
PfHsp90 ATPase activity was verified by its sensitivity to
inhibition by radicicol (100 lM), a specific Hsp90 ATPase
inhibitor. To determine the effect of Pfp23 interaction on
PfHsp90 ATPase activity, Pfp23 was added to the assay
reactions in increasing concentrations (2–30 lM). In
addition, Pfp23 single mutants with differential binding
capacity to PfHsp90 were also tested for their influence on
PfHsp90 ATPase activity. The Pfp23 single mutants were
added in ten-fold molar excess (20 lM), and their effects
on the ATPase activity of PfHsp90 were compared to that
of Pfp23-WT. All measurements were made using the
Tecan Safire spectrophotometer. The ATPase activity
reported is expressed as micromole of ATP hydrolysed per
micromole of PfHsp90 in 1 min at 37C.
Bio-computational analyses of Pfp23 and PfHsp90
Protein sequence alignment was performed using the
CLUSTAL W Multiple Alignment Program [31], and the
percentage identities were determined by MatGAT 2.02
[32]. Tertiary structures of Pfp23 and PfHsp90 were
modeled by the SWISS-MODEL program [33] using the
‘‘First Approach Mode’’. The Hsp82-SbaI crystal structure
complex (PDB accession number: 2cg9) was used as a
template for protein modeling. The modeled protein
structures were subsequently visualized using the Swiss-
PdbViewer (SPdbV) program [34].
Results
Bio-computational analyses of the putative Pfp23
P. falciparum 3D7 genome encodes a putative p23
homologue of 275 amino acid residues. The Pfp23 pos-
sesses the characteristic ‘‘Hsp20-like chaperone super-
family’’ domain (residues 2-106) and a C-terminal tail rich
in acidic residues. The ‘‘Hsp20-like chaperone superfam-
ily’’ domain, which is also present in the yeast SbaI,
is known to be important for Hsp82 interaction [14].
Sequence homology analyses indicated that Pfp23 shared
44% sequence identity with Schizosaccharomyces pombe
p23 homologue [20], but exhibited only 19.6 and 23.6%
sequence identities in common with the human p23 and
Saccharomyces cerevisiae SbaI, respectively. In addition,
the putative Pfp23 (275 residues) has a longer protein
sequence than the human p23 (160 residues) and S. cere-
visiae SbaI (216 residues). Multiple sequence alignment
further revealed the difference in protein length of Pfp23
lies in the presence of the unique tandem repeats,
GNMGGLx7 (between amino acid residues 135–176) and
a longer C-terminal tail (Fig. 1). Similar glycine-rich
tandem repeats were also found in p23 of other Plasmo-
dium species, namely P. chabaudi, P. berghei, P. yeolii
and P. knowlesi [20]. In comparison, the human p23 only
possessed a GGD sequence, whereas the yeast SbaI has
two repeats of GGAGGA and a single GGAGGM sequence.
So far, the significance of these glycine-rich sequences
has yet to be reported and as such its functionality remains
enigmatic.
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Cloning, expression and purification of Pfp23
and PfHsp90
To clone the putative Pfp23 and PfHsp90, reverse tran-
scription and PCR amplifications were carried out using
appropriate primers and mRNA from P. falciparum 3D7.
The resultant ORF of Pfp23 was inserted into the pET24a
expression vector, whereas that of PfHsp90 was ligated
into pET24a and pGK expression vectors. Subsequently,
DNA sequencing was performed to verify their authentic-
ities. The recombinant plasmids were transformed into
E. coli BL21 (DE3) already harboring the RIG plasmid.
The RIG plasmid encodes tRNAs that recognize rare
codons present in the AT-rich plasmodial genes [26].
Hence, it was included in anticipation of improving the
expression of the recombinant proteins.
Pfp23 and PfHsp90 were solubly expressed as recom-
binant proteins. The PfHsp90 fusion protein expressed
from the pGK vector contained an N-terminal GST tag and
a C-terminal His6 tag. The inclusion of a dual tag allowed
an initial purification of PfHsp90 fusion protein using Ni2?
affinity chromatography and gel filtration separation, prior
to immobilization on the glutathione Sepharose for the
GST pull-down assays. As the subsequent ATPase assay
requires large quantities of highly purified proteins, the
recombinant PfHsp90 was expressed using the pET24a
vector. The recombinant pET24a vector provided signifi-
cantly higher quantities of PfHsp90 fusion proteins
compared to the recombinant pGK vector. Pfp23 was also
recombinantly expressed using the pET24a vector, and
similar Ni2? affinity chromatography and gel filtration
separation techniques were utilized to purify these fusion
proteins. After electrophoretic separation, the recombinant
Pfp23 was found to be approximately 36 kDa, whereas
PfHsp90 expressed from recombinant pGK and pET24a
vectors were 114 kDa and 88 kDa, respectively (Fig. 2).
The recombinant Pfp23 possesses chaperone activity
Prior to this study, the functionality of the putative Pfp23
had not been demonstrated. In view of this, Pfp23 was
examined for its intrinsic chaperone activity in preventing
the aggregation of citrate synthase [29]. Pfp23 was added
to citrate synthase in a 5:1 M ratio and incubated at 45C.
Aggregation of citrate synthase was detected by the
increase in absorbance at 334 nm over a 20-min interaction
time.
In the absence of Pfp23, citrate synthase aggregated
spontaneously at 45C (Fig. 3). The addition of Pfp23
suppressed the aggregation of citrate synthase, as reflected
by the decrease in absorbance reading. Similar anti-
aggregation activity was observed in human p23, but was
abolished when its acidic C-terminal tail was truncated by
30 amino acid residues [17]. To investigate whether the
C-terminal tail of Pfp23 also contributes to anti-aggrega-
tion activity, a mutant clone of Pfp23 that lacks the
C-terminal acidic residues was constructed. Deletion of the
C-terminal tail in Pfp23-(D220–275) resulted in a total loss
of the anti-aggregation activity observed in Pfp23-WT,
implying the requirement of the C-terminal tail for its full
chaperone activity. No self-aggregation of Pfp23-WT and
Pfp23-(D220–275) was observed at 45C in the control
Fig. 1 Protein sequence alignment of p23 and related sequences.
Protein sequences of Homo sapiens p23 (NP_006592.3) and Saccha-
romyces cerevisiae SbaI (NP_012805.1) were obtained from
GenBank, whereas that of Pfp23 (PF14_0510) was retrieved from
PlasmoDB. The P. falciparum genome encodes a longer putative p23
homologue that shares only 19.6 and 23.6% amino acid sequence
identities with the human p23 and S. cerevisiae SbaI, respectively.
The glycine-rich GNMGGLx7 sequence repeats in Pfp23 are bold
and underlined. Asterisk identical amino acid residues in all the
sequences, colon indicates conserved amino acid substitutions, dot
indicates semi-conserved amino acid substitutions
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experiments performed without citrate synthase (data not
shown).
Pfp23 interaction with PfHsp90 is dependent
on MgCl2 and ATP
The role of Pfp23 as a co-chaperone of PfHsp90 in
P. falciparum has remained debatable as previous attempts
to identify their interaction via co-immunoprecipitation
techniques were unsuccessful [20, 23]. As such, their
interaction was probed in this study using recombinant
proteins and GST pull-down assays. Purified Pfp23
recombinant protein was added to PfHsp90 immobilized on
glutathione Sepharose in a 5:1 ratio and incubated either in
the presence or absence of 5 mM MgCl2, 5 mM ADP or
5 mM ATP. Under the different conditions tested, the
binding of Pfp23 to PfHsp90 was only observed in the
presence of MgCl2 and ATP (Fig. 4). Recombinant GST-
His6 fusion protein without PfHsp90 was used as a control
to ensure that the recombinant tags do not contribute to the
interaction observed. Pfp23 binding was absent in the
control experiments performed under similar conditions
(data not shown).
Sequential N-terminal truncation of Pfp23 affects
interaction with PfHsp90
As Pfp23 shares low amino acid sequence identities with
the human p23 and yeast SbaI, its interaction with PfHsp90
may potentially differ from that of their homologues.
Hence, the interaction between Pfp23 and PfHsp90 was
further analyzed. Pfp23 was sequentially truncated by 25
amino acid residues from the N-terminal end to identify
regions that are essential for binding PfHsp90 (Fig. 5a).
A total of five Pfp23-truncated mutants (T1 to T5) were
constructed, cloned, expressed and purified under similar
conditions to those described for Pfp23-WT. All the trun-
cated mutants were solubly expressed in E. coli BL21
(DE3) (data not shown). Pfp23-truncated mutants T1, T2
and T3 retained their binding to PfHsp90, whereas further
truncations in T4 and T5 abolished interaction with
PfHsp90 (Fig. 5b). The results indicated that certain amino
acid residues located between the 75th to 100th positions in
Fig. 2 SDS-PAGE analyses of purified Pfp23 and PfHsp90 recom-
binant proteins. PfHsp90 was expressed from recombinant pGK and
pET24a vectors separately. PfHsp90 expressed from the pGK vector
contained an N-terminal GST tag and a C-terminal His6 tag, whereas
PfHsp90 from the pET24a vector possessed only the C-terminal His6
tag. Similarly, Pfp23 expressed from the recombinant pET24a vector
harbored a C-terminal His6 tag. The molecular weights of the
recombinant proteins are approximately 114 kDa (PfHsp90 from
pGK), 88 kDa (PfHsp90 from pET24a) and 36 kDa (Pfp23). M protein
marker (Biorad)
Fig. 3 The Pfp23 recombinant protein exhibited intrinsic chaperone
activity. The intrinsic chaperone activity of Pfp23 was determined by
citrate synthase aggregation assay. Spontaneous aggregation of citrate
synthase was monitored continuously over 20 min at 45C by the
increase in absorbance. Addition of Pfp23-WT suppressed the
aggregation of citrate synthase. The anti-aggregation activity was
abolished when Pfp23-WT was substituted with Pfp23-(D220–275),
which has a truncated C-terminal tail. Results shown are represen-
tative of three independent experiments. CS citrate synthase
Fig. 4 SDS–PAGE analyses of Pfp23 interaction with PfHsp90. The
interaction between Pfp23 and PfHsp90 was tested in the presence or
absence of 5 mM MgCl2, 5 mM ADP and 5 mM ATP as indicated.
Pfp23 was bound to PfHsp90 only in the presence of MgCl2 and ATP.
Results shown are representative of three independent experiments
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Pfp23 are crucial for binding PfHsp90. To identify these
amino acid residues, the corresponding region in yeast SbaI
was determined by primary sequence alignment and
examined for the presence of Hsp82-interacting residues.
Inspection of the region using the yeast Hsp82-SbaI crystal
structure complex revealed an interface in SbaI (K113,
Y114, P115, Y116, I117 and K118) that interacts with the
closed ‘lid’ segment of Hsp82 (Fig. 6a) [14]. This interface
corresponded to the amino acid residues K91, K92, H93,
W94, V95 and K96 in Pfp23 and was observed to be in
proximity to PfHsp90 in the modeled complex (Fig. 6b).
Hence, these residues may potentially be essential for
PfHsp90 interaction, such that when deleted (in Pfp23-
truncated mutants T4), Pfp23’s competency in binding
PfHsp90 is undermined.
Residues K91, H93, W94 and K96 in Pfp23
are essential for PfHsp90 interaction
To investigate the importance of the amino acid residues
K91, K92, H93, W94, V95 and K96 in Pfp23 for PfHsp90
interaction, single mutants were generated. Firstly, Pfp23
residues K91, K92 and K96 were each mutated to an ala-
nine to examine the importance of the lysine side chains for
binding PfHsp90. As for residues H93 and W94, mutation
to a polar serine residue was proposed to disrupt any
hydrophobic interaction formed between Pfp23 and
PfHsp90. Similarly, the hydrophobic amino acid residue,
V95, was mutated to a polar asparagine residue as a pre-
vious study showed that substitution at the corresponding
position in SbaI (I117N) abolished interaction with Hsp82
[35]. All the Pfp23 mutant proteins were solubly expressed,
purified and tested for PfHsp90 interaction under similar
binding conditions to those described for Pfp23-WT. Pfp23
mutants K91A, H93S, W94S and K96A displayed signifi-
cant reduction in their binding to PfHsp90, retaining less
than 25% of Pfp23-WT’s binding (Fig. 7). However, Pfp23
mutants K92A and V95 N retained more than 85% of
Fig. 5 Interaction between Pfp23-WT and truncated mutants with
PfHsp90. a Schematic representation of the Pfp23-truncated mutants
constructed in this study. A 25-amino acid serial truncation was
performed from the N-terminal end of Pfp23 (T1 to T5) to identify the
region that is essential for binding PfHsp90. Pfp23-(D220–275) was
constructed to investigate the intrinsic chaperone activity of Pfp23.
On the other hand, Pfp23-(D135–275) was generated to determine
whether the GNMGGLx7 sequence repeats are essential for PfHsp90
interaction. b Purified Pfp23-WT and the respective truncated mutants
were incubated with PfHsp90 in the presence of 5 mM MgCl2 and
5 mM ATP. Truncated mutants T4 and T5 were unable to bind
PfHsp90, as shown in the SDS-PAGE analysis. Results presented are
representative of three independent experiments
Fig. 6 Analyses of the modeled structures of Pfp23 and PfHsp90.
a PfHsp90 (orange) and Pfp23 (green) were modeled against the yeast
Hsp82 (gold)-SbaI (brown) crystal structure complex (PDB accession
number: 2cg9). The modeled Pfp23 shares similar structural features
with SbaI and possesses an extended loop (highlighted in grey) that is
projected towards the closed ‘lid’ segment of PfHsp90. Only the
N-terminal domains of PfHsp90 and Hsp82 were shown in the graphical
presentation. b Amino acid residues K91, K92, H93, W94, V95 and
K96, located at the extended loop of Pfp23, were observed to be in
proximity to the closed ‘lid’ segment of PfHsp90. Pfp23 residue H93
was observed to be in close contact with the hydrophobic residues F104
and I114 in PfHsp90 (top right). Similarly, the residue W94 in Pfp23 is
directed towards residues I108 and M105 in PfHsp90 (bottom right).
AMP-PNP a non-hydrolysable analogue of ATP
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Pfp23-WT’s binding to PfHsp90. Recombinant GST-His6
fusion protein without PfHsp90 was used as a control, and
no interaction with Pfp23 mutants was observed when
tested under similar conditions (data not shown).
The GNMGGLx7 sequence repeats in Pfp23
are not essential for PfHsp90 interaction
The protein sequence of Pfp23 contains GNMGGLx7
sequence repeats, which have yet to be functionally char-
acterized. To determine if the sequence repeats are
important for PfHsp90 interaction, two additional truncated
mutants, Pfp23-(D220–275) and Pfp23-(D135–275), were
constructed. The Pfp23-(D220–275) mutant contained the
GNMGGLx7 sequence repeats but lacked the C-terminal
tail, whereas Pfp23-(D135–275) had both the sequence
repeats and the C-terminal tail deleted (Fig. 8). SDS-PAGE
analysis showed that Pfp23-(D220–275) retained interac-
tion with PfHsp90. Similarly, further removal of the
GNMGGLx7 sequence repeats in Pfp23-(D135–275) did
not affect the mutant’s competency in binding PfHsp90.
Hence, the results indicated that the GNMGGLx7
sequence repeats are not essential for PfHsp90 interaction.
Pfp23 inhibits the ATPase activity of PfHsp90
The binding and hydrolysis of ATP are known to induce
conformational changes in Hsp90, essential for the chap-
eroning of its client proteins [3–5]. To determine whether
the binding of Pfp23 affects the hydrolysis of ATP in
PfHsp90, and henceforth, the regulation of its chaperone
function, ATPase assay was carried out.
Using a sensitive enzyme-coupled assay, PfHsp90 was
shown to have an ATPase activity of 0.504 ± 0.044
lmolATP/min/lmolPfHsp90 at 37C. The activity measured
was sensitive to inhibition by radicicol, a specific Hsp90
ATPase inhibitor, and thus ensured that the activity
detected was not attributed to other co-purified ATPase
contaminants. The activity observed is approximately ten
times more than the human Hsp90 ATPase activity (0.034–
0.089 lmolATP/min/lmolHsp90) [10, 36], but comparable to
that reported for yeast Hsp82 (0.40–1.05 lmolATP/min/
lmolHsp82) [5, 6, 37, 38].
The effect of Pfp23 interaction on PfHsp90 ATPase
activity was subsequently investigated by the addition of
Pfp23 in increasing concentrations to the assay reactions
(Fig. 9a). Introduction of an equimolar concentration of
Pfp23 had a negligible effect on the ATPase activity of
Fig. 7 Effects of Pfp23 mutations on PfHsp90 interaction. a Pfp23-
WT and mutants were incubated with PfHsp90 in the presence of
5 mM MgCl2 and 5 mM ATP. The complexes formed were analyzed
by SDS-PAGE. b The binding of Pfp23 mutants to PfHsp90 was
analyzed by densitometry. The percentage of PfHsp90 bound was
calculated with respect to the PfHsp90 control (single asterisk),
whereas Pfp23 mutants binding to PfHsp90 was determined with
respect to Pfp23-WT (double asterisk). Pfp23 single mutants K91A,
H93S, W94S and K96A displayed drastically reduced binding to
PfHsp90, whereas single mutants K92A and V95 N retained binding
comparable to Pfp23-WT to PfHsp90. Results shown are represen-
tative of three independent experiments
Fig. 8 SDS-PAGE analyses of Pfp23-(D220–275) and Pfp23-(D135–
275) interactions with PfHsp90. To investigate the importance of the
GNMGGLx7 sequence repeats in Pfp23 for PfHsp90 interaction,
Pfp23-(D135–275) was constructed. Using Pfp23-(D220–275)
mutant, the C-terminal tail of Pfp23 was shown to be dispensable
for PfHsp90 interaction. Further deletion of the GNMGGLx7
sequence repeats in Pfp23-(D135-275) did not affect its binding to
PfHsp90, indicating that the sequence repeats are not essential for
PfHsp90 interaction
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PfHsp90. However, when added in ten-fold molar excess,
Pfp23 reduced the ATPase activity of PfHsp90 to
approximately 20% of its original activity.
To further verify whether the ATPase inhibitory effect
was due to the interaction of Pfp23 with PfHsp90, Pfp23
single mutants with differential PfHsp90 binding levels
were used. As expected, Pfp23 single mutants (K91A,
H93S, W94S and K96A), which displayed drastically
reduced PfHsp90 binding, had little inhibitory effect on the
ATPase activity of PfHsp90 (Fig. 9b). PfHsp90 retained
approximately 90% of its ATPase activity in the presence
of Pfp23 single mutants K91A, H93S and W94S, respec-
tively. Nevertheless, Pfp23 single mutant K96A was able to
suppress the ATPase activity of PfHsp90 to approximately
65% of its original activity. On the contrary, Pfp23 single
mutants (K92A and V95 N) that have a binding capacity to
PfHsp90 similar to Pfp23-WT significantly inhibited the
ATPase activity of PfHsp90 to approximately 35% of its
original activity. The results clearly demonstrated the
inhibitory effect that Pfp23 binding has on the ATPase
activity of PfHsp90, and this may have significance in the
regulation of PfHsp90 chaperone function in vivo.
Discussion
Treatment of malaria is increasingly challenging with the
emergence of new strains that are resistant to conventional
anti-malaria drugs such as chloroquine and pyrimethamine-
sulfadoxine [39, 40]. Coupled with the lack of efficacious
vaccines, there is a need to search for new anti-malarials
and drug targets. Recent studies have recognized the
potential of targeting PfHsp90 for malaria therapy as its
inhibition effectively arrests the intra-erythrocytic devel-
opment of P. falciparum [23, 41, 42]. Nevertheless, there
are some considerations on the use of Hsp90-specific inhibi-
tors as anti-malarials. How selective inhibition of PfHsp90
can be achieved in humans remains a concern since the
Hsp90s in the two organisms are fairly conserved, with 63%
amino acid identity [43]. Furthermore, the paucity of knowl-
edge on the Hsp90 chaperone system in P. falciparum hinders
the understanding of its function in the malaria parasite.
Hence, identifying factors that regulate the function of
PfHsp90 and its affinity for the inhibitors is imperative to
facilitate the assessment of its relevance as a drug target.
One of the factors that influences Hsp90 activity and
sensitivity to the inhibitors is the binding of co-chaperones
[44–48]. However, thus far, PfHsp90 has only been dem-
onstrated to form complexes with P. falciparum Hsp70,
PP5, PKBP35 and a-tubulin [23, 49, 50]. It is surprising
that homologues of co-chaperones (e.g., p23, Hop), which
are known to be essential in regulating the chaperone
function of Hsp90 in human and yeast [2], were not
detected in those PfHsp90 complexes isolated. Inevitably,
this has raised doubts about the functional conservation of
these putative co-chaperones in P. falciparum. As the
interaction between p23 and Hsp90 is essential for client
protein activation, and recently has been shown to influ-
ence the sensitivity of yeast to Hsp90-specfic inhibitors
[44], the interaction status of their homologues in P. fal-
ciparum may have implications on the modus operandi of
PfHsp90 and its affinity for the drugs. Hence, in this study,
the putative co-chaperone Pfp23 was investigated for its
functionality and interaction with PfHsp90.
The purified Pfp23 recombinant protein was shown to
possess intrinsic chaperone activity by virtue of its ability
to suppress the aggregation of citrate synthase at 45C.
However, removal of the C-terminal tail of Pfp23 resulted
in the loss of this anti-aggregation activity and attests to the
need to have a full-fledged Pfp23 protein to elicit the
Fig. 9 Effects of Pfp23-WT and mutants on PfHsp90 ATPase
activity. a Pfp23 was added in increasing concentrations to the
ATPase assay reactions containing a fixed amount of PfHsp90
(2 lM). The ATPase activity of PfHsp90 was inhibited by Pfp23 in a
concentration-dependent manner. At ten-fold molar excess, Pfp23
inhibited the ATPase activity of PfHsp90 to approximately 20% of its
original activity. b Pfp23 single mutants were tested for their ability
to inhibit the ATPase activity of PfHsp90. Pfp23 single mutants
known to have reduced binding to PfHsp90 (K91A, H93S, W94S and
K96A) displayed a negligible inhibitory effect on its ATPase activity.
However, Pfp23 single mutants (K92A and V95 N) that exhibited
comparable binding to PfHsp90 as Pfp23-WT inhibited PfHsp90
ATPase activity to approximately 35% of its original activity. Pfp23-
WT and mutants were added in ten-fold molar excess to PfHsp90 in
all the assay reactions. Results shown are representative of two
independent experiments
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chaperone activity. Pfp23 was subsequently probed for its
interaction with PfHsp90 to assess its potential role as a co-
chaperone in P. falciparum. Using GST pull-down assays,
Pfp23 was observed to bind PfHsp90 in the presence of
MgCl2 and ATP. The conditions conducive for binding
were similar to that of the human and yeast homologues [7,
8], where the Mg2? ion is essential as a cofactor for ATP
binding in Hsp90 [51]. Truncation experiments indicated
that the unique GNMGGLx7 sequence repeats in Pfp23
are dispensable for PfHsp90 interaction. Instead, when
coupled to computational analyses, the results from the
truncation study suggested that the 91st to 96th amino acid
residues in Pfp23 may form an essential interface for
binding PfHsp90. This interface (consisting of amino acid
residues K91, K92, H93, W94, V95 and K96) is located at
an extended loop of Pfp23 and was observed to be in
proximity to the closed ‘lid’ segment of PfHsp90 (Fig. 6a).
Site-directed mutagenesis experiments affirmed the impor-
tance of residues K91, H93, W94 and K96 for PfHsp90
interaction. Their respective single amino acid substitutions,
K91A, H93S, W94S and K96A, resulted in drastically
reduced binding to PfHsp90. However, Pfp23 mutants with
K92A or V95 N substitution displayed PfHsp90 binding
levels comparable to Pfp23-WT. The effects of these muta-
tions were analyzed by computationally modeled structures
to further comprehend the molecular forces that are involved
in their interaction.
With the aid of modeled tertiary structures, the side
chains of K91, H93, W94 and K96 in Pfp23 were observed
to be projected towards the closed ‘lid’ segment of
PfHsp90 (Fig. 6b). Under the in vitro binding conditions
used (at pH 7.5), the side chain of the histidine residue
(H93) would be uncharged, suggesting that the main force
of interaction is hydrophobic in nature. This was supported
by the observation that its side chain is located close to the
hydrophobic residues F104 and I114, of PfHsp90 (Fig. 6b).
Similar hydrophobic interaction would be expected of
Pfp23 residue W94, which was visualized to be in proximity to
I108 and the aliphatic side chain of M105 in PfHsp90. Con-
ceivably, substitutions of H93 and W94 to a polar serine
residue, respectively, would disrupt the hydrophobic interac-
tion and result in the diminished binding to PfHsp90, as
observed in this study.
Apart from that, in silico analyses of the Pfp23 residues,
K91 and K96, did not reveal any electrostatic interaction
between the charged group in the lysine side chains with
PfHsp90 residues. This is consistent with the observation
that the interaction between Pfp23 and PfHsp90 was stable
at high salt concentrations of up to 300 mM KCl (data not
shown), suggesting that electrostatic force plays a minor
role in their interaction. Instead, results from the mutation
study suggest that the long aliphatic side chains of the
lysine residues may be important in contributing to the
hydrophobic interaction between the Pfp23 residues, H93
and W94, with PfHsp90. Substitution to an alanine with
a much shorter side chain would greatly diminish the
hydrophobicity and proximity required for binding
PfHsp90, and this may account for the lack of PfHsp90
interaction as observed.
On the contrary, the Pfp23 mutant K92A retained a
similar PfHsp90 binding capacity to that of the Pfp23-WT.
This implies that the residue K92 is not essential for
PfHsp90 interaction. Likewise, replacing V95 with an
asparagine resulted in a mutant that retained comparable
binding to PfHsp90 as the Pfp23-WT. This result is sur-
prising as the corresponding mutation in yeast SbaI
(I117N) had rendered it defective in binding Hsp82 [35].
However, using the modeled structures, the side chain of
V95 was observed to be projected away from PfHsp90.
In view of this, Pfp23 mutant V95N’s ability to retain
its binding to PfHsp90 is likely to be attributed to the lack
of interaction between the amino acid residue V95 and
PfHsp90.
The results of the truncation study have also highlighted
that a large segment of Pfp23’s N-terminal domain (1st to
74th amino acid residues) can be deleted without affecting
its interaction with PfHsp90. This segment corresponds to
the region in SbaI (1st to 93rd amino acid residues) where
three other Hsp82-interacting interfaces (amino acid resi-
dues 13–16, 31–37, 85–91) were found [14]. It is difficult
to postulate whether the deletion of these interfaces in SbaI
(similar to that of Pfp23-truncated mutants T4) would
affect Hsp82 interaction, as only a few amino acid residues
located at these interfaces were conserved at the corre-
sponding positions in Pfp23.
Probing the significance of Pfp23 binding on PfHsp90
function, results from the ATPase assays revealed that
Pfp23 is capable of suppressing the hydrolysis of ATP by
PfHsp90. The ATPase inhibitory effect of Pfp23 is posi-
tively correlated with its binding capacity to PfHsp90.
Pfp23 single mutants (K91A, H93S, W94S and K96A) that
were defective in binding PfHsp90 were unable to inhibit
PfHsp90 ATPase activity as effectively as Pfp23-WT. The
observation is consistent with that reported for the human
and yeast homologues [10, 11, 52], and it was suggested
that the binding of p23 traps Hsp90 in the ATP-bound
state and prolongs its interaction with the client proteins.
Nevertheless, it is noteworthy that the ATPase inhibitory
effect was only observed when Pfp23 was added in large
molar excess. While this may indicate limitations of the
in vitro environment for stable binding of Pfp23 to
PfHsp90, it may also highlight the transient interaction
between the two proteins. Coupled with semi-quantitative
mass spectrometry data that suggested that Pfp23 is
present at a low physiological concentration in P. falci-
parum [53, 54], these observations could explain why
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previous studies were unsuccessful in identifying the
PfHsp90-Pfp23 complex through co-immunoprecipitation
techniques [20, 23].
With the recognition of PfHsp90 as a potential drug
target against malaria, there is increasing interest in the
development of assays for testing Hsp90-specific
inhibitors as anti-malarials. In a recent study, PfHsp90
was shown to be capable of supporting the survival of a
yeast strain with both Hsp90 genes (Hsc82 and Hsp82)
deleted, which is otherwise lethal [42]. This has led to
the proposal of exploiting the viable yeast strain com-
plemented with PfHsp90 to screen for inhibitors that are
selective against the parasite Hsp90. While this method
offers the advantage of an in vivo setting for drug
screening, the slower growth profile reported may
reflect non-optimal heterologous interaction between
PfHsp90 and the yeast co-chaperones and client pro-
teins. Since the binding of co-chaperones has a major
influence on the affinity of Hsp90 for the inhibitors
[44–48], it alerts us to the need to assess the sensitivity
of PfHsp90 to the inhibitors in the presence of native
P. falciparum co-chaperones, using a priori an in vitro
assay system. Providing an experimentally endorsed
PfHsp90 chaperone complex is important to set the
stage correctly for testing inhibitors against this protein
consortium in P. falciparum. To this end, it is thus
essential to determine and validate experimentally the
interaction between PfHsp90 and its putative co-chap-
erones, particularly that of p23 with its underscored
regulatory function and influence on Hsp90’s affinity
for the inhibitors [44, 55].
Taken together, this study demonstrated that the
P. falciparum genome encodes a functional p23 homo-
logue and has provided valuable evidence concerning its
in vitro interaction with PfHsp90. The inhibitory effect
that Pfp23 exerts on the ATPase activity of PfHsp90
further highlighted its potential regulatory role on the
chaperone function of PfHsp90 in vivo. In addition,
truncation experiments and site-directed mutagenesis
demonstrated significant roles played by certain amino
acid residues in Pfp23, i.e., K91, H93, W94 and K96 in
PfHsp90 interaction. Analyses of the modeled structures
further revealed these residues to be strategically located
at an extended loop of Pfp23 that presumably interacts
with the closed ‘lid’ segment of PfHsp90 via hydrophobic
forces. As the interaction between Pfp23 and PfHsp90
was not observed in previous studies [20, 23], this may
underline the technical difficulties in using co-immuno-
precipitation to identify PfHsp90 complexes. In view of
this, a similar GST pull-down approach would be useful
and may be adopted to investigate the interactions
between PfHsp90 and other putative co-chaperones (e.g.,
Hop), which were also not detected in previous studies.
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Abstract A mitogen-activated protein kinase (MAPK),
Pfmap2, has been identified in Plasmodium falciparum.
However, its bona fide activator remains elusive as no
MAPK kinase (MAPKK) homologues have been found so
far. Instead, Pfnek3, a NIMA (never in mitosis, Aspergil-
lus)-related kinase, was earlier reported to display a
MAPKK-like activity due to its activating effect on
Pfmap2. In this study, the regulatory mechanism of Pfnek3
was investigated. Pfnek3 was found to possess a SSEQSS
motif within its activation loop that fulfills the consensus
SXXXS/T phospho-activating sequence of MAPKKs.
Functional analyses of the SSEQSS motif by site-directed
mutagenesis revealed that phosphorylation of residues
S221 and S226 is essential for mediating Pfnek3 activity.
Moreover, via tandem mass-spectrometry, residue T82 was
uncovered as an additional phosphorylation site involved in
Pfnek3 activation. Collectively, these results provide
valuable insights into the potential in vivo regulation of
Pfnek3, with residues T82, S221 and S226 functioning as
phospho-activating sites.
Keywords Activation loop  MAPK  Phosphorylation 
Plasmodium falciparum  Site-directed mutagenesis
Introduction
Malaria remains a leading cause of morbidity and mortality
in many tropical countries despite continuous efforts to
eradicate it or control its spread. Each year, this disease
affects 350–500 million people worldwide and accounts
for over 1 million deaths [1]. The most lethal form of
human malaria is caused by infection with Plasmodium
falciparum. These parasitic protozoa undergo complex
physiological and morphological changes as they develop
through their life cycles within the mosquito and human
hosts [2]. Although various stages of the P. falciparum life
cycle have been defined, little is known about the mecha-
nisms regulating the growth and differentiation of these
parasites. With the emergence of P. falciparum resistance
against many of the existing anti-malarial drugs, elucidat-
ing these mechanisms would enhance our knowledge of the
parasite pathogenesis and facilitate the design of novel
treatments against malaria.
The mitogen-activated protein kinase (MAPK) signaling
pathways are among the most widespread mechanisms
involved in cell regulation. They are highly conserved
throughout eukaryotic evolution and mediate crucial bio-
logical processes including cell proliferation, differentiation,
migration, and apoptosis [3]. A distinctive feature of MAPK
pathways is the presence of a three-kinase phosphorelay
module which includes a MAPK, a MAPK kinase
(MAPKK), and a MAPKK kinase (MAPKKK). In response
to various stimuli, such as growth factors and inflammatory
cytokines, MAPKKKs activate MAPKKs via phosphoryla-
tion of the serine and serine/threonine residues within the
SXXXS/T activation site [4]. The dual-specificity MAPKKs
in turn phosphorylate the MAPKs on both threonine and
tyrosine residues within the TXY motif to activate them.
Upon activation, MAPKs exert their influences on different
physiological processes through phosphorylation of appro-
priate downstream substrates [5].
As MAPK signaling pathways play pivotal roles in the
cellular processes of many eukaryotes, it is plausible that
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similar mechanisms might be adopted by P. falciparum to
regulate its complex life cycle. To date, only two MAPK
homologues (Pfmap1 and Pfmap2) have been identified in
these parasites [6–8]. In a previous gene knock-out study,
Pfmap2, but not Pfmap1, was found to be essential for
P. falciparum to complete its intraerythrocytic develop-
ment [9]. This study thus shed light on the importance of a
MAPK in mediating the growth and proliferation of these
parasites. Prior biochemical characterizations of Pfmap2
revealed that it possesses a TSH motif in place of the
consensus TXY activation site found in most MAPKs [8].
As such, activation of Pfmap2 in vivo may require phos-
phorylation within the TSH motif by upstream kinases.
However, analyses of the P. falciparum kinome did not
uncover sequences that are obvious homologues of typical
MAPKKs. In view of this, the identity of a MAPK activator
and the existence of a complete MAPK signaling pathway
in P. falciparum remain to be established [10, 11].
Nevertheless, attempts to isolate plasmodial MAPKK-
related genes using a degenerate oligonucleotide-based
PCR method and BLAST analyses of the Plasmodium
genome have led to the identification of Pfnek1 (P. falci-
parum NIMA-like kinase 1) and PfPK7 (P. falciparum
protein kinase 7) [12, 13]. Although Pfnek1 shares low-
protein sequence identity (10%) with the mammalian
MAPKKs, it possesses an activation motif reminiscent of
those found in the MAPKKs [12]. On the other hand, the
similarity between PfPK7 and MAPKKs is restricted to the
C-terminal lobe of the kinase domain [13]. Of these two
kinases, only Pfnek1 was capable of phosphorylating
Pfmap2 in vitro [12]. Moreover, Pfnek1 and Pfmap2 act
synergistically in exogenous substrate phosphorylation
[12]. Typically, NIMA-like kinases function as important
cell cycle regulators in eukaryotic cells [14]. The ability of
Pfnek1 to phosphorylate Pfmap2 suggests the possibility of
Pfnek1 as a MAPK regulator, and that NIMA-like kinases
may adopt unique functions in the malarial parasite.
Interestingly, a second plasmodial NIMA-like kinase,
Pfnek3, was subsequently found to be competent in phos-
phorylating and activating Pfmap2 [15]. The mechanism by
which Pfnek3 activates Pfmap2 was further validated to
involve phosphorylation of the conserved threonine residue,
T290, within the latter’s TSH activation motif [16]. Despite
sharing only 17–19% amino acid sequence identity with the
mammalian and yeast MAPKKs, these observations support
Pfnek3 as a plasmodial kinase displaying a MAPKK-like
activity. Hence, in the absence of a typical MAPKK, Pfnek3
could potentially function as a MAPK regulator in P. fal-
ciparum, similar to that of Pfnek1. Currently, the regulatory
mechanism of Pfnek3 remains enigmatic. As such, this
study aimed to examine the regulation of Pfnek3 activity
and assess if it possesses additional biochemical properties
that are similar to the MAPKKs.
Materials and methods
Homology modeling of Pfnek3
Tertiary structure of Pfnek3 was predicted using the
SWISS-MODEL program (http://www.swissmodel.expasy.
org//SWISS-MODEL.html) [17], based on templates which
share at least 25% primary sequence similarity. The Pfnek3
amino acid sequence submitted for modeling process was
retrieved from the Plasmodium genome database (Plas-
moDB; http://www.PlasmoDB.org). The Pfnek3 tertiary
model, together with the crystal structure of human
MAPKK1 (1S9J) [18], were analyzed and compared using
the Swiss-PdbViewer (http://expasy.org/spdbv/) [19].
Construction of Pfnek3 mutants via site-directed
mutagenesis
The truncated Pfnek3 gene, encoding a catalytically active
form of Pfnek3, was expressed by the GST-encoding pGEX-
6P-1 vector [15]. The resultant recombinant expression
plasmid was used as the template for site-directed muta-
genesis reactions. All GST-Pfnek3 mutants were generated
according to the QuikChangeTM site-directed mutagenesis
protocol (Stratagene), using mutagenic primers summarized
in Table 1. Following which, DNA sequencing was
performed to verify the authenticity of the respective
GST-Pfnek3 mutants and to ensure that no spontaneous
nucleotide substitution was introduced during the PCR
amplification process. The catalytically inactive recombi-
nant Pfnek3 (GST-DPfnek3) harboring a K102M mutation
at the ATP binding site was previously constructed and used
as a negative control in kinase assays [15].
Heterologous expression and purification
of recombinant proteins
Recombinant pGEX plasmids expressing GST-Pfnek3,
GST-Pfnek3 mutants, and GST-Pfmap2 (a gift from
C. Doerig) were independently electro-transformed into
Escherichia coli BL21-CodonPlusTM cells (Stratagene).
Transformants obtained were inoculated into 100 ml Luria
Bertani broth supplemented with ampicillin and chloram-
phenicol (100 and 40 lg/ml, respectively) for vector
propagation. The cultures were grown at 37C with con-
tinuous agitation at 220 rpm until an OD600 of 0.6–0.8 was
reached, after which they were induced with 1 mM
isopropyl-beta-D-thiogalactopyranoside (Sigma) and incu-
bated at room temperature overnight with shaking at
220 rpm. Following this, the cells were harvested and lysed
by sonication as previously described [16]. Fusion proteins
were purified from soluble cell free extracts by affinity
chromatography using the Microspin GST Purification
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Module (GE Healthcare) according to manufacturer’s
instructions. The eluted proteins were subsequently ana-
lyzed by 10% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE). Gel images of separated
proteins were captured using the Bio-Rad Molecular Ima-
ger Gel Doc XR system equipped with the Quantity One
software. Protein concentration of the purified samples was
determined by the Bio-Rad protein assay, using bovine
serum albumin (BSA; Sigma) as the reference protein
standard. In experiments that required cleavage of the GST
fusion partner, purified proteins were incubated overnight
at 4C with the PreScission Protease (GE Healthcare).
Protein phosphorylation analysis of GST-Pfnek3
and its mutants
Following bacterial expression and purification, wild-type
and mutant GST-Pfnek3 proteins were separated by
SDS-PAGE using 10% polyacrylamide gels. After electro-
phoresis, the gels were stained with Pro-Q Diamond
phosphoprotein gel stain (Invitrogen) according to manu-
facturer’s protocol and visualized on a UV transilluminator.
The gels were subsequently stained with Coomassie Blue to
ensure uniform loading of protein samples for each lane.
Dephosphorylation of GST-Pfnek3 by lambda
phosphatase
For dephosphorylation reactions, 10 lg of wild-type GST-
Pfnek3 was treated with 500 U of lambda phosphatase
(Millipore) in 40 ll of reaction buffer supplied by the
manufacturer. The phosphatase was omitted from mock-
treated samples which served as negative controls. Incu-
bations were carried out for 30 min at 30C before the
reaction mixture was supplemented with a 109 phospha-
tase inhibitor cocktail (Thermo Fisher Scientific) to
terminate the phosphatase activity. One-half of the reaction
mixture was thereafter subjected to phosphorylation anal-
ysis to ensure dephosphorylation of the protein had
occurred. The remaining half was used in kinase assays to
examine the activity of dephosphorylated GST-Pfnek3.
ELISA-based protein kinase assay
Kinase assays were performed using 96-well microtiter
plates (Costar) coated with dephosphorylated myelin basic
protein (MBP; Millipore). Each kinase assay reaction mix
of 60 ll comprised of 10 lg of wild-type or mutant GST-
Pfnek3 enzymes, 500 lM ATP, 40 mM MgCl2 and 50 mM
Tris–HCl (pH 7.2). The assay was initiated upon addition
of the kinase reaction mix to each well. The microplates
were then incubated at 30C for 30 min before the reac-
tions were quenched by repeated washing with phosphate-
buffered saline (PBS). Mixed monoclonal anti-phospho-
serine/threonine antibodies (1:500 dilution; Millipore) were
subsequently added to each well and incubated at room
temperature for 1 h. During this period, any phosphoryla-
tion of MBP that arose from the activities of the kinases
would be detected by these antibodies. After another round
of extensive washing with PBS, the wells were incubated
with a peroxidase-conjugated secondary antibody (1:2,000
dilution; Thermo Fisher Scientific) for 45 min. The wells
Table 1 Mutagenic primers
used for the construction of
GST-Pfnek3 mutants
The designations F and R
denote the forward and reverse
primers, respectively, with the
sites of mutagenesis underlined
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were again rinsed, followed by addition of the SuperSignal
West Femto peroxidase substrate (Thermo Fisher Scien-
tific). The resulting chemiluminescent signal arising from
the presence of phosphorylated serine and/or threonine
residues was measured using the GeniosTM microplate
reader (Tecan).
For co-incubation kinase assays, the same protocol was
adopted except that each MBP-coated well was incubated
for 15 min with a kinase reaction mix that contained 5 ng
of wild-type or mutant GST-Pfnek3 and 3 lg of GST-
Pfmap2.
Liquid chromatography-tandem mass spectrometric
(LC-MS/MS) analysis
To determine the phosphorylation sites present in Pfnek3,
10 lg of wild-type GST-Pfnek3 was gel-purified by 10%
SDS-PAGE and the coomassie-stained band containing the
protein of interest was excised. In-gel digestion with
trypsin and the subsequent LC-MS/MS analysis were per-
formed by A*STAR Experimental Therapeutics Centre
using API QSTAR Pulsar (Applied Biosystems). The
experiment was repeated with the catalytically inactive
GST-DPfnek3 to ascertain that any phospho-sites detected
in the wild-type kinase were indeed due to autophospho-
rylation and not attributed to the kinase activities of any
contaminating bacterial kinases.
All MS/MS samples were analyzed using Mascot (ver-
sion 2.2.0; Matrix Science, London, UK). Mascot was set
up to search the NCBInr_20070223 database, specifying
trypsin as the digestion enzyme. Mascot was searched
with a fragment ion mass tolerance of 0.80 Da and a parent
ion tolerance of 500 ppm. Scaffold (version Scaffold-
01_07_00; Proteome Software, Portland, OR, USA) was
used to validate MS/MS-based peptide and protein identi-
fications. Peptide identifications were accepted if they
could be established at greater than 95.0% probability as
specified by the Peptide Prophet algorithm [20]. Protein
identifications were accepted if they could be established at
greater than 95.0% probability and contained at least 2
identified peptides. Protein probabilities were assigned by
the Protein Prophet algorithm [21].
Results
The activity of Pfnek3 was abrogated in the absence
of phosphorylation
From an earlier study, recombinant wild-type GST-Pfnek3
was observed to display a significant level of phosphory-
lation [15]. As its kinase inactive counterpart (GST-
DPfnek3) lacks detectable phosphorylation, Pfnek3 was
proposed to exhibit an autophosphorylation property [15].
To exclude the possibility that phosphorylation had occur-
red solely on the GST moiety, GST-Pfnek3 was subjected to
PreScission protease cleavage and the resultant untagged
Pfnek3 was examined for its phosphorylation status. As
shown in Fig. 1a, the untagged kinase retained a level of
phosphorylation that was comparable to GST-Pfnek3, hence
confirming the autophosphorylation ability of Pfnek3.
To determine whether phosphorylation of Pfnek3 plays
a crucial role in regulating its kinase activity, wild-type
GST-Pfnek3 was treated with lambda phosphatase to
eliminate phosphoryl groups on serine, threonine, and
tyrosine residues. Upon incubation with lambda phospha-
tase, a significant reduction in the phosphorylation level of
GST-Pfnek3 was observed (Fig. 1b, lane 2), validating the
dephosphorylated status of the kinase. In addition, phos-
phatase-treated GST-Pfnek3 exhibited a complete loss of
kinase activity using MBP as the exogenous substrate
(Fig. 1c, lane 2). On the contrary, preincubation of lambda
phosphatase with the phosphatase inhibitor cocktail
blocked both dephosphorylation and inactivation of GST-
Pfnek3 (Fig. 1b, c, lane 3). These results indicate that the
loss of kinase activity observed earlier was indeed associ-
ated with the absence of phosphorylation and therefore
highlight the importance of phosphorylation in the activa-
tion of Pfnek3.
Pfnek3 possesses a SSEQSS motif that is analogous
to the activation sites of MAPKKs
Several classes of eukaryotic protein kinases, including the
MAPKKs, are regulated via phosphorylation at the acti-
vation loop [22]. This segment is commonly defined as the
region that spans the DFG and APE motifs within kinase
subdomains VII and VIII, respectively [23]. In Pfnek3, the
APE motif has been altered to a SYE, and the region that
represents its putative activation loop is highlighted in
Fig. 2. Interestingly, a SSEQSS motif within this loop
fulfills the conserved SXXXS/T phospho-activating
sequence found in the MAPKKs. To further assess whether
this motif is analogous to the activation sites of MAPKKs
in terms of its tertiary structure, the three-dimensional
model of Pfnek3 was generated using the SWISS-MODEL
program. When the Pfnek3 model was compared with the
crystal structure of human MEK1 (PDB identifier: 1S9J), a
well-characterized MAPKK, it was observed that the
SSEQSS motif of Pfnek3 coincides with the SMANS
activation site of MEK1 (Fig. 2). It has been established
that phosphorylation of the two serine residues within the
SMANS motif is critical for the activation of MEK1 [22].
Hence, these observations provide a strong indication that
the SSEQSS motif could adopt a similar function as the
SMANS motif in mediating the activation of Pfnek3.
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Mutations of residues S221 and S226 in the SSEQSS
motif affect autophosphorylation and kinase activity
of Pfnek3
To investigate whether any of the serine residues in the
SSEQSS motif could serve as phospho-regulatory sites,
they were independently substituted with a non-phospho-
rylatable alanine via site-directed mutagenesis. Each of
these GST-tagged mutants (hereafter known as S221A,
S222A, S225A, and S226A) was similarly expressed in
E. coli cells and assayed to determine their relative auto-
phosphorylation levels. While both S222A and S225A
mutants exhibited a level of autophosphorylation that was
similar to the wild-type enzyme, significant reductions in
autophosphorylation levels were observed for the S221A
and S226A mutants (Fig. 3a). A double mutant (S221A/
S226A) was thereafter constructed, and it displayed a much
lower autophosphorylation signal as compared to either of
the individual single mutants.
The effect of these mutations on Pfnek3 activity was
then analyzed using the microtiter plate kinase assay.
Consistent with the phenomenon observed in Fig. 3a, the
kinase activities of both S221A and S226A mutants were
lower than that of the wild-type kinase (Fig. 3b). Likewise,
the activity of the S221A/S226A double mutant was sig-
nificantly lower as compared to its respective single
mutants. The concomitant reductions in autophosphoryla-
tion levels and kinase activities of the S221A and S226A
mutants indicate the potential of these serine residues to
function as crucial phospho-activating sites in Pfnek3.
Phospho-mimic mutants (S221D/E and S226D/E) were
subsequently constructed in an effort to further examine the
above postulation. Aspartates and glutamates are utilized,
with varying competency, to simulate the effects of phos-
phorylation and maintain kinases in the activated states
[24]. Replacing S221 with either aspartate or glutamate
Fig. 1 Activation of Pfnek3 is correlated with its phosphorylation
status. a To authenticate the autophosphorylation ability of Pfnek3,
GST-Pfnek3 was subjected to PreScission protease cleavage to
remove the GST moiety. The phosphorylation level of the untagged
recombinant kinase was subsequently analyzed using the Pro-Q
Diamond phosphoprotein gel stain. The untagged Pfnek3 displayed a
similar level of phosphorylation as its GST-fused counterpart. Lane M
denotes the protein standard marker (Fermentas) used for estimating
the protein sizes. b Purified GST-Pfnek3 was treated with lambda
phosphatase in the presence (lane 3) or absence (lane 2) of the
phosphatase inhibitor cocktail. In the mock-treated sample (lane 1),
lambda phosphatase was omitted. c Following lambda phosphatase
treatment in (b), an aliquot of the respective reaction mixture was
transferred to MBP-coated microtiter plates to assay for the activity of
dephosphorylated GST-Pfnek3. ND Kinase activity not detected
Fig. 2 Pfnek3 possesses a MAPKK-like activation site within its
activation loop. Top The Pfnek3 amino acid sequence corresponding
to the putative activation loop is illustrated. The underlined SSEQSS
motif bears a resemblance to the SXXXS/T activation sites of
MAPKKs. Bottom The Pfnek3 model was generated using SWISS-
MODEL and subsequently compared with the crystal structure of
human MEK1 (1S9J). The putative activation loop of Pfnek3 is
highlighted in yellow. The SSEQSS motif was observed to locate at
the surface of this loop and reside in a position analogous to the
SMANS activation site of human MEK1 (both boxed up in blue)
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residues resulted in a loss of Pfnek3 activity (Fig. 4).
Conversely, the activity of the S226D mutant was
approximately half of the wild-type kinase activity. When
S226 was altered to a glutamate residue, the activity of the
mutant was increased by approximately 50% as compared
to wild-type Pfnek3. This finding supported our speculation
that S226 is an activating phospho-acceptor site, whose
functionality could be substituted by the negatively
charged glutamate. At this point, however, it is difficult to
unequivocally rule out the possibility of S221 as a phos-
phorylation site. Since the catalytic activity of Pfnek3 was
completely abrogated upon mutation of S221 to either an
aspartate or a glutamate, these mutations may have led to
unfavorable conformational changes resulting in the loss of
kinase activity.
LC-MS/MS analyses revealed amino acid T82
as a crucial phosphorylation site in Pfnek3
The low level of autophosphorylation and kinase activity
retained by the S221A/S226A double mutant implies that
additional phosphorylation sites are present in Pfnek3,
which could potentially be involved in regulating its kinase
activity. As such, LC-MS/MS was employed to verify this
speculation. In total, seven tryptic peptides were identified
which made up 30% of the Pfnek3 amino acid sequence. A
single phosphorylation site was detected in the 74FET-
VLDFMTSDSEIHLIR91 peptide, and amino acid residue
T82 was validated as the site of phosphorylation (Fig. 5a).
The loss of 80 Da detected on this residue corresponds to
the neutral loss of a phosphate group. When LC-MS/MS
was repeated using the catalytically inactive GST-DPfnek3,
no phosphorylation was detected on the same site (Fig. 5b).
These observations thus validate that residue T82 is an
autophosphorylation site. To elucidate whether phosphor-
ylation of T82 serves as a mechanism to regulate the kinase
activity of Pfnek3, the amino acid residue was similarly
replaced with an alanine to prevent phosphorylation from
occurring at this site. Absence of the T82 phosphorylation
site provoked a loss of wild-type activity by over 80%
(Fig. 3b), suggesting its importance in modulating the
catalytic activity of Pfnek3. A significant drop in auto-
phosphorylation level was also observed for the T82A
mutant (Fig. 3a). This finding was somewhat expected
since removal of this phospho-site is likely to reduce the
overall phosphorylation content of the kinase.
As both the S221A and S226A mutations were earlier
found to reduce autophosphorylation level and kinase
activity of Pfnek3, T82A/S221A, T82A/S226A, and T82A/
S221A/S226A mutants were also constructed to investigate
their combined effects on the autophosphorylation status
and catalytic activity of Pfnek3. The T82A/S221A mutant
displayed a slightly lower catalytic activity as compared to
the single T82A mutant (Fig. 3b). On the other hand,
activities of both the T82A/S226A and T82/S221A/S226A
mutants were nearly eliminated completely (Fig. 3b). It
was also found that all these mutants exhibited drastic
reductions in autophosphorylation levels as compared to
Fig. 3 Autophosphorylation levels and kinase activities of GST-
Pfnek3 alanine-substituted mutants. a Purified wild-type GST-Pfnek3
and the indicated mutants were resolved by SDS-PAGE and stained
with the phosphoprotein gel stain to assess their autophosphorylation
levels. In the protein standard marker (M), the 70-kDa protein band
corresponds to a phosphoprotein that could be detected using the
phosphostain. Following phosphostaining, the gel was stained with
Coomassie Blue to ensure that relatively equal amounts of proteins
were loaded. b The in vitro kinase activities of the respective GST-
Pfnek3 mutants were subsequently determined by their ability to
phosphorylate the MBP substrates. ND Kinase activity not detected
Fig. 4 Kinase activities of phospho-mimic GST-Pfnek3 mutants.
Residues S221 and S226 were each replaced with either aspartate or
glutamate to mimic phosphorylation at these residues. Activities of
these mutants were analyzed using the ELISA-based kinase assay as
described in ‘‘Materials and methods’’. ND Kinase activity not
detected
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the wild-type kinase (Fig. 3a). Collectively, these data
strongly suggest the importance of T82, S221 and S226 in
regulating the activity of Pfnek3.
Amino acid residues T82 and S226 are crucial
for Pfnek3 to activate Pfmap2 in vitro
Since Pfnek3 was reported to function as a Pfmap2 acti-
vator in vitro [15], we postulate that any alteration in
Pfnek3 activity could affect its ability to phosphorylate and
trigger Pfmap2 activation. As the S221A, S226A, and
T82A mutants displayed reduced activities towards the
exogenous MBP substrate, their influence on GST-Pfmap2
activation was also assessed via a co-incubation kinase
assay. In this assay format, GST-Pfmap2 was mixed with
GST-Pfnek3 or its mutants in the MBP-coated microtiter
wells. It was previously noted that, when GST-Pfnek3
activates GST-Pfmap2, a synergistic increase in the phos-
phorylation of MBP would be observed [15].
GST-Pfmap2 alone, or when mixed with the kinase-dead
GST-DPfnek3, displayed a modest level of kinase activity
(Fig. 6a). The co-incubation of GST-Pfnek3 and GST-
Pfmap2 led to the activation of GST-Pfmap2 by approxi-
mately 70-fold (Fig. 6a). When residue T82 or S226 was
replaced with an alanine, the ability of GST-Pfnek3 to
activate GST-Pfmap2 was reduced by at least 50%
(Fig. 6a). Surprisingly, the S221A mutant was able to
stimulate GST-Pfmap2 to a similar extent as the wild-type
GST-Pfnek3. One possible explanation for this outcome
could be that S221 is not fundamental for Pfnek3 to
phosphorylate and activate Pfmap2. To examine this
notion, the phosphorylation status of GST-Pfmap2 was
analyzed following incubation with the various GST-
Pfnek3 proteins. Indeed, the S221A mutant retained the
ability to phosphorylate the GST-Pfmap2 substrate
(Fig. 6b). On the other hand, both the S226A and T82A
mutants phosphorylated GST-Pfmap2 to a lower extent.
These data thus indicate that residues T82 and S226 are
essential for Pfnek3 to stimulate the activity of Pfmap2,
and we propose phosphorylation at these residues might be
responsible for this phenomenon.
Discussion
Pfnek3 was previously validated to exhibit a MAPKK-like
activity due to its activating effect on Pfmap2 via phos-
phorylation at the signature TSH activation motif. This
triggered our interest in investigating the regulation of
Pfnek3 activity to elucidate additional properties that might
be common between Pfnek3 and the MAPKKs. Kinase
activities are commonly modulated by several strategies
including changes in cellular localization, binding of reg-
ulatory subunits and phosphorylation by upstream kinases
or via autophosphorylation [25]. The authentication of
Pfnek3 autophosphorylation (Fig. 1a) led us to hypothesize
that phosphorylation of the kinase plays a crucial role in
regulating its activity. This notion was further supported
when GST-Pfnek3 activity was abrogated upon dephos-
phorylation with lambda phosphatase (Fig. 1c).
For a number of kinases, phosphorylation within specific
motifs found in the kinase activation loop is essential for
enzyme activation [26]. In NIMA-like kinases, for instance,
stimulation of kinase activity requires phosphorylation of
Fig. 5 Pfnek3 autophosphorylates at residue T82. a After bacterial
expression and purification, GST-Pfnek3 was subjected to SDS-
PAGE. The desired protein band was in-gel digested with trypsin
before analysis by LC-MS/MS. Amino acid T82, which resides within
the tryptic peptide 74FETVLDFMTSDSEIHLIR91, was identified as a
phosphorylation site. The neutral loss of 80 Da corresponded to the
mass of a phosphate group. b LC-MS/MS analysis was repeated with
the catalytically inactive GST-DPfnek3. The same peptide was devoid
of phosphorylation at residue T82, confirming the phosphoryl-group
detected in (a) was a result of autophosphorylation reaction
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the threonine residue within the consensus FXXT motif [27].
However, this motif is absent in Pfnek3. Instead, Pfnek3 was
found to possess a SSEQSS motif which resembles the
characteristic SXXXS/T activation site of MAPKKs. Simi-
lar MAPKK-like activation motif has also been reported in
Pfnek1 [12].
A comparison of the Pfnek3 tertiary model with the
human MEK1 crystal structure revealed that the SSEQSS
motif resides in a position that is analogous to the SMANS
activation motif of MEK1 (Fig. 2). Phosphorylation of
both serines within the SMANS motif has been validated
to be a prerequisite for MEK1 activation [22]. Thus, the
co-location of SSEQSS motif with the known activation
site of MEK1 highlights its potential to serve as a phospho-
regulatory site in Pfnek3. In support of this, our results
showed that the S221A and S226A mutants displayed
significant reductions in kinase activities that were
accompanied by decreases in autophosphorylation levels
(Fig. 3). Therefore, out of the four serines within the
SSEQSS motif, phosphorylation of S221 and S226 is likely
to induce the activation of Pfnek3.
We also attempted to replace S221 and S226 with either
an aspartate or a glutamate to mimic phosphorylation at
these residues. Among these mutants, only S226E exhibited
a considerably higher activity than the wild-type Pfnek3
(Fig. 4), suggesting that phosphorylation of S226 indeed
occurs. Additionally, this observation may signify that the
phosphorylation state of S226 could only be efficiently
mimicked by glutamate, and not aspartate, to maintain
Pfnek3 in an active conformation. On the other hand, the
inability of the S221D and S221E mutants to activate
Pfnek3 cannot completely revoke the potential of S221 as a
phospho-activating site. This is because, in certain kinases,
negatively charged amino acids may be incompetent in
emulating the function of experimentally verified phospho-
sites. For instance, although the second serine within the
SMANS activation site of human MEK1 has been validated
as an important phosphorylation site for kinase activation,
its mutation to either glutamate or aspartate did not con-
stitutively activate the kinase [24]. It was suggested that the
phospho-mimic mutations may have led to conformational
changes in the kinase structure that prevented them from
simulating the effect of serine phosphorylation [24]. Like-
wise, the S221D and S221E mutations may also have led to
undesirable conformational changes in the Pfnek3 structure,
rendering their inability to simulate the effect of the nega-
tive charges arising from phosphorylation at this position.
Given that phosphorylation at the activation loop is a
widespread mechanism in mediating kinase activation, we
are in favor of the proposal that both S221 and S226 serve as
phospho-activating residues in Pfnek3.
In this study, amino acid residue T82 is a novel phos-
phorylation site authenticated via LC-MS/MS analysis
(Fig. 5). To evaluate the implication of T82 phosphoryla-
tion in regulating the kinase activity of Pfnek3, the
threonine residue was mutated to a non-phosphorylatable
alanine. The T82A mutant displayed a more drastic reduc-
tion in autophosphorylation and kinase activity as compared
to the S221A and S226A mutants, suggesting that phos-
phorylation at this residue plays a more crucial role in
stimulating Pfnek3 activity (Fig. 3). Interestingly, residue
T82 is located within a unique FMTSDS motif which was
earlier reported to replace the highly conserved glycine
triad (GXGXXG) in kinase subdomain I [15]. In general,
this glycine triad is essential for modulating the activity of
eukaryotic protein kinases due to its involvement in
anchoring ATP during the phospho-transfer reaction [23].
In the absence of this motif, ATP binding in Pfnek3 might
involve an unusual mechanism that potentially requires the
phosphorylation of residue T82. Hence, the huge decrease
Fig. 6 Effect of T82A, S221A, and S226A mutations on the ability
of GST-Pfnek3 to activate GST-Pfmap2. a Adopting the co-incuba-
tion kinase assay, 5 ng of wild-type GST-Pfnek3 or the respective
mutants were mixed with 3 lg of GST-Pfmap2 in MBP-coated wells.
When existing alone, or mixed with the kinase-dead GST-DPfnek3
mutant, GST-Pfmap2 displayed a low level of kinase activity (lanes 1
and 3). In the presence of wild-type GST-Pfnek3, the activity of GST-
Pfmap2 was stimulated by approximately 70-fold. Only the S221A,
but not the S226A or T82A mutants, retained the ability to activate
GST-Pfmap2. b After GST-Pfmap2 was incubated with the indicated
GST-Pfnek3 proteins in a kinase assay mix, the kinases were resolved
by SDS-PAGE and subjected to phosphorylation analysis to deter-
mine the phosphorylation status of GST-Pfmap2. The Coomassie
staining of the same gel is shown in lower panel. M Protein standard
marker
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in Pfnek3 activity upon mutation of T82 could be attributed
to its importance in triggering efficient ATP binding during
phosphorylation reactions. However, the amino acid resi-
dues flanking T82 were not visible in the modeled Pfnek3
structure, conceivably due to the low sequence homology
between Pfnek3 and the modeling templates at this region.
As such, until the structure of Pfnek3 in both the unphos-
phorylated and phosphorylated state is made available, the
bona fide role of T82 phosphorylation in regulating Pfnek3
activity remains debatable.
Since Pfnek3 was earlier reported to modulate the
activity of Pfmap2, it was also of interest to examine
whether phosphorylation of S221, S226, and T82 was
crucial for Pfnek3 to activate Pfmap2. From the results
illustrated (Fig. 6), only residues T82 and S226 were found
to be essential for Pfnek3 to phosphorylate and trigger
GST-Pfmap2 activation. The outcome was unexpected
since the absence of these three residues has rendered
Pfnek3 less capable of phosphorylating the exogenous
MBP substrate. Consequently, this may imply that phos-
phorylation of T82 and S226 is more crucial for Pfnek3 to
recognize the Pfmap2 substrate.
The results of this study have strengthened the notion
that Pfnek3 is a MAPKK-like kinase in P. falciparum with
an activation mechanism similar to the well-known MAP-
KKs. On top of this, Pfnek3 activation further requires
phosphorylation at residue T82, suggesting the regulation of
Pfnek3 activity might involve a more complex mechanism
as compared to the MAPKKs. Moreover, since the T82A/
S221A/S226A triple mutant retained a low, but observable,
level of phosphorylation, it is plausible that additional
phosphorylation sites are present that may contribute to the
regulation of Pfnek3 activation. It is also noteworthy to
mention that, although phosphorylation of T82, S221 and
S226 in vitro is a result of Pfnek3 autophosphorylation, the
possibility remains that phosphorylation of these residues in
vivo may be performed by upstream kinases and/or require
binding with regulatory subunits. In view of this, it is
imperative to identify interacting partners of Pfnek3 so as to
fully understand its regulation in the malarial parasite.
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Eukaryotes generally rely on signal transduction by mitogen-activated protein kinases (MAPKs) for activating their regulatory path-
ways. However, the presence of a complete MAPK cascade in Plasmodium falciparum is debatable because a search of the entire genome
did not portray known MAPK kinase (MAPKK) sequences. Via homology PCR experiments, only two copies of plasmodial MAPK
homologues (Pfmap1 and Pfmap2) have been identiﬁed but their upstream activators remain unknown. In an earlier experiment, Pfnek3
was found to be an unusual activator of Pfmap2 in in vitro experiments, despite its molecular identity as a malarial protein kinase from
the NIMA (Never in Mitosis, Aspergillus) family. In this study, the role of Pfnek3 as a likely upstream MAPKK is deﬁned through
molecular and biochemical characterization. Since a previous report proposes a TSH motif as an activation site of Pfmap2, its site-direc-
ted mutants, T290A, S291A, and H292K were constructed to elucidate the involvement of Pfnek3 in phosphorylating and activating
Pfmap2 in a battery of kinase assays. The results suggested that residue T290 is the site of phosphorylation by Pfnek3. This supposition
was further supported by liquid chromatography mass spectrometry. Although P. falciparum does not appear to possess a conventional
MAPK cascade, they may rely on other kinases such as Pfnek3 to carry out similar phosphorylation to activate its signaling pathways.
 2007 Elsevier Inc. All rights reserved.
Keywords: Malaria; Mass spectrometry; MAP kinasesMalaria remains a leading cause of death in developing
countries despite major attempts to eradicate or control its
spread. Each year, approximately 350–500 million people
are infected with malaria and more than one million people
die from this deadly disease [1]. Concurrently, the eﬀective
control of malaria is greatly hindered by increasing antima-
larial drug resistance. Parasitic protozoa belonging to the
Plasmodium genus are the causative agents of malaria. Of
the four species that parasitize human, Plasmodium falcipa-
rum is responsible for the most lethal form of human
malaria.
The plasmodial life cycle is extraordinarily complex,
alternating between a human host and a female Anopheles
mosquito [2]. Infection of a human host begins with the bite
of a malaria-infected female Anopheles mosquito. Sporozo-
ites inoculated into the bloodstream rapidly target the liver,
where exo-erythrocytic schizogony occurs, leading to the0006-291X/$ - see front matter  2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2007.07.047
* Corresponding author. Fax: +65 67766872.
E-mail address: micsimts@nus.edu.sg (T.-S. Sim).release of thousands of merozoites that speciﬁcally infect
erythrocytes. Intra-erythrocytic schizogony subsequently
occurs within erythrocytes where more merozoites are pro-
duced. Concomitantly, some parasites deviate from the
asexual blood stages and become engage in the sexual cycle,
whereby newly invaded merozoites develop into male and
female gametocytes. These gametocytes are picked up by
another feeding mosquito. In the mosquito midgut, the
fusion of the gametocytes generates zygotes which escape
the midgut and transform into sporozoites. These sporozo-
ites consequently accumulate in the mosquito’s salivary
glands, ready to infect the next host. Although the malarial
parasite is one of the most comprehensively studied intra-
cellular parasites, signaling mechanisms regulating its
growth and development are still poorly understood [3].
Molecular signaling plays central roles in the cellular devel-
opment of many eukaryotes. Therefore, signal transduction
control may also be tightly correlated to the regulation of
the complex life cycle of the malarial parasite. Eukaryotic
protein kinases belonging to the mitogen-activated protein
440 H. Low et al. / Biochemical and Biophysical Research Communications 361 (2007) 439–444kinase superfamily (MAPK, also known as ERK, extracel-
lular regulated kinase) are currently among the best studied
signal transduction molecules [4]. MAPKs have been found
to be well-conserved in all eukaryotes investigated so far
and are major components of signaling pathways control-
ling cell diﬀerentiation and proliferation [5]. Two MAPK
homologues from P. falciparum (Pfmap1 and Pfmap2) have
been previously identiﬁed, both of which display atypical
features as compared to classical MAPKs [3,6]. MAPKs
are regulated via phosphorylation cascades. Convention-
ally, their activation is dependent on phosphorylation of
threonine and tyrosine residues in the conserved threo-
nine-x-tyrosine (TXY) sequence motif by an upstream
MAPK kinase (MAPKK). This motif is completely con-
served in Pfmap1 (PlasmoDB identiﬁer: PF14_0294) as
TDY but is altered to a TSH motif in Pfmap2 (PlasmoDB
identiﬁer: PF11_0147).
The presence of an atypical activation motif suggests
that the mode of activation of Pfmap2 may diverge from
the regular MAPKs. Unsurprisingly, the regulation of
Pfmap2 remains a mystery as its typical upstream activa-
tors have yet to be established. Nevertheless, Pfnek1, a
malarial protein kinase belonging to the NIMA (Never in
Mitosis, Aspergillus) protein kinase family, was reported
to speciﬁcally phosphorylate Pfmap2 but not Pfmap1 [7].
Although the co-incubation of Pfnek1 and Pfmap2 led to
a synergistic rise in exogenous substrate labeling [7],
whether Pfnek1 is capable of activating Pfmap2 by phos-
phorylating at its activation motif remains questionable.
A search in the PlasmoDB repository (www.Plas-
moDB.org) revealed a sequence annotated as PFL0080c.
Analysis of the parasite’s transcriptome indicated that the
expression of its gene product is up-regulated in the game-
tocytes, where Pfmap2 is speciﬁcally expressed [6,8].
PFL0080c was placed together with members of the NIMA
kinase family in a phylogenetic analysis of the protein
kinases from P. falciparum and the encoded gene product
was later referred to as Pfnek3 [9]. To investigate whether
Pfnek3 is a candidate plasmodial MAPK regulator, the
gene was cloned and its product was characterized [10].
Recombinant Pfnek3 was found to phosphorylate Pfmap2
and stimulate its kinase activity in in vitro experiments. It
was therefore proposed that Pfnek3 is a likely activator
of Pfmap2. As Pfnek3 displays low sequence homologyTable 1
List of primers used in this study for generating various GST-Pfmap2 mutant









The mutation sites are indicated in bold and underlined.to the well-conserved MAPKKs, the fact that it is capable
of stimulating Pfmap2 activity has led us to inquire further
about the mechanism by which it activates Pfmap2 and
whether it possesses any MAPKK-like functionality. The
speciﬁc aims of this study are (1) veriﬁcation of the TSH
signature motif as the site of phosphorylation by Pfnek3
and (2) validation of the role of Pfnek3 in phosphorylating
Pfmap2 at the TSH activation site.Materials and methods
Three-dimensional (3D) structure prediction. SWISS-MODEL, a fully
automated comparative protein modeling server (http://swissmodel.exp-
asy.org//SWISS-MODEL.html) [11], was engaged in predicting the 3D
structure of Pfmap2. The ‘‘ﬁrst approach mode’’ was chosen for the
modeling process and the submitted sequence was modeled using tem-
plates which shares at least 25% sequence identity. The predicted structure
of Pfmap2, together with suitable modeling templates, were analyzed using
the Swiss-PdbViewer (http://expasy.org/spdbv/) [12].
Construction of Pfmap2 mutants. A T290A, T290E, S291A or H292K
mutation was introduced into the plasmid carrying GST-Pfmap2 (a gift
from C. Doerig, Wellcome Centre for Molecular Parasitology) to generate
GST-Pfmap2 single mutants. A catalytically inactive recombinant Pfmap2
(GST-DPfmap2) carrying a K135M mutation at the conserved ATP-
binding lysine residue has been previously constructed [10]. All mutations
were carried out according to the QuikChange site-directed mutagenesis
protocol (Stratagene, USA) using mutagenic primers summarized in Table
1. Prior to protein expression, DNA sequencing was performed to verify
the respective mutation sites.
Recombinant kinase expression and puriﬁcation. Generation of GST-
Pfnek3 and its catalytically inactive counterpart (GST-DPfnek3) was
performed previously [10]. Escherichia coli BL21-CodonPlus (Strata-
gene, USA) was used as host strain for the expression of GST-Pfmap2,
GST-Pfmap2 mutants, GST-Pfnek3, and GST-DPfnek3. This strain is
engineered to alleviate codon bias and facilitate the translation of genes
containing rare codons. Host cells expressing respective fusion proteins
were induced by overnight incubation with 0.5 mM IPTG (isopropyl-b-D-
thiogalactopyranoside) at 22–25 C before being harvested by centrifu-
gation. Cells were sonicated (MSE Soniprep, Sanyo) and the resulting cell
debris was removed by centrifugation. The fusion proteins from the cell
lysates were aﬃnity-puriﬁed with glutathione-sepharose according to
manufacturer’s instructions (Amersham, Sweden). Eluted proteins were
analyzed with SDS–polyacrylamide gel electrophoresis and Coomassie
blue staining. Protein concentration in the samples was determined using
the Protein Assay Reagent (Bio-Rad, USA) according to the manufac-
turer’s recommendations with bovine serum albumin (Sigma–Aldrich,
USA) as a standard.
Protein adsorption and ELISA-based protein kinase assay. A chemilu-
minescent microplate assay was employed in this study. Myelin basic
protein (MBP) was reported to be a suitable substrate for both Pfmap2s
Purpose
GTAGTTAC Forward primer for generating T290A mutant
TATTATG Reverse primer for generating T290A mutant
GTAGTTACTAG Forward primer for generating S291A mutant
TTTTTATTATG Reverse primer for generating S291A mutant
Forward primer for generating H292K mutant
Reverse primer for generating H292K mutant
GTAGTTAC Forward primer for generating T290E mutant
TATTATG Reverse primer for generating T290E mutant
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(0.5 mg/ml; Upstate, USA) was adsorbed onto protein-binding 96-well
plates (Costar, USA). Immobilization of proteins onto microplate wells
was achieved by overnight incubation at 4 C in a carbonate buﬀer
(0.15 M sodium carbonate and 0.35 M sodium bicarbonate, pH 9.6). Prior
to use, the remaining adsorptive surfaces were blocked with PBS/1% BSA
for one hour at room temperature.
Kinase assay reaction mix of 60 ll comprising 30 lg of the respective
wildtype or mutant GST-fusion kinases, Tris–HCl (50 mM, pH 7.2), ATP
(500 lM), MgCl2 and/or MnCl2 (20 mM and 5 mM, respectively) was
added into substrate-coated microplate wells. The microplates were
incubated at 30 C for 30 min and the kinase assays were subsequently
quenched by repeated washing with PBS. Mixed monoclonal antiphos-
phoserine/threonine antibodies (1:500 dilution; Upstate, USA) were added
into each well and incubated at room temperature for one hour. After
another round of repeated washing with PBS, the wells were incubated
with a peroxidase-conjugated secondary antibody (1:4000 dilution;
Upstate, USA) for 45 min. The wells were again rinsed with PBS, followed
by incubation with the SuperSignal West Femto peroxidase substrate
(Pierce, USA). Any resulting chemiluminescent signal arising from the
presence of phosphorylated serine and/or threonine residues was mea-
sured using the Genios microplate reader (Tecan, Austria).
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) of
phosphorylated Pfmap2. To rule out autophosphorylation, catalytically
inactive GST-Pfmap2 was used a substrate for either active or inactive
GST-Pfnek3 in a kinase assay reaction mix. The assay mix was gel-puriﬁed
by SDS–PAGE and the Coomassie-stained band that corresponded to
Pfmap2 was excised and sent for LC–MS/MS analysis at the Proteomics
Laboratory (Biopolis Shared Facilities).
All MS/MS samples were analyzed using Mascot (Matrix Science,
London, UK; version 2.1.03). Mascot was set up to search the
MSDB_20060831 database (3239079 entries) assuming the digestion
enzyme trypsin. Mascot was searched with a fragment ion mass tolerance
of 0.80 Da and a parent ion tolerance of 1000 PPM. Oxidation of
methionine, iodoacetamide derivative of cysteine, and phosphorylation of
serine, threonine and tyrosine were speciﬁed in Mascot as variable
modiﬁcations.
Scaﬀold (version 1.6.6, Proteome Software Inc., Portland, OR) was
used to validate MS/MS based peptide and protein identiﬁcations. Peptide
identiﬁcations were accepted if they could be established at greater than
95.0% probability as speciﬁed by the Peptide Prophet algorithm [13].
Protein identiﬁcations were accepted if they could be established at greater
than 99.0% probability and contained at least 2 identiﬁed peptides. Protein
probabilities were assigned by the Protein Prophet algorithm [14].Fig 1. Comparison of the P. falciparum Pfmap2 model with the Rattus
norvegicus ERK2 template. The modeled structure of Pfmap2 is reminis-
cent of the tertiary structure of ERK2. The TSH motif of Pfmap2 was
found to locate at a corresponding position as the TEY activation motif in
ERK2 (highlighted in red). An enlarged view showing the side chains of
the TEY and TSH motifs from the respective enzymes revealed that the
side chains of residues T290, S291, and H292 in Pfmap2 are projected in a
similar manner to the corresponding residues in ERK2 (T183, E184, and
Y185). (For interpretation of the references in color in this ﬁgure legend,
the reader is referred to the web version of this article.)Results and discussion
A 3D model of Pfmap2 supports the TSH motif as a
phosphorylation site
It was previously observed that Pfnek3 was able to
directionally phosphorylate and stimulate the activity of
Pfmap2. However, the mechanism by which Pfnek3 regu-
lates the activity of Pfmap2 remains elusive. A sequence
alignment revealed that Pfmap2 possesses a TSH in place
of the TXY motif which is present in the activation loop
of most MAP kinases [6]. One possibility of Pfnek3–
Pfmap2 interaction may involve phosphorylation of
Pfmap2 by Pfnek3 at the TSH signature motif within the
activation loop (also known as the phosphorylation lip),
which is an essential regulatory element of MAPKs [15].
These observations have prompted us to explore the possi-
bility that Pfnek3 stimulates Pfmap2 activity by phosphor-
ylating at its TSH motif.While the TSH motif in Pfmap2 overlaps with the con-
served activation sequence present in classical MAPKs, it
remains uncertain whether this atypical sequence motif is
conserved to facilitate phosphorylation as the structure of
Pfmap2 has not been solved. Therefore, prior to validating
whether TSH motif is the genuine phosphorylation site, the
tertiary structure of Pfmap2 was modeled to assess whether
the motif, which comprises residues T290, S291, and H292,
is a favorable site for phosphorylation. Comparative mod-
eling of the 3D structure of Pfmap2 was performed using
the SWISS-MODEL program based on existing structures
in the protein database (PDB) which shares at least 25%
protein sequence identity.
The 3D model of Pfmap2 was compared with the struc-
ture of unphosphorylated ERK2 from Rattus norvegicus
(PDB identiﬁer: 1erk). ERK2, which is a conserved MAPK
from the Ras-activated signaling pathway, contains an
invariant threonine-glutamate-tyrosine (TEY) activation
motif [16]. Since ERK2 is a well-studied MAPK, and it
possesses experimentally veriﬁed phosphorylation sites
(residues T183 and Y185), a comparison between the
ERK2 structure and the Pfmap2 model would be useful
in gaining insights into the atypical TSH motif of Pfmap2.
A close examination of the Pfmap2 model revealed that
its TSH motif is located along a loop that exists on the sur-
face of the protein (Fig. 1). Upon superimposition of the
Pfmap2 model on ERK2, the former was found to be very
similar to the structure of ERK2, with which it shares only
45.4% sequence identity (Fig. 1). Additionally, the TSH
442 H. Low et al. / Biochemical and Biophysical Research Communications 361 (2007) 439–444motif was observed to overlap with the activation lip of
ERK2 where its TEY phosphorylation motif resides. Res-
idues within the TSH and TEY motifs of the respective
enzymes were also found to occupy corresponding posi-
tions. Thus, the co-location of the TSH motif in Pfmap2
with the known phosphorylation motif of ERK2 renders
the hypothesis, that Pfnek3 phosphorylates Pfmap2 at the
TSH motif, a favorable and testable one.Residue T290 is essential for activation of Pfmap2 by Pfnek3
To investigate whether residues in the TSH motif are
essential for its activation by Pfnek3, GST-Pfmap2
mutants carrying a T290A, S291A or H292K mutation
were generated via site-directed mutagenesis. These
mutants were hereafter named as Pfmap2-T290A,
Pfmap2-S291A, and Pfmap2-H292K, respectively. All
three mutants did not exhibit kinase activity (Fig. 2). This
observation diﬀers from a previous study where a GST-
Pfmap2-S291A mutant remained active [6]. The variation
in the results observed could be due to the use of diﬀerent
detection methods.
When GST-Pfmap2 was co-incubated with GST-Pfnek3
in a kinase assay mix, the level of phosphorylation on MBP
was higher than the summation of the individual kinase
activities (Fig. 2). This synergistic increase in MBP phos-
phorylation has been demonstrated to be a reﬂection of
GST-Pfmap2 activation [10]. When Pfmap2-T290A was
co-incubated with GST-Pfnek3, there was a drastic fall in
the level of MBP phosphorylation (Fig. 2), which was








































































Fig. 2. Residue T290 is essential for the activation of Pfmap2. Residues T290 a
site-directed mutagenesis. Assay mixtures containing the respective puriﬁed
processed for chemiluminescence as described in Materials and methods. Indiv
not demonstrate kinase activity compared to wildtype Pfmap2. When wildtype
in kinase activity was observed. Similarly, when GST-Pfnek3 was co-incubate
increase in phosphorylation on MBP was retained. Interestingly, when the Pf
decreased markedly from approximately 1000-folds to 10-folds over bacteria-eH292K mutant was used. As controls, GST-DPfmap2 or
GST-DPfnek3 was used to substitute their respective active
enzymes. These data provided evidence that residue T290
plays a crucial role in the activation of Pfmap2 by Pfnek3.Pfnek3 phosphorylates Pfmap2 at residue T290
Since Pfnek3 is a ser/thr kinase, residue T290 is a poten-
tial phosphorylation site which Pfnek3 may phosphorylate
and in turn regulate the activity of Pfmap2. To conﬁrm this
postulation, LC–MS/MS was employed to identify amino
acid modiﬁcations in Pfmap2. Prior to LC–MS/MS analy-
ses, catalytically inactive GST-Pfmap2 was co-incubated
with GST-Pfnek3 in a kinase assay and subsequently sepa-
rated by SDS–PAGE. This excludes the possibility of auto-
phosphorylation by Pfmap2. A neutral loss of phosphoric
acid (98 Da) was detected on the peptide QLTSHVVTR
and the phosphorylated residue was found to be T290
(Fig. 3A). To ascertain that the phosphorylation was
indeed mediated by Pfnek3, the experiment was repeated
using the ‘kinase dead’ Pfnek3 (GST-DPfnek3), which
abolished the phosphorylation on residue T290 (Fig. 3B).
Therefore through LC–MS/MS analyses, it was conﬁrmed
that Pfnek3 phosphorylates Pfmap2 at residue T290. These
data point towards Pfnek3 as the upstream kinase capable
of activating Pfmap2 by phosphorylating at residue T290,
conﬁrming that the TSH motif is the activation site. Most
importantly, the postulation that Pfnek3 functions as a
‘‘MAPKK’’ in the malarial parasite is now strengthened.
As an attempt to recapitulate the eﬀect of phosphoryla-





























































nd S291 were mutated to alanine while H292 was substituted with lysine by
recombinant kinases were transferred to MBP-coated microplates and
idual GST-Pfmap2 mutants with threonine, serine or histidine mutated did
GST-Pfmap2 was co-incubated with active GST-Pfnek3, a marked increase
d with either Pfmap2-S291A or Pfmap2-H292K mutants, the synergistic
map2-T290A mutant was incubated with GST-Pfnek3, the kinase activity
xpressed GST controls.
Fig. 3. MS/MS spectra of the QLTSHVVTR peptide isolated from a tryptic digest of Pfmap2. Catalytically inactive GST-Pfmap2 was added to kinase
assay mixture containing either wildtype or ‘kinase dead’ GST-Pfnek3. Each mixture was gel-puriﬁed by SDS–PAGE prior to excising the band
corresponding to GST-DPfmap2 for LC–MS/MS analysis. (A) When GST-DPfmap2 was isolated from the kinase assay mixture containing GST-Pfnek3,
the MS/MS analysis detected a neutral loss of 98 Da, which corresponds to the mass of phosphoric acid, in the peptide QLTSHVVTR and the phosphate
group was found to be on residue T290 (T+80). (B) When GST-Pfnek3 was substituted with GST-DPfnek3, no phosphorylation was detected on the same
peptide.
H. Low et al. / Biochemical and Biophysical Research Communications 361 (2007) 439–444 443glutamate which carries a negative charge at its side chain
and mimics the eﬀect of phosphorylated threonines [15].
Phosphomimic mutants are utilized, with varying eﬀective-
ness, to simulate constitutive phosphorylation and the acti-
vation of protein kinases. However, the Pfmap2-T290E
mutant did not demonstrate constitutive kinase activity
(not shown), as was the case for ERK2, whereby the
T183E/Y185E dual phosphomimetic mutant demonstrated
only a basal level of activity [15].
Conclusion
The mechanism by which Pfnek3 regulates the activity
of Pfmap2 remains poorly understood. In the predicted
3D model of Pfmap2, the TSH motif is located at the
conserved phosphorylation lip that is essential for regu-
lating the activity of protein kinases. We attempted to
unveil the mechanism by which Pfnek3 regulates Pfmap2
and determined that the threonine residue, T290, within
the TSH motif to be a critical residue involved in the
activation of Pfmap2. This conserved threonine residue
was also found to be phosphorylated by Pfnek3. Collec-
tively, the results obtained in this study have demon-
strated that Pfnek3 regulates the activity of Pfmap2 by
phosphorylating at residue T290. Furthermore, since
Pfnek3 activates Pfmap2 by phosphorylating at the
TSH activation site, it strongly suggests that the former
is a functional in vitro ‘‘MAPKK-like’’ enzyme of
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